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SUMMARY
CARDIOPULMONARY RESPONSES TO ACUTE HYPOXIA AND EXERCISE 
IN RELATION TO THE ACE INSERTION/DELETION GENE POLYMORPHISM 
Dr Sameer Patel. BSc, MBChB, MRCP
The physiological response to environmental hypoxia encountered at high altitude has a wide 
range o f cardiovascular and pulmonary effects. The insertion allele o f the angiotensin 
converting enzyme (ACE) gene polymorphism has been found to be more prevalent in 
endurance athletes and is associated with beneficial anabolic and functional responses in 
muscle. Furthermore, the insertion allele o f this functional genetic polymorphism has been 
associated with enhanced physical performance at altitude, as defined by the successful 
ascent o f peaks over 4800 metres. This thesis examines the cardiopulmonary responses 
during exercise and hypoxia in order to elucidate any genotype dependent differences in 
cardiopulmonary response that could explain this observation.
The main body o f this work was carried out between August 1999 and September 2001. The 
studies involved 60 healthy subjects performing a maximal cardiopulmonary exercise test to 
determine ventilatory threshold (VT). At the second visit the subjects underwent a second set 
o f steady state exercise tests, performed at 50% of the work rate attained at VT, under 
normoxic and hypoxic conditions (Fi02 12.5%). Metabolic and ventilatory measurements 
were made during tests and the changes between normoxic and hypoxic response during rest 
and exercise were analysed. A second smaller study examined cardiac output response during 
hypoxia and exercise using bioimpedance cardiography. These studies were performed 
simultaneously with the cardiopulmonary exercise tests and included 31 subjects. Similar 
analyses were performed on cardiac output variables between normoxia and hypoxia. The 
repeatability of the steady state cardiopulmonary exercise experimental protocol was verified 
by repeat testing and analyses. Bioimpedance cardiography measurements were validated 
against simultaneous measurements during pulmonary catheter studies and thermodilution 
cardiac output measurement.
The results of the tests and the comparison o f response demonstrated a larger increase in 
ventilation during exercise from normoxia to hypoxia in the insertion homozygous group. 
This was accompanied by a genotype dependent decrease in end-tidal carbon dioxide, 
suggesting a higher alveolar ventilation. There was no increase in oxygen saturations in the 
insertion homozygous group, which may have been due to the technical limitations o f the 
oximeters. The cardiac output studies did not reveal any significant difference between 
genotype. The ventilatory study has demonstrated a response that may contribute to enhanced 
performance during prolonged hypoxic exposure, as experienced at high altitude.
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the left shows changes during rest; the panel on the right shows 
changes during hypoxia. These plots demonstrate the increase in 
VCO2 from normoxia to hypoxia; due to increased CO2 
elimination during hypoxia. This is attributable to the increase in 
ventilation during hypoxia due to hypoxic ventilatory drive. 
Furthermore, there is a wide variation in individual responses. 
The red data sets demonstrate a decrease in VCO2 in 6 
individuals from normoxia to hypoxia during rest; this maybe 
explicable by a degree of hyperventilation during the normoxic 
resting phase.
Figure 3.9 {Page 163) The change in PetC02 from normoxia to hypoxia. The panel on 
the left shows changes during rest; the panel on the right shows 
changes during exercise. These plots demonstrate the decrease in 
PetC02 from normoxia to hypoxia. This reflects the increase in 
alveolar ventilation during hypoxia due to hypoxic ventilatory 
drive. There is a wide variation in individual responses. The red 
data sets demonstrate an increase in PetC02 in 5 individuals 
from normoxia to hypoxia during rest; these were 5 of the 6 
subjects that demonstrated a greater increase in VCO2 , during 
rest. Similarly this could be attributable to a degree of 
hyperventilation during the normoxic resting phase.
Figure 3,10 {Page 165) The change in Sa02 from normoxia to hypoxia. The panel on the 
left shows changes during rest; the panel on the right shows 
changes during exercise. These plots demonstrate the decrease in 
Sa0 2  from normoxia to hypoxia, reflecting the hypoxaemia 
during hypoxic exposure which intensified during exercise. 
Lower than expected normoxic exercise resultrs were noted; the
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Figure 3.11 {Page 167)
Figure 3.12 {Page 169)
Figure 3.13 {Page 171)
Figure 3.14 {Page 173)
cause o f this was individuals gripping the handel bars of the 
ergometer too tightly, despite instructions not to do so.
The change in tidal volume from normoxia to hypoxia. The 
panel on the left shows changes during rest; the panel on the 
right shows changes during exercise. These plots demonstrate 
the wide range o f responses of tidal volume during rest and 
exercise during hypoxic exposure. Some individuals 
demonstrated a rise in Vt, whilst others had a decrease in Vt (in 
red) during hypoxic exposure. The majority of subjects 
demonstrated a rise in Vt during exercise, but o f a variable 
degree. Two subjects exhibited clear evidence of 
hyperventilation at rest, one during normoxia, the second during 
hypoxia.
The change in respiratory rate from normoxia to hypoxia. The 
panel on the left shows changes during rest; the panel on the 
right shows changes during exercise. Similar to the responses 
seen with tidal volume, there is a wide range o f response in RR, 
with both increases and decrease (in red) evident. The high RR 
evident in some o f the subjects a degree o f hyperventilation.
The change in minute ventilation from normoxia to hypoxia. The 
panel on the left shows changes during rest; the panel on the 
right shows changes during exercise. The wide variation in 
response is seen as with the other plots. The resting plot shows 6 
subjects that demonstrated a higher Ve during normoxic rest in 
comparison to hypoxia; these subjects also had a decrease in 
VCO2  and increase in etCOz. This suggests that hyperventilation 
during this portion o f the protocol was present.
Regression plots o f minute ventilation and etC02 in normoxic 
conditions. The left panel shows resting response; the right panel 
shows the exercise response. The red dashed lines are the 95% 
confidence intervals. There is no significant correlation between 
etC02 and Ve during rest or exercise (p=0.16 and 0.97 
respectively). The resting plot demonstrates a trend toward a 
negative conelation that might belie a degree o f hyperventilation 
during rest whilst connected to the circuit. The lack of 
correlation during normoxic exercise is to be expected since 
exercise ventilation is closely coupled to CO2  production and 
elimination.
Figure 3.15 {Page 174) Regression plots o f minute ventilation and PetC02 in hypoxic 
conditions. The left panel shows resting response; the right panel 
shows the exercise response. The red dashed lines are the 95% 
confidence intervals. There is a highly significant correlation 
between PetC0 2  and Ve during rest and exercise (p<0.0001 and 
p=0.008 respectively). This is expected, since ventilation in 
hypoxic conditions is driven by hypoxia as opposed to CO2 . The 
resting response is made more significant by one individual that
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Figure 3.16 {Page 174)
Figure 3.17 {Page 175)
may have exhibited a degree of hyperventilation; however 
removal o f this subject retained the significance o f this 
correlation (p=0.03)
Regression plots of respiratory rate and PetCOz in normoxic 
conditions. The left panel shows resting response; the right panel 
shows the exercise response. The red dashed lines are the 95% 
confidence intervals. There was no significant correlation
between RR and PetC02 during rest (p=0.75), but a significant 
correlation during exercise (p=0.001).
Regression plots of respiratory rate and PetC02 in hypoxic 
conditions. The left panel shows resting response; the right panel 
shows the exercise response. The red dashed lines are the 95% 
confidence intervals. There was no significant correlation
between RR and PetC02 during rest (p=0.13), but a significant 
correlation during exercise (p<0.0001).
Figure 3.18 {Page 175)
Figure 3.19 {Page 176)
Figure 3.20a {Page 178)
Regression plots o f tidal volume and PetC02 in normoxic 
conditions. The left panel shows resting response; the right panel 
shows the exercise response. The red dashed lines are the 95% 
confidence intervals. There was no significant correlation 
between V t and PetC0 2  during rest (p=0.66), but a significant 
correlation during exercise (p=0.01).
Regression plots o f tidal volume and PetC02 in hypoxic 
conditions. The left panel shows resting response; the right panel 
shows the exercise response. The red dashed lines are the 95% 
confidence intervals. The resting plot suggests a significant 
negative correlation between PetC0 2  and V t during hypoxic 
rest; however this appears to be the effect o f one outlier, who 
demonstrated a significant degree of hyperventilation during this 
portion o f the protocol (the same subject increased the 
significance o f the minute ventilation plot during hypoxic rest). 
The removal of this subject from the correlation calculation 
produced a non-significant result (p-0.85). There was no 
significant correlation between V t and PetC0 2  during exercise
(p=0.66).
Bland Altman plot comparing raw cardiac output measurements 
using bioimpedance and thermodilution simultaneously. 
Measurements were made during rest and exercise and have 
been pooled. The two methods show reasonable agreement, with 
the exception of one outlier.
Scatter plot o f raw cardiac output measurements 
bioimpedance and thermodilution simultaneously.
usingFigure 3.20b {Page 178)
Figure 3.21a (Prtge 779) Bland Altman plot comparing the mean o f 3-4 measurements
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made in succession. The measurements are o f pooled rest and 
exercise recordings. The degree o f agreement is much improved 
by averaging several results.
Figure 3.21b 779) Scatter plot o f the mean o f 3-4 measurements made in
succession, using bioimpedance and thermodilution 
simultaneously. The measurements are of pooled rest and 
exercise recordings.
Figure 3.22 {Page 182) The change in heart rate from normoxia to hypoxia. The panel 
on the left shows changes during rest; the panel on the right 
shows changes during exercise. The wide variation in response 
is seen as with the other plots. One subject had a higher heart 
rate during normoxic rest in comparison to hypoxic rest (data 
point in red), this subject did not have concurrently elevated 
ventilation during this part o f the protocol; therefore it is 
difficult to assess whether this was due to anxiety. All subjects 
increased their heart rate from normoxia to hypoxia during 
exercise.
Figure 3.23 {Page 184)
Figure 3.24 {Page 186)
Figure 3.25 {Page 188)
Figure 3.26 {Page 189)
The change in stroke volume from normoxia to hypoxia. The 
panel on the left shows changes during rest; the panel on the 
right shows changes during exercise. The wide variation in 
response is seen as with the other plots. There were 6 subjects 
that demonstrated a decrease in SV from normoxia to hypoxia 
during rest and 4 different subjects decreased their SV during 
exercise (data sets in red).
The change in cardiac output from normoxia to hypoxia. The 
panel on the left shows changes during rest; the panel on the 
right shows changes during exercise. The wide variation in 
response is seen as with the other plots. There were 3 subjects 
that demonstrated a decrease in CO from normoxia to hypoxia 
during rest (data sets in red), this may have been due to a degree 
o f anxiety when being initially connected to the exercise 
equipment and circuit. All subjects demonstrated a rise in CO 
from normoxia to hypoxia during exercise.
ANOVA analysis of change in VO2 from normoxia to hypoxia. 
The left panel shows the response during rest; the right panel 
during exercise. The central point marks the group mean, the 
bars represent the 95% confidence interval for each group. 
Neither the response during rest or exercise demonstrates any 
significant difference between normoxia and hypoxia (ANOVA 
p values: rest p= 0.15, exercise p= 0.54).
ANOVA analysis of change in VCO2 from normoxia to hypoxia. 
The left panel shows the response during rest; the right panel 
during exercise. The central point marks the group mean, the 
bars represent the 95% confidence interval for each group. 
Neither the response during rest or exercise demonstrates any
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Figure 3.27 {Page 190)
Figure 3.28 {Page 191)
Figure 3.29 {Page 192)
Figure 3.30 {Page 193)
Figure 3.31 {Page 194)
Figure 3.32 {Page 196)
significant difference between normoxia and hypoxia (ANOVA 
p values: rest p= 0.24, exercise p= 0.67).
ANOVA analysis o f change in SaOa from normoxia to hypoxia. 
The left panel shows the response during rest; the right panel 
during exercise. The central point marks the group mean, the 
bars represent the 95% confidence interval for each group. 
Neither the response during rest or exercise demonstrates any 
significant difference between normoxia and hypoxia (ANOVA 
p values: rest p= 0.13, exercise p= 0.66).
ANOVA analysis o f change in etC02 from normoxia to hypoxia. 
The left panel shows the response during rest; the right panel 
during exercise. The central point marks the group mean, the 
bars represent the 95% confidence interval for each group. 
During exercise the II group demonstrated a greater fall in etC02 
(p=0.003), no significant decrease was evident at rest (p=0.38).
ANOVA analysis of change in respiratory rate from normoxia to 
hypoxia. The left panel shows the response during rest; the right 
panel during exercise. The central point marks the group mean, 
the bars represent the 95% confidence interval for each group. 
There appears to be trend toward a higher RR in the II group but 
this is not significant (rest: p=0.15, exercise p=0.71).
ANOVA analysis o f change in tidal volume from normoxia to 
hypoxia. The left panel shows the response during rest; the right 
panel during exercise. The central point marks the group mean, 
the bars represent the 95% confidence interval for each group. 
Neither the response during rest or exercise demonstrates any 
significant difference between normoxia and hypoxia (ANOVA 
p values: rest p= 0.86, exercise p= 0.55).
ANOVA analysis o f change in Ve from normoxia to hypoxia. 
The left panel shows the response during rest; the right panel 
during exercise. The central point marks the group mean, the 
bars represent the 95% confidence interval for each group. 
During exercise the II group demonstrated a greater increase in 
Ve (p=0.008), no significant decrease was evident at rest 
(p=0.49). In addition, there is no evidence o f a co-dominant 
effect with the heterozygous group.
ANOVA analysis o f change in heart rate from normoxia to 
hypoxia. The left panel shows the response during rest; the right 
panel during exercise. The central point marks the group mean, 
the bars represent the 95% confidence interval for each group. 
Neither the response during rest or exercise demonstrates any 
significant difference between normoxia and hypoxia (ANOVA 
p values: rest p -  0.94, exercise p= 0.75).
Figure 3.33 {Page 190) ANOVA analysis o f change in stroke volume from normoxia to
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hypoxia. The left panel shows the response during rest; the right 
panel during exercise. The central point marks the group mean, 
the bars represent the 95% confidence interval for each group. 
Neither the response during rest or exercise demonstrates any 
significant difference between normoxia and hypoxia (ANOVA 
p values: rest p= 0.60, exercise p= 0.70).
Figure 3.34 {Page 197) ANOVA analysis o f change in cardiac output from normoxia to
hypoxia. The left panel shows the response during rest; the right 
panel during exercise. The central point marks the group mean, 
the bars represent the 95% confidence interval for each group. 
Neither the response during rest or exercise demonstrates any 
significant difference between normoxia and hypoxia (ANOVA 
p values: rest p= 0.85, exercise p= 0.76).
Figure 4.1 {Page 213) The interaction of the peripheral and central chemoreceptors in
response to hypoxia, hypocapnia and the effects o f local RAS. 
The proposed effects of a reduction in ACE activity, as seen in 
insertion homozygotes are shown by the red arrows and 
notation. The reduced stimulatory effect at the carotid body is 
shown by the |+  symbol; the enhanced phrenic nerves discharge 
by the f+  symbol. The effect of reduced CO2  is also shown.
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CHAPTER ONE: INTRODUCTION
Oxygen is one o f the fundamental requirements for life. The basic requirement is the same 
whether we consider a unicellular organism or an evolved mammal such as ourselves. Food 
is metabolised using oxygen to produce energy, some of which maybe used to move the 
organism from one point to another. In a single cell organism the environment determines the 
availability o f food and oxygen whereas eliminating the products o f metabolism is simply a 
matter o f diffusion into the environment. Land animals however have had to evolve complex 
systems which allow the same processes to occur. Physiological systems couple the uptake 
o f oxygen from the atmosphere by the lungs, via the circulation to the tissues and in 
combination with food substrate produce energy. Yet other systems eliminate the products of 
metabolism and in doing so aid homeostasis. The mechanisms for energy production, 
irrespective of the site or purpose within the organism are the same, but during exercise there 
are dynamic changes in oxygen requirement as the intensity o f exercise increases; these 
requirements are met by dynamic changes in circulatory and ventilatory systems. 
Furthermore in conditions of hypoxia the cost of work is maintained, whereas the availability 
o f oxygen is reduced. This is overcome by hypoxic responses in the same physiological 
systems and act in concert to effect an observable adaptation.
Research in the field of hypoxic response is extremely active and broad in the disciplines it 
encompasses. In the last few decades the biochemical and molecular mechanisms that affect 
hypoxic responses have been elucidated and described. In the last few years the actual 
mechanisms o f oxygen sensing have become clearer, though many details remain unresolved 
and contested. Research into the bioenergetics o f exercise has elucidated many o f the 
mechanisms o f these cardiopulmonary responses. Finally, research at high altitude has 
furthered our understanding of physiology, hypoxic adaptation and high altitude diseases.
The purpose of this thesis is to present work which examines some o f the cardiopulmonary 
responses to both acute and chronic hypoxia and relates them to a specific genetic 
polymorphism. This chapter will review: the fundamental mechanisms o f cellular respiration; 
the physiological mechanisms o f cardiopulmonary response to exercise and adaptations to 
hypoxia; the molecular and biochemical factors involved in these adaptations as well as the 
genetics of hypoxic response. The final section will review the work on high altitude 
adaptation and disease.
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1.1 D efinitions
The physiological response to hypoxia occurs at several points from the cellular level to 
entire homeostatic mechanisms affecting several organ systems. In examining these 
responses it is essential to distinguish the terms used to describe low oxygen environments 
and hypoxia at the organismal, cellular and molecular levels.
1.1.1 Hypoxia and hypoxaemia
In biological terms hypoxia can be defined as an ‘inadequate supply o f oxygen sufficient to 
compromise function’. This broad term is further defined by the point at which the 
insufficiency arises and offers further clarification. For example; the interruption to oxygen 
utilization at the cellular level due to toxins (e.g. cyanide) gives rise to cytotoxic hypoxia; 
changes in morphology can lead to diffusional hypoxia; disruption in blood supply either 
localised or systemic can cause ischaemic hypoxia; reduced haemoglobin levels or disrupted 
haemoglobin function causes anaemic hypoxia and reduced oxygen tension in arterial blood 
(due to primary pulmonary disease) causes hypoxaemic hypoxia. This list omits a 
fundamental cause for inadequate oxygen supply: Low ambient oxygen or environmental 
hypoxia. Low ambient oxygen concentrations or hypobaric hypoxia as encountered at high 
altitude is the most basic level of oxygen insufficiency and though it results in hypoxaemia it 
is important to draw a degree of distinction from hypoxaemic hypoxia as a result of 
pulmonary disease. Hypoxaemia is the stimulus to some o f the physiological adaptations 
shared by both these situations, but adaptation to environmental hypoxia is distinguished by 
the absence o f pathological processes that cause the hypoxaemic hypoxia o f pulmonary 
disease. That being said, environmental hypoxia can cause disease in otherwise healthy 
individuals as a result o f maladaptive hypoxic response.
The response to environmental hypoxia affects every level o f biological function since it 
occurs at the source. As a consequence physiological adaptation is seen in every step of 
ventilation, gas exchange, pulmonary and systemic circulation, oxygen carriage and cellular 
metabolism.
1.1.2 Hypoxic environments
Hypoxia occurs at high altitude because of two fundamental physical properties o f gases. 
Firstly, atmospheric pressure decreases as altitude increases. Secondly Dalton’s Law of 
partial pressures states, that the pressure exerted by an individual gas in a mixture is the
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product of the proportional concentration o f that gas and the ambient pressure; therefore the 
actual oxygen concentration may remain the same, but the partial pressure oxygen exerts is 
reduced at high altitude since barometric pressure is reduced. This is crucial at the alveoli, 
where the reduction in oxygen partial pressure results in a reduction o f oxygen transfer across 
the alveolar/ endothelial interface, hence the potential for hypoxaemia.
The effect o f altitude on barometric pressure was first described by Blaise Pascal (1623- 
1662) in 1647. Though his experiments were simple and elegant, the implications o f his 
discovery have had a profound influence on all forms of activity at high altitude, whether it is 
in the ascent o f mountains or in any method of manned flight. The effect o f altitude on 
barometric pressure is illustrated in figure 1 . 1 .
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Figure 1.1 Relationship between barometric pressure and altitude. The right axis 
demonstrates the decline in Pa0 2  [ 1 ].
As is shown above there is a negative relationship between altitude and barometric pressure 
which is slightly curvilinear. At the highest altitudes the degree o f pressure drop is less than 
one would expect from a linear relationship such as the standard models used in the aviation 
industry; furthermore, there are variations in this relationship according to geography. This 
arises because of variations in the height o f earth’s atmosphere at different latitudes. Nearer 
the equator, where the atmosphere is at its thickest, barometric pressures for a particular 
altitude are higher than expected and coincides with the location o f the highest mountain 
regions in the world.
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The ascent o f Mount Everest without supplementary oxygen would not have been possible 
without this variability between altitude and pressure at equatorial latitudes. The 
physiological stresses o f hypoxia at the summit o f Everest are such, that even seasonal 
variation in barometric pressures influences survival with such attempts.
1.1.3 Adaptations to acute and chronic hypoxia
The chronicity of hypoxic exposure is an important factor in the type and extent of 
physiological adaptation. Changes in ventilation, pulmonary circulation and cardiac output 
can be seen within the first minutes of exposure and develop as hypoxia persists. The effects 
these have on an individual’s physiology can vary widely and are thought to determine how 
well that individual will perform in low oxygen environments and in some circumstances 
whether they will develop pathology associated with prolonged hypoxic exposure. The 
degree o f hypoxia is also a crucial factor since many of the physiological effects are directly 
proportional to the oxygen deficit. What is becoming increasingly evident is the rate at which 
hypoxia increases is as important. High altitude disease, developing in the first few days of 
altitude exposure, is known to occur more frequently upon rapid ascents, when insufficient 
time is allowed for adaptive changes to take place and is classified as acute high altitude 
disease. Individuals exposed over a longer period, over months or years develop a different 
group of conditions associated with pathological cardiorespiratory adaptation and are classed 
as chronic high altitude disease. In terms o f pathological disease obstructive and interstitial 
pulmonary diseases do result in persistent hypoxic states, with cardiopulmonary features that 
share similarities with chronic altitude diseases.
The focus of this thesis is the cardiopulmonary response to acute hypoxia, both at rest and 
during exercise. Furthermore, these responses are examined in relation to the angiotensin 
converting enzyme (ACE) gene polymorphism in order to determine how individual 
variations in these responses may influence the ability to cope in hypoxic environments and 
at altitude.
Before describing the control mechanisms and responses o f cardiovascular and ventilatory 
systems, it is important to review the fundamental necessity of oxygen in energy generation 
which is the cause of adaptive changes in these systems in response to hypoxia. Furthermore 
recent research suggests that the basic mechanisms of energy generation are intrinsically 
linked to oxygen sensing in several organs and cell types.
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1.2 C ellu lar respiration
Energy is vital for cellular activity and at the molecular level there is only one currency -  
adenosine triphosphate. The cleavage o f the terminal high energy bond in this molecule 
produces energy for cellular processes. In skeletal myocytes, ATP is cleaved by myosin, 
enabling movement against actin molecules and elicit myofibril contraction. This system is 
dependent on calcium release stimulated by action potentials generated by an activated 
neuromuscular endplate. Calcium is released from the sarcoplasmic reticulum in close 
apposition to the myofibrils; however in order to allow myofibril relaxation the calcium is 
then removed by active uptake into the sarcoplasmic reticulum which also requires ATP. 
Therefore both muscular contraction and relaxation requires the cleavage o f ATP. In smooth 
muscle cells there is a similar requirement for calcium influx into the cytoplasm, but in 
contrast to skeletal myocytes, there is a poorly developed sarcoplasmic reticulum and 
extracellular influx of calcium is an important factor. In smooth muscle various 
environmental stimuli can elicit contraction; whereas in skeletal muscle, contraction is 
dependent on neuronal stimulation o f motor units. The features o f hypoxic smooth muscle 
responses are discussed in detail further on, but for the purpose o f the following review of 
cellular respiration, the skeletal myocyte is used as the model of the respiring cell. 
Irrespective of which cell is discussed the fundamental processes are the same.
1.2.1 Energy generation at the cellular level
Cellular respiration can occur in low oxygen conditions or with adequate oxygenation; this 
determines whether respiration terminates at the glycolytic pathway or proceeds, in the 
presence o f oxygen, to the Tri-carboxyl ic acid cycle and oxidative phosphorylation. Both 
these pathways are discussed below, but terms such as ‘anaerobic and aerobic respiration’ 
have been used to describe these states. These terms can only provide a label for the overall 
state of respiration in a cell since both forms of respiration can occur simultaneously. It is the 
net state of the cell or tissue which determines whether it is classed as respiring ‘aerobically 
or anaerobically’.
1.2.2 The glycolytic pathway
Glucose is a basic substrate for respiration, the initial process o f ATP production is via the 
glycolytic pathway. The triose pathway o f glycolysis, utilising triose molecules is illustrated 
in figure 1.2 and is called the Embden-Meyerhof pathway [2]. Glycolysis utilizes 2 molecules
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of ATP to phosphorylate the early intermediaries in the pathway; each molecule o f glucose is 
then cleaved to form two triose molecules: Glyceraldehyde-3-phosphate. Each molecule then 
undergoes reduction, isomerization and phosphoryl cleavage to produce pyruvate; therefore 
each glucose molecule produces two molecules o f pyruvate. In the process, a total o f 4 
molecules of ATP are produced, giving a net gain o f 2 ATP for each glucose molecule that 
enters the glycolytic pathway. Glycolysis also reduces 2 molecules o f the electron transport 
molecule nicotinamide adenine dinucleotide (NAD^), generating 2 molecules o f NADH. In 
aerobic conditions NADH enters the electron transport chain and generates energy by 
oxidative phosphorylation; however in conditions of hypoxia the pyruvate is reduced by 
NADH, thereby regenerating itself and produces lactate.
Intermediate points in this pathway offer a means of introducing carbon skeletons from 
amino acids for the purpose o f generating energy, equally the same intermediate molecules 
can be sequestered into amino acid synthesis. Similarly fatty acids can undergo metabolism 
to glycerol which can participate in the glycolytic pathway. In itself glycolysis is a relatively 
limited means o f energy generation, with much o f the potential energy o f the carbohydrate 
substrate locked in either pyruvate or lactate. In order to fully metabolise substrate and 
maximise energy generation, pyruvate must enter the tri-carboxylic acid cycle. This pathway 
produces no ATP directly, but does allow the complete catabolism o f carbohydrate whilst 
generating NADH for oxidative phosphorylation.
Figure 1.2 also shows the isomerization step for the production o f 2,3-diphosphoglycerate, a 
molecule important in determining the affinity o f haemoglobin at various oxygen tensions.
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Figure 1.2 The Embden-Meyerhof pathway with sites of ATP utilisation and production. The 
pathway is discussed in detail in the text above.
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1.2.3 Oxygen and respiration
The Tri-carboxylic acid cycle
Oxygen dependent respiration occurs in two parts, both within the mitochondria. The first 
part incorporates the pyruvate from glycolysis into the Tri-carboxylic acid cycle (TCA) 
(figure 1.3) which is located in the mitochondrial matrix. Pyruvate is converted into acetyl 
CO enzyme A (acetyl-CoA) by pyruvate dehydrogenase, producing a molecule o f reduced 
NAD (NADH'*'). Acetyl-CoA then enters the TCA, replenishing it and allowing its continued 
function.
Pyruvate
NAD
NADH Acetyl-CoA
Citrate
NADH
H2O
Oxaloacetate
c/s-Aconitate
M atate
Isocitrate
Succinate
SuG cinyl-
CoA NADH + CO2
GTP
Figure 1.3 The Tri-carboxylic acid cycle, with constituent intermediate molecules and the 
points at which NADH and FADH are generated. Abbreviations as per the text.
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The cycle then undergoes several enzymatic steps the products o f which are 6  molecules of 
CO2 , 6  molecules o f N A D H \ 2 molecules of reduced flavin adenine dinucleotide (FA D H \ 
another electron transport molecule) and 2 molecules o f ATP for each molecule o f glucose 
that enters the cycle (the guanidine triphosphate (GTP) produced by the hydrolysis of 
succinyl-CoA donates its phosphate to ADP to produce ATP).
At this point the direct net gain in terms o f ATP is 4 molecules per molecule o f glucose 
metabolised thus far; however the TCA cycle produces in total 8  molecules o f NADH^ and 2 
molecules of FADH^. On a molecular level, this burden on the reduction/oxidation (REDOX) 
state o f the cell would be untenable; however the reduced state o f these electron donors is 
resolved by entry into the electron transport chain (ETC) and further metabolism.
Oxidative phosphorylation
The electron transfer chain is located on the inner membrane o f the mitochondrion. This 
membrane is relatively impermeable to molecules unless via specific transporter proteins. In 
contrast the outer membrane is permeable to most small molecules and ions v iaporins, large 
transmembrane proteins with a large central pore. In essence the electron transfer chain 
transfers electrons donated by NADH from the TCA cycle and as they are conveyed across 
the constituent complexes, the energy released is used to transport protons across the 
membrane. This creates a proton gradient which is used by ATP synthase to phosphorylate 
adenosine diphosphate (ADP) to ATP (figure 1.4). Complexes I to IV are NADH 
dehydrogenase, succinate dehydrogenase, cytochrome bel and cytochrome oxidase 
respectively. This description is o f course simplified; the reality is that each complex has 
several constituent sub-units that rely on cofactors to perform their tasks. Complex I for 
example has between 42-43 subunits, one flavin mononucleotide, 8  different iron sulphide 
centres and is over 900 kilodaltons in size. The final complex in the chain is ATP synthase 
(complex V) and the final reduction reaction occurs with oxygen to produce water [3].
The energy generated per molecule o f NADH was previously thought to be 3 ATP 
molecules; however this estimate seems to be overly generous. A more accurate figure is 2.5 
molecules o f ATP per NADH^ oxidized and 1.5 molecules per FA D H \ allowing for 
variations in site of generation this gives a total o f 26 molecules o f ATP produced by aerobic 
respiration (table 1.1). This combined with the 2 molecules o f ATP from glycolysis and the 2 
molecules generated by the TCA cycle gives a sum total o f 30 molecules o f ATP per 
molecule of glucose [4].
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Intermembrane space 
Matrix
X M itochondrionInner 
mitochondrial 
membrane
Cisternae
m m m m
Cyanide sv n th ase
R otenone TTFA Myxothiazol 
Antimycin A
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Figure 1.4. The electron transfer chain. NADH-DH; NADH dehydrogenase; SDH: succinyl 
dehydrogenase: bel: cytochrome bel; COX: cytochrome oxidase. The specific blocking 
agents for each complex are in red; TTFA: thenoyltrifluoroacetone. The final electron 
transfer between cytochrome bel and COX is illustrated by the dashed line.[3]
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Oxidative phosphorylation (mitochondrial) A TP yield/glucose
2 NADH formed in glycolysis; each yields 1.5ATP +3
2NADH formed in the oxidative decarboxylation o f pyruvate; each yields 2.5ATP +5
2 FADHzformed in the TCA; each yields 1.5ATP +3
6 NADH formed in the TCA; each yields 2.5 ATP +15
Net yield per glucose +26
Table 1.1 ATP yield from oxidative phosphorylation o f one glucose molecule 
1.3 V entilatory adaptations to hypoxia
The discussion thus far has established the need for oxygen at the cellular level, but in order 
to meet that requirement systems have evolved to extract oxygen from the environment and 
deliver it to respiring cells; furthermore these systems are dynamic as oxygen requirement is 
variable with activity and as ambient oxygen varies with environment. The first step in this 
process is the ventilation of air to the gas exchange surfaces.
Ventilatory control regulates oxygen uptake, carbon dioxide elimination and acid-base 
balance. At sea level it is one o f many mechanisms which maintain homeostasis during 
exercise and ensures an optimum operating environment for the body tissues; at altitude it is 
a fundamental response to allow survival in hypobaric hypoxia. Sensory systems, both 
peripheral and central relay information on oxygen and carbon dioxide concentration as well 
as plasma pH to the ventilatory motor centres in the brainstem. In addition, the entire control 
mechanism can be overridden by higher cortical centres that enable controlled airflow for 
speech, but can also produce hyperventilation in response to emotional and physical stress. 
The sensory and motor components of control have been researched extensively, but despite 
this their precise mechanism and interaction is not fully understood.
1.3.1 The motor control o f ventilation
Ventilation is mediated through skeletal muscle and is therefore entirely dependent on central 
nervous system (CNS) control. The brainstem motor neurones are situated in the pons and the 
medulla oblongata (figure 1.5). The pontine respiratory group is located around the 
parabrachial nuclei and is thought to play a role in the transition from inspiration to 
expiration. The medullary centres are divided into the dorsal and ventral respiratory groups
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(DRG and VRG respectively). The DRG is in the dorsomedial medulla and is associated with 
nucleus of the tractus solitarius (nTS). The DRG contains mainly inspiratory neurones and 
receives afferent input from the lungs and airways via tlie vagus nerve. Slow adapting stretch 
receptors in lung airways inhibit the inspiratory neurones via this pathway and are thought to 
be part of the Hering-Breuer reflex. The VRG is located in the ventral medulla and 
comprises the Botzinger complex, the nucleus paraambigualis (NPA), the nucleus 
retroambigualis (NRA) and the nucleus ambiguus (NA). The first three nuclei are within the 
nucleus retrofacialis, the NPA lies in parallel with the NA. These centres contain both 
inspiratory and expiratory neurones. Caudal to the Botzinger complex are a group of 
neurones thought to be the site o f ventilatory rhythm generation (pre-Botzinger complex).
Cerebral cortex
Hypothalamus Bôtzingercomplex
Spinal cord
Fourth
Ventricle
nPCL
Midline
Figure 1.5. The ventral medullary nuclei. The nuclei lie in pairs on both sides of the midline, 
only some are demonstrated on each side for clarity. nA= nucleus ambiguous, nPA= nucleus 
paraambigualis, nRA= nucleus retroambigualis, nTS= nucleus tractus solitarius, nPCL= 
nucleus paragiganto cellularis lateralis.
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The voluntary control o f ventilation is transmitted via the corticospinal tract; however there 
are mechanisms of automatic ventilatory control that are transmitted in the bulbospinal tracts 
and are thought to mediate ventilation at rest [5]. The muscles o f respiration under the control 
o f these central motor centres are the diaphragm via the phrenic nerves and the intercostal 
muscles. Transection above the roots of the phrenic nerve at C3 results in the abolition o f all 
ventilatory motor activity. The inspiratory phase of ventilation is mediated predominantly by 
the diaphragm and inspiratory intercostal muscles. Expiration is initially passive process 
(relying on the elastic recoil o f the lung and chest wall) up to tidal volumes o f around 50% of 
total vital capacity; thereafter expiratory intercostal muscle and abdominal wall contraction 
contribute to expiratory effort [6 ].
1.3.2 Central chemoreeeptors
The classical model o f central chemoreception places ventilatory sensing on the ventral 
surface of the medulla, [7]. This area responds to changes in blood CO2 and pH, but 
demonstrates no direct response to changes in oxygen tension. Forty years has passed since it 
was first proposed and despite extensive work in this area, the precise identification o f the 
chemoreceptor cells and their signalling pathways has yet to be described. The most recent 
evidence suggests that neurones utilising ATP as neurotransmitter are involved in CO2 
sensing [8 ]. An alternate hypothesis proposes that there is no cellular chemoreceptor on the 
ventral medulla, but rather dendritic projections of deeper neurones that perform the task [9]. 
Others posit the theory that the respiratory pattern generators in the ventral respiratory group 
themselves exhibit chemosensory properties and are responsible for chemoreception [ 1 0 , 1 1 ]. 
Irrespective o f the controversy surrounding the identity of the central chemoreceptor, its 
fundamental properties remain the same. The central chemoreeeptors respond to changes in 
cerebrospinal fluid (CSF) pH; however the brain is never in direct contact with the blood and 
is protected by the blood brain barrier (BBB). Carbon dioxide can pass freely across the BBB 
and is ionised to form bicarbonate (HCO 3) and hydrogen ions (H^) according to the 
Henderson-Hasselbach equation. Unlike blood, the CSF lacks a significant buffering 
capacity; therefore the hydrogen remains ionised and is the stimulus to central ventilation. 
The subsequent transmission o f this signal to the respiratory groups seems to be via 
cholinergic neurones, since atropine can block this effect [ 1 2 ].
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Hypoxia does not have a direct influence on central chemoreception; peripheral 
chemoreeeptors fill the role of oxygen sensing and have an afferent input to the respiratory 
motor groups o f the medulla (this is discussed in detail below). Hypoxia does have a global 
inhibitory affect on central ventilatory response. This effect has been attributed to a reduction 
in excitatory neurotransmitter such as acetyl choline (ACh), glutamate and glycine in favour 
of an increase in inhibitory neurotransmitters (y-aminobutyric acid (GABA), adenosine and 
serotonin). Specific antagonists o f these transmitters can partially ameliorate the effect 
suggesting a combined action o f these transmitters or other unknown influences. Another 
theory is that hypoxia results in a reflex increase in cerebral blood flow that may wash out 
CO2 and result in a depression o f central chemoreceptor drive [6 ]. Central hypoxic 
depression is only evident in adults under circumstances o f severe hypoxia, since peripheral 
hypoxic drive is dominant in these circumstances. Many details o f the functioning o f central 
ventilatory chemoreceptor remain unanswered. In contrast the work on peripheral 
chemoreeeptors in the last few years has revealed some of the fundamental mechanisms of 
oxygen sensing and signal transduction.
1.3.3 Peripheral chemoreeeptors; The carotid body
The peripheral chemoreeeptors form the oxygen sensing limb o f ventilatory control. The 
carotid body is the main oxygen sensor o f ventilatory control and section of its afferent 
nerves results in abolition o f hypoxic ventilatory response. The aortic body demonstrates 
some oxygen sensing capability, but has a negligible contribution to peripheral oxygen 
sensing; therefore it does not form part o f this review. The carotid body is located at the 
bifurcation o f the common carotid artery and receives its blood supply from a branch of the 
internal carotid artery. Each weighs around 1 gram, but in relation to their mass the carotid 
bodies have an abundant blood supply in the form of fenestrated sinusoidal capillaries 
organised into glomeruli. The generous blood supply means that most o f the cellular oxygen 
requirement is extracted directly from soluble oxygen rather than 0 % bound to haemoglobin; 
therefore the carotid body response is to arterial oxygen tension and remains unaffected by 
anaemia. Each capillary tuft is surrounded by an arrangement o f two cell types: type I and 
type II glomus cells. Glomus type I cells are responsible for oxygen sensing, whereas the 
type II cells seem to have a more sustentacular function; therefore the discussion, from this 
point on, will focus on the type I cells. Each glomus cell is rich in a variety of
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neurotransmitter substances and has a receptor/neuronal synapse with branches o f the carotid 
sinus nerve (a branch o f the glossopharangeal nerve) [13]. Sensory afférents relay 
information to the respiratory groups o f the medulla, predominantly to the nucleus o f the 
tractus solitarius (nTS).
It is generally accepted that the type I glomus cell is the transducer for oxygen tension in 
blood; however the glomus cell releases a number of neurotransmitters in response to 
hypoxia. These fall into several categories: biogenic amines (ACh, dopamine (DA), 
noradrenaline (NA), 5-hydroxytryptamine (5-HT)); neuropeptides (enkephalins, substance P, 
endothelins); ATP and amino acids (GABA) [14-16]. The role o f these transmitters is mixed 
and species specific: dopamine inhibits the activity of cat, but not rabbit carotid bodies; 
whereas acetyl choline is stimulatory in cats, but inhibitory in rabbits [13]. Currently, it is 
thought that dopamine and enkephalins are inhibitory neurotransmitters in humans, whereas 
substance P, ATP, noradrenaline and acetyl choline are excitatory [15].
Neurotransmitter release and membrane ion channels
The release of neurotransmitters in response to hypoxic stimulus is dependent on 
depolarisation o f the glomus cell membrane and secretion of transmitters into the synaptic 
space between glomus cell and branches o f the carotid sinus nerve [17]. The glomus cell has 
a resting negative membrane potential maintained by an electrochemical imbalance of ions 
across the membrane. Potassium (K"^ ) concentrations within the cell form a crucial part of 
this balance and efflux of K+ maintains the hyperpolarised state o f the cell. Potassium flux in 
glomus cells is maintained and regulated by several different classes o f potassium channel, 
those that exhibit sensitivity to hypoxia are: Kv channels (voltage gated), Kca channels (Ca^^ 
activated) and TASK like channels. Kv channels are activated usually by voltage changes 
or depolarisation across the membrane; whereas Kca channels open in response to an increase 
in intracellular Ca^^ (a result of membrane depolarisation). Two pore acid-sensitive (TASK) 
type K"^  channels are unlike the other channels in that they possess two transmembrane ion 
pores and remain open at negative membrane potentials.
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Figure 1.6. The carotid body with type 1 glomus cells in close apposition to the glomerular 
capillary and sustentacular type 2 cells. The type 1 cells contain neurosecretory particles that 
release into the synaptic cleft between carotid sinus nerve and glomus cell.
TASK channels appear to have a basal current o f K  ^and maintain basal membrane potential. 
TASK channels are not usually sensitive to hypoxia; however in the carotid body, channels 
with similar properties to TASK channels have been identified [18]. Inhibition o f these K" 
channels results in depolarisation o f the membrane and influx o f calcium through voltage 
gated L-type calcium channels (Long lasting Ca^  ^ channels). Calcium influx seems to be the 
critical event in glomus cell activation since calcium channel blockers inhibit the effect of 
hypoxia on glomus cells and activation of glomus cells is not possible without extracellular 
Ca^  ^ [19, 20]. Furthermore, dopaminergic release from glomus cells has been demonstrated 
in response to Ca^  ^influx [21].
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Which o f these channels is responsible for the agonal depolarisation event in response to 
hypoxia is yet to be discovered, though it may be that each plays a role in membrane 
depolarisation; however the question that has generated much debate between researchers in 
the field is: how is oxygen sensed?
Oxygen sensing in the carotid body
The coupling of oxygen tension to the observed changes in glomus cell ion channels remains 
unknown; however intense research in this field has proposed several plausible models for 
oxygen sensing and transduction o f this signal. The earliest of these is the role of the 
mitochondrion as an oxygen sensor [2 2 ], though alternative hypotheses o f reactive oxygen 
species generation (ROS) and membrane bound haem-oxidases have been proposed as 
alternative mechanisms of oxygen sensing. This is a brief review o f these different 
perspectives.
The evidence supporting mitochondrial involvement in oxygen sensing stems originally from 
the observation that uncoupling o f the ETC by mitochondrial poisons (see figure 1.4) results 
in an increase of carotid sinus nerve discharge [22]. Furthermore these uncoupling molecules 
result in inhibition of channel flux [18]. The suggestion is that ATP generation is an 
integral feature o f oxygen sensing; however work by Lopez-Barneo et al. suggests a different 
explanation. Their experiments demonstrate a quantal increase in neurotransmitter release in 
response to hypoxia and the mitochondrial uncouplers: rotenone, antimycin A, myxothiazole 
and cyanide (figure 1.4). They hypothesised that hypoxia in addition to an uncoupling agent 
would give an additive signal if each agent acted at a separate site; this they found for all the 
uncoupling molecules, except rotenone. Rotenone did not demonstrate any additional effect 
with hypoxia, suggesting its action at complex one o f the ETC; however the action o f other 
complex I antagonists did not reproduce these results. Furthermore, 1-methyl-4- 
phenylpyridinium (MPP^), a molecule which acts at the same site on complex I reproduced 
the effect. They surmised that another, yet unknown molecule, was crucial in glomus cell 
oxygen sensing and that this molecule was sensitive to rotenone [23]. This would seem to be 
supported by the fact that rotenone inhibits iC' channels in cells with no mitochondria [24].
The second theory proposes a role for ROS in the oxygen sensing signal pathway; however 
there is disagreement as to whether increases in ROS are stimulatory or inhibitory. Reactive
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oxygen species arise from either inefficiency in mitochondrial electron transfer or via the 
action o f cytoplasmic molecules such as NADPH oxidase. The molecules formed are 
superoxide ions (O2 ') which is transformed to hydrogen peroxide (H2 O2 ) by superoxide 
dismutase. This in turn is converted to water by catalase or glutathione peroxidase [25]. The 
problems with this model are the inconsistencies in ROS generation. Proponents of the 
NADPH oxidase pathway postulate that in normoxic conditions, the availability of O2 
facilitates the production o f ROS. In hypoxic conditions the production o f ROS is diminished 
thereby altering the REDOX state o f channels [26]. There is conflicting evidence to 
support this hypothesis, neuroepithelial cells demonstrate enhanced activity in knock out 
mice deficient in a NADPH oxidase subunit[27], but there are also reports that suggest either 
no effect or the opposite o f NADPH oxidase knockout[28].
The alternate model proposes increases in mitochondrial ROS generation in response to 
stalling o f the ETC at complex IV (due to the absence o f O2 for the final oxidation step). 
Reactive oxygen species can then form at complex I and complex III o f the ETC and the use 
o f antagonists at various points has demonstrated increased generation of ROS points before 
complex III o f the ETC [29]. The role o f increased ROS in the carotid body’s responses to 
hypoxia is further supported by studies in intermittent hypoxia. Under these circumstances 
there appears to be an amplification o f the hypoxic response which is inhibited by the effect 
o f superoxide dismutase [30].
Research in the field o f oxygen sensing at the tissue level is fertile as well as contentious, it is 
complicated by numerous factor, not least o f which is the variability in response of different 
tissues, let alone different species. The two models reviewed are currently the most favoured 
theories for oxygen sensing, other theories include direct oxygen sensing by ion channels and 
the effects o f nitric oxide and carbon monoxide (produced by haem-oxygenases) as 
intracellular second messengers [31], these have not been discussed here in detail since the 
purpose o f this review is to highlight the possible mechanisms in a field that is continually 
changing with new discoveries. As will be described in the section reviewing hypoxic 
pulmonary vascular responses, similar mechanisms have been proposed as a model for 
oxygen sensing; however the body o f work in this field is more extensive as is the 
controversy.
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1.3.4 Ventilatory signal transduction in the brainstem
The peripheral and central mechanisms o f chemosensation are integrated in the brainstem to 
affect response at the ventilatory motor centres located in close proximity. The relay 
pathways for central chemosensation remain unclear, though muscarinic neurones have been 
implicated in the transduction o f this signal [12]. The peripheral chemoreeeptors relay their 
afferent input to the nucleus o f the tractus solitarius and the first synaptic relays from the 
carotid sinus nerve to the brainstem reside in the nTS [32]. Retrograde tracer studies have 
identified several areas o f the nTS that receive dense innervation from peripheral 
chemoreeeptors. Furthermore, microinjection studies using neurotoxins at the commissural 
area o f the nTS demonstrated an attenuation o f the hypoxic response whereas lesions induced 
in other areas had no effect [33]. The nTS response during the early part o f the hypoxic 
ventilatory response appears to be mediated via the action o f excitatory amino acids, 
glutamate in particular. Inhibition o f N-methyl-D-aspartate (NMDA) glutamate receptors 
attenuates the hypoxic ventilatory response across several species [34-36]. The role of 
glutamate in the ventilatory response to hypoxia is also evident at points downstream from 
the nTS. The role of NMDA receptors in excitation of expiratory bulbospinal neurones has 
been demonstrated in dogs, and increases in phrenic nerve discharge seen in cat and rat 
models by both NMDA and non-NMDA mechanism [37-39]. The brainstem neural pathways 
have yet to be fully described; however the role o f the nTS appears to be central in the acute 
response to hypoxia.
1.3.5 Hypoxic ventilatoiy response
Ventilation increases in response to hypoxia as a response to hypoxaemia, as arterial oxygen 
partial pressures fall below 60 mm Fig the hypoxic ventilatory response (HVR) becomes the 
dominant drive to ventilation. The carotid bodies are responsible for this response, since in 
addition to hypoxia induced neurotransmitter release, the hypoxic response is abolished by 
carotid body denervation in a number of species [40] Hypoxic response eventually returns in 
these animals and this seems attributable to the aortic bodies assuming the role o f the 
peripheral chemoreceptor [41]. The denervation of both vascular bodies does not abrogate the 
hypoxic response either and there is evidence that suprapontine structures have the capacity 
to take over hypoxic sensation [42]. This suggests that there are several sensory systems for 
oxygen homeostasis, ‘hardwired’ into the ventilatory control system and underlines the 
importance of maintaining adequate cerebral oxygenation.
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The effect of hypoxic exposure can be seen within one breath o f PaOz change at the carotid 
body by increases in phrenic nerve discharge [43]. The hypoxic drive to ventilation results in 
a lower CO2 tension and a rise in pH as CO2  elimination is increased as a consequence. This 
has two effects: firstly there is reduced ventilatory stimulus at the central chemoreceptors; 
secondly there is a relative inhibitory affect upon the carotid bodies themselves. The carotid 
bodies are sensitive to lower pH and higher CO2 ; in combination with acute hypoxia, both 
have a synergistic effect and enhance the carotid response to hypoxia [40]. A decrease in this 
stimulus has the potential to attenuate the carotid body response to hypoxia. In addition, the 
hypoxic response demonstrates a biphasic response, with the initial rise in ventilation 
declining with time to a level above normoxic ventilation in adults. This is independent o f the 
effects o f CO2 , since isocapnic experiments have shown this to be a truly hypoxia dependent 
phenomenon [44, 45]. The time course of the decline occurs between 5 and 30 minutes of 
hypoxic exposure and has been attributed to mechanisms within the central nervous system 
[43, 46]. An attenuating effect on the hypoxic ventilatory response may result either from a 
decreased CO2  stimulus or direct effects on the ventilatory centres; however the net effect is 
an increase in ventilation in response to acute hypoxia. Once dissected out using isocapnia, 
the relationship between ventilation and arterial oxygen tension is hyperbolic. In contrast the 
relationship between ventilation and oxygen saturation is linear down to saturations of 70%, 
mainly as a result o f the sigmoid nature o f the oxygen dissociation curve. These responses 
are seen in all mammals, including man. Furthermore, there is a marked reproducibility o f the 
acute hypoxic ventilatory response for an individual, but a wide variation between 
individuals. [47].
With more prolonged exposure, over days and weeks there is a further increase in the 
hypoxic ventilatory response and enhancement o f glomus cell responsiveness is thought to be 
contributory [48]. Inhibition o f dopaminergic neurotransmission at the carotid body as a 
possible mechanism has also been examined, and though there is some evidence to support 
this model in cats [49], there is lack o f evidence in humans [50]. The responses described are 
over the first few minutes then days and weeks o f altitude exposure. It is o f interest that a 
lifetime’s exposure to altitude can result in a blunted response to hypoxia. The change is 
associated with a diminished hypercapnie drive and in some subjects a near absence o f HVR 
[51].
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1.4 Skeletal m uscle function  and adaptation
The previous sections have described the processes of energy generation at the cellular level 
and the influences that O2 demand and CO2 elimination impose on the control mechanisms of 
ventilation. Ventilatory control is tightly coupled to CO2 production in normoxic conditions; 
whereas oxygen demand is the driving force to ventilation in hypoxic conditions. The 
dynamic nature of exercise both in terms o f onset and variability in intensity has profound 
effects at both the cellular and the ventilatory level for these reasons. The following section 
considers the function and demands of respiring muscle, as well as the utilisation of substrate 
for energy generation, before considering the effects exercise has on ventilation under both 
conditions o f normoxia and hypoxia.
1.4.1 Structure
Skeletal muscle mainly comprises o f regimented arrays of muscle fibres or myocytes 
arranged in parallel, each fibre is a multinucleated cell encapsulated by a cell membrane or 
sarcolemma. Each muscle fibre consists of numerous myofibrils, the functional unit o f which 
is the sarcomere. Myofibrils contain 4 main proteins: myosin, actin, tropomyosin and 
troponin. Myosin forms thick filaments which interdigitate with actin thin filaments. There 
are binding sites on actin for ATPase subunits o f the larger myosin molecule; the interaction 
between the two is prevented at rest by tropomyosin, which covers these binding sites. 
Troponin is attached to tropomyosin; contraction depends on an influx of Ca^^ which binds to 
troponin and results in a shift in tropomyosin, revealing the myosin binding sites. The 
ATPase subunits on the myosin molecule then attach themselves and ATP is hydrolysed; this 
results in shortening the myofibril by moving thick filaments along the actin filaments. Once 
ATP is hydrolysed the myosin head uncouples from actin, the process is repeated as long as 
Ca^^ and ATP are available. Muscle contraction is initiated by depolarisation o f the 
sarcolemma and conduction along T-tubules that penetrate from the sarcolemma, this results 
in the release o f intracellular Ca^’*' from stores held in the sarcoplasmic reticulum. The 
termination of contraction is dependent on the removal of Ca^ "^  into the sarcoplasmic 
reticulum and is an active process, requiring energy. Muscle fibre depolarisation and 
contraction is under the control o f motor neurones, which synapse on the fibres at the motor 
end-plate. Multiple muscle fibres are innervated by a single motor neurone and constitute a 
motor unit.
50
1.4.2 Muscle fibre types
The basic architecture o f myocytes is the same in every skeletal muscle, but there are 
different sub-populations of myocyte. There are two main types o f muscle fibres in humans; 
type I and type II. They differ in the speed o f contraction, oxidative capacity and substrate 
stores. Type 1 or ‘slow twitch’ fibres are characterised by a slower activity in myosin 
ATPase, troponin activity and calcium re-uptake to sarcolemma. They have greater stores o f 
myoglobulin, lipid and higher levels of oxidative enzymes; hence they are geared for 
oxidative function and are slower to fatigue. Type 11 or ‘fast twitch’ fibres are more 
dependent on glycolysis for energy generation, as a consequence have fewer mitochondria 
and little myoglobulin stores. These cells posses a faster myosin heavy chain isoform than 
type 1 cells [52]. Furthermore, type II myocytes are further subdivided according to their 
speed of contraction and their dependence on oxygen for energy generation. These are 
identifiable by different myosin heavy chain isoform, types Ila, llx and 11b, with varying 
oxidative capacity from high to low [53]. The slow twitch fibres are presumed to have a 
greater role to play in sustained work, maintenance o f posture and have better endurance than 
the fast twitch fibres. In addition, the distribution of fibre type differs according to the 
location and function of the muscle. There is a capacity for switching between muscle fibre 
types and the transition between type II fibre types can be stimulated by physical training and 
muscle stretching; this process has been attributed to the degree o f Ca^ "^  influx related to the 
frequency of depolarisation events [54]. The switch between type 1 and type 11 cell types in 
humans is less straight forward. Muscle fibre subclasses differ not only in their biochemical 
structure, but also in their innervation. It appears that the neurones that innervate a particular 
motor unit can determine the properties o f those muscle fibres. The switch between slow and 
fast fibres by cross innervation was first demonstrated by Vrbova in 1963 [55], and there is a 
demonstrable difference in the motor neurone morphology innervating these types of fibre 
[56]. Nevertheless, the transition between type 1 and 11 suggested by animal experiments does 
seem to occur in humans [57, 58].
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1.4.3 Muscle adaptations to hypoxia
The different types and subtypes o f muscle fibre represents a level of individual variability in 
the response to exercise and the potential effects of hypoxia on exercise; furthermore the 
composition o f muscle is amenable to the effects o f physical training and therefore is not a 
fixed entity for an individual. Aside from the type o f myosin chains expressed in these fibres
f
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the concentrations o f mitochondria, myoglobulin and capillary density have implications for 
oxidative capacity and endurance during exercise. These demonstrate plasticity in response to 
exercise and hypoxia. Endurance training results in an increase in muscle size, mitochondrial 
concentration and capillary density. The effects of activity at altitude are somewhat different. 
Animal experiments demonstrate loss o f muscle mass on hypoxic exposure [59] which is also 
evident in humans [60, 61]. Exposure to high altitude over a period o f 2 months, such as that 
encountered on mountaineering expeditions, resulted in a loss o f body mass with a similar 
decrease in muscle volume. The loss in muscle mass was reflected in a decrease in muscle 
cross-sectional area of around 2 0 % [62], a similar decrease in both type 1 and 11 fibres was 
reported during the hypobaric chamber study: Operation Everest 11 [63], but there was no 
evidence o f transition from Type 1 to Type II fibres [64]. Capillary density increases with 
altitude exposure, but the same studies demonstrate the fibre to mitochondria ratio is 
preserved. The effect is thought to reflect muscle atrophy in hypoxia rather than 
neovascularisation. The muscle mitochondria are also diminished with similar altitude 
exposures, with a proportional loss of sub-sarcolemmal mitochondria in preference to 
interfibrillar populations [62]. The combined effect o f this duration o f exposure is a reduction 
in diffusion distance, but also a reduction in the oxidative capacity o f muscle; however the 
maintained capillarity could reflect improved oxygenation o f the remaining mitochondria. 
Though the responses described are not a significant factor during short exposures to 
hypoxia, they are an important feature during longer exposures o f hypoxia (weeks rather than 
minutes).
1.4.4 Muscle metabolism
The fundamental mechanisms for energy generation at the respiring muscle are the same as 
those utilised by all tissues, but there are some particular considerations in reference to 
muscle. Firstly, the energy requirement o f muscular contraction at the onset of exercise is 
rapid; however the absolute quantities of ATP in the myocyte are relatively small and are 
insufficient to meet this demand. Muscle fibres contain a store o f energy in the form of 
phosphocreatine a molecule present in myocytes which also possesses a high energy 
phosphate bond. Cleavage o f this molecule provides the energy for the regeneration o f ATP 
during initial muscular contraction. Again there are only limited intracellular stores of 
phosphocreatine which are quickly consumed on commencing exercise, but these are also 
regenerated by ATP once the processes of cellular respiration have increased to meet
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muscular demand. Phosphocreatine is a weak acid in its phosphorylated state and its 
consumption at the onset o f exercise results in a net increase in intracellular pH early in 
exercise.
ADP + P i -N. X" Phosphocreatine
ATP ^  ^  Creatine+P/
Myofibril
Figure 1.7. The phosphocreatine shuttle
Secondly, the mass of muscle used in physical activity can be considerable, with a sudden 
increase in oxygen demand and substrate utilisation; the net effect o f these metabolic changes 
at the cellular level are reflected in the individual’s oxygen consumption (VO2 ) and carbon 
dioxide production (VCO2 ). The type of substrate used for respiration, determines the 
stochiometric relationship between the amount of oxygen required for its complete 
metabolism and the CO2 produced in the process. This can be described by tlie ratio of VO2 
to VCO2 to give a respiratory quotient (RQ) for a particular substrate. In the earlier 
discussion, where glucose is metabolised, oxygen consumption and carton dioxide 
production is stochiometrically equal; this gives an RQ of 1. In muscle, after stored glycogen, 
lipids form the next most abundant store of substrate for respiration. Palmitic acid is a free 
fatty acid which when metabolised aerobicall, liberates 16 molecules of CO2 , using 23 
molecules of O 2 to give an RQ  o f 0.73. In oxygen terms, FFA is a costly substrate, but more 
efficient in terms o f CO2  production. In nonnoxia CO2 tensions are the dominant stimulus to 
ventilation and therefore lipid metabolism can be viewed as less of a ventilatory burden; 
fiutliermore each molecule o f palmitate gives rise to 130 molecules o f ATP, which makes 
lipid an ideal substrate store for myocytes. In reality the average western diet results in an RQ 
ofO.8 .
Measuring oxygen consumption and carbon dioxide at the cellulai' level is not usually 
peifonned, nor is it a feasible undertaking in an exercising system; tlierefore RQ  is usually
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inferred from the measurements o f V0% and VCO2 to give a gas exchange ratio (R). The 
implications o f using R as a surrogate indicator of gas exchange at the cellular level are 
important when the body’s capacity for CO2  storage is taken into account. The body’s storage 
capacity for CO2 also carries implications for CO2 coupling o f ventilation to pulmonary gas 
exchange during exercise.
1.5 D ynam ic changes in ventilation  during exercise
1.5.1 Phase one & two of the ‘on-transient’
At the onset of exercise there is an increase in oxygen demand and carbon dioxide 
production. Ventilation also increases at the onset o f exercise, but the changes exhibited are 
not entirely coupled to metabolic change. During low to moderate intensity constant-load 
exercise VO2 , VCO2 and ventilation ( Y e) all increase before levelling out once steady state is 
achieved. This period, termed the ‘on-transient phase’, is further characterised by two phases. 
Phase one (or early dynamic phase) occurs immediately at the onset o f exercise, with a near 
instantaneous increase in ventilation [65] and VO2 (in response to a corresponding increase in 
cardiac output and pulmonary blood flow), the mechanism remains unclear since the time 
course is too rapid to be linked to muscle metabolism. Historically this effect has been 
attributed to neurogenic factors originating from exercising limbs and directly affecting the 
respiratory centres, but the degree o f initial hyperpnoea is relatively constant and independent 
of the number o f exercising muscle units since increasing load produces no demonstrable 
increase in initial hyperpnoea [6 6 ]. Furthermore there is an observed increase in ventilation 
on commencing unloaded exercise, but no additional hyperpnoea component when a load is 
subsequently imposed [67]. Phase one lasts from 10-15 seconds before the onset of phase two 
or late-dynamic phase which does demonstrate a relationship between muscle metabolism 
and gas exchange at the lung. VO2  increases in a mono-exponential fashion, but increase in 
VCO2 has a demonstrable lag, and since ventilation and arterial CO2 are coupled there is also 
a lag in Vg. This is due to the capacity for CO2  storage in muscle itself and the blood flowing 
from a respiring muscle [67]; therefore VCO2 only demonstrates an increase once these 
stores are saturated. This means that the CO2 drive to ventilation temporarily lags behind the 
increase in VO2 during exercise and as a consequence there is a brief transient hypoxaemia at 
this point [6 8 , 69].
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1.5.2 Carotid body influences
Phase one occurs during the first few seconds of exercise, whereas the duration o f phase two 
can demonstrate some variability. The carotid bodies have an influence on this time course, 
as demonstrated by experiments designed to influence carotid body input. Carotid body 
stimulation using hypoxia or metabolic acidosis (by ammonium chloride ingestion) can 
shorten phase two duration [70, 71]; whereas reducing peripheral chemosensitivity with 
hyperoxia, metabolic alkalosis (by sodium bicarbonate ingestion), dopamine infusion or 
bilateral carotid body resection can lengthen the duration [70-74]. At low and moderate 
exercise intensities (i.e. below anaerobic threshold) metabolic and ventilatory variables 
stabilise at a ‘steady-state’ level, this is labelled ‘phase three’ exercise. The transition through 
phase one and two on to steady state is usually complete in the first 3-4 minutes of exercise 
during low to moderate intensity exercise. During high intensity, exercise steady state is not 
achieved because of lactate accumulation. Identifying and correctly labelling the point at 
which lactate contributes significantly to the metabolic influence on ventilation-gas exchange 
coupling has been a topic of controversy.
1.5.3 Anaerobic, Lactate and Ventilatory Thresholds
Exercise at low to moderate intensity with a constant load eventually results in steady state; 
however serial increments in the work load would eventually reach a point where steady state 
could not be attained before exercise is terminated because o f fatigue (figure 1.8). The 
reasons for muscle fatigue are manifold, but in the simplest o f terms the oxygen supply to the 
muscle is outstripped by demand. The effects o f cardiac output limitation and circulatory 
variations across the exercising muscle as a contribution to lactate build up are discussed in 
the review of cardiovascular considerations during exercise further in this chapter; however 
the importance o f oxygen in the increased rate o f lactate production is demonstrable by 
experiments with various inspired oxygen concentrations. Hyperoxia delays the onset of 
lactic acidosis for a given work rate, whereas hypoxia reduces the lactate threshold and 
increases the concentration of lactate for a given high intensity work rate [75]. The emphasis 
is on the rate o f production, since lactate is utilised as an energy source in muscle (in the 
presence of oxygen) and by the liver for gluconeogenesis. Lactate accumulates when 
production outstrips demand; the point o f increased lactate production can be measured 
directly by arterial blood sampling, either from an exercising muscle group or the whole 
body. This requires sampling o f blood via an arterial or venous catheter and then
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measurement o f lactate biochemically. Modern blood gas analysers with lactate electrodes 
are capable of performing this measurement quickly and reliably. This makes real time 
measurement o f lactate feasible, but there is an inherent time course from the onset o f net 
anaerobic respiration at the muscle to a measurable increase in lactate. The point at which 
this occurs was called the anaerobic threshold (AT), but a more accurate description is the 
lactate threshold (LT).
400  w atts
100 w atts
50 w atts
25 w atts
Time
Figure 1.8. VO2 increases with work loads in serial steady state exercise tests (25, 50 and 
1 0 0  watts). In situations which are at the highest work intensity above anaerobic threshold, 
steady state is not achieved because exercise is terminated by fatigue (400 watts).
The increased rate o f lactate production also has effects on ventilation and gas exchange. The 
ionised lactate liberates ions which are predominantly buffered by bicarbonate. This 
generates CO2 which stimulates an increase in ventilation and eliminates the excess CO2 in 
expired gas. Calculations based on the proportion o f CO2 produced for aerobic and anaerobic 
mechanisms o f respiration during the production o f the same amount o f ATP, result in an 
estimated 2.5 fold increase in CO2 production [76]. The term ‘isocapnic buffering’ is used to 
describe this portion o f high intensity exercise, since arterial CO2 tension is maintained at a 
constant level through the coupled increase in ventilation; however VO2 is not coupled to
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ventilation in normoxic conditions and there is a divergence o f VO2 from VCO2 and 
ventilation. This point is evident during incremental exercise tests and is the central basis for 
non-invasive estimation o f anaerobic threshold at high work intensity. The term used for the 
point o f divergence is the ventilatory threshold (VT) and can be determined by a number of 
measured and calculated variables from a standard incremental exercise test. A plot of VO2 
against VCO2 demonstrates an inflection point at the ventilatory threshold (Figure 1.9); 
monitoring end-tidal CO2 (PetC02) and end tidal O2 demonstrates a similar divergence with 
an increase in PetC02 at the VT. The degree of increased ventilation is reflected in the 
efficiency of ventilation to clear CO 2 and is determined by the alveolar CO 2 and arterial CO2 
partial pressure gradient or ‘set-poinf at the onset of exercise (PaC 0 2  and PaC0 2  
respectively) and the amount o f physiological dead space ( V d/V j ) . Calculated values such as 
ventilatory equivalents for CO2 and O2 are useful indicator for this and represent ventilation 
in relation to CO2  production and O2 consumption (VeCOi and Ve0 2  respectively).
VeVC02 = Ve/VC02  
VeV 0 2 = V e /V 0 2
As VCO2 and Ye are coupled (allowing for the small variations in body CO2  stores) then 
there is little discernable change in VeVC02 when VT is reached, however the marked 
increase in ventilation is evident in the ventilatory equivalent o f oxygen since VO2  is not 
coupled to ventilation (in normoxia) there is a marked increase in VeV02. Furthermore the 
effects o f CO2 storage in the body has to be taken into account since there is evidence that 
altering pre-test stores using measures such as hyperventilation can affect estimation o f VT 
[77].
The use o f gas exchange measurements to non-invasively estimate AT has limitations, but is 
useful as long as these limitations are taken into account, consequently it is important to 
make a clear distinction between the two and the term ventilatory threshold (VT) is used for 
this inferred measure of AT. Furthermore exercise at work rates below the anaerobic 
threshold (providing they are at constant load) allow the entire system o f ventilation, oxygen 
delivery and consumption to reach metabolic homeostasis or ‘steady state’; this is termed 
‘Phase three’ exercise. For the purposes o f the studies performed in this thesis measurement
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of the VT was used to determine a level of exercise that would be high enough to provide a 
useful stressor, but not sufficient to result in anaerobic respiration and its effect on 
ventilation.
VC02
Figure 1.9. A panel from a standard incremental exercise test. The plots VO2 against VCO2 
(right hand vertical axis), the vertical bar demonstrates tlie inflection point at the ventilatory 
threshold.
1.5.4. Hypoxic ventilatory responses during exercise
The discussion thus far has described the response of ventilation to hypoxia and exercise, as 
well as the interaction o f PaC0 2  and Pa0 2  at the central and peripheral chemoreceptors. 
Acute hypoxia during exercise further augments the increase in ventilation normally coupled 
to VCO2, but under hypoxic conditions the increase in ventilation during exercise is mediated 
by the carotid bodies rather than CO2 drive to the brainstem [78-80]. The effects of diffusion 
limitation at the lung and muscle under conditions of ambient hypoxia and the resultant 
hypoxaemia are discussed in the section dealing with cardiovascular response; however, 
exercise under such conditions increases the degree of hypoxaemia through increases in O2 
extraction, hence further stimulation o f the carotid bodies. Carbon dioxide and pH changes 
during hypoxic exercise certainly have an influence on the response both in absolute terms 
and in the dynamic phases of exercise. The interpretation o f incremental exercise under
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conditions of hypoxia is complex given the variables, but the tests performed as part o f the 
experiments described later were designed to exercise under constant load at low to moderate 
exercise intensity in order to avoid exercising above the VT, even under conditions of 
hypoxia. This was deliberate, in order to ensure steady state for measurements, but also to 
avoid the dynamic shifts in PaCOi and pH that might further influence carotid body drive to 
ventilation if anaerobic muscle metabolism were to become dominant. However at work rates 
below VT and at steady state the effect o f an augmented carotid body stimulus increases total 
ventilation for a given work load, whilst reducing PaCOz and raising pH; indeed it is one 
compensatory measure to overcome the effects of pulmonary diffusion limitation [80].
A final point is that as during normoxia the use o f lipid substrate stoichiometrically produces 
less CO2 per molecule of O2 than the use o f glucose (23 0% & 16 CO 2 vs. 6 O2 & 6 CO2 for 
the metabolism o f palmitate and glucose respectively). A consequence is a reduced burden on 
ventilation during normoxia; however ventilation is dependent on hypoxaemic drive during 
hypoxic exercise, hence palmitate would not be an ideal substrate in hypoxic environments 
because o f the heavier oxygen burden it incurs. This suggests that carbohydrate, as a source 
of substrate, is a more efficient choice.
1.6 The pulmonary circulation: adaptations to hypoxia and exercise.
The fundamental necessity of oxygen in energy generation has been described, as have the 
mechanisms required to ventilate air from the environment to the gas exchange surfaces. The 
following section reviews the convective mechanisms that circulate blood across the lung and 
then deliver oxygen bound to haemoglobin in that blood to the respiring tissues. Each 
circulatory system is intrinsically bound to the other, but is very different in their responses 
to hypoxia. Both are reviewed in the following sections, with a particular emphasis on the 
pulmonary circulation and the cardiac output response to exercise and hypoxia.
1.6.1 The Pulmonary circulation
In contrast to the systemic circulation the role o f the pulmonary circulation is to efficiently 
circulate deoxygenated blood from the body via the right side o f the heart and through the 
pulmonary capillaries to allow oxygenation. The function of gas exchange necessitates the 
reduction o f impedance to diffusion wherever possible; consequently, the lung has evolved a 
thin and attenuated interstitial space, minimizing the distance between the alveolar space and 
the pulmonary capillary lumen. In order to perfuse such a system without resulting in
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haemodynamic stress and capillary damage, the pulmonary circulation has evolved into a 
low-pressure, low resistance system; this is not to say that it is not capable o f accommodating 
high blood flows. The systemic circulation supplies the entire body, from the resting state up 
to and including exhaustive exercise; however the dramatic increases in cardiac output would 
not be possible without a matching preload at the left ventricle. This arrives at the left cardiac 
chambers after oxygenation by the lungs; therefore, even at maximal exercise the right sided 
cardiac output must match the left, and the pulmonary circulation must be able to 
accommodate this flow.
The pulmonary circulation is unique in its vasoconstrictor response to hypoxia (hypoxic 
pulmonary vasoconstrictor response or HPVR); this enables the matching of pulmonary 
blood flow to well ventilated segments o f lung. The response is to alveolar hypoxia, as 
opposed to hypoxaemia, as seen in experiments using simultaneous, but separate ventilation 
of the left and right lung. A rise in pulmonary vascular resistance (PVR) is demonstrable in 
the hypoxic lung whilst normal flow is maintained in the hyperoxic lung (FiOz 100%); this is 
in the absence o f mixed venous oxygen desaturation during unilateral hypoxia [81]. The 
HPVR has a function in the transition from the in utero environment, where the foetus’s 
oxygen requirements are met by the maternal circulation via the placenta. There is little need 
to ventilate the lungs in a fluid environment and the lungs remain in a collapsed state; 
consequently they have a high vascular resistance. Outflow from the right ventricle bypasses 
the lungs via the ductus arteriosus and into the aorta. At birth, with the first breath of life, the 
lungs expand with air causing the pulmonary vascular resistance to drop. In addition, the 
oxygen rich environment causes pulmonary vasodilatation and a further drop in vascular 
resistance; this causes right ventricular blood flow to enter the lungs, bypassing the ductus 
arteriosus, which closes [82]. In post-uterine life, the benefits o f the HPVR are optimization 
of pulmonary perfusion to alveolar ventilation ( V a ); this is especially relevant in humans due 
to the erect posture. Pulmonary blood flow favours the bases because of the effects of 
gravity, but despite the better ventilation (due to diaphragmatic contraction), blood flow is in 
excess o f alveolar ventilation. Therefore, there is variation in ventilation and perfusion across 
the lung. The hypoxic pulmonary vascular response ameliorates this situation by diverting 
blood from poorly ventilated segments of lung to better ventilated segments; however, even 
in an optimized state o f perfusion to ventilation, ratios are estimated at 0.8. A further 
adaptive benefit o f the HPVR is implicit during illnesses that cause pulmonary atelectasis, 
such as acute asthma or pneumonia, where the shunting o f blood from affected or diseased
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segments o f lung to well ventilated regions could influence recovery or survival. Animal 
models o f such conditions confirm the shunting of pulmonary blood flow away from these 
poorly ventilated areas whilst maintaining oxygenation [83].
1.6.2 Pulmonary vascular responses to hypoxia
Isolated lung specimens demonstrate elevated pulmonary artery pressure (PAP) within 
seconds o f hypoxic challenge [84] and vary according to the degree of hypoxia [85]. A rise in 
pulmonary artery pressure and vascular resistance are seen during right heart catheter studies 
in hypoxic conditions; this occurs in the absence o f raised pulmonary capillary wedge 
pressure (PCWP) and indicates the effect is due vasoconstriction in the pre-capillary vessels 
[86-88]. In vitro pulmonary artery specimens [89, 90] and cultured pulmonary artery smooth 
muscle cells (PASMC) [91] contract in hypoxic conditions; however there is controversy 
surrounding the mechanism of pulmonary vasoconstriction and the role of the endothelium in 
this response.
Hypoxic pulmonary vasoconstriction is a rapid process, which demonstrates a biphasic 
response; an initial phase o f vasoconstriction is seen that lasts between 10-15 minutes which 
then subsides, but not to baseline levels. A second slower phase then develops which reaches 
a maximum at 40 minutes [92]. Phase one is evident in isolated pulmonary artery smooth 
muscle cells (PASMC) and in specimens denuded of the endothelium; however the slower 
sustained phase two does require the presence o f an intact endothelium. [93-95]. These 
findings suggest the importance o f the endothelium in effecting phase two o f the HPVR; 
however a more recent report by one group disputes this and suggests that there is a 
monophasic response which is independent o f the endothelium [96]. The distinction this 
group makes is that hypoxic vasoconstriction is a property o f PASMCs and that the 
endothelium acts by modulating this effect. This disagreement is yet to be resolved; however 
it does lead to the second point o f controversy surrounding the HPVR: what is the 
mechanism o f pulmonary artery vasoconstriction and how is hypoxia sensed in the 
pulmonary circulation?
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Pulmonary arterial smooth muscle responses to hypoxia
Smooth muscle activity in common with all muscular contraction is dependent on cell 
membrane depolarisation and the subsequent influx o f calcium ions. PASMCs have a resting 
membrane potential between -40 to -60 mV, the potential difference is the result o f ion 
differences across the membrane. Key to maintaining this potential difference is membrane 
bound potassium channels and in this they share a similarity with carotid body glomus cells; 
however they do differ in the types o f potassium channels. Whereas Kca+ channels are an 
important factor in carotid bodies, they are not a major influenee in maintaining PASMC 
trans-membrane potential in the adult [17, 97]. Voltage-gated K^ (Ky) channels appear to be 
the oxygen responsive channel in PASMCs; there are several families o f Ky channel, each 
with several isoforms (denoted by the nomenclature Ky l.x - Ky 9.x) [98], O f these, the Ky 
1.5 and 2.1 appear to be responsible for the HPVR [17, 96]. These channels maintain an open 
state at resting membrane potentials, allowing K^ efflux from the cell (down an intracellular: 
extracellular concentration gradient of 145mM to 5mM), thereby hyperpolarising the cell 
membrane. Hypoxia inhibits this effect and allows membrane polarity to rise, once the 
critical trans-membrane potential o f -30mV is reached calcium channels are activated and 
allow the influx o f Ca^ "^  into the cytoplasm. In addition to Ky channels, a population of 
TASK-like channels are also expressed in PASMCs (similar to those described in type 1 
glomus cells). These have a demonstrable response to hypoxia and seem to form part o f the 
HPVR seen in PASMCs [99].
There are points o f controversy in this simplified pathway: what are the mechanisms of 
oxygen sensing; which K^ channel is responsible for the agonal depolarisation seen during 
HPVR and does depolarisation release intracellular Ca^^ stores in addition to extracellular 
stores? The question of which channel is responsible for the HPVR remains hotly contested, 
whereas the question o f oxygen sensing in PSMCs and the role o f calcium in the HPVR is 
reviewed below.
Oxygen sensing in pulmonary artery smooth muscle.
The actual mechanism o f oxygen sensing during hypoxic vasoconstriction remains disputed, 
K^ channels possess domains that have potential oxygen sensing capabilities; however there 
is no direct evidence that they are solely responsible for signal transduction. The focus has 
direct towards the role o f ROS and mitochondria, similar to the mechanisms discussed in 
carotid body signal transduction. Initial theories that mitochondria themselves are responsible
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for HPVR through impaired production of ATP are not supported simply because the degree 
o f hypoxia required to elicit the HPVR is not sufficient to limit mitochondrial ATP 
production significantly[100, 101]. The observed effects of ETC inhibitors that mimic HPVR 
[102] and attributed to this role have now been reinterpreted in light o f the emerging role of 
ROS as intracellular second messengers for oxygen sensing [96]. Similar to the debate on 
carotid body oxygen sensing mechanisms, the controversy centres on whether an increase or 
decrease in ROS is responsible for oxygen sensing. The focus has been the role of 
mitochondria as a source o f ROS, at complex I and III of the ETC. These issues have been 
recently reviewed at length and many discrepancies between conflicting studies have been 
attributed to differences in method; however the role of the ETC in the generation of ROS 
and their importance in oxygen sensing in PASMC is generally agreed [96, 98, 103].
Calcium influx/ release and PASMC contraction
Calcium is as essential for contraction in smooth muscle as it is in skeletal muscle. The 
source of calcium for contraction was thought to be predominantly extracellular through the 
action o f voltage operated L-type Ca^ "^  channels (VOCC), in response to membrane 
depolarisation elicited by channel inhibition by hypoxia [104, 105]. This model of 
activation is supported by the observed attenuation o f pulmonary hypertension in suffers of 
chronic pulmonary disease by L-type channel blockers (e.g. Nifedipine) [106]; however 
intracellular stores o f Ca^^ are also an important contributory source for PASMC activation 
[107]. Depletion experiments have shown the importance of calcium release from the 
sarcoplasmic reticulum of PASMCs and their contribution to HPVR [108, 109]; furthermore 
depletion of these stores facilitates extracellular Ca^ "^  influx (whilst these stores remain 
deplete) and form a basis for sustained contraction during prolonged hypoxic exposures [110, 
111]. The channels responsible for what is termed ‘capacitative calcium entry’ are labelled 
store operated Ca^^ channels (SOCC) and their contribution to HPVR has recently been 
described [112]; furthermore inhibition of these store operated Ca^ "^  channels inhibits HPVR 
by pulmonary artery smooth muscle [113].
Similar to skeletal muscle, calcium is required for contraction; however the mechanism of 
excitation-contraction coupling is different. Smooth muscle contains actin and myosin as in 
skeletal muscle, but contraction is modulated by calcium-calmodulin dependent myosin light 
chain kinases (MLCK) which phosphorylate myosin light chains, thereby enhancing myosin
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ATPase activity and contraction [114], Myosin phosphorylation therefore has a direct 
influence on contraction dependent on the balance between phosphorylation and 
dephosphorylation (mediated by myosin light chain phosphatase -  MLCP). Rho-kinase is an 
inhibitor o f MLCP and pushes the balance towards myosin light chain phosphorylation; 
therefore enhancing contraction. Rho-kinase is activated by the binding of RhoA, a small 
monomeric G protein. Rat lung models and isolated PASMC demonstrate inhibition of 
sustained contraction to hypoxia in the presence of Rho-kinase inhibitors [115]; furthermore 
Rho-kinase is activated by hypoxia in a RhoA dependent manner which can be inhibited by 
specific antagonists [116]. This suggests an integral role for Rho-kinase 
The role of the various caleium channels in the HPVR adds a further level o f complexity to 
the controversy surrounding oxygen sensing and channel contributions to the pulmonary 
vascular responses; however this is an area of intense research and as with carotid body 
mechanisms developments can only be anticipated.
1.6.3 Endothelial influences on the pulmonary circulation
The role of the endothelium has fallen from the forefront of research in hypoxic pulmonary 
vascular responses; however the endothelium does exhibit an effect in response to hypoxia. 
The release o f mediators in response to hypoxia is a demonstrable fact, whether these play a 
direct role in the HPVR or modulate the effect is currently a point o f disagreement. The 
following section reviews some o f the mediator that have such a role, it is by no means 
exhaustive, but the molecules discussed have been studied in the context of hypoxic 
pulmonary vascular response.
Nitric oxide
Nitric oxide was first characterised as endothelium derived relaxing factor in 1987, but since 
then its role in numerous biological systems other than vasodilatation have become apparent. 
It is produced by nitric oxide synthase (NOS) which occurs in several different isoforms 
dependent on which role NO is filling. Two main forms of NOS occur, Ca^Vcalmodulin 
dependent or constitutive (cNOS) or Ca^ "^  independent or inducible form (iNOS). cNOS is 
stimulated by bradykinin, acetylcholine, histamine, leukotrienes and platelet activating factor. 
iNOS is regulated at the transcriptional level and iNOS mRNA production is a response to 
pro-inflammatory mediators such as interferon (INF), tumour necrosis factor a  & p (TNF) 
and interleukin-1 (Il-l). In addition to smooth muscle relaxation, NO plays a role in
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immunity, inflammation, neurotransmission and hormone release. In the lungs macrophages, 
neutrophils, mast cells, non-adrenergic non-cholinergic inhibitory (iNANC) neurones, 
fibroblasts, vascular smooth muscle cells, pulmonary arterial and venous endothelium and 
pulmonary epithelial cells are capable o f producing NO.
Nitric oxide’s role in hypoxic vasoconstriction has been demonstrated by attenuated hypoxic 
pulmonary vasoconstriction in response to inhaled NO in both animal models [117] and man. 
Experiments using infusions o f N  ^-monomethyl-L-arginine (L-NMMA), a competitive 
inhibitor o f NOS, produced vasoconstriction in normoxic and hypoxic conditions in the 
pulmonary circulation and diminished the systemic vasodilator response to hypoxia [118]. 
Transgenic mouse models deficient in endothelial NOS (eNOS) or nitric oxide synthase 3 
(NOS-3) demonstrate raised PAP, increased pulmonary vascular resistance in response to 
hypoxia when compared to wild type mice or NOS deficient mice raised in normoxic 
conditions [119, 120]. These mice also demonstrate increased muscularisation o f pulmonary 
arterial wall and increased right ventricular mass, changes which were preventable with the 
administration o f inhaled nitric oxide. Therefore nitric oxide plays an integral part in the 
maintenance o f basal vascular tone in the pulmonary circulation; however NO has numerous 
other roles, including second messenger functions and indirect influences on vasopressive 
mechanisms [121].
Endothelin
Endothelins are a family of potent vasoactive peptides produced in response to various 
stimuli included amongst these is hypoxia. Endothelin-1 (ET-1) was the first to be discovered 
[122] and the most widely studied. Endothelin-1 is produced by endothelin converting 
enzyme (ECE) from a peptide precursor, big ET-1. ET-1 mediates its effects through two 
types of endothelin receptor, endothelin A (ETa) and endothelin B (ETb). ETa receptors are 
found on pulmonary smooth muscle cells and causes vasoconstriction and proliferation of 
cultured smooth muscle cells [123, 124]. Endothelin-1 is produced in the lung by endothelial 
cells, epithelial cells and tissue macrophages, but the secretion o f ET-1 by endothelial cells is 
mainly abluminal [125], directed towards the muscular media, in vivo. Hypoxia is a potent 
stimulus for the production and release o f ET-1 [126, 127] and levels o f ET-1 are elevated in 
normal individuals exposed to hypoxia as well as in patients with hypoxic lung disease [128]. 
Furthermore other vasoactive mediators can modulate ET-1 expression and action. ET-1
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expression in hypoxia is diminished by nitric oxide and L-NMMA potentiates the action of 
ET-1 [Î29]. Endothelin is a vasopressive mediator and has antagonistic actions to NO. Both 
are important mediators produced by the pulmonary endothelium, however the current 
thinking is that they play a modulatory role in HPVR and remodelling, influencing the direct 
effect of hypoxia on PASMC stated previously.
Atrial and Brain natriuretic peptides
Atrial natriuretic peptide (ANP) was discovered in 1981 by infusing extracts of atrial tissue 
into rats, producing a marked natriuresis [130]. Two further natriuretic peptides have since 
been discovered. Brain and C-type natriuretic peptides (BNP and CNP respectively). ANP 
and to lesser extent BNP have been studied in the context o f hypoxic response. Both peptides 
are the product of cleavage from a larger precursor resulting in 28 and 32 amino acid 
biologically active carboxyl peptide fragments. ANP is produced by the cardiac atria and 
atrial wall distension is the strongest stimulus for secretion, though endothelins, arginine 
vasopressin (AVP) and catecholamines can directly stimulate ANP production. BNP is 
predominantly produced in the ventricles and ventricular hypertrophy or congestive cardiac 
failure stimulates secretion [131, 132]. The natriuretic properties o f both peptides depend on 
increasing glomerular filtration by dilating afferent renal arterioles whilst vasoconstricting 
efferent ones. In addition they both inhibit the angiotensin II (AT-2) dependent sodium (Na" )^ 
and water reabsorption from the proximal renal tubule as well as inhibit the anti-diuretic 
actions o f AVP on the collecting ducts. ANP also inhibits the AT-2 stimulated release of 
aldosterone [133]. The mechanism is not entirely clear, but seems to be via a reduction in the 
conversion o f endogenous cholesterol into pregnenolone [134], a process stimulated by AT-2 
and adrenocorticotrophic hormone (ACTH), A reduction in aldosterone would reduce Na"^  
and water reabsorption in the distal renal tubule, further reducing plasma volume and 
therefore atrial distension. This mechanism is described in detail below.
Acute hypoxia produces an increase in ANP secretion dependent on the intensity and 
duration o f hypoxia [135], however the degree o f response is also dependent on dietary salt 
and adrenocortical activation [136]. The acute rise in ANP and BNP concentration, before 
fluid changes have an opportunity to occur has been attributed to hypoxic pulmonary 
vascular responses [137]. The direct effect of natriuretic peptides in the pulmonary 
circulation is demonstrable in animal models. Exogenous BNP and ANP blunt the acute
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hypoxic vascular response in rats and right ventricular hypertrophy in rats raised in a hypoxic 
environment [138]. Gene knockout mice deficient in ANP receptor develop pulmonary 
hypertension and the morphological changes associated with the condition [139]. Similar 
pulmonary vascular relaxing effects of ANP and BNP can be seen in humans [140]. ANP 
also rises rapidly in response to exercise during short duration [141] and prolonged exercise 
[142]. The combination o f hypoxia and exercise on ANP levels remain unclear with 
conflicting results in the laboratory and the field. To date no clear relationship between 
natriuretic peptide levels and high altitude disease has been demonstrated.
The role o f the endothelium in the hypoxic vascular response, though overshadowed by 
recent advanees in the understanding o f oxygen sensing and membrane channels, remains an 
important focus of research. The potential for developing novel pharmacological agents has 
implications in the treatment o f human diseases, such as pulmonary hypertension and high 
altitude pulmonary oedema.
1.6.4 The pulmonary circulation during exercise and hypoxia
Pulmonary blood flow increases with the near instantaneous increase in cardiac output at the 
onset o f exercise and the pulmonary vascular bed dilates; this has two effects; the first is the 
accommodation of the increased pulmonary blood flow (Q) and secondly there is recruitment 
of previously poorly perfused units o f lung in synergy with increased ventilation. This 
enables the near instantaneous rise in oxygen uptake and delivery during the early dynamic 
phase o f exercise. The increase in Q, results in a measurable rise in pulmonary artery 
pressure despite vasodilatation o f the pulmonary arterioles [143-145]. In normal exercising 
humans at sea-level the pulmonary circulation can accommodate these haemodynamic 
stresses; however at the extremes o f performance there is the potential for endothelial 
damage. This is evident in racehorses which can develop pulmonary haemorrhage at the peak 
of exertion during a race, and similarly elite athletes can have demonstrable red blood cells in 
the alveolar space after sustained maximal exercise [146].
Hypoxia adds a further point o f stress to this model. Though the HPVR is beneficial in 
allowing perfusion to match alveolar ventilation across the lung, the effects of ambient 
hypoxia are less specific. Ambient hypoxia in animals causes a heterogeneous pattern of
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vasoconstriction and blood flow [147, 148]; whereas in humans a similar response is 
suggested by the heterogeneous pattern o f smooth muscle remodelling in the terminal 
arterioles of hypoxic lung [149]. High altitude pulmonary oedema is a disease of hypobaric 
hypoxia and an exaggerated HPVR is a prominent feature associated with its pathogenesis. 
Chest radiographs o f sufferers demonstrate patchy infiltrate, again suggesting a non-uniform 
process. The consequences o f a heterogeneous HPVR in the face o f ambient hypoxia have 
been investigated in animal models; these suggest that areas of lung which are relatively 
vasodilated can be exposed to increased flow as blood is diverted from hypoxia 
vasoconstricted regions [150]. As a consequence, capillary beds which have lost the 
protection of pre-capillary arteriolar constriction are exposed to high pulmonary artery 
pressure, haemodynamic shear forces and capillary stress [151]. Animal models have 
demonstrated that there is sufficient disruption of pulmonary endothelium, basement 
membrane and epithelium to allow the leakage o f red blood cells (RBC) and large molecular 
weight plasma proteins [152]; these are similar to the findings in HAPE. Though these are 
not an inevitable consequence o f hypoxic exposure in humans, they may represent one 
extreme in the spectrum of response.
1.6.5 Diffusion limitation at the lung
After the increase in blood flow through the lungs the second consideration is the passage of 
oxygen; this needs to diffuse from the alveolar space across the alveolar epithelium, 
interstitial space, through plasma and the RBC cell membrane to haemoglobin. In normal 
humans exercising at sea level this does not pose a significant barrier to oxygen diffusion 
since the uptake o f oxygen by deoxyhaemoglobin is rapid in comparison to the transit time 
across the pulmonary capillary bed. The exact time taken for oxygen uptake by RBC is 
somewhat disputed since factors such as RBC mixing, diffusion distances within the 
capiliary/RBC and blood viscosity are variables that must be taken into aecount [153], but it 
can be assumed that haemoglobin saturation is near completion within 0.2 seconds [154]. The 
transit time, as estimated by using traditional physiological measurements and extrapolations 
is thought to be 0.75 seconds [155]. The increase in pulmonary blood flow that accompanies 
the increase in cardiac output is a further consideration since it reduces the transit time across 
the pulmonary capillary bed by up to two thirds. Modern radiolabelling techniques have 
demonstrated that cardiopulmonary transit time (a surrogate for pulmonary capillary transit
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time) is variable with the exercise intensity up to a minimum value [156]; however there is 
still time for oxygenation of Hb to occur in normoxic conditions.
One major discrepancy is that systemic artery PO2 is demonstrably lower than alveolar 
oxygen tensions when considering the whole lung (i.e. the alveolar-arterial oxygen difference 
(PA-aOz)). The main reason for this is the ventilation to perfusion (V/QJ inequality that occurs 
in normal humans at rest which becomes more evident with exercise [143]. Right-to-left 
shunts can also contribute to the PA-a0 2  difference by allowing the admixture of 
deoxygenated and oxygenated blood; in normal humans this can occur in Thebesian vessel in 
the heart and bronchial vessels in the lung. A final reason for the PA-a02 difference is the 
possibility of gas exchange inefficiencies through incomplete alveolar/airway gas mixing in 
some segments of lung. These factors are relatively trivial in normal individuals exercising at 
sea-level, but become more important as maximal exercise is reached especially in elite 
athletes. As mentioned diffusion limitation is not a feature of exercise by normal individuals 
at sea level; however there is an exception to be found in elite athletes. Individuals trained for 
peak physical performance can demonstrate exercise induced arterial hypoxaemia (EIAA). 
The causes for the PA-a02 difference are thought to be contributory, but the main reason is the 
exceptionally low mixed venous oxygen tensions due to increased extraction o f O2 by these 
individuals at maximal exercise. In these circumstances, with the pulmonary capillary transit 
time at its minimum and V/Ç inequality maximised, then there is insufficient time for 
complete oxygenation of blood entering the lungs and diffusion limitation can occur in 
normoxic conditions [157].
Ambient hypoxia affects this process in a number of ways: firstly, low ambient oxygen 
partial pressure decreases the oxygen diffusion gradient across the alveolar/endothelial 
interface. If the degree o f hypoxia were severe enough then blood crossing the pulmonary 
capillary bed may not be fully oxygenated as a result o f diffusion limitation. The PaOl of 
arterial blood under circumstances o f acute hypoxia then equilibrates at a lower level. 
Secondly, the effects of hypoxia on the pulmonary circulation can result in heterogeneous 
pulmonary vasoconstriction and can exacerbate F/Q inequalities, short periods of hypoxia 
suggest this can be a major factor and widen the PA-aÛ2 [158]; however prolonged exposure 
over days or weeks results in an optimised F/Q [159]. During prolonged exposures to altitude 
deterioration in the PA-aÛ2 can develop in some individuals, but this is thought to become 
significant only in the presence of interstitial oedema [160]. Thirdly, if exercise is then 
introduced into this hypoxic system then oxygen extraction by respiring muscles would
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further reduce the mixed venous oxygen tension returning to the lungs; thus resulting in a 
further decrease in arterial oxygen tension due to inadequate oxygenation by the lungs due to 
the initial effect of diffusion limitation. If steady state is attained (at sufficiently low enough 
exercise intensity for the given hypoxia) then Pa02 equilibrates at a lower level. The resultant 
hypoxaemia drives ventilation via the carotid body mechanisms described; however the 
reduced oxygen diffusion gradient in combination with reduced pulmonary transit times 
offsets any benefit derived from increased ventilation. The most extreme example o f this is at 
the summit of Mount Everest, where calculated values of arterial oxygen tension were 
28mmHg, derived from a measured end-tidal CO2 o f 7.5mmHg [161].
1.6.6 The relationship between ventilation and pulmonary perfusion
The relationship between ventilation and pulmonary vascular response has been alluded to in 
the previous sections: gas exchange is dependent on the matching o f alveolar ventilation to 
perfusion of pulmonary capillary beds. Hypoxia has effects upon response in both of these 
physiological systems that results in a matching of ventilation to perfusion; however the 
efficacy o f V/Q matching is affected by both individual response and the effeets o f exercise. 
Total ventilation is the product of tidal volume and respiratory rate, but the alveolar 
ventilation is dependent on the effective tidal volume that reaches the gas exchange surfaces. 
A part o f the tidal volume ventilates the airways, which are incapable o f gas exchange and 
forms the anatomical deadspace; this is about 150mls in the average human. A further portion 
of tidal volume is ‘wasted’ by ventilating regions of lung which are poorly perfused and 
hence are less effective in gas exchange. This volume in combination with the anatomical 
deadspace constitutes the physiological deadspace (Vo). As reviewed previously, both 
hypoxia and exercise can influence V/Q matching and therefore Vo. One method of 
calculating the ratio of physiological deadspace to tidal volume is the Bohr method; this 
relies on differences in CO2 concentration in the alveoli and expired gas. Since CO2  excreted 
is produced by the alveoli then:
alveolar PaC 0 2 - expired PaC 0 2
Vd/Vj  — alveolar PaC0 2
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Since alveolar PaC02 is virtually identical to arterial PaCOi in normal subjects, then arterial 
CO2  tensions can be substituted to give:
arterial PaC0 2  - expired PaC 0 2
V d / V j — ~ arterial PaC0 2
Therefore the accurate calculation o f physiological deadspace to tidal volume ratio requires 
the measurement of expired CO2 and arterial CO2 tensions. The use of this equation requires 
the measurement of arterial blood gas tensions and the siting of an arterial catheter during 
exercise testing. Jones et al. described an equation based on end-tidal CO2 partial pressures, 
derived from multiple regression analyses, which seemed to provide a reliable estimate of 
alveolar CO 2 partial pressures [162]:
Alveolar PaC02-  5.5 + (0.90 x PetCOz) -  0.002 l(V j)
where PetC02 is the partial pressure of CO2 in end tidal gas. This appeared to give a reliable 
measure o f alveolar PaC 0 2  with a correlation coefficient of r=0.915 during steady state 
exercise in healthy subjects; however experiments during incremental exercise protocols 
demonstrated a widening degree o f error between calculated V d/ V j  using arterial sampling 
and calculations based on measurements of PetC02 upon increased work rates. Furthermore, 
it appeared that estimations o f V d/ V j  based on the Jones formula were no better than those 
based on PetC02 alone [163]. The reasons cited were the effects o f impaired air flow in 
patients with obstructive airways disease, but more importantly the effect o f increased V/Q 
inequalities, resulting in a widening o f the difference between arterial and end-tidal C02.
The effect o f physiological deadspace ventilation has implications for the efficiency of 
ventilation and although the effects o f hypoxia during exercise may preclude the use of 
extrapolations such as the Jones equation, PetC02 remains a useful indicator o f alveolar 
ventilation.
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1.6.7 Patterns of ventilation
The observed increases in ventilation elicited by hypoxia or exercise are the product of 
increased tidal volume and respiratory rate; furthermore, the respiratory rate can be further 
divided into the times for inspiration (T|) and expiration (Te). Hypoxia, hypercapnia and 
exercise cause an increase in tidal volume which is the result o f increased airflow; however, 
the increase in respiratory rate is produced by a decrease in Te, whilst T, remains fairly 
constant up to maximal ventilatory rates. As tidal volume approaches 50% of the vital 
capacity, T; decreases, due to the inhibitory effect of the Hering-Breuer reflex upon lung 
hyperinflation. During rest the pattern o f ventilation is similar, irrespective of the stimulus; 
this suggests the presence o f convergence o f ventilatory signal from peripheral and central 
chemoreceptors on a central ventilatory pattern generator [164]. During the dynamic transient 
phase before steady state has been reached there is an observable difference in ventilatory 
patterns between different stimuli during rest. Hypercapnia produces the longest time course 
toward steady state ventilation during rest, taking up to 4 minutes. The increase in ventilation 
is mediated as in steady state by an increase in tidal volume, with a prolongation o f the T] and 
shortening o f Te; consequently respiratory rate does not change significantly during the 
initial phases o f hypercapnia. The response to hypoxia is much more rapid, achieving steady 
state within a minute; interestingly the T, is relatively constant, but the Te is increased for the 
first few breaths before shortening and achieving a steady state pattern [165].
Respiratory flow cycles also have a demonstrable individuality and reproducibility, at rest 
[166, 167] and during exercise [168]; furthermore the similarity in breathing patterns in 
monozygotic twins suggests a genetic component [169]. The pattern of breathing has 
implications for pulmonary gas exchange that extend beyond the necessities o f alveolar 
ventilation. As described previously, deadspace ventilation ( V d) is an important 
consideration during exercise and hypoxia; the pattern of ventilation has a significant effect 
upon alveolar ventilation in this context; alveolar ventilation is dead space subtracted from 
tidal volume. For example, to achieve a certain level of ventilatory change, increasing tidal 
volume is more efficient than increasing respiratory rate, in terms of alveolar ventilation, 
since less of the minute ventilation is wasted upon deadspace ventilation. This adds further 
value to Vd measurements in the interpretation of ventilatory responses in the context of 
altered V/Q matching or air flow limitation, which can significantly reduce the effective 
alveolar ventilation
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1.7 Cardiovascular adaptations to hypoxia and exercise.
The heart and circulation provide the convective mechanism for the transport o f oxygen and 
carbon dioxide to and from the respiring tissues and are intimately linked with the onset of 
exercise in a similar fashion to ventilatory responses. Blood oxygenated at the lung, must 
then be delivered to the respiring tissues; this is dependent on the saturation o f haemoglobin, 
the concentration of that haemoglobin, but most importantly cardiac output. The systemic 
circulation and its responses are also crucial and by controlling blood flow in response to the 
changes in requirement it directs oxygen delivery. At the capillary level, local circulation in 
respiring muscle has implications for oxygen delivery, especially under hypoxic conditions. 
The following section reviews in detail the cardiovascular responses to upright exercise and 
how hypoxia influences them.
1.7.1 Cardiac output
Cardiac output (CO) is closely linked to VO2 and increases in response to oxygen demand. 
Cardiac output increases almost instantaneously upon the onset of exercise with increases in 
stroke volume and heart rate. In combination with the increase in ventilation during Phase 
one exercise results in a rapid increase in VO2 . The increase in stroke volume is almost 
instantaneous and reaches a maximum up to the first third of the VO2 max workload for an 
individual [170]; thereafter further increases in CO are dependent on increases in heart rate. 
Stroke volume increases in response to increase vascular return, as a consequence o f the 
thoracic pump and muscular contraction in exercising limbs. It is determined by age, sex and 
size, as well as physical fitness [171].
As work rate increases a point is reached where demand outstrips the capacity o f the 
cardiovascular system and anaerobic threshold is reached. Further increases in load results in 
the accumulation of lactate, muscle fatigue sets in and eventually exercise has to stop. The 
term used so far in the discussion for this point is VO2 max; however this can only be 
accurately determined over a series o f tests, is affected by the type of exercise and the 
proportion o f total muscle exercised [17!]. A more accurate description for the maximum 
attained oxygen consumption for a particular exercise test would be VO2 peak. In order to 
avoid confusion the term VO2 max will be used in this thesis when referring to maximal
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exercise since the same form o f exercise was used in the experiments described in the 
methods.
1.7.2 Circulatory limitation on exercise
The increased cardiac output during exercise is diverted to the exercising muscles with 
smaller fractional increase in skin circulation to allow thermoregulation during exercise, with 
a fractional decrease in CO to the splanchnic and renal circulations [172]. The increase in 
muscle circulation is almost instantaneous with the onset o f exercise and is proportional to 
the strength o f the contraction [173]. The mechanism is thought to be via the autonomic 
nervous system and local humoral effects o f metabolism due to low oxygen tensions, raised 
CO], acidosis, adenosine and temperature. Increased muscle blood flow is undoubtedly 
crucial during exercise, but the local circulation through the muscle capillary bed is equally 
important. In order for oxygen to diffuse from haemoglobin to the respiring mitochondria 
there must be a sufficient gradient for this to occur. A reduction in the pH o f respiring muscle 
due to CO] production with the associated rise in temperature during exercise both facilitate 
the release o f O]; however oxygen must then diffuse through the plasma, across the 
endothelium, the interstitial space into the myocyte and into the mitochondrion. Isolated 
mitochondria can function at very low oxygen tensions, between 0.5 and 1 mmHg [154, 174]. 
However, a sufficient capillary oxygen tension must be present to create a gradient across the 
physical barriers to oxygen diffusion and allow aerobic respiration; this is estimated to be 
between 15 and 20 mmHg [175]. The implications are twofold; firstly, myocytes at the 
arterial end o f the capillary bed have sufficient oxygen to allow aerobic respiration whereas 
those at the venular end struggle to receive sufficient oxygen due to O] extraction proximal!y. 
During exercise, the increase in oxygen demand exacerbates the situation and although local 
humoral factors may offset this effect by increasing local blood flow there is the potential for 
a heterogeneous pattern of respiration, with both aerobic and anaerobic respiration occurring 
simultaneously within the muscle. Secondly, the concept o f a critical capillary PaO] means 
that blood returning from an exercising muscle cannot drop below this value and increases in 
work load beyond this point result in an increase in lactate. This has been demonstrated in 
exercising humans with simultaneous sampling o f the femoral vessels during cycle ergometry 
at work rates above and below LT; during high intensity the lowest PaO] is 20mmHg in the 
femoral venous effluent and does not fall lower despite increasing work loads[I76]. 
Therefore, the muscle capillary represents the second point o f diffusion limitation to oxygen
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passage from the environment to the respiring mitochondria, but in contrast to the pulmonary 
circulation during hypoxia, occurs in normoxic conditions.
1.7.3 Circulatoiy limitations during acute hypoxia
The consequences of exercise under hypoxic conditions are diffusion limitation at the lung 
and the potential worsening of the diffusion gradient across the muscle capillary. The result is 
hypoxaemia due to these two effects; therefore, in order to maintain oxygen delivery CO 
must be higher for any given work load since the oxygen cost for that work is the same [143, 
177, 178]. In contrast maximal cardiac output is reduced by hypoxic exposure as is VO] max; 
however CO at a specific VO] remains higher during acute hypoxia in comparison to 
normoxic values [143]. Several theories have been posited for this decline, one cause is based 
on the link between the effects o f diffusion limitation and the burden o f lactate build up. Up 
to the reduced VO] max, under hypoxic conditions, oxygen uptake matches exercise in a 
similar pattern to exercise in normoxia [160, 179]. Lactate builds up as a consequence of 
increasing anaerobic respiration and contributes to muscle fatigue. The reduction in oxygen 
at the arteriolar end of the muscle capillary means that the critical PaO] for diffusion from 
vascular lumen to mitochondria will be reached earlier in the passage o f blood through the 
muscle capillary bed. Therefore the potential for anaerobic respiration is increased and occurs 
earlier during exercise during hypoxia. Cardiac output increases to offset this effect, but is 
only effective up to a certain level o f hypoxaemia. The effects of diffusion limitation and the 
earlier onset o f muscle fatigue have been cited as one cause of diminished VO] max under 
hypoxic conditions; however circulatory factors other than diffusion limitation are also 
thought to have a bearing. Recent work suggests that the blood flow to exercising muscle 
may not be as high in hypoxia despite identical work loads during normoxic exercise [180]. 
The fractional distribution o f CO in normoxia favours the exercising muscle units; however 
in hypoxic conditions there is a minimal oxygen requirement of the organs which must be 
met. This is thought to result in a reduced fraction of CO flowing to exercising muscle; 
instead blood flow to critical organs is maintained by a higher fractional CO. This ensures a 
minimal oxygen delivery during hypoxia and therefore is a potential limitation to VO]max. 
One site o f muscular respiration seems to be spared the limiting effects o f hypoxia, the 
myocardium. It was thought that cardiac dysfunction under conditions o f hypoxia was a 
factor in VO] max limitation. This is not the case as several echocardiographic studies have
75
demonstrated that myocardial function is well preserved up to quite profound levels of 
hypoxia and during exercise [160, 181, 182].
The reduction in arterial oxygen tension and increasing hypoxaemia enhances the hypoxic 
ventilatory drive, but also influences the cardiovascular response to VO] during exercise. The 
effects on cardiac output and VO] limitation during prolonged hypoxia are discussed further 
in this chapter, but one immediate question remains: how does cardiac output increase in 
response to hypoxia?
1.7.4 Sympathetic activation during acute hypoxia
Sympathetic activity is exhibited by the release of endocrine mediators such as adrenaline or 
increased activity in the sympathetic nerves. In acute hypoxic conditions there is evidence of 
sympathetic stimulation, seen in the increase in cardiac output. Heart rate rises in response to 
brief exposures to hypoxia; however this is not accompanied by an increase in adrenaline or 
noradrenaline [183, 184]. Sympathetic nerve activity (SNA) is elevated in hypoxic 
conditions, as measured by SNA to skeletal muscle [184-186]. The stimuli that affect the 
level o f response are the degree of hypoxia, arterial carbon dioxide partial pressures (PaCO]) 
and ventilation. An increase in ventilation has a negative influence on SNA and this is 
independent of PaCO] [187], furthermore the inhibitory effect o f increased ventilation on 
SNA seems to be reduced with breath-hold manoeuvres [188]. Many o f these effects have 
been under conditions o f isocapnic hypoxia, since elevated carbon dioxide tensions appear to 
intensify SNA in hypoxic conditions and normoxic conditions [186]. In healthy humans, 
ventilation rises and PaCO] falls in response to hypoxic exposure thereby potentially 
attenuating the effeet o f hypoxia, however in pathologies such as obstructive sleep apnoea 
there is increasing evidence that the effects of apnoeic episodes, hypoventilation and 
intermittent hypoxaemia combine to increase SNA with an increase in heart rate and systemic 
blood pressure [189-191]. These findings support the role o f intermittent hypoxia in the 
pathogenesis o f persistent hypertension during waking periods.
The mechanism of signal transduction seems to rely on peripheral chemoreceptors with 
modulating effects of pH and PaCO] exhibiting effects similar to those seen in ventilatory 
responses [192-194]. The role o f the ventrolateral medulla in further sensing and then 
effecting the response to hypoxia has also been demonstrated by experiments in anaesthetised 
animals and direct measurement [193, 195]. The nucleus o f the tractus solitarius is thought to 
play a role in cardiovascular sympathoreflexes; however the precise locations of the
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brainstem centres responsible for sympathetic response during profound hypoxia remain 
unknown. The carotid body response has been discussed, but whether specific 
neurotransmitters play a role in hypoxic SNA tone is also unknown.
1.7.5 Sympathetic activation during prolonged hypoxia
The effects of more prolonged exposures to hypoxia on sympathetic activation differ from 
acute exposures. Brief exposure to hypoxia do not demonstrate any measurable rise in 
catecholamines such as adrenaline and noradrenalin; however, field studies have 
demonstrated elevated catecholamine levels at altitude with exposure over one weeks 
duration [196, 197]. Sympathetic activity is elevated at altitude; however the level of 
activation remains high despite oxygenation improving as acclimatisation occurs [198-200]. 
One explanation is that increased sympathetic activity may compensate for the loss in plasma 
volume that occurs at altitude by increasing vascular tone and offsets the vasodilator effects 
of hypoxia, thereby maintaining blood pressure [172, 185, 201].
The cardiac response to prolonged hypoxia differs from acute exposures. Cardiac output to 
work load relationships return to near sea-level values in well acclimatised individuals, but 
up to a reduced VO2 max; however peak heart rate is reduced at altitude [202]. Cardiac 
parasympathetic tone appears to be responsible and cholinergic blockade restores maximal 
heart rate to sea-level values, but has no effect on maximal cardiac output or exercise 
capacity [203, 204]. Furthermore, there is evidence in animal models that prolonged hypoxic 
exposure down regulates p-adrenergic myocardial receptors and up regulates cholinergic 
receptors [205]. The effect in humans appears to be similar, with a decline in leucocyte p 
adrenergic receptors during prolonged exposures; p receptor blockade causes a fall in 
maximal heart rate, but does not affect VO2 max at altitude [206]. Despite the demonstrable 
effects o f hypoxia on adrenergic (and cholinergic) receptors at the heart and effects that 
antagonists have on heart rate, maximal cardiac output and exercise remain unchanged; 
increased stroke volume seems to be a compensatory mechanism that maintains CO under 
these circumstances [207]. A more controversial issue is the reason for the decrease in 
maximal exercise and CO in acclimatised individuals.
1.7.5 Cardiac output adaptations during prolonged hypoxic exposure
The discussion thus far has focussed on cardiac output response during acute hypoxic 
exposures. In healthy humans, outwith the laboratory, prolonged hypoxic exposure is only 
really experienced at altitude; although there are fundamental similarities with acute exposure
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in terms of a V02max limitation, the responses change over time. Cardiac output increases 
upon initial exposure to hypoxia for the reasons explained, but then declines over a period of 
days to eventually return to sea level values for specific work rates [160, 202, 208]. The 
reason for the reduction in CO is thought to be due to the adaptations in various systems that 
effect the process o f acclimatisation; these occur at several levels. Hypoxia stimulates 
ventilation, as an adaptive measure it improves alveolar ventilation to offset alveolar 
hypoxia, maximising the diffusion gradient between blood and air. In this way it ameliorates 
the effects of diffusion limitation at the lung. The oxygen carrying capacity of blood is 
increased by a combination o f reduced plasma volume and increased haemoglobin synthesis 
through the effects of erythropoietin. At the muscle, diffusion distances are reduced by 
increases in capillary density; this is thought to be predominantly due to the effects of 
reduced muscle mass in response to chronic hypoxic exposure rather than neovascularisation. 
The question remains; why is maximal CO and VO2 max reduced in acclimatised 
individuals?
The most commonly accepted theory is that diffusion limitation at the muscle in the context 
o f hypoxia is the limiting factor, where increases in CO beyond a certain point are 
ineffectual, as described previously. There are however several other theories. The effect of 
autonomic changes at the heart during prolonged hypoxia is one, but the effects of receptor 
blockade demonstrate that there is no appreciable change in exercise capacity or CO in 
response to enhancing or inhibiting heart rate responses. Another possibility is the effect of 
increased plasma viscosity due to erythropoiesis. Polycythaemia does increase blood 
viscosity and can affect cardiac output, but experiments examining isovolumetric 
haemodilution demonstrate no effect on maximal cardiac output or VO2 max [207]. The 
exact mechanism of VO2 max and CO reduction in acclimatised individuals remains 
controversial; however the fact that VO2 max and CO are restored to near normal levels by 
oxygen inhalation lends credence towards the diffusion limitation theory [179].
1.8 Haematological adaptations
The oxygen carrying capacity is a crucial step in the delivery o f oxygen from lung to tissues; 
since oxygen is relatively poorly soluble in water, much o f this is carried by haemoglobin 
molecules within red blood cells. Haematological adaptation to hypoxic conditions relies on 
the changes in concentration of haemoglobin and red blood cells and although it is not a
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significant influence during acute hypoxic exposure, it is an important factor over prolonged 
exposures.
1.8.1 Haemoglobin
Over ninety nine percent of oxygen is carried in the blood attached to haemoglobin (Hb) 
within red blood cells (RBC). This molecule consists of four pyrole rings each with an iron 
ion in the ferrous state arranged within four separate globulin chains. Each molecule binds 
four oxygen molecules; the affinity of the molecule for O2 is dependent on the binding state 
o f each of its subunit, such that as oxygen affinity increases as successive O2 molecules are 
bound. More molecules bind as the O2 partial pressure (Pa02) increases until saturation is 
reached (i.e. the lungs). As saturation approaches there is little increase in binding despite 
further increase in PaCL and the curve plateaus, explaining the sigmoid shape o f the 
dissociation curve for haemoglobin; however there are several factors that influence the 
affinity o f Hb for oxygen. The Bohr Effect describes the lowered affinity of Hb at low pH; 
this is due to the higher affinity deoxygenated haemoglobin demonstrates for H^ ions in 
relation to O2 . Elevated CO2 tensions (which liberate H^ and reduce pH) and increased 
temperatures also reduce haemoglobin’s affinity for O2 . All three factors are found in the 
exercising muscle and therefore facilitate the release of O2 at the point o f consumption. A 
further influence on Hb affinity is the molecule 2,3-diphosphoglygerate (2,3-DPG), a product 
of the Embden-Meyerhof glycolytic pathway. This highly charged anion binds to the p chains 
of deoxygenated haemoglobin, reducing its affinity for oxygen. 2,3-DPG; the concentration 
of 2,3-DPG is elevated on ascent to high altitude and returns to normal on descent to sea 
level. This reflects the 6 hour half life o f the molecule
1.8.2 C anying capacity of blood
Oxygen delivery is a function of cardiac output and the oxygen carrying capacity o f blood; 
this fact is the basis of the Pick method of cardiac output measurement. The amount of 
oxygen carried for a given volume o f blood can be calculated using the oxygen content 
equation:
Ca02 = (Sa02 x Hb x 1.34) + 0.003(Pa02)
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Where CaO] is the oxygen content in g/dl and SaO] is percentage oxygen saturation o f blood, 
each gram of haemoglobin carries 1.34 mis of oxygen and 0.003 mis o f oxygen are dissolved 
in every decilitre (dl) plasma per  mmHg o f PaOz.
1.8.3 Red blood cell mass and plasma volume
Red blood cell mass is affected in two ways during prolonged hypoxic exposure, increased 
production by erythropoiesis and reduction in plasma volume. The effect o f increased 
ventilation causes an alkalosis which is compensated by renal mechanisms; bicarbonate is 
eliminated in the renal tubules and results in a diuresis. In the absence o f adequate fluid 
intake plasma volume is reduced and causes a rise in the haematocrit. Prolonged hypoxia can 
also have an effect on the renin-angiotensin system and maladaptive processes can cause 
fluid retention; this is discussed further in this chapter. The second and perhaps the most 
striking feature is the ability to increase the bloods carrying capacity by increasing the 
production o f red blood cells. Polycythaemia at altitude was first described by Viault in 1890; 
however the mechanisms of this response were not fully understood until quite recently. 
Erythropoiesis is under the control of the hormone erythropoetin (Epo), a circulating 
glycoprotein made of 165 amino acids and 4 oligosaccharide side chains. It is secreted 
predominantly by renal tissue close to the juxtaglomerular apparatus; unlike the carotid body, 
anaemia in addition to ischaemia and hypoxia can produce stimulate secretion. Epo acts on 
erythroid precursor cells to increase production and accelerate maturation o f red blood ceils. 
The effects of increased Epo levels on RBC mass are not evident for some days at altitude 
and therefore have little effect on acute hypoxic challenges, however there are measurable 
increases in production o f Epo within hours [209]. Hypoxia controlled gene transcription was 
first described in the Epo gene and has proved to be a milestone in the understanding of 
hypoxic response at the molecular level. The effects of hypoxia on gene transcription are 
described later in this chapter.
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1.9 The Renin-angiotensin system
The renin-angiotensin system (RAS) has a number o f physiological roles. At the systemic 
level it forms an integral part o f the humoral control for sodium and water homeostasis; 
whereas at the cellular level the renin-angiotensin system is a prolific paracrine and cellular 
control pathway found in a wide range o f tissues. This section describes the various roles of 
RAS in the response to hypoxia and exercise; however local RAS is a relatively recent 
discovery. The classical role o f RAS in fluid homeostasis under hypoxic conditions had been 
the focus o f research decades before the discovery o f local systems; hence the review of RAS 
and hypoxia starts there.
1.9.1 Renin, Angiotensin and aldosterone
Aldosterone stimulates the resorption o f sodium and water from the renal tubules in response 
to changes in intravascular volume, stress, low sodium intake and hypotension. Aldosterone 
is secreted by cells in the zona glomerulosa located in the adrenal cortex and is under the 
control o f the endocrine RAS. Renin is secreted from the renal juxtaglomerular apparatus in 
response to changes in blood pressure and the direct neurohumoral effect of the sympathetic 
system. Renin then cleaves angiotensinogen to form angiotensin I; this in turn is cleaved by 
angiotensin converting enzyme (ACE) to angiotensin II (AT-2), predominantly by membrane 
bound ACE in the pulmonary endothelium. Angiotensin 11 stimulates the secretion of 
aldosterone via angiotensin type 1 receptors (AT]) on cells in the zona glomerulosa 
activating phospholipase C; this produces an increase in protein kinase C. The result is an 
increase in the conversion o f cholesterol to pregnenolone; this in turn is converted to 
aldosterone by aldosterone synthase. As described in the review o f the effects o f ANP, 
ACTH also stimulates the production of pregnenolone and enhances the effect o f AT-2 on 
aldosterone production (Figure 1.10). The effect is an increase in plasma volume through the 
retention o f sodium (Na'*') and water.
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Figure 1.10 The Renin-angiotensin system and aldosterone mediated control o f sodium and
fluid homeostasis. Hypotension or hypovolaemia result in an increase in renin synthesis, with 
the subsequent resorption o f fluid and vasoconstriction; this corrects the imbalance and acts 
as a negative feedback. This action is mediated via AT% receptors (ATiRc).
Renin secretion is measured as plasma renin activity (PRA); therefore sympathetic neural 
tone can increase PRA. Hypoxia increases SNA (as reviewed previously) and studies have 
demonstrated elevated PRA during hypoxia and at altitude [210, 211]; however at altitude the 
degree o f aldosterone release does not match PRA [212]. A reduction in ACE activity does
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not appear to be responsible for the uncoupling o f PRA and aldosterone secretion since ACE 
activity is well maintained at high altitude [213]. The cause o f dissociation from PRA seems 
to be a direct effect on aldosterone synthesis, in rat models there is a reduction in gene 
expression o f enzymes in the aldosterone synthetic pathway [214]. As yet there is no direct 
evidence in humans that a similar pattern o f reduced gene expression (since this would 
involve tissue sampling of the adrenal cortex). The increase in ANP at altitude could be a 
contributory factor; ANP can inhibit the aldosterone response to AT-2 and ACTH and could 
play a role in the uncoupling o f aldosterone response from PRA during hypoxia. The 
responses described are during prolonged exposures to altitude; there is no evidence that 
acute hypoxia has any effect on aldosterone secretion [215]
1.9.2 Tissue and circulating RAS
Local tissue renin angiotensin systems, as characterised by the expression o f ACE, have been 
identified in adipose tissue [216], skeletal muscle [217], the heart [218] and the lung [219]; 
furthermore ACE can also be cleaved from membrane sites to form part o f a circulating RAS 
[220]. The discovery o f the widespread distribution o f RAS has been driven by research into 
the cardiovascular effects of the RAS, as well as intervention using ACE inhibitors and ATi 
receptor antagonists. The use o f ACE inhibitors has a demonstrable influence on the outcome 
o f disease. The HOPE study demonstrated a 25% reduction in death from cardiovascular 
disease; 20% reduction in myocardial infarction; 30% reduction in stroke; 22% reduction in 
heart failure and a 16% reduction in complications associated with diabetes mellitus [221]. 
The discovery of the ACE gene polymorphism is discussed in detail below, but similar 
incentives have driven research on the effects of this gene polymorphism. The result of this 
research is an understanding o f RAS and its interaction with the kallikrien-kinin system that 
extends well beyond the role o f an endocrine mediator of salt and fluid homeostasis. Figure
1.10 alludes to this interaction, but the interaction between RAS and the kinin system is more 
profound. This review examines the presence of RAS in some o f the tissues involved in the 
response to exercise and hypoxia, including the pulmonary vasculature, the carotid bodies, 
the brainstem and skeletal muscle. Furthermore the discovery of active peptide fragments of 
angiotensin, the antagonistic nature o f AT, and AT2 receptors o f AT-2, in addition to the 
ACE homologue -  ACE-2 have clarified the RAS and revealed some of the autoregulatory 
mechanisms within this system.
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1.9.3 Angiotensin peptides and bradykinin.
As described in the classical pathway; angiotensinogen, produced by the liver, is cleaved to 
the decapeptide -  angiotensin-1 (AT-1 ) by renin. This in turn is cleaved to the octapeptide 
AT-2 by the dipeptidyl-carboxypeptidase -  ACE. AT-2 is a potent vasoconstrictor in the 
systemic and pulmonary circulations [222, 223]; however there are several other peptide 
fragments o f AT-1 that are biologically active. Angiotensin-4 (AT-4), angiotensin 3 (AT-3), 
angiotensin (1-9) (AT-(l-9)) and angiotensin (1-7) are fragments of AT-1 which are 
produced by a variety of peptidases, including ACE; however the homologue ACE-2 appears 
to be a key participant. ACE is not the only mechanism o f AT-2 generation and cardiac mast 
cell chymase can also cleave AT-1 to AT-2 [224]. Angiotensin (1-9) (AT-(l-9)) is produced 
by proteolytic cleavage of AT-1 by the recently discovered homologue ACE2.
Angiotemin-2
Angiotensin-2 is perhaps the most widely studied peptide o f the renin-angiotensin system; it 
has potent vasoconstrictor effects at the pulmonary and systemic circulations via the A T, 
receptor (AT, Rc), but also has the potential to autoregulate via the action o f the AT2  receptor 
(ATzRc). In addition to eliciting vasoconstriction, the action of AT-2 on the ATiRc has 
demonstrable effects on cellular remodelling in blood vessels and tissues; in contrast the 
effect at the ATiRc appears to be the opposite with inhibition o f proliferation and enhanced 
apoptosis [225, 226]. The distribution of angiotensin receptor subtypes does vary across the 
human lung; AT,Rc appears to be localised to the pulmonary endothelium, whereas the 
ATiRc is mainly located in the alveolar epithelium (though there is a presence on the 
endothelium). The expression of both these receptors is increased under hypoxic conditions 
[227, 228]. The role of AT-2 is further supported by the effects on RAS in the lung during 
hypoxic exposures. ACE expression increases during hypoxia and hypoxia induces 
remodelling of the pulmonary circulation which is reversed by ACE inhibitors [229-231]. 
Acute hypoxic pulmonary vasoconstriction in humans is attenuated by ACE inhibitors and 
AT|Rc antagonists whereas AT2 RC blockade has no effect [232-234]. This suggests that the 
AT-2 effect under hypoxic conditions is predominantly mediated via the action on AT, 
receptors. The effects o f RAS and AT-2 in systems relevant to the work presented in this 
thesis are described further in this chapter.
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Angiotensin-4
Angiotensin-4 is produced by two pathways; the first is by the cleavage o f AT-2 and 
angiotensin-3 (AT-3) by aminopeptidase (AMP) or dipeptidyl-aminopeptidase (D-Amp). The 
second is via an intermediate angiotensin fragment (AT-(2-10) - see figure 1.11). AT-4 is a 
NOS dependent vasodilator in the pulmonary and systemic circulation, as well as 
demonstrating activity in the heart and kidney [235]. The mechanism of action is receptor 
mediated and appears to be an insulin regulated aminopeptidase (IRAP) [236]. The receptor 
was first located in rat adipocytes, within vesicles containing the glucose transporter GLUT4 
[237]. In response to insulin these vesicles translocate to the cell surface and enable increased 
cell glucose uptake by GLUT4, IRAP is a zinc dependent metalloproteinase capable of 
cleaving several peptides including vasopressin, lys-bradykinin, met-enkephalin, dynorphin 
A, somatostatin and cholecystokinin [238, 239]. One proposed mechanism o f action for 
IRAP as the AT-4 receptor is by inhibition o f the molecules peptidase action, enhancing the 
action o f its usual peptide substrate.
Angiotensin-(1-7)
Angiotensin-(l-7) is formed in systemic vessels and the heart by a variety o f pathways; the 
dominant mechanism is from AT-2 by the action o f prolyl-carboxypeptidases (PCP), prolyl- 
endopeptidases (PEP) or ACE-2. The two lesser pathways are via the action o f ACE or 
neprilysin {aka. neutral-endopeptidase 24.11) on AT-(l-9) and by the action of ACE-2 on 
AT-1. The breakdown o f A T-(l-7) is ACE dependent. AT-(l-7) has demonstrable systemic 
vasodilator properties in animal models [240] and is thought to act via a combination of 
bradykinin potentiation [241] and NO release [242]. Furthermore cardiac infusions AT-(l-7) 
have a dose dependent effect and can be cardioprotective during ischaemia and even enhance 
cardiac output at low doses in rat models; whereas higher doses can result in reperfusion 
arrhythmias [243]. The tissue activity o f AT-(l-7) has been suggested by the presence of 
A T-(l-7) mRNA, direct sampling and infusion studies in rat heart models, although the 
mechanism of action remains unclear; furthermore AT-(l-7) has diuretic properties, via 
alterations in renal blood flow and a direct tubular action [244]. The receptor(s) responsible 
for the action of AT-(l-7) remains unclear. A G-coupled receptor with a high affinity for AT- 
(1-7) has been described (Mas), but the mechanism of effect is not known [240]; furthermore 
AT] and AT2 receptor antagonists block some of the effects o f AT-(l-7), suggesting 
interaction with these receptors. The role o f AT-(l-7) in the pulmonary circulation has yet to
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be demonstrated and at least one study, examining responses in isolated rat lung, failed to 
show any effect o f BK or neprilysin inhibition on pulmonary vasoconstrictor responses to 
AT-1 infusion [245].
Angiotensin converting enzyme-2
Angiotensin converting enzyme-2 is a homologue of ACE, which is similarly expressed on 
the endothelium and is also secreted by enzymatic cleavage. Previously, ACE-2 was thought 
to be limited to heart, kidney and testicular tissues in humans [246]; however it has since 
been described in the pulmonary endothelium and has been identified as the receptor for the 
severe acute respiratory syndrome-coronavirus (SARS Co-V) [247-249]. Unlike ACE, ACE- 
2 has only one active metallopeptidase domain and is unaffected by ACE inhibitors [250, 
251]; however ACE-2 expression is increased by ACE inhibition and AT, receptor 
antagonists in the heart. ACE-2 degrades AT-2 to AT-(l-7) and acts as a counter effect to the 
vasoconstrictor effect o f ACE and AT-2. The generation of AT-(l-7) from AT-1 by ACE-2 is 
controversial, since the kinetics of this reaction draws into question the significance of this 
pathway in vivo [252]; however, ACE-2 does generate angiotensin-(l-9) which is then 
cleaved by ACE and neprilysin to form AT-(1~7). The role o f ACE-2 in the heart has been 
demonstrated by knockout mouse models and the increased expression in failing hearts [253, 
254]; however the role in the lung is less clear. There is evidence from rescue experiments in 
models of acute lung injury in knock out mice that ACE-2 plays a protective role in the 
pathogenesis o f ARDS [255]; however there is no direct evidence o f a vasoregulatory role in 
the human pulmonary circulation.
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Figure 1.11 Angiotensin peptides and their generation. Angiotensin peptides discussed in the 
text are highlighted in blue; ACE and ACE2 are highlighted in red. ACE = angiotensin 
converting enzyme; ACE2 = angiotensin converting enzyme-2; PEP = prolylendopeptidase; 
NEP = neutral endopeptidase 24.11 (neprilysin); D-Amp = dipeptidyl-aminopeptidase; AMP 
= aminopeptidase; IRAP = insulin regulated aminopeptidase; Mas = AT-(l-7) receptor. [256]
Bradykinin
Bradykinin (BK) is a vasoactive nonapeptide liberated by cleavage of high and low 
molecular weight kininogens by kallikrein. Kallikrein in turn is activated by tissue 
inflammation and by prolyl-carboxypeptidase (PCP) which forms one of the degradation 
pathways o f AT-2. Bradykinin is degraded by ACE in two dipeptide hydrolytic steps and is
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also known as kinase II [257, 258]; furthermore ACE has a twenty fold greater affinity for 
BK than AT-1 [259]. In contrast, ACE-2 does not degrade BK; it does however degrade the 
related molecule Des-Arg^-BK an inflammatory mediator which is released in response to 
inflammation and elevates blood pressure [260]. Bradykinin stimulates vasodilatation and 
NO formation; liberates tissue plasminogen activator; releases the vasodilator, prostacyclin 
and generates superoxide [261-263]. The interaction between A T-(l-7) and BK is suggested 
by the attenuation of vasodilator response o f  AT-(l-7) by the BK Pi receptor antagonist 
HOE 140 [241]; furthermore the action o f AT-(l-7) on ATi receptors has the potential to 
release BK [264], The vasodilator effect o f BK on the pulmonary circulation has been 
demonstrated in cat models [265] and in humans [266].
The action of ACE inhibitors has been partly attributed to the effects o f increased BK, via its 
anti-thrombotic and vasodilatatory actions [221, 241]; however it is apparent that the 
kallikrein-kinin system and RAS are linked at fundamental level, each with the ability to 
modulate the effects of the other.
1.9.4 Angiotensin-2 and local RAS
The prolific nature of local RAS suggests a role across multiple physiological systems; the 
following section examines the evidence o f RAS in some o f the systems reviewed in 
previous sections. The evidence for local RAS can be suggested by the expression o f the 
various components o f this system, the identification of receptors and the effect of 
intervention on the normal response of tissues. These points have been reviewed for the 
pulmonary circulation; however there is similar evidence of activity in the carotid body, the 
brainstem and skeletal muscle.
Carotid body RAS
As we have seen, carotid body responses are complex, demonstrating variation between 
species. Glomus type 1 cells are capable o f releasing numerous neurotransmitter substances 
in response to hypoxia, some o f which are capable o f autoregulating their own response; in 
addition there is a further level o f modulation by the carotid sinus nerve itself. Furthermore, 
the carotid body is a highly vascular tissue and autocrine/ paracrine factors produced at the 
endothelium can modulate blood flow, but potentially have an effect upon the glomus cells in 
their response to hypoxia, pH and circulating hormones. Autoradiographic studies have
demonstrated a high concentration of AT-2 receptors [267] and that chronic hypoxia 
Lipregulates the expression and function o f AT-2 receptors, predominantly via the action of 
AT,Rc [268],
The response appears to be biphasic with an initial inhibition followed by a marked 
stimulation o f carotid sinus nerve activity. Infusion studies, using AT-2 in fresh ex vivo 
samples o f carotid body suffused with bicarbonate buffer, demonstrate a two-fold increase in 
carotid sinus discharge up to a threshold concentration (which is within physiological levels). 
The AT I Rc, losartan inhibits excitation, whereas AT2 RC bloekade (using the antagonist PD- 
123319) has no effect [267, 268]. The mechanism o f action maybe an indirect effect 
modulating the release o f neurotransmitter substance rather than a direct action,; however 
AT-2 can directly affect glomus cell activation, as demonstrated by increases in intracellular 
Ca^ "^  in response to AT-2 [269]. Again, this appears to be via the action o f A T,Rc, since 
losartan inhibits this effect whereas PD -123319 has no effect. AT,Rc have been localised to 
glomus cells containing tyrosine hydroxylase and adds further weight to AT-2’s role in 
chemosensitive cells; AT2 RC mRNA has been loeated within type 1 cells, but as yet no 
functional effect has been demonstrated in ex vivo preparations [269].
The localisation of AT-2 receptors in glomus cells and the response to AT-2 infusion does 
suggest the role of RAS in modulating response to hypoxia; however direct evidence o f a 
local carotid body RAS has been found by the expression and localisation of angiotensinogen 
and ACE within glomus cells [270]. The absence o f renin within glomus cells is a factor 
against a functioning local RAS; however there is evidence that uptake o f  circulating RAS 
components can play a role in the action o f local RAS [271]. Furthermore AT-2 can be 
generated by enzymes other that renin, including cathepsin G and tonin [272]. The direct 
effect o f AT-2 on hypoxic sensitivity has recently been demonstrated in models o f heart 
failure in rabbits, Li and Schultz have shown that AT-2/AT|Rc effects increase hypoxic 
sensitivity o f carotid body Ky channels and that high concentrations o f AT-2 can inhibit 
intracellular currents; in this model, the effect was associated with a shift in Ky channel 
subtype from Ky3.4 to Ky4.3 [273].
The evidence supports the role o f AT-2 in animal models o f hypoxia at the carotid body, but 
as yet similar responses In humans have yet to be ascribed. Chronic hypoxia causes 
morphological change in the carotid bodies, including increased vascularisation, hypertrophy 
and hyperplasia of glomus cells [274, 275]. The proliferative effect o f AT-2 at ATiRc,
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similar to that seen in other tissues has been offered as a possible explanation for this, but 
currently lacks direct evidence.
Brainstem RAS
The ventilatory centres located in the brainstem are less well defined in terms o f precise 
location and function. The research on the effects of RAS on the brainstem has mainly 
focussed on the blood pressure control and responses to baroreflexes in the pathogenesis of 
essential hypertension [276]. However, RAS has been demonstrated in the brain and direct 
injection o f AT-2 in to the nucleus o f the tractus solitarius (nTS) has demonstrable effects on 
ventilation in rats [277]. With the exception o f the circumventricular organs, circulating RAS 
has limited access to the brain since RAS components do not cross the blood brain barrier 
[278]. RAS components have been located in various brain structures. Angiotensin peptides 
(AT-1, AT-2, AT-3 and A T-(l-7)) have all been identified in nerve terminals and neuronal 
cell bodies including the paraventricular nucleus and the nTS. Renin mRNA has been located 
in nerve cells, but the majority of angiotensin production is thought to be via the action of 
cathepsin G [279, 280]. Autoradiographic studies have mapped angiotensin receptors to 
many regions o f the brain; ATiRc have been located in the NTS, the rostral and caudal 
ventrolateral medulla and midline raphe [281]; AT]Rc distribution varies between species 
and in humans is located in cerebellum.
AT-4 receptor mapping has revealed a highly conserved pattern of distribution between 
species; the receptor has been located in the basal nucleus o f Meynert, the hippocampus and 
throughout the neocortex. [282-284]. AT-4 receptors have been associated with cholinergic 
fibres, the enhancement o f memory and motor control, but have yet to be associated with any 
o f the brainstem centres linked with ventilatory control. ACE has been identified throughout 
the brain with the highest concentrations in the circumventricular organs. ACE has been 
localised to nigrostriatal structures, NTS and dorsal motor nuclei across several species, 
including man [285-288]. Brain RAS has been linked to blood pressure control, thirst 
sensation and vasopressin secretion [289]; however the function o f RAS components in 
central ventilatory control is less defined. One study has demonstrated a link between AT-2 
and ventilatory response. Microinjection studies o f AT-2 into rat NTS has a negative effect 
on phrenic nerve discharge which exhibits some dose response [277]; therefore implies that 
brain RAS has the potential to modulate ventilation.
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Skeletal muscle RAS
The evidence for skeletal muscle RAS originated from observed ACE activity in excess of 
serum ACE levels in muscle biopsy preparations [290]. Animal studies in muscle 
preparations and cultured myocytes demonstrate the presence o f ACE, with demonstrable 
AT-2 production and bradykinin degradation [217, 291]. Studies in muscle, bereft of 
circulating ACE, continue to demonstrate vasoconstriction to AT-1 infusions that is blocked 
by ACE inhibitors [292]. Both subtypes o f the AT-2 receptor are present in rat skeletal 
muscle, the receptors being distributed between the endothelium and the myocytes [293, 
294]. The AT,Rc mediates myoeyte hypertrophy, whereas the AT2 RC inhibits proliferation 
[295, 296]. The AT2 RC has also a vasodilatatory function which appears to be mediated via 
the p2 BK receptor [264, 297], suggesting the involvement o f AT-(l-7). Despite the wealth 
o f evidence for AT2 RC involvement in animal models of skeletal muscle function, only the 
AT]Rc has been described in adult humans [298].
The identification o f AT-2 receptors types sets the stage for RAS function at the skeletal 
musele, but to what degree systemic RAS or local RAS stimulates these receptors is more 
difficult to differentiate. Whether muscle vascular endothelium or the myocytes themselves 
are the source of endogenously produced AT-2 also remains unknown. Irrespective o f the 
uncertainty surrounding the exact source o f AT-2 in muscle there is evidence o f de novo 
synthesis of AT-2 from the conversion of intrinsic and circulating AT-1. Radiolabelled 
infusion studies have demonstrated that 67% of venous AT-1 and 55% o f venous AT-2 are 
derived from skeletal muscle in pig models [299]. In humans, conversion of AT-1 to AT-2 
across the forearm is 36% and this is virtually abolished by ACE inhibition [300].
The presence o f skeletal muscle RAS has implications for exercise and performance; 
although no clear relationship has been demonstrated there are several possible areas of 
effect. Firstly, ACE inhibition attenuates overload stimulated muscle hypertrophy in rats and 
AT-2 infusion rescues this response. Furthermore, AT,Rc blockade prevents the subsequent 
rescue effect o f AT-2; this suggests a role for AT-2/AT,Rc in muscle hypertrophy response 
[301]. Secondly, muscle blood flow also appears to be RAS dependent at least in the rat; 
there is evidence for redirection o f blood flow from type 1 fibres to type 2 in isolated muscle 
preparations [302], supporting a model o f enhanced power orientated performance with AT- 
2. Finally, RAS regulation o f substrate utilisation at the muscle is implied by experiments 
using retrograde infusion of ACE inhibitors in human muscle; these experiments result in an 
increase in interstitial glucose and facilitated glucose transport [303, 304]. The effect appears
91
to be independent o f AT-2, since AT,Rc blockade has no effect in rat muscle; however the 
response does appear to be due to BK effects mediated by NO at the muscle, since the 
response is abolished by (32 BK receptor blockade or NOS inhibition [305].
Skeletal muscle RAS has been linked to muscle substrate utilisation. The translocation of the 
glucose transport molecule GLUT4 is found in muscle and adipose tissue; GLUT4 
translocation can be stimulated by insulin dependent mechanisms, but also by insulin 
independent pathways such as BK [306]. Bradykinin increases GLUT4 translocation during 
exercise [307] and ACE inhibition has an enhancing effect, reversible by (32 BK receptor 
antagonists [308]; the effect is via translocation of GLUT4 rather than increased mRNA 
expression and transcription [309].
The roles of RAS and bradykinin in skeletal muscle have implieations for exercise 
performance. ACE inhibitors appear to have a beneficial effect on muscle performance in 
heart failure patients and animal models, but no clear enhancement in healthy humans. The 
ACE gene polymorphism is a further point o f endogenous ACE attenuation that has been 
extensively studied in relation to physical performance.
1.10 Angiotensin converting enzyme and genetic polymorphisms
Angiotensin converting enzyme is a dipeptidyl-carboxypeptidase responsible for many roles 
in the renin-angiotensin system and the degradation of bradykinin (see above). ACE exists in 
a membrane form, but can also be released by proteolytic cleavage to form a circulating 
ACE. The discovery o f a physiologically significant polymorphism o f the ACE gene resulted 
in a broad spectrum of research examining the effect o f ACE insertion/ deletion 
polymorphism in both health and disease. The following section reviews some o f the points 
of this research in reference to exercise physiology and hypoxic responses.
1.10.1 The link between phenotype and genotype
The information encoded within our genes determines our physical characteristics or 
phenotype. Genes are encoded within deoxyribonucleic acid (DNA) by a unique sequence o f 
purine and pyrimidine bases linked covalently to give a highly conserved code (genotype) 
from which is transcribed messenger ribonucleic acid (mRNA), that in turn is translated into 
a polypeptide chain or protein. Genes have sections that are meaningful in terms o f protein
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production (exons) interspersed with non-transcribed segments (introns) which are excised 
from the final mRNA used for transcription.
Through the action of structural proteins, enzymes, signalling pathways and transcriptional 
activators, genes determine how we look, the diseases we are susceptible to and how we 
respond to the physical stimuli in our environment. This extends from the organismal through 
the tissue level down to the cellular environment. We share many o f our genes not only with 
other humans, but other species, with the most fundamentally important genes found in 
common with almost all forms o f life. The differences are in the fine details o f genetic 
structure. In higher organisms genes are located in discrete organelles, the cellular nucleus, in 
the form o f chromosomes. A healthy human possesses 46 chromosomes in each somatic cell, 
however 22 o f these occur as duplicate or pairs, encoding the same genes. The remaining two 
determine sex of the individual and are heterologous in males and homologous in females. 
The reason why the majority o f our genetic make up is in duplicate lies in the need for 
variability. Each chromosome pair carries genes with subtle differences in the coding for the 
same proteins, these are termed alleles. Alleles for a certain gene are termed dominant if they 
have a demonstrable phenotype despite the presence o f an alternate copy o f the same gene 
which is termed recessive. In order for recessive genes to exhibit their phenotype two copies 
must be present on each chromosome, since transcription from one chromosome or another 
carries an equal probability. In the event that both alleles for a gene have an equal chance o f 
affecting the phenotype then the genes are termed co-dominant, the result is an intermediate 
phenotype. During gametogenesis recombination occurs between the ehromosome pairs and 
a re-assortment o f alleles occurs whilst preserving the genes themselves. This occurs in both 
male and female, thereby increasing the genetic variability of the resulting offspring. This not 
only introduces variability in physical appearance, but raises the possibility of variability in 
the genes that encode for every aspect o f life down to the cellular level. In the face of 
environmental change or disease subtle differences in phenotype may prove advantageous 
ensuring survival of the individual, successful mating and the conservation o f the genes 
encoding the beneficial trait.
The term allele only has meaning at the organismal level describing the possible genetic re­
assortment or phenotypical outcome o f translation. Genes coding for a protein can exist in 
more than two forms, but only two forms are present in an individual as alleles. These 
variations are called genetic polymorphisms and constitute another level o f individual 
variability.
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1.10.2 ACE gene polymorphisms
Until recently, the ACE gene was thought to possess one functional polymorphism; however 
there is evidence that at least one other functional polymorphism exist [310]. The focus of 
much o f the research to date has been on the insertion/deletion ACE polymorphism (ACE I/D 
polymorphism); this thesis presents work based on physiological response in relation to this 
gene polymorphism. The ACE I/D polymorphism comprises o f two forms of the ACE gene, 
distinguished by the presence o f a 287 bp Alu repeat sequence in intron 16 (insertion, 1-allele) 
as opposed to its absence (deletion, D-allele). Alu  repeat sequences are a common occurrence 
in the human genome and are associated with many gene polymorphisms, some o f which are 
directly linked with disease [311]. The functional aspects o f the ACE I/D polymorphism are 
a 47% reduction in enzyme activity associated with 1-allele homogenicity in comparison with 
the D-allele homozygote. Furthermore, the ACE I/D polymorphism demonstrates co- 
dominance and heterozygotes exhibit an intermediate level o f ACE activity. [312, 313].
The mechanism of variable ACE activity between individuals is not known. The I/D 
polymorphism is in a non-transcribed portion o f the genome which makes it unlikely that it is 
directly responsible for the variation in activity. In addition to the 1/D polymorphism there 
are a number of other single nucleotide polymorphisms (SNPs) in close proximity, o f which 
some lie in exon segments o f the gene; currently it is thought that one o f these 
polymorphisms may be directly responsible or close to the exact loci responsible for the 
observed effect. There are a number o f possible candidate loci that have been investigated; 
however the responsible locus or loci remain elusive [314-316].
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Figure 1.12 Diagram of the human ACE gene with 10 polymorphic sites labelled. 
Horizontal bars represent exons. The I/D polymorphism is labelled in intron 16 (From 
Keavney et al [315]).
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The ACE I/D polymorphism has been studied in the context of disease epidemiology; in this 
context it is necessary to ensure that the gene frequency and genotype within a population are 
constant or in genetic equilibrium. This principle was described by the English 
mathematician G.H. Hardy, but previously outlined by the German physician Wilhelm 
Weinberg; consequently it is termed to Hardy-Weinberg equilibrium. In order for equilibrium 
to be reached the population must be allowed to breed freely, with no inter-breeding, 
mutation, migration or selection. In considering two alleles for a particular gene ‘A ’ and ‘a’ 
with frequencies ‘p’ and ‘q’ respectively; then the expected frequency o f genotypes can be 
calculated from the possible permutations o f allele combination using a distribution square:
A (p) a (q)
A (p) AA (p^) Aa (pq)
a (q) Aa (pq) aa (q^)
The resulting frequencies for each genotype are:
AA= p^
Aa = 2pq 
aa = q^
If we consider the allele frequency for the insertion and deletion polymorphisms to be equal, 
as one would expect in a Caucasian population, then the expected ratio o f genotypes would 
be:
II : 2 ID: DD
In order to confirm whether a sample population conforms to the expected genotype 
frequency statistical analyses can be applied. Non-conformity can result from consanguinity, 
mutation, positive selection or negative selection on the basis o f disease associated with a 
particular genotype.
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1.10.3 ACE gene polymorphisms and physical performance
The variability o f ACE activity across a population, in light o f the widespread distribution of 
RAS in the body, has the potential to influence a wide variety of physiological systems. The 
point at which ACE I/D polymorphism may exert an influence is not limited to AT-2 
generation and may include effects on other angiotensin peptides and bradykinin. The ACE 
I/D polymorphism has been widely studied in the context of a diverse range of pathological 
conditions and in epidemiological studies as a marker of cardiovascular risk; however, 
another facet of the insertion/ deletion polymorphism is the link between genotype and 
physical performance. This has proved a contentious area with conflicting results amongst 
investigators; however in studies examining elite athletes performing solely one endurance 
discipline, there is a significant excess frequency o f the I-allele above that expected within 
the populations studied. [317-319]. The conflicting results produced by some investigators 
have been attributed to samples that include heterologous groups o f athletes, with only a 
portion from endurance disciplines [320, 321].
The precise mechanism o f the advantage conferred by the 1-alIeIe is not known, but the 
widespread presence o f ACE raises several possibilities, from muscle substrate utilisation to 
central nervous system affects. In terms o f measures of physical fitness there is disagreement 
as to the influence o f ACE I/D polymorphism. One study examining VO2 max in post­
menopausal women demonstrated a higher VO 2 max in women with the II genotype in 
comparison to women with the DD genotype [322]; however the HERITAGE (health, risk 
factors, exercise training and genetics) study produced a conflicting result. The response of a 
standardised exercise program in 724 adults divided into: Caucasian and black subjects; 
parent and offspring groups, was assessed by ACE genotype. There was no difference in VO2 
max at baseline, but after 20 weeks o f training the Caucasian offspring group demonstrated 
an enhanced metabolic response during exercise. VO2 max and 80% o f VO2 max were 
increased by 14-38%; heart rate at 50 watts was decreased by 36%. A possible explanation is 
the close association between VO2  and cardiac output; the ACE deletion allele is associated 
with increased left ventricular mass after a program of army basic training [323] and in 
athletes after training [324, 325]. Therefore, young Caucasian deletion homozygotes may 
exhibit the effect o f increased left ventricular mass by an enhanced cardiac output response 
during exercise with improved oxygen delivery and VO2 .
The effects of ACE I/D polymorphisms on skeletal muscle have been examined in the 
context o f performance enhancement. Studies examining military recruits have shown an
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enhancement in muscle endurance [326] and efficiency after 11 weeks o f physical training in 
the II individuals in comparison with the those possessing the DD genotype (there were no 
demonstrable differences at baseline) [327]. The study that reported an increase in V02max 
in postmenopausal women with the II genotype, also reported a greater arterio-venous 
oxygen difference across exercising muscle; this suggests local factors contribute to oxygen 
uptake [322]. Local ACE response to genotype is illustrated by the enhanced arterial 
contractile response to AT-1 infusion into internal mammary artery preparations from DD 
individuals [328]. In vivo experiments confirm the variation in local RAS activity with 
infusional studies demonstrating higher AT-2 concentration in forearm venous blood 
following AT-1 infusion in DD subjects. These experiments confirm the variable activity of 
ACE in muscle RAS, but do not confirm AT-2 as the mediating peptide. Bradykinin has 
demonstrable effects on muscle blood flow and substrate utilisation; furthermore, ACE 1/D 
polymorphisms have a measurable effect on BK levels, with higher levels in I-allele 
homozygous individuals [329].
The debate over the relevance and mechanism o f ACE 1/D polymorphism influence on 
physical performance remains unresolved; however the observed association of the insertion 
allele with endurance performance is real and demands explanation.
1.10.4 ACE gene polymorphisms and hypoxia
ACE 1/D polymorphism involvement in hypoxic physical performance was first indicated by 
frequency disequilibrium in elite mountaineers, Montgomery et al. reported an excess o f the 
I-allele in a group of 33 elite mountaineers who had ascended above 7000m without 
supplementary oxygen; furthermore, o f the 15 individuals who had ascended above 8000m 
without oxygen, none were homozygous for the D-allele [326]. A more recent study has 
confirmed this finding in a larger group o f mountaineers ascending Mount Blanc (altitude: 
4807m). In this study, 235 mountaineers were genotyped on the ascent; the 1-allele frequency 
was 0.47 in those who completed the ascent in comparison to an I-allele frequency o f 0.21 in 
those who were not successful [330]. The precise mechanism o f these findings remains 
obscure; however a further study demonstrated enhanced oxygen saturations in insertion 
homozygous individuals during rapid ascent over 12 days to 5000m. Furthermore, the rate of 
ascent appears to be a crucial factor, since a second group o f climbers ascending over 18 days 
did not demonstrate any significant difference in oxygen saturation at the same altitude [331]. 
This suggests enhanced performance at altitude may be attributable to differences in the
97
cardiorespiratory response to hypoxia by individuals of different ACE genotypes. The work 
presented in this thesis attempts to identify some of these differences by examining some of 
the cardiorespiratory responses during acute hypoxic exposure.
1.10.5 ACE genotype in high altitude disease
The association of ACE polymorphism with altitude performance has raised the question: Is 
there an association between the ACE genotype and high altitude disease that could account 
for the variation in performance? Several studies have examined the genotype frequency in 
groups o f subjects susceptible to HAPE in comparison with controls; all failed to demonstrate 
any association with either allele [332, 333]. Furthermore, studies investigating a link 
between genotype and acute mountain sickness (AMS), showed either no association or 
inconclusive results [330, 334]. Therefore there appears to be no direct link between ACE 
I/D polymorphism and high altitude disease. One interesting feature noted in one o f these 
studies was the increase in pulmonary vascular resistance during pulmonary catheter studies 
o f HAPE patients with the D-allele; this suggests an enhanced HPVR in association with D- 
allele positivity, but no link with the development of HAPE [332]. The features of high 
altitude disease are described further in this chapter.
1.11 The Genetic response to hypoxia
The previous sections have reviewed the hypoxic physiological response and have touched 
on the relationship between ACE polymorphism and physical performance under conditions 
o f hypoxia; however it is now apparent that the response to hypoxia is a more ubiquitous 
occurrence at the cellular level. The ACE polymorphism alludes to one aspect of genetic 
involvement in these responses, but in the last 15 years the discovery o f oxygen dependent 
transcription from these genes has meant a whole new insight into hypoxic responses from 
the molecular perspective.
1.11.1 Hypoxia dependent gene expression
Erythropoietin was the first example of oxygen dependent gene expression to be described. 
EPO produces polycythaemia in response to hypoxia, through the aceelerated maturation of 
red blood cell progenitor cells and by inhibition o f progenitor cell apoptosis [335]. The 
resultant increase in the oxygen carrying capacity is one o f the most fundamental responses
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to prolonged hypoxia. An increase in EPO mRNA can be seen within one hour of hypoxic 
exposure which declines with a return to normoxic conditions [336]. If hypoxia is maintained 
then the increase in mRNA results in an increase in circulating EPO and erythropoesis. 
Transcription activation o f the EPO gene is dependent on a 3' transcriptional activation 
sequence called the hypoxia response element (PIRE) [337-339]. This sequence confers 
hypoxia sensitivity to genes if inserted into their promoter sequences and it is known that 
mutations within the HRE render it insensitive to hypoxic stimulation.
The hypoxia response element has been found in a wide range o f genes which are sensitive to 
hypoxia. The genes responsible for glycolysis, glucose transport as well as cellular and 
vascular proliferation (vascular endothelial growth factor (VEGF), placental growth factor, 
angiopoetin -1 and -2 and platelet derived growth factor) demonstrate HREs and are oxygen 
sensitive [340-343]. In addition, the genes encoding vasoactive mediators such as NOS and 
endothelin possess HREs [344, 345]. Furthermore, the tyrosine hydroxylase gene possesses 
an HRE [346]; thus conferring hypoxia responsiveness on the crucial-rate limiting enzyme in 
the synthesis o f ventilatory neurotransmitters [347].
1.11.2 Hypoxia inducible factor
Transcription o f these ‘oxygen sensitive’ genes is promoted by binding o f the HRE by a 
nuclear protein complex identified as hypoxia-indueible-factor-1 (HIF-1) [348]. HIF-I 
consists o f two basic helix-loop-helix subunits; both are required for binding to the HRE and 
activation o f transcription. One subunit, HIF-1 p is constitutively produced in normoxic cells 
and is also known as the aryl hydrocarbon receptor (ARNT). The second subunit, HIF-1 a  is 
an oxygen-regulated 826 amino acid peptide. HIF-1 a  is degraded rapidly under normoxic 
conditions, but has a prolonged half life in hypoxia with raised levels measurable within 2 
minutes [349]. The rapid elevation in HIF-1 a  is most likely due to inhibited degradation 
since mRNA levels are unaffected by oxygen tensions. The peptide is hydroxylated at proline 
residues 402 and 564 in the oxygen dependent domain (ODD) by HIF-1 a proline 
hydroxylase which is an oxygen dependent process [350]. Hydroxylation at these residues 
allows binding of von Hippel-Lindau tumour suppressor protein (pVHL) which then allows 
recognition by E3 ubiquitin-protein ligase and degrades HIF-1 a  [351, 352]. In hypoxic 
conditions the hydroxylation o f pro line residues does not occur and H lF -la  levels increase. 
The promoter function of HIF-1 is also sensitive to hypoxia. Oxygen dependent 
hydroxylation of the asparagine residue 803 by Factor inhibiting HIF-1 (FlH-1) blocks the
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interaction of HIF-1 a and coactivators required for HIF-I mediated activation of 
transcription [353, 354]. HIF-2a is structurally homologous hypoxia inducible transcription 
regulator which shares similar properties and functions to HIP-la and is similarly regulated 
by prolyl and asparginyl hydroxylation [350, 353, 355]. The difference lies in the distribution 
of HIF-2a since it appears to be limited to specific tissues in particular endothelial cells 
which may lend it a role in the response to hypoxic stress [356-358].
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Figure 1.13 Oxygen dependent transcription by HIF-I a.
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1.11.3 Oxygen sensing and gene expression
The demonstration of oxygen sensitive genes and HIF-1 mediated transcription has been a 
crucial step in the understanding of the body’s response to hypoxia, but the exact mechanism 
o f oxygen sensing and subsequent stabilisation and promotion o f H IF-la  activity remained 
elusive for some years. Early evidence suggested a haem-based molecule as an oxygen 
sensor [359], however this was not supported by iron chelator or haem-synthesis inhibitor 
studies [348, 360]. The simplest model for an oxygen sensor is H IF -la  proline hydroxylase 
itself, since oxygen is the rate limiting substrate for its function [350]. In vitro studies have 
demonstrated 3 forms o f H IF-la  proline hydroxylase [350, 361] which share a similar 
function and are expressed in similar tissues. Recombinant forms o f these prolyl 
hydroxylases have affinities for oxygen near that of atmospheric concentrations [362] and are 
far in excess o f oxygen tensions found in tissues. In vivo, assuming a similar oxygen affinity, 
these hydroxylases would be not be at equilibrium; therefore small fluctuations in oxygen 
concentration would have an affect on function, satisfying the primary prerequisite for an 
oxygen sensor. Furthermore mRNA of two of the prolyl hydroxylases involved accumulates 
in hypoxia with an increase in protein levels [350, 363, 364]. This has the potential to 
attenuate the effects o f hypoxia, but most likely plays the important role o f rapidly degrading 
H IF -la  upon reoxygenation, halting the hypoxic signal [365, 366].
H IF -la  prolyl hydroxylases appear to be the best candidate for oxygen sensing at the 
transcriptional level for genes possessing HREs, however this is a very active field o f interest 
and further discoveries in this pathway can only be anticipated.
1.11.4 Carotid bodies and hypoxia induced gene regulation.
The transduction o f oxygen chemoreception to sinus nerve activations by the carotid body 
glomus cell is dependent on catecholamine synthesis and release. Tyrosine hydroxylase (TH) 
is the rate limiting enzyme in the synthesis of dopamine and its gene contains a HRE; 
furthermore hypoxia induces the transcription of TH mRNA in a HIF dependent manner
[367]. In rat carotid body glomus cells H IF-la  and HIF-2a are demonstrable in neonatal 
animals and adolescent rats exposed to hypoxia. The increased level o f H IF-la  & 2a is 
accompanied by a measurable increase in TH; thus demonstrating a hypoxia induced 
activation of catecholamine pathway that participates in the hypoxic ventilatory response
[368]. Similar expression in humans has yet to be described, but this animal model provides
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an insight into a possible mechanism for hypoxic ventilatory adaptation in peripheral 
chemoreceptors at the genetic level.
1.12 High altitude disease
The topics reviewed thus far have focussed predominantly on acute hypoxic responses; 
however one of the most dramatic and relevant settings for hypoxic physiology is at altitude. 
The following is a brief review o f the research into and the diseases encountered at high 
altitude.
1.12.1 History
There is some disagreement as to whether the earliest written record o f altitude disease dates 
to the time o f the Chinese Han dynasties in 30 BCE or 300 years earlier and are attributable 
to Aristotle [369]; in either case man has been aware o f the travails o f high altitude since 
ancient times. Unsurprisingly the source o f these illnesses was tainted by superstitious belief 
and attributed to noxious vapours, maliferous spirits or toxic flora. It was not until the era of 
scientific enquiry that light was cast on the causes o f altitude disease. Blaise Pascal’s may 
have discovered the fall in barometric pressure at altitude, but it was the French Physiologist 
Paul Bert (1833-1886) who made the link between the low partial pressures of oxygen at 
altitude and the effects on human physiology {La Pression Barométrique, 1848).
Whilst scientists such as Bert were at work pushing forward the boundaries o f physiology, so 
explorers were mapping every corner of the globe and the dangers posed by high altitude 
became all too real; it was not long before research moved from the laboratory into the field. 
Expeditions to the Alps and Rocky mountains preceded research at higher altitudes in the 
Andes and the Himalayas. Permanent research stations such as the Capanna Regina 
Margherita hut on the summit o f Monte Rosa (4559m) have stood since 1893 and its facilities 
still permit sophisticated research in one o f the world’s most inhospitable environments. 
Whilst advances were being made in both laboratory and the field, mountaineers were 
ascending ever higher, culminating with the first ascent o f Everest in 1953 by Hillary and 
Tensing. The work o f figures such as Christian Bohr, John Scott Haldane, Joseph Barcroft 
and August Krogh at the beginning o f the century is continued today, though extends beyond 
the remit of traditional physiology. Modern altitude research utilises all the disciplines of the 
biosciences, examining the biochemistry and genetics of hypoxic response in an attempt to
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unrave! the processes that belie the physiological responses that have been described 
previously. Some of the work described in this thesis utilises the ‘new science’ to examine 
the physiological responses at altitude.
1.12,2 Acute high altitude disease
The descriptive terms for high altitude diseases have developed over the last one hundred 
years, but a common theme amongst the varied nomenclatures has been the appreciation of 
duration of altitude exposure in the development of disease. As a consequence high altitude 
disease is divided into acute conditions that occur in the first few days o f exposure and 
chronic, that occurs over weeks and months. Acute high altitude disease develops at altitudes 
over 2500m and is associated with rapid ascent in poorly acclimatised individuals. The 
conditions are directly attributable to hypoxia, though viral illness, dehydration and cold 
exposure can contribute. Descent to lower altitude is the treatment o f choice and sometimes 
the only effective therapy. The current nomenclature divides acute altitude disease into three 
main entities; acute mountain sickness, high altitude cerebral oedema (HACE) and high 
altitude pulmonary oedema (HAPE); the first two conditions are considered to be opposite 
ends o f the spectrum for the same disease process whereas HAPE is considered as a distinct 
pathology. The brief review that follows will concentrate on these acute conditions.
Acute mountain sickness and high altitude cerebral oedema.
Acute mountain sickness (AMS) is an almost universal occurrence at altitude and its 
principle symptom is headache (the Chinese writings mentioned refer to ‘Big and Little 
headache mountains’). Other symptoms include anorexia, nausea and vomiting, fatigue, 
light-headedness and sleep disturbance. Signs maybe absent or manifest as peripheral 
oedema or low grade fever. The onset is usually after the first 6-12 hour at altitude, is at its 
worst on days 2 to 3, with complete resolution by day 5. In an attempt to categorise the 
symptomatic severity o f AMS the Lake Louise score was devised and is still used as a 
subjective score o f altitude illness [370]. AMS in itself is usually a benign self limiting 
condition; however it can progress to high altitude cerebral oedema (HACE), a much more 
serious and potentially fatal condition. HACE is characterised by ataxia, impaired 
consciousness, coma and eventual death; though it usually occurs in a progressive manner, 
HACE has been reported in conjunction with high altitude pulmonary oedema de novo. In
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these cases, severe HAPE induced hypoxaemia is thought to precipitate the rapid 
development of HACE, without allowing time for the development o f AMS symptoms.
AMS and HACE are thought to share a common pathophysiology; moderate to severe AMS 
is thought to be due to a mild form of cerebral oedema, HACE by definition is cerebral 
oedema. The precise cause for this oedema remains unclear and much debate exists whether 
the cause of raised intracranial pressure (ICP) is due to true oedema, fluid shift from 
extracellular to intracellular compartments or increased cerebral blood volume. Blood brain 
barrier (BBB) permeability is thought to play a crucial role in the pathology; due either 
mechanical stresses and/ or the action o f mediators on the cerebral endothelium to produce a 
vasogenic oedema [371]. Another proposed factor is disturbance o f the vascular endothelium 
by hypoxic angiogenesis [372], whereas the closed box theory suggests that abnormalities of 
cranial anatomy limits the flow of cerebrospinal fluid and thus facilitates the development of 
HACE [373].
The best preventative measure for any acute altitude illness is slow ascent with adequate time 
for acclimatisation. Acetazolamide has been used to facilitate acclimatisation and can be 
effective in the prevention o f and treatment o f AMS. HACE is a more serious condition and 
can be fatal within a matter o f hours if no action is taken. As a consequence, immediate 
descent is the safest and optimum treatment, though dexamethasone and oxygen can be 
supportive in the short term.
1.12.3 High altitude pulmonary oedema
High altitude pulmonary oedema is potentially fatal. It initially manifests as excessive 
dyspnoea, dry cough and lethargy; AMS is invariably a feature. Symptoms precede signs that 
include pulmonary crackles; tachycardia is present and mild pyrexia is common; white frothy 
sputum develops, which eventually becomes blood stained. In a matter o f hours the 
dyspnoea worsens with bubbling respirations, coma sets in and eventually death. Chest 
radiographs in those that receive medical attention demonstrate irregular patchy infiltrates in 
both lung fields, sometimes favouring the dependent side with prominent pulmonary arteries. 
X-ray findings tend to resolve within one week of descent [87, 374]. The condition is 
unpredictable in whom it affects. Young, fit individuals are susceptible and this may be more 
related to a higher level of physical activity; a known association with HAPE. Cold and rapid 
ascents are other contributory factors, though most intriguing is the individual susceptibility
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towards HAPE; those that have been affected before are prone to subsequent episodes upon 
further ascents.
The pathophysiology of HAPE is dependent on an exaggerated HPVR as demonstrated by 
pulmonary artery catheterisation in HAPE susceptible individuals [86-88]. These studies 
confirmed a raised PAP, but a normal PCWP; thus demonstrating the non-cardiogenic nature 
o f the oedema. The central role of hypoxia in the pathogenesis is demonstrated by 
amelioration of elevated PAP with oxygen inhalation [87]. As previously described HPVR in 
ambient hypoxia can lead to patchy pulmonary vasoconstriction and subsequent 
overperfusion o f spared lung segments [150]. The effects of vascular shear forces can disrupt 
endothelial integrity causing a fluid leak and pulmonary oedema develops [375]. 
Inflammatory processes have been proposed as contributory to the development of HAPE 
since the oedematous fluid is rich in protein and cytokines [376]; however serial 
bronchoalveolar lavage in HAPE susceptible (HAPE-S) subjects demonstrated the absence of 
cytokines early in the development o f HAPE and demonstrated clinically and 
radiographically. One possible explanation is the inflammatory effect o f exposed basement 
membrane after haemodynamic shear effects [377] with subsequent platelet activation [378], 
which would explain the subsequent development of a cytokine rich exudate.
The humoral factors described in hypoxic pulmonary vascular responses have also been 
implicated in the pathogenesis o f HAPE, but the response to sodium transport has been 
examined more closely in HAPE. Impaired sodium transport in HAPE-S individuals has been 
inferred using trans-nasal potential differences [379] and proposed as a contributory factor to 
the development o f HAPE. Furthermore p-agonlsts are known to facilitate sodium pump 
activity and the clearance o f lung water [380]. Trials of inhaled long acting p-agonists 
reduced the occurrence o f HAPE in a susceptible group and improved transcutaneous oxygen 
saturations in HAPE-S subjects [381]. Nitric oxide levels are reduced in HAPE-S individuals
[382] and this is due to a reduced activity o f NOS as demonstrated by a reduction in L- 
citrulline (a stable by-product of NOS produced stochiometrically with NO) and cGMP
[383]. Endothelin levels are demonstrably higher in HAPE-S individuals [384], but whether 
this is a primary pathological response or part o f a wider ‘hypoxic cascade’ remains unclear. 
The link between humoral factors and HAPE remains one o f the most intriguing areas of 
research not least because o f the promise of new therapeutic strategies.
The hypoxic ventilatory response demonstrates individual variability and attenuation o f the 
HVR has been associated with HAPE susceptibility [385-387]; however some individuals
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exhibit a similar level o f HVR as HAPE susceptible subjects, without developing HAPE. 
This suggests that HVR is not a central feature o f HAPE pathogenesis, but might contribute 
by inducing a relative degree o f alveolar hypoxia due to an inadequate HVR to hypobaric 
hypoxia. To date, there is no identifiable marker, either physiological or biochemical that 
reliably predicts the development o f HAPE, This reflects the multiple physiological 
mechanisms that contribute to hypoxic adaptation and that the pathophysiology o f HAPE is 
multifactorial.
1.13 Cardiopulmonary exercise testing
The previous sections have described the physiological and biochemical mechanisms behind 
the response to exercise and hypoxia. This section and the next reviews the practicalities of 
measuring the physiological variables described earlier, in this chapter. Cardiopulmonary 
exercise testing has come a long way from the use of Douglas bags for gas collection during 
exercise tests. Modern cardiopulmonary exercise tests (CPET) are performed on equipment 
utilising rapid gas analysers and flow meters to give breath-by-breath analysis during 
exercise. The different facets of CPET can influence the measured result; furthermore, the 
validity of these tests is reliant on stringent quality control and calibration. These aspects of 
cardiopulmonary exercise testing are briefly reviewed here.
1.13.1 The choice of exercise
The two commonest forms of exercise used in CPET are the treadmill and cycle ergometry, 
each has its own advantages and disadvantages. Treadmill exercise is a more natural form of 
exercise, utilises more o f the major muscle groups and therefore is more likely to give a peak 
VO 2 close to V02max [171]. The disadvantages of treadmill exercise are: the bulkiness of the 
equipment; the potential of injury should the subject stumble; the increase in interference 
introduced into electrocardiographic measurements and that the actual power o f exercise can 
only be estimated from calculation o f incline, weight and the running speed. Cycle ergometry 
facilitates electrocardiographic measurement, since the upper body is relatively static and 
work rate can be measured directly. Ergometers can either be mechanically or electronically 
braked; the advantage o f electronically braked ergometers is that they can maintain a constant 
work load despite variation in cycling speed. The rate of change in work load can also be 
increased in a smooth ramp by a computer attached to the cycle, enabling incremental
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exercise testing without stepwise increase in work. Calibration of electronic ergometers 
requires the use of a dynamometer on a regular basis [388]. Electronically braked cycle 
ergometers are more expensive, but their flexibility during tests and the reliability o f work 
rate (this is usually monitored during the test by the controlling computer) means that this 
form of exercise is the most appropriate for the studies in this thesis. One further 
consideration is that the subject is seated, therefore in the event o f any adverse affect of 
exercising under hypoxic conditions the risk o f injury is minimised.
1.13.2 Gas flow meters
Gas flow meters have replaced the Douglas bag to give expired gas volumes over time and 
there are several possible methods. Pneumotachometers, measure the pressure drop through a 
tube across a point of fixed resistance to air flow, from the differential in pressure gas flow 
can be calculated. Mass flow meters or anemometers rely on the cooling o f a heated wire 
placed in the flow of gas. The degree of cooling and the current required to maintain the wire 
at the set temperature are a function of gas flow across the wire, thus enabling the calculation 
o f flow. The final method of gas flow measurement are turbine spirometers; these give flow 
measurements according to the speed o f rotation o f the turbine located within the spirometer, 
the use o f turbines is not commonly used in static CPET equipment, but is used in portable or 
even wearable units.
1.13.3 Gas analysis
There are several methods o f gas analysis available, the method o f choice for most 
physiologists is mass spectrometry, since it is rapid, accurate and is able to measure all the 
gases in the mixture simultaneously. The disadvantage lies in the expense o f these systems 
and in some models mechanical failure. The principle is based on the acceleration o f ionised 
gas molecules through an electromagnetic field; the degree o f deflection is a property o f mass 
and charge; the intensity o f the beam of ions, as measured by sensors, gives the 
concentration. Commercially available metabolic carts sometimes utilise mass spectrometry, 
but usually employ rapid gas analysers, in order to minimise initial and maintenance costs. 
Whilst these were formerly limited by speed o f response in combination with processing 
time, the vast improvements in the speed o f standard desktop computers has shortened the 
gap between these two sensing modalities. There are two different types of oxygen sensor, 
but only one type o f CO2 sensor utilised in metabolic carts.
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Oxygen sensors using zirconium electrochemical fuel cells utilise the semipermeable nature 
o f zirconium oxide when heated; if placed in apposition to calcium, magnesium or yttrium 
oxides, zirconium oxide acts as a solid electrochemical cell. Exposure to oxygen results in 
the generation of a voltage in proportion to the concentration o f oxygen. These cells are 
accurate, reliable and relatively cheap; the cell itself is a consumable item which requires 
regular replacement and is often performed as part o f manufacturer servicing.
Paramagnetic oxygen analysers rely on the magnetic properties o f the oxygen molecule; 
when O2 enters a strong magnetic field, shifts in electrons within the molecules generate 
strong magnetic moments within the molecule. The paramagnetic sensors usually consist o f 
two spheres arranged in a dumbbell, each containing nitrogen gas, suspended in a magnetic 
field. When oxygen enters the sensor, it becomes magnetised, enters the field and strengthens 
it; the nitrogen within the spheres has an opposing magnetic polarity and is forced out o f the 
field, causing the dumbbell to spin. The rate of spin is proportional to the concentration of 
oxygen within the analyser. Paramagnetic analysers are relatively robust and resistant to 
movement; hence they are often used in portable CPET units.
Carbon dioxide analysers used in non-mass spectrometry metabolic carts are rapid infrared 
CO2 analysers. As the name suggest they rely on the absorption o f light at the infrared 
wavelength; this is proportional to the concentration of CO2 absorption. Whether mass 
spectrometry or gas sensors are used, proper calibration is vital to maintain the fidelity o f the 
measurements.
1.13.4 Quality control
The interpretation of any data from any test is only as reliable as the measuring system. 
Cardiopulmonary exercise testing integrates data from at least three different types o f sensor; 
the integrity of test results is dependent on the validity o f each of these measurements. 
Therefore, rigorous calibration o f the metabolic cart is necessary to ensure reliable 
measurements. Gas flow is often calibrated using a standardised piston or syringe, connected 
to the flow meter; the software included with most commercially available metabolic carts 
enables calibration using this process. Gas analysers on modern metabolic carts use 
standardised calibration gases containing O2 and CO2 mixtures at precise concentrations. 
Prior to testing, the gas analysers are calibrated against two gas mixtures; one containing an 
O2  concentration higher than atmospheric; the second often consists o f CO2 at a
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concentration higher than that of expired air in combination with O2 at concentrations lower 
than expired air. Sampling o f each gas mixture enables the calibration o f the analysers at gas 
concentration above and below that expected physiologically.
Calibration gases have been used in place of traditional Douglas bag calibration. This 
involves the collection of bag samples over one minute periods during exercise at 3 set work 
loads; these samples are then analysed and the volumes measured, to give a standardised 
value for minute ventilation, VO2 and VCO2 for comparison with the data produced by the 
CPET equipment. Many centres do not have the facilities to perform this type o f calibration 
and rely on the standardised gases; however physiological validation is usually performed, 
where two or more subjects perform standard tests on both the CPET equipment being 
evaluated and in a centre capable o f Douglas bag validation. The difference in measurements 
between the two centres should be within 6 percent [389].
Further quality control occurs during actual testing, through the monitoring o f data produced 
during breath-by-breath tests; for example, variation in measurements such as VO2 can give 
an early indication of error if they are higher than expected (e.g. air leak from mask or 
tubing). The duration of CPET should aim for exercise duration o f 10-12 minutes, since 
longer durations can lead to erroneously high measurements of VO2 and cardiac output; this 
occurs when there is a fractional increase in blood flow to the skin for thermoregulation, 
during prolonged exercise [171].
1.13.5 Oximetry and electrocardiographic data
The safety of CPET, as with all forms o f exercise testing, requires the monitoring o f cardiac 
function during the test. This is usually performed by electrocardiography (ECG) and is 
monitored during the test by trained personnel. Furthermore, the data from the ECG can be 
integrated into the test data and allow further analyses.
Oximetry
The oxygen saturation of the subject can be recorded during the test using a pulse oximeter, 
which works on the principle of the difference in absorption spectra between haemoglobin 
and oxyhaemoglobin. Two light emitting diodes, one red (660nM, absorbed by Hb) the other 
near infra-red (940nM, absorbed by oxyhaemoglobin) shine light through either the finger or 
the ear to a detector, within a specifically designed probe The absorption of these light 
spectra by tissues, venous and arterial blood result in a difference in absorption; the oximeter 
calculates the ratio of red:infra-red absorption and using algorithms gives a value o f oxygen
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saturation. The accuracy of pulse oximeters is around 2% between saturations o f 70-100% 
[390-393]; however values lower than this are usually given by extrapolations; consequently, 
the accuracy of oximeters can vary by as much as 10% at values lower than 70-80% [391, 
394, 395]. Oximeters made by different manufacturers can also give variable results, due to 
variations in the computer algorithms used by different makers [396]. Motion artefact, low 
temperatures and hypotension can all impair the accuracy o f oximeter measurements [397, 
398]. The choice o f oximeter probe has an influence on accuracy, with finger oximetry 
demonstrating greater accuracy than ear or forehead probes [399]; furthermore, 
malpositioning of the probe can greatly reduce the accuracy o f the measured SpOz [400]. 
Despite the limitations, pulse oximetry has become widely accepted in most clinical settings 
as a useful indicator o f oxygenation; however the limitation of poor accuracy at low oxygen 
saturations is particularly relevant for these studies. Oximetry data is often integrated into the 
final test result and forms a vital part of interpretation of test in pathological conditions; in 
addition to providing test data during hypoxic testing, oximetry was a vital piece o f safety 
equipment during the hypoxic studies described in this thesis.
Arterial catheter placement and exercise testing
Some CPET protocols necessitate the insertion of an arterial sampling catheter, thus enabling 
measurement of lactate and arterial O2 and CO2 tensions. The siting o f these catheters are not 
without risk (though rare, embolic complications are recognised) and uncomfortable. 
Arterialised samples o f blood can be acquired by the application o f a vasodilator and the use 
of capillary samples via a pin prick, but again are a surrogate for arterial sampling and 
sometimes unacceptable due to discomfort. Modern gas analysers can rapidly give results for 
lactate and blood gas, but are expensive to buy and maintain; therefore availability is limited.
1.13.6 Breath-by-breath
The output from these various types o f analysers gives O2 and CO2 concentrations of inspired 
and expired gas which are interfaced with a computer. This data is combined with flow meter 
data to enable breath-by-breath analysis. All variables are calculated from the data streams 
from these sensors and include: VO2 , VCO2 , end-expiratory CO2 and O 2 , tidal volume, 
respiratory rate and minute ventilation. Further calculations are possible, such as ventilatory 
equivalents, but are not essential to the requirements of most cardiopulmonary exercise tests. 
The output o f breath-by-breath analysis incurs a variation in measurements between breaths, 
due to variations in ventilation, changes in functional residual capacity and the assumption
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that inspired and expired nitrogen volumes are the same (mass spectrometry overcomes this 
by measuring 0%, CO2 and N 2  simultaneously). Many commercially available metabolic carts 
allow averaging o f the breath-by-breath data over a number of breaths or over a length of 
time. The duration o f the averaging period can influence the variability of the results, with 
shorter durations resulting in greater variability. Breath-by-breath data averaged over 60 
second reduces the degree o f variation to that seen in non-automated systems [401, 402].
1.13.7 Variables that are measured and calculated during CPET
VO 2 , VCO2 , respiratory rate, tidal volume and minute ventilation are considered as measured 
variables since they are directly derived from the measured gas flow and the difference 
between inspired and end tidal gas concentrations. Other variables are calculated from these 
‘measurements’, ventilatory equivalents have been described previously, but the other major 
inferred ratio is the oxygen pulse. This is the ratio o f VO2 to heart rate and is sometimes used 
as surrogate measure for stroke volume. In addition to these basic measurements, modern 
metabolic carts are now capable o f calculating a wide range o f physiological variables. 
Irrespective o f whether the variable is measured or calculated the gas volumes and 
concentrations must be standardised in order to allow comparison o f results between different 
days of testing, let alone different centres. Measured gas concentrations and volumes are at 
ambient temperature and pressure and are standardised to either: body temperature and 
pressure, saturated with water vapour (BTPS); or standard temperature and pressure, dry gas 
(STPD, at 0°C and 760mmHg). By convention BTPS is used for ventilation and STPD for 
gas exchange; however many commercial systems can give all variable in either one 
standardised form or another.
The studies described in this thesis utilise the capabilities of a modern CPET metabolic cart 
to perform testing on healthy subjects at rest and during exercise under normoxic and 
hypoxic conditions.
1.14 Cardiac output monitoring
Cardiac output has been and remains an area of physiological interest in both health and 
disease. As a fundamental part o f the convective mechanism between gas exchange at the
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lung and oxygen consumption at the respiring tissues, cardiac output has been measured by a 
variety o f methods for physiological study as well as the investigation and management of 
disease. The settings for measurement are varied, from the physiology laboratory to the 
intensive care setting. The subjects for measurement are variable too; from normal 
individuals to anaesthetised, critically ill patients. As a result o f the broad range of 
circumstances for which CO measurements are necessary a variety o f methods of 
measurement have been developed which are broadly divided into invasive and non-invasive 
techniques. The following is a brief overview of some of these methods focussing on bio­
impedance cardiac output measurement as used in some o f the studies described as part of 
this thesis.
1.14.1 ‘Gold standard’ cardiac output measuremeut.
Pick first proposed a method o f cardiac measurement based on the conservation of mass in 
1870. The principle is that oxygen uptake at the lung is determined by the product of cardiac 
output and the difference in oxygen content between blood as it enters and as it leaves the 
lung:
V02= CO X (CaOz -  CVO2)
Where CaÜ2 and CVO2 represent the oxygen content of arterial blood and mixed venous 
blood respectively (the calculation for the oxygen content o f blood is described in section A). 
The rearrangement of this equation gives:
CO=V02/ (Ca02-Cv02)
Therefore simultaneous measurement of oxygen uptake, haemoglobin concentration and 
mixed venous and arterial O2 saturation enables the determination o f cardiac output. The 
practicality of such a measurement involves the insertion o f a pulmonary artery catheter and 
arterial line into the subject to enable simultaneous sampling o f blood whilst measuring 
oxygen uptake. Pick first described his principle in 1870, but it was another 70 years before 
this method was actually used in humans. Werner Forssmann was the first to insert a 
pulmonary catheter into a human (using himself!) in 1929; Cournand and Richards were the 
first to make measurements o f chamber pressures and cardiac output in 1940 (on a New York
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policeman). Their efforts earned them the Nobel prize for medicine in 1950 [403]. Since then 
modern pulmonary catheters and gas analysers have simplified the method for direct Pick 
cardiac output measurement and it remains the gold standard against which all other methods 
o f CO measurement are compared. Out with research studies and the validation o f other 
methods for CO, the ‘direct Pick’ method is rarely employed. As a consequence a number of 
methods have been devised to enable CO measurement both invasively and non-invasively.
1.14.2 Rebreathe or the ‘indirect’ Fick method for cardiac output measurement
The inability to sample mixed venous blood in humans made the use o f the direct Fick 
method inapplicable for 70 years and even today the siting o f a pulmonary catheter in 
subjects, especially during exercise is impractical at best. During the intervening years 
physiologists did not remain idle in devising novel and ingenious methods for the 
measurement of cardiac output. The forerunner o f these was the ‘indirect Pick method’ where 
the mixed venous gas pressure is approximated by allowing equilibration with an inspired gas 
combined with a knowledge of the association-dissociation characteristics o f that gas with 
blood at various gas tensions. If sampling o f arterial blood gas tensions are use in the 
application of the Fick equation then the result reflects total cardiac output. If inferences of 
pulmonary end-capillary gas tensions from end expiratory gas concentrations are used then 
the result reflect the effective pulmonary blood flow. In normal lungs, in the absence of 
significant extra-pulmonary shunt or disease that impairs ventilation, then this is a reasonable 
measure of total blood flow.
For many years carbon dioxide rebreathe techniques were used for the ‘indirect method’, 
since it quickly equilibrates with blood. This involves the subject breathing in and out o f a 
bag containing a known concentration of CO2  at a higher partial pressure than mixed venous 
blood. As the CO2 concentration in the bag plateaus so the mixed venous PaC02 tension can 
be viewed as ‘fixed’ and is higher than true mixed venous CO2 (because of the Christiansen- 
Douglas-Haldane effect -  where the CO2 carrying capacity o f Hb is reduced in the 
oxygenated state, i.e. the alveolar capillaries). The measurement o f arterial PaC02 tension 
and knowledge o f its dissociation curve enable the application of the Fick equation. This is 
applicable providing there is no recirculation of CO2 from tissue stores and there is 
equilibration across the alveolar membrane. The effects of pH, Hb concentration and oxygen 
tension o f the blood also affect the CO 2 content. Therefore measurements during exercise 
above the lactate threshold and the inherent pH shifts that occur makes this method o f CO
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measurement only feasible during low and submaximal exercise. Studies o f cardiac output 
using CO2  with the direct Fick method have demonstrated a greater degree o f variability in 
comparison with oxygen; this was attributed to the complexity o f CO2 storage and 
dissociation from blood [404]. Despite this, CO 2 rebreathe measurements are still utilised 
predominantly because o f the availability o f rapid CO2 analysers and cost.
In order to overcome the problems encountered with CO2 and the indirect Fick method 
alternate gases have been tried. O f these, acetylene has become the most favoured, since it is 
rapidly soluble in blood and biologically inert. In essence, the method involves the inhalation 
o f a known concentration of acetylene (since it is not endogenous it has zero concentration in 
mixed venous blood). The decline in concentration of gas as it is breathed from the bag is 
measured and is proportional to uptake of gas by blood circulating through the lung. From 
this the pulmonary blood flow can be calculated in a similar fashion to CO2 rebreatheing 
techniques. O f course this is a gross simplification; the initial alveolar concentration of 
acetylene has to be calculated to account for residual volume at the onset of measurement, 
also the quantity gas stored in the lung tissues has to be considered in the calculations. The 
use o f non-absorbed gases as well as carbon monoxide in the inspired gas mix, in 
combination with rapid gas analysers has meant that these problems are now overcome and 
this technique is widely used in physiological study. There are now open circuit systems that 
deal with the problem o f CO2 rebreatheing and ventilatory effects [405, 406], with at least 
one commercially available single-breath apparatus [407]. The last piece o f equipment was 
evaluated in the development o f methods described later in this thesis; however was deemed 
unsuitable due to the difficulties experienced in performing the single breath manoeuvre 
during hypoxic exercise.
1.14.3 Thermodilution methods
Swan and Ganz first described a method for measuring pulmonary blood flow using a 
thermodilution technique in 1971. The method utilises modified pulmonary artery catheter 
equipped with a thermistor at the tip; a known quantity of normal saline cooled to 4°C is 
injected into a proximal port o f the catheter, as the injectate enters the pulmonary blood flow 
proximal to the thermistor cooling of blood. The temperature decline as it is measured at the 
thermistor when plotted against time, gives an inverted bell shaped curve; the area under this 
plot reflects blood flow across the thermistor and is calculated using the Steward-Hamilton 
equation.
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Q= (V(Tb-Ti)KiK2) / (Tb(t)dt)
Where V is the volume of injectate; Tb is blood temperature; Ti is injectate temperature; Ki 
is the catheter constant; K2 is the apparatus constant and (Tb(t)dt) is the change in blood 
temperature over a given time.
a
Figure 1.14 Temperature change curve o f blood after injection o f thermodilutant. Integration 
of this curve provides a value for cardiac output.
If the tip of the catheter is sited in the pulmonary artery then this value reflects pulmonary 
blood flow and CO. The thermodilution technique, though invasive has been used 
extensively in both medical and physiological studies, including measurements during 
exercise; however its validity has been drawn into question. Thermodilution measurements of 
CO have been used as a validation standard in lieu of the direct Fick technique in assessing 
the validity o f other, ‘non-invasive’ methods of cardiac output measurement. This is 
understandable, since it removes the need for oxygen uptake measurement, and the need for a 
metabolic cart. The use o f stringent quality control and dedicated hardware that monitors the 
thermistor output, injectate temperature and performs the necessary calculations has 
improved the reliability of this method. Though thermodilution measurement of cardiac 
output is widely accepted, it still requires the siting of a pulmonary artery catheter which is 
difficult to justify ethically when studying normal physiology. As a consequence 
physiologists have tended to rely on minimally invasive methods such as CO2 re-breathe and
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acetylene techniques; however technological developments have provided further techniques 
for non-invasive cardiac output measurement.
1.14.4 Echocardiography
Echocardiography has been used to measure cardiovascular variables in the diagnosis of 
pathology and response to therapies. Echocardiography has also been used to study 
physiological responses to stresses such as exercise and hypoxia. Two dimensional (2-D) and 
Doppler echocardiography have been used to measure CO; however Doppler is currently the 
preferred method since 2-D studies during exercise are technically demanding, and require 
measurement o f left ventricular (LV) area and LV length in order to calculate volume. The 
Doppler method relies on measurement of the cross-sectional diameter of the aortic root by 
M-mode echocardiographic (which does not vary significantly during exercise) and the aortic 
blood velocity during systole, as determined by Doppler echocardiography. The product of 
aortic root surface area (as calculated from the measured diameter) and the blood velocity 
gives a value o f stroke volume from which CO can be calculated [408]. Despite being easier 
to perform than 2-D echocardiography, trans-thoracic Doppler measurement o f CO is 
nonetheless taxing on the operator, especially during maximal exercise and the reliability of 
these measurements were questioned, though studies to date demonstrate reasonable fidelity 
[409]. Trans-thoracic Doppler measurement of CO has been used at altitude to assess 
improvements in CO and the possible reduction in diffusion limitation to drugs such as 
Sildenafil [410]; however the major area o f expansion in this measurement modality for CO 
has been in the intensive care setting. Trans-oesophageal Doppler probes are now enabling 
the continuous monitoring o f intubated critically ill patients, providing invaluable 
information which is used to tailor therapy. Exercise echocardiography requires significant 
operator skill which makes it difficult to use in the absence o f expertise and draws into 
question reliability. The placement of trans-oesophageal probes in exercising subjects is 
rarely acceptable and can interfere with the gathering data on ventilatory variables. Therefore 
further wholly non-invasive methods o f measurement have been developed.
1.14.5 Bio-impedance cardiography
Bio-impedance cardiography relies on the variability o f the thoracic cavity resistance during 
the cardiac cycle. In essence blood is mainly water which is an excellent electrical conductor. 
At the end o f systole, blood leaves the heart through the aortic root, this alters the electrical 
resistance o f the thoracic cavity; both in absolute terms, but also dynamically since there is a
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waveform in the resistance trace. Measurement of these changes allows the calculation of 
stroke volume, integrating this with an ECG trace gives a value for cardiac output. Older 
measuring machines were cumbersome, requiring two bands to be placed around the 
subject’s neck and a further two bands around the lower part o f the thorax. A small 
alternating current is passed through the two outer bands (located on neck and thorax), whilst 
the change in the measured voltage across the inner two bands allows the calculation of 
thoracic resistivity according to Ohm’s law:
R= V/I
Where R represents resistance; V represents voltage and I represents current. Electrical 
resistance when using an alternating current is termed ‘impedance’ (Z), hence ‘bio­
impedance’ . Impedance has both a resistive component and a reactive component since it can 
vary with the frequency o f the current applied. Bioimpedance monitoring utilizes a frequency 
that has a predominantly resistive component when applied to biological material (around 
lOOHz). The resultant impedance trace gives an absolute value of baseline impedance (Zo) 
which varies with thoracic blood volume to give a variable wave form (AZ) similar to the 
aortic pressure wave and from this can be calculated the first time derivative dZ/dt.
EKG
Zmax
AZ
Zmln
dZ/dt.
d Z / d t Zero line
VET
Figure 1.15 Bioimpedance waveform demonstrating the electrocardiogram (EKG), AZ and 
dZ/dt waveforms; VET is the ventricular ejection time.
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The AZ waveform has a tendency to vary with respiratory oscillations and has made it less 
reliable; however the dZ/dt trace demonstrates clearly defined segments that facilitate 
automated calculations and are not as sensitive to respiratory change. Kubichek first 
described an equation that allowed calculation of SV based on the supposition that the 
thoracic cavity is a cylinder:
SV= p. [L^]/[Zo^].dZ/dt.t
Where p is the electrical conductivity of blood and L is the mean distance between the two 
inner electrodes (thoracic height) [411]. This equation has been further modified, using the 
assumption that the thoracic cavity approximates to the shape o f a truncated cone (frustrum) 
rather than a cylinder and eliminates the conductivity of blood, which can be assumed as a 
constant [411]. The thoracic length can be derived from the total height (H), thus simplifying 
the equation to:
SV= (0.17H)^ / 4.2.dZ/dt.t/Zo
The limitation of both these equations lies in the use o f a baseline value for thoracic 
impedance (Zo) which is variable with skin thickness, perspiration and electrode position. 
The latest generation of bioimpedance equipment removes this potential source o f error by 
utilising the signal waveform to calculate SV [412]. This equipment (Physioflow PF-05) was 
assessed and then used for the experiments, described later in this thesis, for exercise cardiac 
output measurement. The PF-05 is light, portable and uses electrocardiography electrodes in 
lieu o f metal bands. Bio-impedance signals can be inputted into a notebook computer, 
enhancing the portability of the equipment. Furthermore values of CO and SV can be 
averaged over a number o f heart beats; this data then can be directly exported into a 
statistical program for a more detailed analysis.
The accuracy in terms o f absolute values for CO has been questioned; however bioimpedance 
does seem to accurately reflect changes in CO. Moreover there is agreement that the values 
measured, are reliable and reproducible [413]. The methods section describes validation 
studies comparing the PhysioFlow equipment with thermodilution in the catheter laboratory 
setting; published studies comparing this equipment with the direct Fick method [412]
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suggests an accurate and reliable technique for CO measurement. The Physioflow PF-05 was 
used for cardiac output measurements during some of the exercise test protocols described in 
this thesis; the equipment was not used for all tests, since it became available during the 
course o f subject recruitment and testing. Echocardiography was evaluated and dismissed as 
a means of exercise cardiovascular measurement due to the lack of a suitable supine 
ergometer and dedicated echocardiographic expertise. These methods and those for CPET are 
described in detail in the next chapter.
Summary
This chapter has reviewed the physiological mechanisms underlying the cardiopulmonary 
response to exercise and hypoxia; the latest evidence and theories for oxygen sensing; the 
function of the renin-angiotensin system and ACE gene polymorphism in relation to hypoxia 
and exercise performance. The next chapter describes the methods used to investigate any 
possible link between the ACE 1/D gene polymorphism and the cardiopulmonary response to 
exercise and acute hypoxia.
119
CHAPTER TWO; METHODS
2.1 Study design......................................................................................................................... 121
2.2 Cardiopulmonary exercise testing..................................................................................... 127
2.3 Cardiac output testing .........................................................................................................138
2.4 Genetic analysis...................................................................................................................143
120
LABORATORY STUDY METHODS
2.1 Study design
2.1.1 Overview
The purpose o f these experiments was to examine whether the physiological responses to 
hypoxia during rest and exercise in comparison to measurements under normoxic conditions 
demonstrated any variation in relation to the ACE gene polymorphism. Particular attention 
was given to ventilatory and cardiovascular responses (in the form o f cardiac output 
measurements) in addition to the metabolic measurements o f VO2  and VCO2 . To avoid 
exercising subjects at work rates above their ventilatory threshold (and therefore their 
anaerobic threshold), an initial maximal exercise test was performed. The subsequent steady 
state exercise periods were then performed at a load 50% of that required to reach ventilatory 
threshold as determined non-invasively by the V-slope method. Steady state exercise was 
performed in normoxic conditions and hypoxia (Fi02 12.5%); thereby using normoxic 
measurements for each subject as a control for comparison with their hypoxic response |
during identical test conditions. Normoxic studies were performed first; this was to reduce 
the risk o f lactate build up that might have occurred by performing hypoxic testing first. At 
least 15 minutes were allowed between steady state tests. Measurements were made toward 
the end o f the resting phase, to allow familiarisation with the circuit and then during exercise 
when steady state was reached.
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The aforementioned studies examining the feasibility o f exercise echocardiography were 
performed by a technician in the Cardiac investigation department o f the Western Infirmary.
These studies were abandoned for several reasons. Firstly, the tricuspid regurgitant jet (TR 
jet) whieh would have enabled an estimation of systolic pulmonary artery pressure was not 
reliably detectable in the subject population. Secondly, a suitable supine ergometer was not 
available despite attempts to secure funding for the purchase of one; this may have facilitated 
exercise echocardiographic measurements. Finally, this line of investigation wsa abandoned Ï
after consultation with Dr Simon Cooper (Hammersmith Hospital, London) and Dr Adam 
Torbiki (University o f Warsaw, Poland) both o f whom have extensive experience o f exercise 
echocardiography; in their opinion it was unlikely that sufficient number of subjects would 
demonstrate a significant TR je t in a subject group as young as ours. I:
2,1.2 Subject Selection
Subjects were recruited from the University of Glasgow Officer Training Corps, the Sports 
and recreation service o f Glasgow University and the Department o f Medicine at the Western 
Infirmary, Glasgow. A total o f 60 volunteers were recruited all o f whom had 
cardiopulmonary exercise testing and measurements o f ventilatory and metabolic variables. 
O f these, 30 subjects had non-invasive cardiac output measurement by bio-impedance means 
during rest and exercise in normoxic and hypoxic conditions.
Ethical approval was granted by the West Glasgow Hospitals NHS trust Ethics Committee 
(Study number 99/191(2), Appendix A). Subjects were required to give written informed 
consent and complete a questionnaire for inclusion in the study.
Inclusion criteria
Inclusion criteria were regular exercise for at least 3 hours or more per week for most of the 
preceding year and age between 18 and 40 years.
Exclusion criteria
Exclusion criteria were:
1. A history or examination suggestive o f cardiac or pulmonary disease.
2. No evidence o f current illness o f any description.
3. The use o f prescription medication other than the oral contraceptive pill and simple 
analgesics.
4. The use of medicines prohibited by the International Olympic committee 1998.
5. A history of severe atopy or drug reaction.
6. Excursion to altitude in excess of 2000m in the previous 3 months.
7. Residence at altitude in excess o f 200m for more than 3 months at anytime.
8. Cigarette smoking.
9. Pregnancy
In addition subjects were asked to abstain from caffeine and alcohol 12 hours prior to testing
and to abstain from strenuous exercise in the 24 hours prior to tests, particularly prior to the
maximal cardiopulmonary test.
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2.1.3 Study structure
The laboratory study required two visits to the department. During the first visit subjects 
were required to read the information sheet provided and sign the consent form. They were 
then asked to complete a questionnaire to determine their suitability to participate in the 
study. Prior to testing calibration o f the gas analysers and mass flow sensor was performed. A 
maximal exercise test in normoxic conditions was then conducted, primarily to determine the 
subject’s ventilatory threshold and the work rate at which this was reached. Invariably 
subjects went on to perform a maximal effort test, mainly in order to determine their own 
fitness level as measured by V02max. At the second visit the steady state exercise tests were 
performed. The original protocol allowed a minimum of 6 hours between the maximal 
exercise test and the subsequent steady state tests. In reality the majority (all bar 8 subjects) 
attended the next day for the second phase o f the test protocol.
2.1.4 Development of study design
The basic study structure was designed to give a reproducible measure o f physiological 
response to hypoxia at rest and during exereise. A Fi02 of 12.5% was chosen in order to elicit 
responses over short exposures whilst at the same time maintaining a degree o f safety. 
Furthermore it was felt that exercise at lower Fi02 subjects could reach ventilatory threshold 
during the hypoxic steady state test. Initial experiments performed on volunteers (including 
myself) using a lower Fi02 of 11.5% certainly produced the required desaturation as 
measured by pulse oximetry, but did have symptomatic effects in terms o f light-headedness 
during exercise. Initial tests had to be terminated prematurely because o f adverse symptoms.
Previous studies that demonstrated enhanced performance in association with the 1-allele of 
the ACE gene polymorphism were conducted in the field; hence, poikilocapnic hypoxia was 
used to reflect true environmental hypoxia. Pilot experiments were performed, using the 
available equipment, to establish the feasibility of isocapnic hypoxic challenge; this was in 
order to dissect out the pure hypoxic response in relation to ACE gene polymorphism. A 
1000 litre Douglas bag filled with hypoxic mixture was used as a reservoir to be inhaled 
during the hypoxic phase o f experiments. This was administered by a wide calibre, low 
impedance circuit. Attempts to introduce CO2 into this circuit during the experiment resulted 
in an erratic FiC0 2  and produced variability into the measurements, probably as a result of
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insufficient mixing within the circuit. Unfortunately suitable high flow rotameters which 
would have allowed a finer degree o f control to the introduction of CO2  to allow isocapnic 
hypoxic exercise testing were unavailable.
The metabolic cart used for these experiments (Sensormedics Vmax 29 series, Yorba Linda, 
CA, USA) measured inhaled Fi02 and FiCOa allowing a further degree of quality control. 
The introduction of the circuit onto the mass flow sensor introduced a further 100 mis dead 
space, fortunately the software provided with the metabolic cart allowed adjustment o f circuit 
dead space, and made allowances for this in the calculation o f gas flow.
The use o f hypoxic mixtures introduced lower gas exchange values than would normally be 
expected in normoxic conditions. This raised concerns regarding the reliability of these 
values, since the gases provided by the manufacturer for calibration o f the metabolic cart 
were designed for measurements in room air. This query was raised with the manufacturer 
and assurances were given that the performance o f the O2 detector was reliable at the lower 
oxygen tensions, since it behaved in a direct relationship (straight line) with oxygen tension. 
Calibrating across part o f the actual oxygen vs. measured oxygen plot would ensure fidelity 
of measurements across the entire range. Experiments using calibration gas with 0% FiOi 
compared with the usual 16% Fi0 2  mixture provided, confirmed that there was no difference 
in the recorded values.
2.1.5 Statistical analysis
The biometric and physiological measurements and data derived from them were tested for 
normal distribution for the subject group. To allow for comparisons to be made between 
different subjects o f varying size and degrees o f fitness percentage change between normoxic 
and hypoxic variables during rest and exercise were calculated for each individual. These too 
were tested for a normal distribution between all three genotypes for the ACE gene. 
Statistical tests were then applied to determine whether there were any significant differences 
between the groups for each variable. One way analysis o f variance (ANOVA) testing was 
used to determine any significant difference between the genotypes. The power calculation 
for the cardiopulmonary study was performed on the statistical software. Statistical analysis 
was performed on a generic PC running Minitab 12.1 (Minitab Inc., State College, PA., 
USA) on a Microsoft Windows XP operating system.
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Normality testing
A normal population should have a symmetrical frequency distribution on either side o f the 
mean, where 68% of the points lie within one standard deviation on either side o f the mean 
and 95% within two standard deviations. The application o f many powerful statistical 
analyses is dependent on establishing the normality of the groups being compared. There are 
a number o f methods o f establishing normality; frequency distribution plots can demonstrate 
a symmetrical bell shaped curve and plotting the standard deviation from the mean results in 
a straight-line which is characteristic o f a normal sample population. There are statistical 
tests that offer quantitative and qualitative measure o f normality. The Minitab statistical 
package offers a choice o f tests. The Ryan-Joiner normality test was chosen because it relies 
on plotting the probability o f data point proximity to the mean similar to the normal plot, but 
also gives a correlation coefficient. In this case the aim is not to refute the null hypothesis 
and a p value higher than the arbitrary threshold must be attained. Therefore, the Ryan-joiner 
test enables a qualitative and quantitative measure of straightness of the normal plot (Figure 
2.1). In this way it is similar to the Shapiro-Wilk or Shapiro-Francia tests.
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Figure 2.1 An example o f a Ryan-joiner plot. The distribution of data points is plotted 
according to the probability o f deviating from the mean. The straightness of the plot is 
verified by the correlation coefficient and p value in the bottom right hand comer (in red).
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Parametric and non-parametric tests
Parametric statistical tests can be applied to data sets which demonstrate a normal 
distribution; in the event o f a skewed distribution non-parametric tests are appropriate. In 
normal data sets, paired student t-tests were used to verify significant differences between 
normoxia and hypoxia. In data sets that failed to meet the criteria for normality, the Wilcoxon 
matched pairs signed sum rank test (the non-parametric equivalent to the student t-test) was 
used. Analysis o f variance (ANOVA) was used to determine any significant difference 
between the ACE genotype groups. This test requires normality in the sample being 
compared; this was confirmed using the Ryan-Joiner test for each group. There was one 
occasion where the sample did not demonstrate normality, on this occasion the Kruskal- 
Wallis test was used which is the non-parametric equivalent o f the ANOVA test.
Comparison o f  measuring methods and repeatability
The validation studies required the comparison of thermodilution and bioimpedance cardiac 
output measurement. This was verified, using the method described by Bland and Altman. 
This method plots the average results o f simultaneous measurements using the two methods 
against the difference between the two measurements. An acceptable level o f difference is set 
at two standard deviations (as recommended by British standard 5497 part 1) [414]. The 
same method was used to determine the repeatability of steady state cardiopulmonary 
exercise tests.
Correlation o f  ventilatory response with etC02
The minute ventilation, tidal volume and respiratory rate were compared to the end-tidal CO2 
as an index o f alveolar ventilation. This was achieved using simple correlation plots, which 
included Pearson’s correlation coefficients and regression lines in order to assess the 
presence o f any relationship between ventilatory variables during the normoxic and hypoxic 
parts o f the protocol. This in part was to confirm that the responses were in keeping with 
those expected physiologically, but also to ascertain whether there was any detectable 
evidence o f hyperventilation, particularly during the resting phase o f testing. Pearson 
correlation coefficient was calculated using the Minitab statistical package.
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Conformity to the Hardy-Weinberg equilibrium
The genotype distributions of both the cardiopulmonary exercise group and the bioimpedance 
group were checked to ensure that the allele and genotype frequencies were in Hardy 
Weinberg equilibrium (HWE). This was achieved by calculating the allele frequencies in the 
group:
(2 X observed 11) + observed ID
2 X (observed II + observed ID+ observed DD)
q = 1-p
Therefore expected genotype frequencies can be calculated as follows:
II = p^XM where n = subject number in sample
ID = 2pq X n 
DD = q^xM
Once calculated these values can then be used to calculate the Chi square value (%^ ) against 
the observed genotype frequencies, thereby determining the goodness of fit to the HWE. In 
this case, the null hypothesis is that the population is in Hardy-Weinberg equilibrium. The 
degree of freedom is I (number o f genotypes -  number o f alleles); therefore for a 
significance level of 0.05, must be greater than 3.841 to reject the null hypothesis (from 
standard tables).
2.2 Cardiopulmonary exercise testing
Two visits to the department were necessary; during the first visit physical characteristics 
were measured and entered in to the computer database, before a maximal exercise test was 
performed. The steady state exercise tests in normoxic and hypoxic conditions were 
performed during the second test. The following is a description o f the equipment used, the 
protocol for maximal effort exercise test and the steady state test performed at 50% o f the 
work rate at which ventilatory threshold was reached. The first section describes the main 
exercise protocols. The latter sections describe the measured and calculated metabolic and
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ventilatory variables. The final section describes the quality control measures and the 
validation studies performed to ensure the repeatability of the method.
2.2.1 Equipment
Experiments were performed on level 4 o f the Glasgow Western Infirmary, in the Research 
Exercise laboratory o f the Department o f Respiratory Medicine.
Subject Biometrics
Subject height was measured on a scale mounted measuring rod (Seca 220, Seca, Hamburg, 
Germany) and weight was measured on digital scales (Seca 701, Seca).
Cardiopulmonary exercise testing
A commercially available metabolic cart (Sensormedics Vmax 29 series, Yorba Linda, CA, 
USA) was used for measurement o f all spirometric, ventilatory and gas exchange variables. 
This equipment uses a mass flow sensor to measure gas flow. Sampling tubes were inserted 
into the sides of the sensor to allow gas to be extracted by the gas analyser; these were 
designed to dry the sampled gas before entering the analyser (Perma Pure, Nafion).
In addition to dynamic testing the same equipment was used to measure spirometric values, 
forced expiratory volume in one second (FEV,), forced vital capacity (FVC) and flow 
volume loop data were measured. This was performed to ensure normal values for age and 
height, but to also exclude any air flow obstruction prior to dynamic testing.
Face mask and seals
The subjects were fitted with a reusable face mask with oronasal separator and disposable 
gelatinous seal (Universal seals, Hans Rudolph Inc., Kansas city, MO, USA). This was 
secured by elasticated straps and skull cap. The mass flow sensor could then be attached to 
the mask. In addition to the oronasal separator, the subjects wore nasal clips (similar to those 
used whilst swimming) to ensure oral breathing and reduce air leak.
Computer
Measured data from flow sensor and gas analysers were relayed via a serial interface into a 
generic personal computer (PC), running Microsoft Windows 1998 operating system and 
software provided by Sensormedics for use with the Vmax29 unit.
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Exercise ECG and Puise oximetery
A 12 lead exercise Electrocardiograph recorder (Marquette electronics, MAX-1, Milwaukee, 
Wl, USA) allowed heart rate data to be recorded and a transcutaneous pulse oximeter 
(Ohmeda Biox 3700, Boulder, CO, USA) measured oxygen saturation, both data streams 
were interfaced into the PC and recorded by the Sensormedics software. Oximetry 
measurements were made with a finger probe; experiments with ear probes proved unreliable 
because o f motion artefact.
Cycle Ergometer
An electronically braked upright cycle ergometer (Ergometrics, Ergo line 900, Bitz, 
Germany) was used to provide the exercise work load. This was connected to the PC, 
allowing control of the work load set by the Sensormedics software. During the maximal 
effort exercise test the work load was incremental, in the form of a continuous ramp at a set 
rate set by myself (e.g. 25 watts per minute). The incremental rate was estimated according to 
the subjects exercise history, with the aim o f attaining between 8 and 12 minutes exercise 
before the subject fatigued to the point o f stopping.
Hypoxic circuit
Hypoxic gas mixture was administered from a 1000 litre Douglas bag (Hans Rudolph Inc., 
Kansas city, MO, USA). This was first evacuated using a domestic vacuum cleaner. Air was 
then diluted using a modified flow rotameter originally designed for anaesthetic purposes to 
enrich air with oxygen to give a high FiÜ2 . This was adapted by connecting compressed air 
(Medical grade, Linde Gases Ltd. UK) as per the original design, but to introduce pure 
nitrogen via compressed cylinder (Diving grade, Linde Gases Ltd, Aberdeen, UK) instead of 
oxygen, thereby producing a hypoxic mixture. The percentage O2 o f the gas mix was 
measured using an oxygen analyser connected in series to the evacuated Douglas bag. The 
bag was filled with 12.5% 0 2 , balance nitrogen via 35mm tubing and a three way tap 
attached to the bag (2100 series, Hans Rudolph Inc.). The subject was connected to the 
circuit during steady state tests by a non-re breathe valve (2700 series, Hans Rudolph Inc.) 
and 35mm tubing. The normoxic phase o f the test was performed with the three-way tap 
open to the atmosphere and during the hypoxic phase the subject breathed from the bag.
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Figure 2.2 The layout of the various pieces of equipment during steady state exercise testing. 
During the normoxic part o f the test, the three-way tap was turned to the atmosphere instead 
of the bag.
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2.2.2 Maximal effort exercise protocol.
Prior to testing subjects were given the information sheet to read, consented and filled in the 
questionnaire to ensure they met the required criteria. Tests were carried out in room air. Two 
investigators one of whom was medically trained and familiar with the available resuscitation 
equipment were required to be present throughout testing (i.e me).
1. Height and weight were measured.
2. Subject biometric data, sex, and date o f birth were entered into the Sensormedics 
software. This then calculated predicted values for variables to allow comparison 
[415].
3. Brachial artery pressures were measured using a stethoscope and portable 
sphygmomanometer.
4. Before each set o f tests the mass flow sensor was calibrated using a standard volume 
3 litre calibration syringe (Vitalograph Ltd., Buckingham, UK.) according to the 
manufacturer’s instructions. The software’s own quality control algorithms would 
reject the calibration process if the technique was inadequate or there was fault.
5. Gas sensors were then calibrated using standardized calibration gases provided by the 
manufacturer. These were 16% 02:4% C02:balance N 2 and 24% 02:balance N 2 
(Sensormedics, Yorba Linda, CA, USA)
6. Skin electrodes for 12-lead ECG were placed on the subject chest and proximal limbs.
7. The volume o f dead space introduced into the circuit by the mass flow sensor was 
entered into the software (0.05 litres). The estimated work rate increment was entered 
into the software.
8. A nose clip was fitted to the subject and spirometric measurements (FEVi, FVC and 
flow volume loop) were measured, the best effort o f 3 attempts was recorded.
9. The face mask was attached to the subject, by elasticated straps and a skull cap.
10. The mass flow sensor was then attached and the subject transferred to the ergometer. 
The saddle height was then adjusted for optimal cycling position.
11. A 2 minute period o f familiarisation was allowed before commencing a 3 minute 
period o f unloaded pedalling at a cadence of 60 rpm.
12. The work load was commenced via the software without informing the subject. This 
increased at a smooth ramped rate as determined by the investigator (myself).
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13. Subjects were reminded to monitor their cycling cadence, but only had one verbal 
encouragement towards the end o f the exercise phase to ensure a maximal test was 
achieved.
14. The exercise test was deemed complete when the subject could not continue due to 
leg fatigue (no subjects stopped because o f dyspnoea or other symptoms).
15. Blood pressure measurement was repeated and the subject was required to keep the 
mask on for a further 2 minutes or until heart rate had returned to within 20 beats of 
baseline.
2.2.3 Steady state exercise protocol
Ventilatory threshold (VT) was determined by analysis of the maximal effort exercise test 
using the Sensormedics software. The V-slope method was utilised by the software, but could 
be finely adjusted by the investigator in light of the other plots provided (e.g. PetCOi). The 
work load at which VT was deemed to have been reached was then halved and this work load 
was used during the square wave steady state exercise test.
Similarly the presence o f two investigators, one medical was required.
1. Subjects’ data was retrieved from the computer database and entered automatically 
into the software.
2. Steps 3-9 o f the maximal effort protocol were performed, with the exception o f the 
dead space volume. The hypoxic circuit introduced 150mls o f dead space and this 
value was entered into the software.
3. The mass flow sensor was attached and then the 2700 series non-rebreathe valve was 
attached, using a custom made adaptor. The weight of this circuit was supported by a 
head support worn by the subject. The circuit at this time was open to room air.
4. The subjeet then transferred to the ergometer and sat at rest for 5 minutes. This 
allowed familiarisation with the new circuit and baseline measurements.
5. They were then asked to cycle at a cadence of 60rpm.The calculated work load was 
applied from the onset of exercise as a square wave. Subjects exercised for 8 minutes.
6. The subject then dismounted the ergometer in order to rest and have repeat spirometry 
performed. Ten minutes were allowed for this.
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7. The mask and circuit was reattached and the subject then returned to the ergometer, 
however early during the baseline measurements the valve was switched to the 
Douglas bag and the subject was breathing hypoxic mixture.
8. Steps 4 and 5 above were repeated.
2.2.4 Metabolic, ventilatoiy and cardiac measurements.
Measurements were made on breath-by-breath basis. The metabolic cart measured tidal 
volume (V t) , respiratory rate (R R ), inhaled F1O2  and FiCO:, exhaled FiOi and FeCO]. The 
difference between oxygen and carbon dioxide concentration during inhalation and 
exhalation in combination with the tidal volume (as measured by the mass flow sensor) 
allowed calculation o f oxygen uptake (VO2) and carbon dioxide production (VCO2), end- 
tidal O2 and CO2 (Pet02 and PetC02 respectively). All measurement were made using SI 
units, measurements o f partial pressures were in kilopascals (kPa); a conversion factor of 
7.501 is required for conversion to mmHg. Minute ventilation (V e )  was calculated from the 
product of tidal volume and respiratory rate. Further calculated variables available were 
ventilatory equivalents for O2  and CO2  (VgOz and VECO2), oxygen pulse and gas exchange 
ratio (R); ventilatory equivalents were used to confirm the VT inflection point during 
maximal tests.
Exercise ECG data provided monitoring during tests which satisfied safety concerns and 
pulse rate data which was incorporated into the data. Detailed examination o f exercise ECG 
traces was not performed since they fell out with the aims of this project.
Steady state was considered attained by visual monitoring of the cardiopulmonary variables 
as the test progressed and confirmed by the software’s own algorithms using a plot o f 3 
breath averages.
Dynamic data collected was averaged over the last 90 seconds of the rest period and exercise 
to give a value for steady state rest and exercise during normoxia and hypoxia to allow 
comparative analysis for each subject in these conditions (figure 2.3). Disruptions in normal 
ventilation during swallowing or attempted speech did result in a marked variation in 
ventilatory measurements; the breath-by breath measurements o f all variables during 
disrupted ventilation were edited from the final data set before analysis.
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Figure 2.2 Subject on cycle ergometer performing a steady state test. The Douglas bag is in 
the foreground and the mask, flow meter and non-rebreathe valve connected to the hypoxic 
reservoir are attached to the subject.
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Figure 2.3 Constant load exercise test graph. This plot shows minute ventilation, tidal 
volume, respiratory rate and oxygen saturation during a constant load exercise test in hypoxic 
conditions. The areas highlighted in blue represent the 90 seconds during which mean values 
of each variable were taken. The graph also demonstrates that steady state has been achieved.
2.2.5 Quality control m easures and validation studies 
Quality control
The Sensormedics Vmax29 metabolic cart was central to the measurement of 
cardiopulmonary responses to exercise and static spirometric data. Therefore it was essential 
to ensure the equipment was in good working order and properly calibrated to ensure the
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fidelity of the data collected. This was achieved in several ways. First the equipment was 
serviced regularly as part o f the agreement with the supplier (Sensormedics UK.), this 
included gas analysers, interfaces and software updates. Mass flow sensors and gas sampling 
tubes were also provided to replace old or worn units. Secondly, regular calibration was 
performed. The protocols describe the calibration process for both ventilatory and gas 
exchange measuring systems. If these were not within the tolerances designated by the 
manufacturer, they were rejected by the software and had to be repeated. The software that 
analysed the data from the sensors also required updates o f local barometric pressure to 
compensate for daily variations; this was measured from a mercury barometer (situated on 
the same floor) and inputted into the software. Periodic calibration o f the ergometer was 
performed to ensure the fidelity o f work load. The entire system was then checked by 
biological calibration using a volunteer again on a periodic basis. Thirdly, between tests 
drying tubes were changed and allowed to dry before being reused. This ensured that gases 
sampled were free o f water vapour and would not interfere with gas measurement (the infra­
red method o f C0% measurement is particularly susceptible to this). Finally three sizes of 
mask were available and in combination with the disposable gelatinous seals ensured a good 
fit. This was checked by an inspiratory manoeuvre with the mask attached and the orifice 
occluded.
Disinfection and cleaning
Mass flow sensors, masks, nose clips, mouthpieces, saliva traps (the last two items were used 
for spirometric measurements) were disinfected in a 1% solution o f Virkon® (DuPont, 
France), rinsed in sterile water and allowed to air dry. Each subject had equipment that had 
been sterilized by this method for each test.
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Figure 2.4 Screen shot o f the flow meter calibration sequence.
Validation Studies
The repeatability o f tlie tests was verified by repeating the steady state exercise protocol in 5 
subjects. These tests examined the repeatability o f VO2 and minute ventilation measurements 
between repeated tests. The data is presented in the results section. O f the five subjects, 4 
completed two sets of normoxic and hypoxic steady state protocol. The final subject repeated 
only the normoxic steady state protocol. The results were analysed by direct percent 
difference between the two tests. Furthermore, Bland-Altman analyses of the results from the 
repeated tests were plotted. For this purpose the resting and exercise results were pooled, 
irrespective o f whether they were performed under normoxic or hypoxic conditions; however 
the results of tests were always compared like for like (i.e. normoxic results with the results 
of the repeated normoxic test etc.).
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2.2.6 Data collection
The Sensormedics software allowed steady state averages to be analysed on screen and 
stored. It did not allow a detailed analysis. Therefore data was exported into a Microsoft 
Excel spreadsheet and then into the statistical analysis program. Unfortunately the version of 
the Vmax 29 software we were working with would not allow the direct export o f the data in 
this fashion. To overcome this, a hardcopy o f the breath-by-breath data was printed out in 
12pt Arial font. This was then scanned into the spreadsheet using an optical flat bed scanner 
with automatic paper feed (Epson Perfection 1640SU, Seiko Epson Corp., Japan) using 
Optical character recognition (OCR) software (Omnipage Pro-version 10, Caere corp., Los 
Gatos, CA, USA). The fidelity o f this transfer process was then proof read and checked by 
me. Statistical analysis has been discussed in the section dealing with study structure. Once 
data had been imported into a Microsoft Excel spreadsheet it was exported into a Minitab 
worksheet for analysis.
2.3 Cardiac output testing
The following is a description o f the development of methods and protocols to measure 
cardiovascular variables in relation to exercise and hypoxia.
2.3.1 Development of study design
Systemic cardiovascular variables measured during these experiments took the form o f pulse 
measurement during the entire protocol as outlined above and blood pressure measurement at 
rest and after exercise. The main focus o f these experiments was to measure the pulmonary 
cardiovascular responses to hypoxia and exercise. Potential areas o f focus include pulmonary 
artery pressure and cardiac output responses to hypoxic and exercise stimuli. The choice of 
technique was limited by availability o f equipment and acceptability.
Pulmonary artery catheters with pressure transducers are capable o f measuring pulmonary 
artery pressures and inferring cardiac output by thermodilution methods. These certainly give 
a direct measurement of the variables, but would have involved exposing healthy subjects to
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an invasive procedure with potentially hazardous effects. This was felt to be unacceptable on 
ethical grounds and to the subjects themselves.
Non-invasive measurements of pulmonary artery pressure are possible using 
echocardiography, however these methods are dependent on operator skill and the 
availability o f a supine cycle ergometer that would allow reproducible exercise and leave the 
subject in a suitable position for echocardiography. The development and availability of 
harmonic echocardiography had produced a vast improvement in resolution and Doppler 
measurements and in combination with injected contrast (either agitated saline with 
microbubbles or commercially available contrast) was hoped to provide the best hope of 
achieving reproducible measurements. However a suitable ergometer was not available and 
initial experiments were performed on an old supine ergometer (of unknown vintage or 
origin) to assess the feasibility o f studies. Despite the availability o f an experienced operator, 
the use of the most up to date harmonic echocardiograph equipment and trials of agitated 
saline, we were unable to achieve results with any degree of fidelity. The main problem were 
in identifying the tricuspid regurgitant je t (TR jet) in young healthy subjects and a failure rate 
o f up to 50% meant that this technique would prove unfeasible. The possible use of 
commercially available contrast media was proposed and dismissed because the media itself 
was derived from human albumin there was the small risk o f hypersensitivity reaction and in 
light o f the concerns over prion disease, the risk of possible infection were deemed 
unacceptable to healthy normal subjects.
Single breath inhalation o f acetylene was next investigated as a means o f measuring cardiac 
output. This was available from the manufacturer of the metabolic cart in the form of an add­
on module. Sensormedics were kind enough to loan such a unit for a trial period. In order to 
produce reliable measurements a controlled smooth exhalation manoeuvre was necessary. 
This was problematic since it was a difficult manoeuvre to perform during exercise 
(especially during hypoxic exercise) and tended to interfere with the ventilatory 
measurements during exercise. In addition several volunteers felt the need to cough, again 
introducing further variability and was unpleasant for the subjects (two subjects stated they 
would not wish to repeat the procedure). This method was therefore abandoned.
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The bio-impedance method provide a non-invasive measurement o f cardiac output, using a 
new means of measuring the wave form of the bio impedance signal provides a more 
accurate reflection of stoke volume and in combination with ECG pulse recordings a value 
for cardiac output. A PhysioFlow PF05 Lab I non-invasive cardiac output unit (Manatee 
biomedical, Paris, France) was assessed for accuracy in validation experiments comparing 
measurements o f cardiac output during pulmonary catherisation o f patients undergoing 
investigation of pulmonary arterial hypertension. As part of their investigations patients 
would have cardiac output measured by thermodiiution method, concurrent measurements of 
cardiac output were made with the PhysioFlow equipment. Once satisfied with the fidelity of 
measurements, cardiac output measurement by bio-impedance was incorporated into the 
steady state exercise protocols.
2.3,2 Validation studies using bio-impedance and thermodilution methods
Patients with pulmonary arterial hypertension underwent right heart catheterisation as part of 
their initial investigations in order to establish the severity of their disease, responses to 
exercise and effect of vasodilator challenge. Exercise was in the form of straight leg raises 
(patients with a femoral site for intravenous access were excluded). Vasodilator challenges 
were in the form of inhaled oxygen (Fi0 2  60%), adenosine infusion or nitric oxide inhalation 
(at 40ppm). Patient selection was limited by ability to exercise and site of catheter access. In 
total 4 patients had concurrent bioimpedance and thermodilution methods for measuring 
cardiac performed. This data is presented in the results chapter
The protocol for the validation studies is as follows:
1. Patient details were entered into the PhysioFlow software,
2. Chest and neck electrodes (Blue Sensor R -  stud fixing, Ambu Inc., Linthicum, MD., 
USA) were applied and connected to the unit.
3. Blood pressure was measured with a sphygmomanometer and stethoscope. The values 
were entered into the software.
4. The automatic calibration cycle was commenced and lasted 30 seconds.
5. A venous sheath was inserted into the internal jugular vein under aseptic technique 
with anaesthetic (Lignocaine 2%) instilled locally.
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6. The right heart catheter was inserted and the tip sited in one of the pulmonary arteries 
under radiographic guidance.
7. Cardiac output measurement by thermodilution was then performed. Sterile isotonic 
saline chilled to 4°C (a thermistor had been placed in the cooling bath and was 
connected to the thermodilution computer) was injected into the proximal port o f the 
catheter. The distal thermistor records the temperature and relays this to the 
thermodilution computer. This then calculates the cardiac output.
8. At least 3 measurements were taken by thermodilution with simultaneous 
bioimpedance values recorded.
9. The patient was then asked to raise and lower their legs in turn in order to cause a 
heart rate rise.
10. Steps 7 and 8 were repeated.
The comparison o f measurements during vasodilator studies were not made since the effect 
of pharmacologically altering the intra-thoracic fluid compartment and therefore 
bioimpedance was thought to be a possible confounding factor. These measurements, 
however interesting fell out with the remit of these studies.
Z 4 + EKG3 (neutral)
ELECTRODE POSITIONS
Figure 2.5. PhysioFlow equipment and chest electrode positions
141
Figure 2.6 Fluoroscopic image demonstrating catheter placement in the right main 
pulmonary artery. Some of the PhysioFlow leads are visible in the image. (This patient was 
not included in the validation studies due to the femoral access used for catheter access)
2.3.3 Steady state exercise cardiac ou tpu t protocol
Measurement o f cardiac output was performed concurrently during the steady state exercise 
protocols during normoxia and hypoxia. No measurement of cardiac output was made during 
maximal effort exercise testing.
The equipment used for measurements was a PhysioFlow PF05 bioimpedance unit interfaced 
with a laptop computer (Toshiba Satellite Pro 3000, Toshiba, Tokyo, Japan) running the 
PhysioFlow software on a Microsoft Window 98 operating system. Blue senor R electrodes 
(Ambu Inc., Linthicum, MD., USA) were used throughout the experiments.
The protocol was entirely based on the exercise protocol as described in section 2.2.3. The 
only addition at the onset o f testing was the application of electrodes to the neck and chest as 
described above and the recorded blood pressure was inputted into the PhysioFlow software. 
The only difference was the semi-supine position adopted by subjects during the automated 
calibration period (this was unnecessary in the validation studies since the patients were 
supine). Measurement of cardiac output continued throughout the test period. Points o f note 
during the testing (rest, onset o f hypoxia, exercise etc.) were recorded using the software.
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The data was then electronically exported into an excel spread sheet, cardiac output, stroke 
volume (SV), heart rate (HR) and cardiac output (CO) were plotted against time. 
Measurements over 90 seconds were averaged at the same points as those used for 
cardiopulmonary variables, to give steady state values for rest and exercise in conditions of 
normoxia and hypoxia. These values were entered into a Minitab worksheet. Statistical 
analyses similar to those performed on the ventilatory and metabolic variables were 
performed (e.g. normality plots and ANOVA).
2.4 Genetic analysis
ACE genotyping was performed at the University College London in the centre for 
Cardiovascular Genetics in the Rayne Institute by our collaborators (Drs Hugh Montgomery 
and Dr David R Woods). The method used has been published [416] and used widely. The 
extraction o f DNA and the subsequent ACE genotyping were not performed by me.
2.4.1 Specimen collection
Genetic material was primarily isolated from buccal washings. These were collected by 
asking subjects to rinse their mouths vigorously with lOmls o f sterile saline for 30 seconds 
and then collect the mouthwash in a 20mIs sterile universal container. Specimens were then 
transported by courier to The Rayne institute for analysis. In the rare occasions where 
genotyping was unsuccessful by this method, blood samples were collected from the subject. 
The S-Monovette® system o f venesection was used for this, the sample was collected in 
7.5ml potassium EDTA container, frozen to minus 70°C and transported in dry ice by courier 
to the Rayne institute. Seven subjects had ambiguous results from buccal washing and a 
further blood sample was sent ot confirm the genotyping of these individuals.
2.4.2 DNA extraction protocol
From saliva
1. Centrifuge universal container for 4 minutes at 3000rpm.
2. Decant saliva leaving buccal cells behind.
3. Add 500pl lysis buffer to remaining buccal cells and mix (cell lysis).
4. Transfer contents to a large eppendorf.
5. Add 150pl 5M Sodium Perchlorate. Then add 500pl chloroform.
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6. Agitate vigorously for 3-4 minutes before centrifuging again at 14000rpm for 4 
minutes in micro-centrifuge.
7. Draw off 500pl o f supernatant and place in fresh Eppendorf.
8. Add lOOOpl of 100% ethanol and invert tubes gently 5 mins. (DNA precipitation).
9. Centrifuge at MOOOrpm for 3 minutes in microfuge.
10. Decant ethanol, aspirate remainder and allow DNA pellet to air dry for 10 
minutes.
11. Resuspend DNA in lOOOpl sterile water 
From blood
1. Blood was anti coagulated with 5mM potassium EDTA and stored in 0.5 ml 
aliquots at -20°C.
2. Specimens were thawed and 50pl added to 50pl methanol in deep welled 
Beckham titre plate and evaporated to dryness using a hot air dryer (no exceeding 
55°C)
3. lOOpl sterile distilled water was added; the plate was covered and then heated in 
a water bath at 100°C for 25 minutes.
4. The aqueous DNA extract was withdrawn with a multichannel pipette and 4pl 
transferred to a 96 well Omniplate anmd allowed to air dry prior to PCR.
2.4.3 Genotyping protocol
The insertion/ deletion polymorphism was identified by polymerase chain reaction 
amplification (PCR) and subsequent electrophoretic separation o f fragments. Two priming 
oligonucleotides flank the insertion (Alu) sequence in intron 16 (ACEl, 5' or left hand D 
specific oligonucleotide and ACE3, 3' or right hand common oligonucleotide) and a third 
oligonucleotide is specifically within the insertion sequence (ACE2, the insertion specific 
oligonucleotide). Misclassification o f heterozygotes as being D homozygotes [417] was 
prevented by the use o f an insertion allele-specific third primer as described by Evans [418] 
but with a modified protocol as subsequently described below.
1. 5pi DNA solution was pipetted onto a microsatellite array plate and dried at 80°C for 
lOmins.
2. 20pl PCR mix and then 20pl mineral oil was added to each well. Plates were then 
sealed with a plastic filin and centrifuged at 3000rpm for 1 minute.
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3. DNA samples were then amplified on an Omnigene® (Hybaid, Middlesex, UK) PCR 
block.
4. All 96 wells were always filled with reagents to ensure constant thermal mass on the 
block.
5. 6ul of amplification product was mixed with 2ul formamide dye and then 6ul pipetted
onto a Microtitre Array Diagonal gel (MADGE) in an electrophoresis bath of IxTBE.
6. Electrophoresis was at 150 volts for 40mins before amplification products were
visualised by ultraviolet light.
Constituents o f the PCR mix used in step 2 above:
PCR mix fo r  4mls (192 wells):
1. 10xpolmix-400|Lil.
2. W 1 Buffer-200pl.
3. 50mM Magnesium Chloride ~120pl.
4. Primer mix :30pl ACE 1, 4pl ACE 2, 20pl ACE 3.
5. 8pl Taq {Thermus acquaticus) DNA polymerase (Gibco BRL, Paisley, U.K.).
6. 3218pl sterile water.
Primer sequences:
ACE 1: 5’ CAT CCT TTC TCC CAT TTC TC (FH76)
ACE 2: 5’ TGG GAT TAG AGG CGT GAT ACA G (FH77)
ACE 3: 5’ ATT TCA GAG CTG GAA TAA AAT T (FH78)
A= adenine T=thymidine C=cystine G=guanine
Amplification conditions:
1. 95"C 5 mini cycle for initial dénaturation.
2. 95"C 1 min.
3. 50°C 1 min.
4. 72^C 30secs.
5. Repeat steps 2-4 for 32 cycles.
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7.5% polyacrylamide MADGE (microtitre array diagonal gel electrophoresis) production 
(per 6 MADGE gels),
1. Glass plates cleaned thoroughly with detergent and left to air dry.
2. Clean 1 side with 100% ethanol and again air dry.
3. Apply sticky si lane (1.25mls 0.5% glacial acetic acid, 1.25mls gamma
methacryloxypropyltrimethyl silane made up to 250mls with 100% ethanol) to same 
surface and air dry in fume cupboard.
4. Wash plate with distilled water and dry.
5. Wash and dry MADGE formers (template).
6. Pour 40mIs into beaker, stir, add 150pl 25% Ammonium Persulphate solution, stir 
and immediately pour onto MADGE former.
7. Place glass plate onto MADGE former and solution, and weight down.
8. Leave for 30 minutes and remove new MADGE plate from template and store in 
IxTBE mixed with lOpl per 200mls o f Ethidium Bromide stain.
Constituents oflOxTBE (Tris~borate~EDTA )bujfer used as 1 in 10 dilution to give IxTBE
1. 108gms Tris base (trishydroxymethylaminomethane)
2. 55 gms Boric acid
3. 40mls 0.5M Sodium EDTA (pH 8.0)
4. Dilute to 1 litre with sterile deionised water, the final pH is 8.3.
Constituents o f  lOxpolmix
1. 500 mmol/1 potassium chloride
2. lOOmmol/1 Tris, pH8.3
3. 0.1 g/1 gelatine
4. 2 mmol/1 of each dNTP
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ACE genotype determined by PCR 
1 2 3 4 5 6
2. Control (II)
3. Control (ID)
4. Control (DD)
5. Subject: I (II)
6. Subject: 2 (ID)
7. Subject: 3 (DD)
Figure 2.7 The amplification products are 84bp for allele ACE D and 65bp for allele ACE 1 
which are separated by electrophoresis and interpreted by the naked eye as 2 clearly distinct 
bands. Positive control samples o f II, ID and DD samples were always amplified and 
electrophoresed concurrently.
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3.1 Subject characteristics
The subject gi'oup comprised mainly of students attending Glasgow University recruited from 
the Officer training corp. and the Glasgow University Sports and recreational faculty. There 
were some subjects recniited fr om tlie medical staff of the Western Infirmaiy and Gartnavel 
General Hospital in Glasgow. This is reflected in the biometric data presented. Sixty 
Caucasian subjects were included in tlie laboratory study, 38 male,
3.1.1 Age
The mean age of tlie entire group was 23.7 years (SD ± 4.8 years, range 18-37 years). 
Individual ages ai’e presented on table 3.2 and figure 3.1.
Distribution of age with Normal Curve
20
10
0
Age
(years)
Figure 3.1 Frequency distiibution of 
ages within the subject group with 
normal distribution curve superimposed 
(red). Note the skewed distribution 
towards the younger end of the range.
3.1.2 Heights and weights of subject group
The average subject height was 177.8cm (SD ± 7.96, range 157-193cm). Suimnary data is 
presented on table 3.1 and individual data is on table 3.2 and figure 3.2.
Distribution of heights with normal curve
Height
(cm)
Figure 3.2 Frequency distribution of 
heights with normal distribution ciu ve 
superimposed (red). The distribution of 
heights is skewed toward the taller end 
of the range.
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The mean weight o f the whole group was 73.8kg (SD ± 10.43, range 53.0-100.0kg). 
Summary data is presented on table 3.1 and individual data is on table 3.2 and figure 3.3.
Distribution of weights with normal curve
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5
0
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W eight
(kg)
Figure 3.3 Frequency distribution of 
weiglits witli normal curve superimposed 
(red). The weight distiibution o f the 
subject gi’oup demonstrated normality.
n=60 Age (years) Height (cm) Weight (kg)
Range 18-37 157-193 53.0-100.0
Mean (±SD) 23.7 (±4.8) 177.8 (±7.96) 73.8 (±10.4)
Table 3.1 Summary descriptive statistics of biometric data for the whole subject group 
3.1.3 Maximal oxygen uptake and ventilatory threshold
The mean VO2 max was 50.9 mls/kg/min (SD 10.8, range 30.4-85.5 mls/ltg/min). The mean 
VO2 at ventilatory tlueshold was 30.5 mls/kg/min (SD 8.6, range 17.9-54.8 mls/kg/min). The 
mean maximum work load achieved was 287.8 watts (SD 84.6, range 104-444 watts). The 
mean work load at ventilatory tlireshold was 186.4 (SD 20.7, range 100-242 watts) summary 
and individual data is on table 3.3 and 3.4 respectively.
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Subject Age Sex Height(cm)
Weight
(kg) Subject Age Sex
Height
(cm)
Weight
(kg)
1 24 M 185 70.8 31 21 M 186 82.2
2 22 M 182 74.5 32 27 M 185 76.6
3 19 M 157 58.0 33 20 M 184 84.3
4 24 M 189 100.0 34 24 M 178 79.0
5 21 M 189 82.1 35 21 M 184 85.0
6 21 M 178 70.0 36 23 F 165 58.2
7 22 M 180 83.2 37 33 F 180 72.4
8 21 M 181 75.0 38 32 F 185 74.6
9 23 M 181 90.0 39 21 F 171 53.0
10 20 M 179 66.8 40 30 F 183 72.0
11 29 M 177 80.7 41 19 F 175 58.3
12 20 M 180 80.0 42 20 F 174 71.4
13 31 M 184 76.6 43 21 F 178 74.3
14 21 M 193 91.5 44 22 F 163 60.5
15 23 M 183 89.1 45 22 F 168 58.5
16 22 M 189 83.0 46 23 F 168 58.0
17 22 M 180 76.5 47 19 F 173 70.0
18 21 M 175 75.6 48 20 F 160 63.6
19 20 M 180 72.4 49 20 M 183 80.0
20 37 M 175 67.9 50 21 F 169 67.0
21 25 M 185 80.4 51 21 M 175 75.6
22 35 M 184 78.9 52 21 M 177 88.8
23 18 F 176 74.0 53 27 F 163 62.0
24 20 M 188 84.5 54 28 M 179 71.0
25 23 F 171 60.2 55 37 M 183 92.3
26 22 F 179 63.3 56 20 M 182 82.7
27 21 F 171 56.2 57 24 M 186 76.8
28 23 F 169 59.4 58 26 M 174 74.3
29 34 M 182 78.6 59 20 F 163 73.4
30 21 F 165 57.8 60 21 M 182 76.2
Table 3.3 Individual biometric data for the entire subject group. The individual’s gender is 
denoted b y  ‘M ’ for male and ‘F’ for female.
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Subject ACE genotype VO2 max  (mis/min/kg)
VO2 at VT 
(mls/min/kg)
Work at VT 
(watts)
Maximum work 
(watts)
1 II 6 9 .4 44 .2 191 373
2 DD 4 1 .6 20 .0 181 2 7 0
3 ID 4 7 .9 35 .2 183 204
4 ID 39 .2 18 8 185 368
5 DD 30 .4 19.1 183 35 0
6 II 48 .5 30 .6 189 2 4 0
7 ID 6 5 .9 35 .6 196 4 0 9
8 DD 56.1 30 .9 185 30 7
9 DD 57.5 33.8 185 354
fO ID 75 .9 54.8 192 371
n ID 50 .3 4 0 .0 192 3 2 6
12 DD 4 6 .2 22 .5 195 291
13 II 6 8 .2 46 .5 155 28 4
14 ID 45 .3 27 .7 191 345
15 ID 5 4 .6 35.9 22 2 23 8
16 II 5 7 .0 40 .8 194 43 4
17 ID 7 1 .6 4 3 .0 197 389
18 DD 5 4 .7 30.9 190 26 7
19 ID 54 .7 37.7 192 348
20 ID 4 7 .4 32.1 184 305
21 II 5 2 .7 27 .0 173 337
22 DD 60 .8 36 .3 170 44 4
23 II 52 .3 35 .6 153 208
24 DD 52 .2 29 .9 197 362
2 5 ID 38 .3 25 .2 20 9 142
26 ID 4 3 .6 21 .7 199 2 69
27 ID 41.1 2 0 .6 191 104
28 ID 4 0 .0 29 .2 175 138
29 DD 56 .5 37.3 242 239
30 DD 41 .3 19.6 192 182
31 II 85 .5 46 .8 192 43 5
32 DD 47.1 30 .6 221 196
33 ID 35 .8 22 .3 180 292
34 ID 58 .8 28 .8 194 373
35 ID 46.1 25 .2 171 386
36 DD 34 .4 21 .5 180 166
37 ID 6 5 .9 51 .6 166 354
38 II 68 .2 4 7 .7 174 4 3 6
39 ID 50 .7 23 .9 189 27 2
40 II 4 1 .6 24 .0 173 33 7
41 ID 50 .8 31 .5 181 261
42 ID 55 .7 26 .7 183 21 0
43 II 4 2 .9 26.1 176 251
44 II 43 .3 26 .3 179 20 2
45 II 4 9 .9 27 .2 100 151
46 ID 4 6 .8 28 .2 190 123
47 II 54.3 29 .8 185 275
48 DD 4 1 .7 24.1 187 2 1 4
49 DD 49 .2 28 .8 2 24 31 2
50 ID 52.1 37 .2 192 2 8 4
51 DD 54 .7 30 .9 190 2 6 7
52 ID 50.3 25 .9 196 4 1 9
53 ID 32.1 17.9 173 213
54 II 5 1 .0 29 .7 166 30 6
55 DD 38.3 2 6 .7 176 2 7 6
56 ID 54.5 2 3 .6 160 196
57 ID 4 5 .9 2 5 .0 172 2 68
58 ID 4 1 .2 19.4 180 2 4 6
59 ID 6 1 .6 3 7 .4 2 4 2 320
60 ID 4 5 .5 2 1 .6 208 3 28
M e a n - 5 0 .9 5  ± 1 0 .8 3 0 .5  ± 8 .6 18 6 .4  ± 2 0 .7 2 8 7 .8  ± 8 4 .6
Table 3.4 Summary metabolic data from maximal cardiopulmonary exercise tests.
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3.1.4 Physical activity of the subject group
The physical activity o f each individual was recorded on the pre-test questionnaire as part of 
the consent procedure and assessment o f altitude exposure. None of the subject group had 
been to high altitude in the 6 months preceding the test protocol. None o f the group had been 
born or lived at high altitude. The summary o f physical activity is shown on table 3.5.
Subject Activity Subject Activity
1 L o n g  d is ta n c e  ru n n in g  (c o m p e titiv e ) 31 R ow ing , sa il in g  (b o th  re c re a tio n a l
2 F oo tb a ll, b ad m in to n 32 C y clin g , ru n n in g  (c o m p e titiv e ) , ro ck -c lim b in g
3 S q u ash , Fell ru n n in g  (rec re a tio n a l) 33 S w im m in g , c y c lin g
4 R u n n in g , sw im m in g , k ic k -b o x in g  (all re c re a tio n a l) 34 R o w ing , ru g b y , ru n n in g  (a ll re c re a tio n a l)
5 Fell ru n n in g  (eo m p e titiv e ) , cy c lin g , c a n o e in g , sa ilin g 35 R o ck -c lim b in g , s k iin g , ru n n in g  (all re c re a tio n a l)
6 R u n n in g , foo tba ll 36 F oo tball (c o m p e titiv e ) , c y c lin g
7 S w im m in g , ru n n in g , c y c lin g  - tr ia th lo n  (co m p e titiv e ) 37 S w im m in g  ( re c re a tio n a l)
8 R u n n in g  (rec re a tio n a l) 38 J u d o  (c o m p e titiv e ) , ru n n in g , vo lley b a ll
9 R u n n in g , sk iin g  (co m p e titiv e ) 39 S w im m in g , cy c lin g
10 R u n n in g , sw im m in g , m o u n ta in  b ik in g 40 A d v en tu re  ra c in g  (c o m p e titiv e ) , ro w in g  (co m p e titiv e ), cy c lin g , sw im m in g , sa il in g
11 R u n n in g  (rec re a tio n a l) 41 R ow in g  (co m p e titiv e ) , ru n n in g  (rec re a tio n a l)
12 R u n n in g , c y c lin g 42 R ugby  (c o m p e titiv e ) , ru n n in g
13 F oo tb a ll, sk iin g 43 C y clin g , ru n n in g
14 F oo tba ll, b ad m in to n  (c o m p e titiv e ) , ru n n in g 44 C y clin g , ru n n in g  (rec re a tio n a l)
15 L ong  d is ta n c e  ru n n in g  (co m p e titiv e ) 45 S w im m in g , s q u ash , c y c lin g
16 S w im m in g , ru n n in g  (b o th  rec re a tio n a l) 46 S w im m in g , ru n n in g
17 R u n n in g , w e ig h ts 47 L o n g d is ta n c e  ru n n in g  (co m p e titiv e )
18 F oo tba ll, s q u ash , run n in g 48 R ow ing , ru n n in g  (re c re a tio n a l)
19 F oo tball (co m p e titiv e ) 49 R ock c lim b in g , ru n n in g , h ig h lan d  d a n c in g
20 O rie n te e r in g  (co m p e titiv e ), cy c lin g 50 C yclin g
21 C y c lin g , ru n n in g  (co m p e titiv e ) 51 C y clin g , ru n n in g , ro c k -c lim b in g
22 D is tan c e  ru n n in g  (co m p e titiv e ) , ad v e n tu re  rac in g 52 S k iin g , sw im m in g  (b o th  rec re a tio n a l)
23 S w im m in g , cy c lin g , ru n n in g  (all re c re a tio n a l) 53 R ow in g  (co m p e titiv e ) , ru n n in g
24 R u n n in g , o rie n te e r in g , c y c lin g 54 R unn in g , H ig h la n d  d a n c in g
25 H ig h lan d  d an c in g 55 R unn in g , fo o tba ll (re c re a tio n a l)
26 R u n n in g , c a n o e in g , h o ck e y , ro c k -c lim b in g 56 R unn in g , cy c lin g  (re c re a tio n a l)
27 R u n n in g , sw im m in g 57 T en n is  (rec re a tio n a l)
28 R u n n in g  (rec re a tio n a l) 58 S w im m in g , ru n n in g , c y c lin g  (a ll re c re a tio n a l)
29 R o ck -c lim b in g , c y c lin g 59 R unn in g , c y c lin g
30 R ow ing , sa il in g  (b o th  rec re a tio n a l) 60 S k iin g  (eo m p e titiv e ) , ru n n in g
Table 3.5 The physical activities o f the subject group. There is a wide range in physical 
exercise activity within the subject group, which is also variable in the degree o f participation 
in each sport (recreational vs. competitive).
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3.1.4 Spirometi’y
The individual spirometric data is displayed on table 3.6. The mean FEVi was 4.18 litres (SD 
0.74; range 2.55-5.70 litres). The mean FVC was 5.10 litres (SD 0.91; range 2.97-7.49 litres). 
All subjects were witirin predicted values for height, age arrd sex. There was no evidence of 
significant airflow limitation.
Subject
FEVi
(litres)
FVC
(litres) Subject
FEVi
(litres)
FVC
(litres) Subject
FEVi
(litres)
FVC
(litres) Subject
FEVi
(litres)
FVC
(litres)
1 4.80 6.16 16 4.33 5.42 31 5.01 6.21 46 3.36 4.65
2 4.28 5.67 17 4.10 4.58 32 4.95 5.88 47 3.56 4.52
3 3.74 4.09 18 5.70 7.49 33 4.78 5.58 48 3.02 3.81
4 5.62 7.31 19 5.30 5.99 34 4.22 5.10 49 4.42 5.01
5 5.37 6.36 20 4.34 5.07 35 5.38 6.05 50 3.44 4.35
6 4.10 5.01 21 5.16 6.39 36 2.55 2.97 51 4.29 5.10
7 4.63 5.84 22 4.30 5.36 37 3.14 3.58 52 4.48 5.26
8 4.10 5.85 23 4,15 4.76 38 3.18 4.43 53 3.18 3.87
9 5.38 6.80 24 4.95 5.70 39 3.13 3.70 54 4.31 5.23
10 4.98 6.21 25 3.66 4.51 40 4.22 5.08 55 4.17 4.94
11 4.30 5.21 26 3.75 4.72 41 3.70 4.31 56 4.38 5.37
12 4.92 5.24 27 3.56 4.50 42 3.07 4,30 57 3.98 4.79
13 4.21 4.80 28 3.38 4.18 43 3.77 4.24 58 3.25 3.92
14 4.69 5.75 29 4.48 5.26 44 3.38 4.10 59 4.49 5.18
15 4.94 6.15 30 3.33 4.18 45 3.50 4.48 60 4.21 5.24
Table 3.6 Summary spirometry data for the subject group.
Histogram of group FEV1, with Normal Curve
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Histogram of group FVC, with Normal Curve
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Figure 3.4 Frequency distributions o f FEVj (left panel) and FVC (right panel); both tire 
distribution o f FEVi and FVC demonstrated normality (normality curves are superimposed in 
red).
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3.2 C ardiopulm onary exercise validation  results
The repeatability of steady state CPET for VO2 and VE was verified in 5 subjects, by 
repeating the steady state protocol during normoxia and hypoxia. The variability o f results 
during rest was more noticeable than exercise results; therefore, resting and exercise 
variables from normoxic and hypoxic steady state tests are pooled to give values for 
comparison. Tables 3.7 and 3.8 show the absolute values and the percent difference between 
tests for VO2  and VE respectively; tests 1 to 5 were performed in normoxic conditions, test 6- 
9 were during hypoxia (one subject only repeated the normoxic test). Individual work loads 
for repeated steady state test were the same. Repeatability o f tests is demonstrated by Bland- 
Altman plots in Figures 3.5 and 3.6.
Test Resting VO2  (l/min) Exercise VO2  (l/min)Test a Test I) % difference Test a Test b % difference
/ 0.47 0.43 7.7 1.76 1.69 3.8
2 0.33 0.32 4.4 2.46 2.41 2.0
3 0.37 0.34 8.7 1.25 1.26 -0.3
4 0.47 0.48 -1.7 2.19 2.20 -0.7
5 0.26 0.28 -7.6 1.12 1.10 1.7
6 0.43 0.45 -4.2 1.70 1.76 -3.6
7 0.43 0.42 1.5 2.43 2.33 4.1
8 0.46 0.43 5.3 2.08 2.07 0.4
9 0.30 0.29 3.6 1.09 1.14 -4.1
Table 3.7 Oxygen uptake results o f repeated steady state exercise tests. Test 1-5 were during 
normoxia, test 6-9 were during hypoxia. The work load between test a and test b was the 
same.
Test Resting VE (l/min) Exercise VE (l/min)Test a Test h % difference Test a Test b % difference
1 10.80 9.91 8.3 35.61 36.83 -3.4
2 10.57 10.57 -0.0 44.19 43.81 0.8
3 11.32 10.66 5.8 32.37 32.50 -0.4
4 10.95 11.18 -2.1 39.73 38.93 2.0
5 8.88 8.78 1.1 26.93 28.53 -6.0
6 13.14 13.73 -4.5 45.10 46.62 -3.4
7 14.48 14.48 -0.0 67.39 65.24 3.2
8 12.88 13.60 -5.6 54.70 54.23 0.9
9 9.39 9.80 -4.3 33.54 31.56 5.9
Table 3.8 Minute ventilation results o f repeated steady state exercise tests. Test 1-5 were 
during normoxia, test 6-9 were during hypoxia. The work load between test a and test b was 
the same.
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Figure 3.5a Bland-Altman plots o f oxygen uptake (VO2 ) measurements in 5 subjects. The 
difference in measurements between tests is plotted against the mean VO2  measurement for 
the two tests. The horizontal bars are placed at one and two standard deviations o f the 
differences in VO2  (±1 SD and ±2 SD respectively). The left panel demonstrates the 
repeatability of VO2 during rest (SD 0.021), the right during exercise (SD 0.052).
S ca tte r  plot of resting  V 0 2  re p ea ted  te s ts S ca tte r  plot of ex e rc ise  V 0 2  rep ea ted  te s ts
Fltsl test V 02  (l/ntn)
Figure 3.5b Scatter plots of oxygen uptake (VO2 ) measurements in 5 subjects. The left panel 
demonstrates resting V 02 results from the repeated tests plotted together; the right panel 
plots the exercise V 02 results.
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Figure 3.6a Bland-Altman plots o f minute ventilation (VE) measurements in 5 subjects. The 
difference in measurements between tests is plotted against the mean VE measurement for 
the two tests. The horizontal bars are placed at one and two standard deviations of the 
differences in VE (±1 SD and ±2 SD respectively). The left panel demonstrates the 
repeatability of VE during rest (SD 0.54), the right during exercise (SDl .40).
S ca tte r  plot of e x e rc ise  VE rep ea ted  te s tsS c a tte r  plot of resting  VE re p ea ted  te s ts
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Figure 3.6b Scatter plots of minute ventilation (VE) measurements in 5 subjects. The left 
panel demonstrates resting VE results from the repeated tests plotted together; the right panel 
plots the exercise VE results.
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3.3 Cardiopulmonary exercise test results
The following section presents data for each individual and the entire group. The tables are 
set out in a similar fashion. Each table presents data during rest and exercise under conditions 
o f normoxia and hypoxia (normoxic rest, normoxic exercise, hypoxic rest and hypoxic 
exercise respectively). Data is presented as the mean measurements during breath-by-breath 
cardiopulmonary exercise testing over a period of 90 seconds at the end o f the rest and 
exercise periods. The average measurement during exercise is after 4 minutes to ensure 
steady state had been attained. Furthermore, the change in variables between normoxia and 
hypoxia during rest and exercise are presented, both as absolute value and as a percent 
change o f normoxic measurements.
3.3.1 Oxygen uptake
Oxygen uptake data for the whole subject group is displayed in table 3.9. Complete data 
points for the entire subject group were measured (n=60). The mean VO2 during normoxic 
rest and exercise was; 0.411 l/min (SD 0.10; range 0.23-0.69 l/min) and 1.63 l/min (SD 0.40; 
range 0.95-2.46 l/min) respectively. The mean VO2 during hypoxic rest and exercise was 
0.411 l/min (SD 0.08; range 0.26-0.64 l/min) and 1.62 l/min (SD 0.36; range 1.01-2.43 l/min) 
respectively. The absolute change in VO2  at rest between conditions o f normoxia and 
hypoxia was 0.002 l/min (SD 0.06; range -0.15-0.18 l/min); the percent change was 2.76% 
(SD 18.6; range -32.3-66.0%). The absolute change in VO2 during exercise between 
conditions of normoxia and hypoxia was -0.01 I/m in (SD 0.13; range -0.44-0.21 l/min); the 
percent change was 0.33% (SD 7.6; range -14.8-15.8).
Oxygen uptake during rest and exercise under conditions o f normoxia and hypoxia 
demonstrated a normal distribution. The values for VO2 would not be expected to vary 
significantly between normoxia and hypoxia; therefore paired student t-tests were performed. 
VO2 change at rest and exercise from normoxia to hypoxia did not demonstrate any 
significant difference (p values: 0.89 and 0.53 respectively). Furthermore, Bland Altman 
plots o f VO2  measurements at rest and exercise, between conditions o f normoxia and hypoxia 
were plotted. These are presented in figure 3.7; there is a higher level o f variability in the 
resting values than during exercise. The majority of the recordings lie within two standard 
deviations o f the difference between normoxic and hypoxic measurement at rest; all exercise 
measurements are within 2 standard deviations.
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Table 3.9. Individual oxygen uptake data and changes between normoxia and hypoxia.
Subject
VO2 
Normoxic Rest
V02
Normoxic
VO2
Hypoxic
VO2
Hypoxic
JV O 2
(Rest)
JV O 2
(Exercise)(//mill) Exercise (l/miit) Rest (//milt) Exercise (//miii) //mill % //mill %
1 0 .473  ± 0 .1 2 2 .0 5  ± 0 .2 7 0 ,4 5 0  ± 0 .1 6 1.93 ± 0 .3 8 -0 .02 -5 .0 -0 .1 2 -5 .9
2 0 .4 2 9  ±0.21 2 .1 5  ± 0 .2 9 0 .4 2 5  ± 0 ,1 7 1.90 ± 0 .2 0 -0 .00 -1 .0 -0 .25 -1 1 .7
3 0 .563  ± 0 .2 2 2 .4 2  ± 0 .2 4 0 .5 0 7  ± 0 .1 0 2 .2 6  ± 0 .1 8 -0 .0 6 -9 .9 -0 .1 7 -6 .9
4 0 .533  ± 0 .2 5 2 .2 5  ± 0 .2 5 0 .5 3 7  ± 0 .2 0 2.21 ±0.41 0 .0 0 0.7 -0 .03 -1 .5
5 0 .5 2 8  ± 0 .3 2 1.98 ± 0 .2 7 0 .4 4 8  ± 0 .1 4 1.74 ± 0 .2 9 -0 .0 8 -1 5 .2 -0 .2 4 -1 2 .0
6 0 .3 9 8  ± 0 .13 1,49 ± 0 .2 0 0 .3 9 5  ± 0 .1 5 1.50 ± 0 .1 4 -0 .0 0 -0 .8 0.01 0 .6
7 0 .4 9 0  ± 0 .13 2 ,1 5  ± 0 .2 9 0.491  ± 0 .1 5 1.97 ± 0 .2 4 0 .0 0 0.2 -0 ,1 8 -8 .2
8 0 .373  ± 0 .1 4 1.58 ± 0 .3 4 0 .3 8 7  ± 0 .2 6 1.59 ±0 .33 0.01 3.9 0 .0 2 1.0
9 0 .453  ± 0 .13 1.97 ± 0 .3 7 0 .4 3 8  ± 0 .2 0 1.73 ± 0 .1 9 -0 .0 2 -3 .3 -0 .2 4 -1 2 .0
10 0 .4 8 8  ± 0 .1 9 2 .0 8  ± 0 .2 9 0 .3 4 5  ± 0 .1 2 2 ,0 6  ± 0 .35 -0 .1 4 -29 .3 -0 .0 2 -1 .0
11 0 .5 6 0  ± 0 .3 2 2 .1 9 ± 0 .3 2 0 .5 0 7  ± 0 .1 6 2 .2 0  ± 0 .2 2 -0 .05 -9 .5 0 .0 2 0 .7
12 0 .4 5 4  ± 0 .1 8 1.49 ± 0 .2 5 0 .3 0 7  ± 0 .0 6 1.40 ± 0 .1 8 -0 .15 -32 .3 -0 .1 0 -6 .6
13 0 .4 4 7  ± 0 .1 7 1.54 ± 0.41 0 .3 8 2  ± 0 .1 4 1.50 ± 0 .1 5 -0 .0 7 -1 4 .6 -0 .0 4 -2 .7
14 0 .5 4 8  ± 0 .2 8 1.89 ± 0 .1 6 0 .5 5 4  ± 0 .1 8 1.87 ± 0 .1 7 0.01 1.0 -0 .0 2 -1 .0
15 0 .5 1 9  ± 0 .1 6 2 .1 0 ± 0 .3 1 0 .5 3 6  ± 0 .1 3 2 .1 4  ± 0 .3 3 0 .02 3.2 0 .0 4 1.8
16 0.691 ± 0 .2 8 2 .3 9  ± 0 .4 3 0 .5 9 0  ± 0 .1 6 2 .4 0  ± 0 .33 -0 .1 0 -14 .7 0.01 0,5
17 0 .5 2 9  ±0.31 2 .1 0 ± 0 .1 8 0 .4 3 9  ± 0 .1 4 2 .1 5 ± 0 .1 5 -0 .0 9 -17 .2 0 .0 5 2.5
18 0 .5 4 8  ± 0 .1 8 1.91 ± 0 .3 2 0 .5 1 6  ± 0 .1 5 1.82 ±0.21 -0 .03 -5 .7 -0 .0 9 -4 .7
19 0 .515  ± 0 .1 9 1.96 ± 0.41 0 .5 7 5  ± 0 .1 7 2 .05  ± 0 .3 4 0 .0 6 11.7 0 .0 8 4 .2
2 0 0 .5 1 6  ± 0 .2 0 1.69 ± 0 .4 3 0 .4 5 4  ± 0 .2 3 1.54 ± 0 .1 8 -0 .0 6 -1 2 .0 -0 .15 -9 .7
21 0.611 ± 0 .1 6 2 .4 6  ± 0 .2 7 0 .6 3 8  ± 0 .1 2 2.43  ±0 .43 0 .03 4 .4 -0 .03 -1 .3
22 0 .4 7 4  ± 0 .2 5 2 .3 7  ± 0 .2 2 0 .4 5 0  ± 0 .2 6 2 .1 1 ± 0 .1 5 -0 .0 2 -5.1 -0 .2 6 -10 .9
23 0 .345  ± 0 .1 9 1 .I 9 ± 0 .1 4 0 .3 0 5  ± 0 .1 0 1 .2 4 ± 0 .1 0 -0 .0 4 -1 1 .7 0 .0 5 4 .4
2 4 0 .3 1 8 ± 0 .1 8 1.44 ± 0 .1 2 0 .3 4 9  ± 0 .1 3 1.62 ± 0 .2 2 0 .03 9.9 0 .1 8 12.5
2 5 0 ,2 6 0  ± 0 .1 2 1.30 ± 0 .1 8 0 .3 6 4  ± 0 .1 0 1 .4 2 ± 0 .1 3 0 .1 0 4 0 .3 0 .1 2 9.3
2 6 0 .3 1 5 ± 0 .1 8 0 .9 7  ± 0 .1 8 0 .2 7 5  ± 0 .1 4 1.01 ± 0 .23 -0 .0 4 -1 2 .8 0 .0 4 3.7
27 0 .228  ± 0 .1 2 1.24 ± 0.21 0 ,2 6 9  ± 0 ,0 8 1.31 ± 0 .1 6 0 .0 4 17.9 0 .0 7 5.5
2 8 0 .4 3 6  ± 0 .2 5 1.20 ± 0.21 0 .3 8 6  ± 0 .1 0 1.27 ± 0 .2 2 -0 .05 -11 .5 0 .0 8 6.3
2 9 0 .4 4 9  ± 0 .2 9 1.92 ± 0 .1 9 0 .4 0 4  ± 0 .1 0 2 .0 4  ± 0 .2 8 -0 .05 -10.1 0 .1 2 6.2
3 0 0 .283  ± 0 .1 7 0 .9 5  ± 0 .1 3 0 .3 0 2  ± 0 ,1 9 1.04 ± 0 .2 2 0 .0 2 6 .6 0 .0 9 9.5
31 0 .4 1 9  ± 0 .0 9 1.83 ± 0 .3 2 0.431  ± 0 .0 9 1.73 ± 0 .3 6 0.01 2 .9 -0 .1 0 -5 .4
3 2 0 .4 5 2  ± 0 .2 6 1.46 ± 0.31 0 .4 2 8  ± 0 .2 6 1.64 ± 0 .2 6 -0 .02 -5.3 0 .1 8 12.5
3 3 0 .325  ± 0 .2 8 1.26 ± 0 .2 2 0 .4 1 8  ± 0 .3 6 1.34 ± 0 .2 9 0 .0 9 2 8 .6 0 .0 9 6 .9
3 4 0 .2 7 0  ± 0 .1 0 1.40 ± 0 .1 8 0 .4 4 8  ± 0 .0 5 1.54 ±0.11 0 .1 8 6 6 .0 0 .1 4 10.2
3 5 0 .4 5 6  ± 0 .1 8 1.55 ± 0 .1 7 0.441  ± 0 .1 7 1.55 ± 0 .2 2 -0.01 -3 .2 0 .0 0 0.1
3 6 0 .3 9 9  ± 0 .1 0 1.60 ± 0 .3 3 0 .3 7 4  ± 0 .0 8 1.46 ±0.21 -0 .03 -6.3 -0 .14 -8 .7
3 7 0.351 ± 0 .1 6 1.33 ± 0 .1 5 0 .2 9 5  ± 0 .0 8 Î .38 ± 0 .2 5 -0 .0 6 -1 5 .9 0 ,0 4 3.4
3 8 0 .3 4 7  ± 0 .0 9 1.22 ± 0 .1 7 0 .2 5 8  ± 0 .0 5 1.04 ± 0 .13 -0 .0 9 -25 .8 -0 .18 -1 4 .8
3 9 0 .4 6 8  ± 0 .1 0 1.76 ± 0 .3 2 0 .4 2 5  ± 0 .1 3 1.70 ± 0 .2 9 -0 .0 4 -9 .2 -0 .0 7 -3 .7
4 0 0 .4 3 9  ± 0 .2 4 1.51 ± 0 .1 7 0 .4 3 9  ± 0 .2 4 1.47 ± 0 .1 8 0 .0 0 0 .0 -0 .0 4 -2 .7
41 0 .3 3 2  ± 0 .13 1.46 ± 0 .2 5 0 .2 8 0  ± 0 .0 9 1.40 ±0.21 -0 .05 -1 5 ,6 -0 .07 -4 .7
4 2 0 .3 4 4  ±0.11 1.79 ± 0 .2 4 0 .3 8 5  ± 0 .1 5 1.63 ± 0 .1 9 0 .0 4 1 1.9 -0 .1 6 -9 .0
4 3 0 .4 5 0  ± 0 .1 0 1.50 ± 0.21 0 .4 0 0  ± 0 .1 4 1.38 ± 0 .1 2 -0 .05 -1 1 .0 -0 .12 -7 .8
4 4 0 .2 5 0  ± 0 .1 4 0 .95  ± 0 .1 3 0 .2 9 7  ± 0 .0 8 1 .1 0 ± 0 .1 3 0 .05 18.5 0 .15 15.8
4 5 0.291 ± 0 .1 6 1 .1 9 ± 0 .4 0 0 .4 0 7  ± 0 .2 5 1.27 ± 0 .2 2 0 .1 2 39 .8 0 .08 6 .5
4 6 0 .353  ± 0 .0 9 1.07 ± 0 .3 9 0.371  ± 0 .1 3 1.11 ± 0 .4 5 0 .0 2 5.2 0 .0 4 4.1
4 7 0 .3 0 6  ± 0 .2 5 1.27 ± 0 .1 4 0.351  ± 0 .1 2 1.26 ±0.11 0 .05 14.8 -0.01 -0 .9
4 8 0 .3 1 9  ± 0 .0 9 1.36 ± 0 .2 0 0.311 ± 0 .1 4 1.44 ±0.21 -0.01 -2 .5 0 .08 6.3
4 9 0 .5 1 2  ± 0 .3 2 1.59 ± 0 .1 7 0 .4 7 0  ± 0 .2 8 1.57 ± 0 .3 2 -0 .0 4 -8 .2 -0 .02 -1 .2
5 0 0 .3 3 2  ± 0 .1 5 1.55 ± 0 .2 2 0 .4 4 8  ± 0 .2 9 1.76 ± 0 .2 6 0 .1 2 35 .2 0.21 13.3
51 0 .3 7 4  ± 0 .1 9 1.26 ± 0.21 0.391 ± 0 .2 0 1.31 ± 0 .13 0 .0 2 4 .7 0 .05 4 .0
52 0 .3 8 8  ± 0 .1 0 1.68 ± 0 .2 2 0 .4 8 2  ± 0 .2 2 1.74 ± 0 .1 7 0 .0 9 24 .2 0 .0 6 3.3
53 0 .2 6 7  ± 0 .1 0 1 .1 0 ± 0 .1 7 0 .3 3 4  ± 0 .0 9 1.23 ± 0 .1 7 0 .0 7 2 5 .4 0 .14 12.4
54 0 .3 5 8  ± 0 .0 8 1.57 ± 0 .1 2 0 .3 7 5  ±0.11 1.57 ± 0 .1 4 0 .02 4 .8 -0 .0 0 -0.1
55 0 .353  ± 0 .1 4 1.55 ± 0 .3 6 0 .4 2 0  ± 0 .1 9 1.66 ± 0 .2 2 0 .0 7 19.0 0.11 6 .8
56 0.291 ± 0 .1 2 1.37 ± 0 .3 0 0 .3 7 9  ± 0 .2 9 1.34 ± 0 .2 2 0 .0 9 30.2 -0 .03 -2 .0
57 0 .3 7 4  ± 0 .2 8 1.30 ± 0 .2 8 0 .4 7 3  ± 0 .3 2 1.38 ± 0 .2 7 0 .1 0 26 .5 0 .08 6 .4
58 0 .2 3 6  ±0.11 1.17 ± 0 .2 3 0 .2 6 5  ± 0 .1 2 1.24 ± 0 .25 0 .03 12.5 0 .0 7 6 .2
59 0 .4 0 7  ± 0 .3 6 1.87 ± 0 .3 3 0 .4 6 8  ± 0 .3 5 1.92 ±0.31 0 .0 6 15.0 0 .05 2 .6
60 0 .4 0 0  ±0.21 1.64 ± 0 .2 0 0 .4 2 0  ± 0 .1 2 1.64 ± 0 .2 2 0 .02 5.3 -0.01 -0 .0
Group
Mean 0.411  ± 0 .1 0 1 .63  ± .4 0 0.411 ± 0 .0 8 1.62 ± 0 .3 6 0 .0 0 2± 0 .0 6
2.8
± 1 8 .6
-0 .01
± 0 .1 3
0 .33
± 7 .6
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Figure 3.7 Bland-Altman plots and scatter plots of oxygen uptake (VO2) measurements for 
the entire subject group. The difference in measurements between normoxic and hypoxic 
tests is plotted against the mean VO2 measurement for the two tests. The horizontal bars are 
placed at one and two standard deviations o f the differences in VO2  (±1 SD and ±2 SD 
respectively). The upper left panel compares measured VO2 between normoxia and hypoxia 
during rest (SD 0.065), the upper right panel during steady state exercise (SD 0,13). The 
lower panels are scatter plots of the data; the left panel is o f resting results, the right is from 
the exercise data. The resting values demonstrate a wider degree o f variability in relation to 
measured VO2 in comparison to exercise results. Three subjects were outwith 2 standard 
deviations of observed difference in VO2 between normoxia and hypoxia during rest; 
however 95% of subjects did demonstrate consistency in VO2 . All the exercise results were 
within 2 standard deviations.
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3.3.2 Carbon dioxide production
Carbon dioxide production (VCO2) data for the whole subject group is displayed in table 3.10 
and figure 3.8. Complete data points for the entire subject group were measured (n=60). The 
mean VCO2 during normoxic rest and exercise was; 0.340 l/min (SD 0.09; range 0.18-0.54 
l/min) and 1.41 l/min (SD 0.32; range 0.90-2.18 l/min) respectively. The mean VCO2 during 
hypoxic rest and exercise was 0.408 l/min (SD 0.11; range 0.23-0.85 l/min) and 1.58 l/min 
(SD 0.36; range 0.95-2.39 l/min) respectively. The absolute change in VCO2 at rest between 
conditions of normoxia and hypoxia was 0.069 l/min (SD 0.06; range -0.03-0.32 l/min); the 
mean percent change was 21.95% (SD 19.0; range -10.6-66.0%). The absolute change in 
VCO2 during exercise between conditions of normoxia and hypoxia was 0.176 l/min (SD 
0.12; range -0.16-0.65); the mean percent change was 12.3% (SD 0.02; range -10.2-37.3%). 
Paired student t-tests demonstrated a significant difference between normoxia and hypoxia at 
rest and during exercise (both p<0.0001).
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Figure 3.8 The change in VCO2 from normoxia to hypoxia. The panel on the left shows 
changes during rest; the panel on the right shows changes during hypoxia. These plots 
demonstrate the increase in VCO2 from normoxia to hypoxia; due to increased CO2 
elimination during hypoxia. This is attributable to the increase in ventilation during hypoxia 
due to hypoxic ventilatory drive. Furthermore, there is a wide variation in individual 
responses. The red data sets demonstrate a decrease in VCO2 in 6 individuals from normoxia 
to hypoxia during rest; this maybe explicable by a degree o f hyperventilation during the 
normoxic resting phase.
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Table 3.10. Individual VCO2 data and changes between normoxic and hypoxic conditions.
Subject Normoxic Rest (l/miu)
Normoxic
Exercise
Hypoxic
Rest
Hypoxic
Exercise
A VCO 2  
(Rest)
AVCO 2
(Exercise)
(l/min) (l/miu) (l/miu) l/miu % l/miu %
I 0 .393  ± 0 .0 9 1.81 ± 0 .2 4 0 .4 7 6  ± 0 .1 8 1.89 ± 0 .3 6 0 .08 21.1 0 .08 4 .4
2 0 .3 7 2  ± 0 .1 9 1.69 ± 0 .2 4 0 .4 2 9  ± 0 .1 7 1.84 ± 0.21 0 .0 6 15.5 0 .14 8.5
3 0 .4 9 0  ± 0 .2 0 2 .1 8  ± 0 .2 5 0 .5 6 9  ± 0 .1 0 2 .2 6  ± 0 .4 7 0 .08 16.2 0 .07 3.3
4 0 .4 2 9  ± 0 .1 9 2 .0 4  ± 0 .2 2 0 .5 2 8  ±0.21 2 ,2 6  ± 0 .43 0 .1 0 23 .2 0 .22 10.8
S 0 .4 5 2  ± 0 .2 7 1.63 ± 0 .23 0 .4 4 9  ± 0 .1 4 1.71 ± 0 .3 0 -0 .00 -0 .8 0 .08 5.0
6 0.321 ±0.11 1.27 ± 0 .1 7 0 .3 9 6  ± 0 .1 5 1.45 ± 0 .13 0 .08 2 3 .4 0 .1 9 14.7
7 0 .4 6 4  ± 0 .1 4 1.82 ± 0 .2 5 0 .5 2 9  ± 0 .1 6 1.86 ± 0 .23 0 .0 7 14.2 0 .0 4 2 .2
8 0 .3 3 9  ± 0 .13 1.42 ± 0 .3 0 0.431 ± 0 .3 0 1.60 ± 0 .3 6 0 .0 9 2 7 .4 0 .1 9 13.1
9 0 .3 3 6  ± 0 .0 9 1.57 ± 0 .2 9 0 .4 5 6  ± 0 .2 1 1.75 ± 0 .1 8 0 .1 2 3 5 .6 0 .1 9 11.8
10 0 .3 8 6  ± 0 .1 5 1.78 ± 0 .2 7 0 .3 7 4  ± 0 .1 4 1.99 ± 0 .3 6 -0.01 -3 .0 0.21 12.0
II 0 .473  ± 0 .2 8 1.84 ± 0 .2 7 0 .4 9 4  ± 0 .1 6 2 .1 9  ± 0 .2 2 0 .02 4 .4 0 .35 19.1
12 0 .3 5 8  ± 0 ,1 4 1.30 ± 0 .2 2 0 .3 5 0  ± 0 .0 6 1.36 ± 0 .23 -0.01 -2 .4 0 .0 6 4 .8
13 0 .3 5 7  ± 0 .1 4 1.35 ± 0 .3 6 0 .3 9 5  ± 0 .1 5 1.45 ± 0 .1 4 0 .0 4 10.5 0 .10 7.2
14 0 .5 0 4  ± 0 .2 5 1.63 ± 0 .1 5 0 .5 5 2  ± 0 .1 8 1.80 ± 0 .1 8 0 .05 9.6 0 .1 7 10.4
IS 0 .3 6 9  ±0.11 1.55 ± 0 .2 3 0 .5 4 6  ± 0 .13 1.84 ± 0 .28 0 .18 4 7 .9 0 .29 18.5
16 0 .5 4 4  ±0.21 1.93 ± 0 .3 9 0 .6 0 8  ± 0 .1 7 2 .3 8  ± 0 .3 2 0 .0 6 11.7 0 .45 2 3 .4
17 0 .428  ± 0 .2 5 1.80 ± 0 .1 6 0 .4 2 6  ± 0 .1 4 2.11 ± 0 .1 6 -0 .0 0 -0 .6 0 .30 16.7
IS 0 .455  ± 0 .1 5 1.68 ± 0 .2 9 0 .5 3 5  ± 0 .1 4 1.85 ±0.31 0 .08 17.6 0 .17 10.0
19 0 .3 6 9  ± 0 .1 4 1.55 ± 0 .33 0 .5 1 4  ± 0 .1 8 1.84 ± 0 .33 0 .15 3 9 .5 0 .30 19.3
20 0 .3 7 2  ± 0 .1 5 1.56 ± 0 .33 0 .4 0 8  ±0.21 1.40 ± 0 .1 6 0 .0 4 9.5 -0 .16 -1 0 .2
21 0 .5 2 7  ± 0 .1 5 1.97 ±0.21 0 .8 4 8  ± 0 .1 6 2 . 19 ± 0 .3 6 0 .3 2 6 1 .2 0 .22 11.3
22 0 .3 7 7  ± 0 .2 0 1.77 ± 0 .1 8 0.471 ± 0 .2 8 2.01 ± 0 .15 0 .0 9 2 4 .8 0 .24 13.7
23 0 .285  ± 0 ,2 8 5 1.03 ± 0 .1 3 0 .2 9 5  ± 0 .1 0 1 .1 7 ± 0 .!0 0.01 3 .6 0 .14 13.8
24 0 .2 7 5  ± 0 .1 6 1.36 ± 0 .1 2 0 .3 4 7  ± 0 .1 3 1.61 ± 0 .23 0 .0 7 26 .3 0 .25 18.1
25 0 .1 9 8  ± 0 .0 9 1.30 ± 0 .1 8 0 .3 2 8  ± 0 .0 9 1.41 ± 0 .1 4 0.13 6 5 .4 0.11 8.5
26 0 .3 0 9  ± 0 .1 9 0 .9 0  ± 0  18 0 .2 7 7  ± 0 .1 5 0 .98  ± 0 .2 4 -0 .03 -1 0 .6 0 .08 8.7
27 0 .183  ± 0 .1 0 1.04 ± 0 .1 7 0 .233  ± 0 .0 7 1 .1 2 ± 0 .1 5 0 .05 27.1 0 .09 8.6
28 0.311 ± 0 .1 7 0 .9 9  ± 0 .1 7 0 .3 1 2  ± 0 .0 9 1.05 ± 0 .1 8 0 .0 0 0.4 0 .0 6 6 .2
29 0 .4 3 4  ± 0 .2 8 1.67 ± 0 .1 7 0.421  ±0.11 1.91 ± 0 .2 7 -0.01 -2 .9 0 .2 4 14.5
30 0.221 ± 0 .1 3 0.91 ± 0 .1 3 0 .2 6 8  ± 0 .1 9 1.03 ± 0 .2 2 0 .05 2 1 .5 O i l 12.3
31 0 .4 5 8  ± 0 .1 0 1.74 ± 0 .4 3 0 .5 1 7  ±0.11 2 .3 9  ± 0 .3 6 0 .0 6 12.8 0 .65 37 .3
32 0 .3 4 8  ± 0 .2 2 1.23 ± 0 .2 7 0.361 ± 0 .2 5 1.49 ± 0 .2 5 0.01 3.8 0 .2 6 20 .9
33 0 .2 8 !  ± 0 .2 6 1.19 ± 0 .2 4 0 .4 1 2  ± 0 .4 0 1.32 ± 0 .28 0.13 4 6 .6 0 .13 10.5
34 0 .2 3 5  ± 0 .0 8 1 .1 6 ± 0 .1 5 0 .3 8 5  ± 0 .0 5 1.53 ±0.11 0 .15 6 3 .8 0 .3 7 32 .0
35 0 .3 9 6  ± 0 .1 6 1.47 ± 0 .1 8 0 .4 3 9  ± 0 .1 7 1.55 ± 0 .2 4 0 .04 10 9 0 .0 9 5.8
36 0 .3 4 4  ± 0 .0 9 1.43 ± 0 .2 8 0.391  ± 0 .0 7 1.82 ± 0 .2 6 0 .0 5 13.5 0 .3 9 27 .5
37 0 .273  ± 0 .1 2 1 .1 5 ± 0 .1 3 0 .2 9 4  ± 0 .0 8 1.34 ± 0 .2 4 0 .02 7.8 0 .18 16.0
38 0 .2 5 9  ± 0 .0 7 0 .9 6  ± 0 .13 0 .2 3 9  ± 0 .0 5 0 .95  ±0.1 ! -0 .0 2 -7 .8 -0 .0 0 -0 .5
39 0 .3 7 9  ± 0 .0 8 1.44 ± 0 .2 5 0 .4 3 6  ± 0 .1 4 1.66 ±0.31 0 .0 6 14.9 0.23 15.7
40 0 .375  ± 0 .1 9 1.26 ± 0 .1 4 0 .4 3 5  ± 0 .23 1.48 ± 0 .1 9 0 .0 6 16.0 0 .22 17.5
41 0 .2 9 !  ±0.11 1.26 ± 0 .2 3 0 .3 2 2  ±0.11 1.39 ± 0 .3 9 0.03 10 8 0 .13 10.4
42 0 .2 6 9  ± 0 .0 9 1.52 ±0.21 0 .3 6 5  ± 0 .1 4 1.57 ± 0 .1 9 0 10 35 .5 0 .06 3.7
43 0 .3 8 3  ± 0 .0 8 1.26 ± 0 .1 7 0 .4 1 9 ± 0 .1 4 1.39 ± 0 .13 0 .04 9.6 0 .13 10.3
44 0 .2 2 9  ± 0 .13 0 .92  ± 0 .13 0 .3 0 5  ± 0 .0 9 1 .1 6 ± .0 1 4 0 .08 33 .5 0 .23 25 .4
45 0 .2 I9 ± 0 .1 1 1.02 ± 0 .3 5 0 .3 3 9  ± 0 .23 1.08 ± 0 .2 0 0 .12 5 4 .9 0 .06 5.9
46 0 .2 7 7  ± 0 .0 7 0 .9 2  ± 0 .3 3 0 .3 3 9  ± 0 .13 1 .1 7 ± 0 .4 i 0 .0 6 22 .3 0 .25 27.1
47 0.261 ±0.21 1.08 ± 0 .1 3 0 .3 2 8  ± 0 .1 3 1.28 ± 0 .13 0 .0 7 2 5 .5 0 .2 0 18.5
48 0 .2 6 7  ± 0 .0 8 1.38 ± 0 .2 2 0 .2 8 2  ± 0 .1 4 1.48 ± 0 .23 0.01 5.4 0  10 7.2
49 0 .4 1 8  ± 0 .2 6 1,49 ± 0 .1 6 0.441  ± 0 .2 9 1.53 ± 0 .3 4 0 .02 5.6 0 .04 2.9
50 0 .255  ± 0 .1 2 1.26 ± 0 .1 7 0 .3 6 2  ± 0 .2 6 1.48 ± 0 .2 2 0.11 4 2 .3 0 .22 17.8
51 0 .3 0 4  ± 0 .1 5 I .1 4 ± 0 .1 9 0 .3 6 5  ± 0 .1 9 1.25 ± 0 .13 0 .0 6 20.1 0.11 9.7
52 0 .3 2 7  ± 0 .0 8 1.54 ± 0 .2 0 0.441  ± 0 .23 1.71 ±0.21 0.11 34 .7 0 .17 10.8
53 0 .1 9 7  ± 0 .0 8 0 .9 5  ± 0 .1 4 0.281  ± 0 .0 8 1.08 ± 0 .15 0 .08 4 2 .6 0 .13 13.7
54 0 .2 8 9  ± 0 .0 6 1.34 ±0.11 0 .3 7 0  ±0.11 1.40 ± 0 .1 4 0 .08 28 .3 0 .07 5.0
55 0 .2 8 8  ± 0 .1 2 1.45 ± 0 .3 4 0 .3 9 6  ± 0 .1 9 1.71 ± 0 .2 4 0.11 37 .6 0 .2 6 18.2
56 0 .273  ± 0 .1 2 1.32 ± 0 .2 9 0 .4 2 6  ± 0 .3 7 1.43 ± 0 .2 6 0 .1 5 56 .2 0.11 8.1
57 0 .3 1 0  ± 0 .2 4 1.22 ± 0 .2 7 0 .5 1 4  ± 0 .3 7 1.42 ± 0 .3 0 0 .2 0 6 6 .0 0 .2 0 16.2
58 0 .1 8 7  ± 0 .0 8 1.00 ±0.21 0 .2 3 7  ±0.11 1.09 ± 0 .2 4 0 .0 5 2 6 .7 0 .0 9 9.3
59 0 .323  ± 0 .33 1.60 ± 0 .2 7 0 .3 8 3  ± 0 .2 7 1.65 ± 0 .2 9 0 .0 6 18.8 0 .05 3.2
60 0 .3 3 0  ± 0 .0 9 1.41 ± 0 .1 4 0 .4 0 0  ±0.11 1.57 ±0.21 0 .0 7 2 0 .9 0 .1 6 11.3
Group
Mean 0.340 ±0,09 1.41 ±0.32 0.408 ±0.11 1.58 ±0.36
0.07
±0.06
22.0
±19.0
0.176
±0.12
12.3
±0.02
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3.3.3 End-tidal CO2
End-tidal CO2 (PetCOi) data for the whole subject group is displayed in table 3.11 and figure 
3.9. Complete data points for the entire subject group were recorded (n=60). Data is 
presented in SI units (kPa, to convert to mmHg apply a conversion factor of 7.501). The 
mean PetCOz during normoxic rest and exercise was 4.96 kPa (SD 0.38) and 5.82 kPa (SD 
0.45) respectively. The mean PetCO] during hypoxic rest and exercise was 4.60 kPa (SD 
0.41) and 4.90 kPa (SD 0.40) respectively. The mean absolute change in PetCO] at rest 
between conditions of normoxia and hypoxia was -0.37 kPa (SD 0.31); the mean percent 
change was -7.3% (SD 6.2). The mean absolute change in PetCOi during exercise between 
conditions of normoxia and hypoxia was -1.04 kPa (SD 1.0); the mean percent change was - 
16.5% (SD 7.7). End-tidal CO2 measurements demonstrated a normal distribution; paired t- 
tests showed a significant change in PetC0 2  during rest and exercise between normoxia and 
hypoxia (P <0.0001 for both rest and exercise).
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Figure 3.9 The change in PetC02 from normoxia to hypoxia. The panel on the left shows 
changes during rest; the panel on the right shows changes during exercise. These plots 
demonstrate the decrease in PetC02 from normoxia to hypoxia. This reflects the increase in 
alveolar ventilation during hypoxia due to hypoxic ventilatory drive. There is a wide 
variation in individual responses. The red data sets demonstrate an increase in PetC02 in 5 
individuals from normoxia to hypoxia during rest; these were 5 o f the 6 subjects that 
demonstrated a greater increase in VCO2, during rest. Similarly this could be attributable to a 
degree o f hyperventilation during the normoxic resting phase.
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Table 3.11. Individual etCOi data and changes between normoxic and hypoxic conditions.
Subject Normoxic Rest (kPa)
Normoxic
E.Kercise
Hypoxic
Rest
Hypoxic
Exercise
AETCOz
(Rest)
AETCO2
(Exercise)
(kPa) (kPa) (kPa) kPa % kPa %
1 4 .7 6  ± 0 .2 5 .7 0  ±0.1 4 .5 3  ± 0 .3 4 .7 2  ± 0 .3 -0 .23 -4 .9 -0 .9 7 -17.12 4 .6 7  ± 0 .4 6 .25  ± 0 .2 4 .8 5  ± 0 .2 5 .3 6  ±0.1 0 .1 9 4 0 -0 .8 9 -14 .2
3 4.81 ± 0 .2 5.71 ± 0 .2 4 .43  ±0.1 4 .8 2  ±0.1 -0 .3 8 -7 .9 -0 .8 9 -15 .64 5.01 ± 0 .2 6 .0 8  ± 0 .2 4 .7 8  ± 0 .2 5 .14  ± 0 .2 -0 .23 -4 .6 -0 .93 -15 .4
S 5 .3 4  ± 0 .3 6 .0 7  ± 0 .2 4 .9 5  ±0.1 5 .28  ± 0 .2 -0 .3 9 -7 .3 -0 .7 9 -136 4 .7 7  ± 0 .2 5 .93  ±0.1 4 .5 0  ±0.1 5 .0 4  ±0.1 -0 .26 -5 .5 -0 .8 9 -15.17 4 .7 8  ± 0 .3 5.91 ± 0 .2 4 .5 6  ± 0 .2 5 .09  ± 0 .2 -0.21 -4 .5 -0 .8 2 -13 .88 5 .15  ± 0 .2 5 .8 8  ± 0 .3 4.71 ± 0 .3 5 .0 9  ±0.3 -0 .4 5 -8 .7 -0 .7 9 -13 .59 5 .2 2  ± 0 .2 6 .2 0  ± 0 .2 4 .8 5  ± 0 .3 5 .03  ±0.1 -0 .3 6 -6 .9 -1 .17 -18 .910 5 .03  ±0.1 6 .1 7  ± 0 .2 4 .5 7  ± 0 .4 5 .1 6 ± 0 .2 -0 .46 -9.1 -1 -16.3II 4 .8 5  ± 0 .5 6 .55  ± 0 .2 5 .0 9  ± 0 .2 5.41 ±0.1 0 .24 5.0 -1 .1 4 -17 .4
12 4 .9 5  ± 0 .3 5 .5 7  ± 0 .2 4 .6 8  ± 0 .8 5 .02  ± 0 .2 -0 .27 -5 .5 -0 .55 -9 .813 4 .9 0  ± 0 .2 5 .5 4  ± 0 .4 4 .5 0  ± 0 .2 4 .5 6  ±0.1 -0 .39 -8 .0 -0 .9 9 -17 .814 4 .6 8  ± 0 .4 5 .6 2  ± 0 .2 4 .4 6  ± 0 .3 4 .8 2  ±0.1 -0 .23 -4 .8 -0 .8 -14 .215 4 .6 3  ±0.1 5 .6 2  ± 0 .2 4 .01 ± 0 .3 4 .5 6  ±0.1 -0.61 -13 .3 -1 .0 6 -18 .816 5 .5 2  ± 0 .2 6 .7 7  ± 0 .2 5 .23  ± 0 .2 4 .8 8  ± 0 .2 -0 .30 -5 .4 -1 .8 9 -27 .917 5 .03  ± 0 .2 5 .9 0  ±0.1 4 .5 9  ±0.1 4 .7 0  ±0.1 -0 .43 -8 .6 -1 .2 0 -20 .418 4 .7 8  ± 0 .2 5 .62  ± 0 .3 4 .2 6  ± 0 .3 4 .4 5  ± 0 .3 -0 .52 -1 0 .9 -1 .1 7 -20 .819 5.01 ± 0 .2 5 .78  ± 0 .3 4 .71 ± 0 .2 4 .6 5  ±0,1 -0 .30 -6 .0 -1 .13 -19 .620 5 .0 0  ± 0 .2 5 .8 0  ± 0 ,3 4 .41 ± 0 .2 5 .15  ± 0 .2 -0 .59 -1 1 .7 -0 .65 -11 .221 4.61 ± 0 .2 6 .13  ± 0 .2 3 .1 0 ± 0 .2 4 .43  ±0.1 -1 .52 -3 2 .9 -1 .70 -27 .722 4 .8 9  ±0.1 5 .38  ±0.1 4 .53  ± 0 .3 4 .2 4  ±0.1 -0 .36 -7  3 -1 .13 -21.123 4 .8 9  ± 0 .3 5.81 ± 0 .4 4 .5 7  ±0.1 5 .1 2  ±0.1 -0 .32 -6 .6 -0 .69 -11 .924 5.11 ± 0 .2 5 .94  ± 0 .2 4 .6 2  ± 0 .2 5 .1 2 ± 0 .1 -0 .49 -9 .5 -0 .83 -13 .925 4 .8 9  ± 0 .2 5 .63  ± 0 .2 4 .5 8  ±0.1 4 .8 7  ±0.1 -0.31 -6 .3 -0 .75 -13 .426 4 .6 2  ± 0 .5 5 .62  ± 0 .2 5 .0 2  ± 0 .3 5 .25  ± 0 .2 0 .4 0 8.6 -0 .3 6 -6 .527 4 .33  ± 0 .2 4 .9 8  ±0.1 4 .0 7  ±0.1 4 .2 9  ±0.1 -0 .26 -6 .0 -0 .68 -13 .728 4 .33  ± 0 .5 5.01 ±0.1 4 .0 4  ±0.1 3 .9 9  ±0.1 -0 .29 -6 .6 -1 .0 2 -20.329 5.11 ± 0 .5 6 .7 0  ± 0 .2 5 .1 4 ± 0 .2 5 .23  ± 0 .2 0 .03 0 .6 -1 .48 -22 .030 4 .7 8  ± 0 .3 5 .1 7  ± 0 .2 4 .4 5  ±0.3 4 .7 7  ± 0 .2 -0 .33 -6 .8 -0 .4 0 -7 .631 4 .1 3  ±0.1 5 .5 6  ± 0 .3 3 .6 7  ±0.1 4 .4 6  ± 0 .2 -0 .46 -11.1 -1 .1 0 -19 .832 4.71 ± 0 .3 5 .35  ± 0 .2 4 .4 0  ± 0 .3 4 .4 9  ± 0 .2 -0.31 -6 .6 -0 .8 6 -16.133 4.91 ± 0 .4 5 .63  ± 0 .2 4 .5 8  ± 0 .4 5 .14  ± 0 .2 -0 .33 -6 .8 -0 .4 9 -8 ,734 4.91 ± 0 .3 5 .95  ±0.1 4 .9 3  ±0.1 5 .49  ±0.1 0 .02 0.5 -0 .4 6 -7 .735 5 .25  ± 0 .2 6 .03  ± 0 .2 4 .9 5  ± 0 .2 5 .28  ± 0 .2 -0 .30 -5 .7 -0 .7 6 -12 .636 5 .4 6  ± 0 .2 6 .1 8  ± 0 .2 5 .1 3 ± 0 .1 5.71 ± 0 .2 -0 .34 -6.1 -0 .4 7 -7 .637 5 .03  ± 0 .2 5 .28  ±0.1 4 ,4 0  ±0.1 4 .6 0  ± 0 .2 -0 .63 -1 2 .6 -0 .6 8 -12 .9
38 4 .3 4  ± 0 .2 5 .03  ± 0 .3 4 .1 2 ± 0 .1 4 .3 2  ± 0 .2 -0 .2 2 -5 .0 -0.71 - 1 4 2
39 5 .5 2  ±0.1 6.51 ± 0 .2 5.01 ± 0 .2 5 .07  ± 0 .2 -0.51 -9 .2 -1 .44 -22,1
40 5 .2 7  ± 1 .2 6 .5 0  ±0.1 4 .9 6  ± 0 .3 5 .0 2  ± 0 .2 -0 .3 2 -6 .0 -1 .48 -22.841 5 .3 9  ± 0 .2 6 .4 0  ± 0 .3 5 .1 0  ± 0 .2 5-72 ± 0 .2 -0 .2 9 -5 .4 -0 .67 -10-542 4 .8 3  ± 0 .2 5 .95  ± 0 .2 4 .2 5  ± 0 .7 4 .5 9  ± 0 .2 -0 .5 8 -1 2 .0 -1 .3 6 -2 2 .843 4 .9 7  ±0.1 5 .78  ± 0 .2 4 .6 8  ±0.1 4 .9 4  ±0.1 -0 .2 9 -5 .9 -0 .84 -14 .544 4 .2 5  ± 0 .2 4 .7 9  ±0.1 3 .5 9  ±0.1 4.01 ± 0 .2 -0 .6 6 -15 .5 -0 .78 -16  345 4 .4 5  ± 0 .4 5 .1 6  ± 0 .3 4 .3 3  ± 0 .3 4 .4 2  ±0.1 -0 .12 -2 .6 -0 .74 - 1 4 346 5 .6 6  ±0.1 6 .0 9  ± 0 .3 5 .05  ± 0 .2 5 .18  ±0.3 -0 .6 0 -1 0 .7 -0 .9 0 -14 .947 5 .2 4  ± 0 .4 6 .38  ± 0 .2 4 .8 2  ±0.1 4 .9 6  ±0.1 -0 .43 -8.1 -1 .42 -22 .2
48 5 .4 7  ±0.1 6 .0 3  ± 0 .3 4 .8 6  ± 0 .3 4 .95  ± 0 .2 -0.61 -11.1 -1 .08 -17 .9
49 5.71 ± 0 .4 6 .08  ± 0 .2 5 .2 0  ± 0 .9 5 .2 6  ±0.3 -0,51 -8 .9 -0 .82 -13 .4
50 4 .8 2  ± 0 .2 5 .4 4  ± 0 ,2 4 .4 9  ± 0 .2 4 .4 4  ± 0 .2 -0 .33 -6 .8 -1 .00 -18 .4
51 5 .2 7  ±0.1 6 .35  ± 0 .2 5 .0 2  ± 0 .3 5 .5 6  ± 0 .7 -0 .2 5 -4 .7 -0 .7 9 -12 .552 4 .7 4  ±0.1 5 .45  ± 0 .2 4 .4 8  ±0.1 4 .4 6  ±0.1 -0 .2 5 -5 .3 -0 .9 9 -18.1
53 4 .9 8  ±0.1 5.61 ± 0 .2 4 .4 7  ±0.1 4 .7 0  ±0.1 -0.51 -1 0 .3 -0.91 -16.1
54 4 .8 8  ± 0 .2 6.11 ± 0 .3 4.71 ± 0 .3 4 .9  0± 0 .2 -0 .1 8 -3 .7 -1.21 -19 .8
55 4 .5 5  ±0.1 5 .53  ±0.3 4 .2 5  ± 0 .4 4 .4 8  ± 0 .2 -0 .3 0 -6 .6 -1 .05 -1 9 .0
56 4.51 ± 0 .5 6 .33  ± 0 .2 4 .9 2  ± 0 .9 5 .43  ± 0 .2 0.41 9.1 -0  90 -14 .2
57 5 .1 8  ± 0 .2 5.81 ± 0 .4 4 .3 3  ± 0 .2 4 .7 9  ±0.3 -0 .8 4 -16 .3 -1.01 -17 .558 4 .4 9  ± 0 .4 5 .3 6  ± 0 .2 4 .0 7  ± 0 .3 4 .35  ±0.1 -0 .42 -9 .4 -1 .0 0 -1 8 .759 5 .2 9  ± 0 .2 6 .0 8  ± 0 .3 4 .9 6  ±0.1 5 .40  ± 0 .2 -0 .3 4 -6 .3 -0 .6 7 -11.160 4 .7 6  ± 0 .2 5 .7 0  ±0.1 4 .5 3  ± 0 .3 4 .7 2  ±0.3 -0 .23 -4 .9 -0 .9 7 -17.1
Group
Mean 4.96 ±0.38 5.82 ±0.45 4.60 ±0.41 4.90 ±0.40
-0.37
±0.31
-7.3
±6.2
-1.04
±1.0
-16.5
±7.7
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3.3.4 Oxygen saturation.
Oxygen saturation (SaOz) data for the whole subject group is displayed in table 3.12 and 
figure 3.10. Complete data points for 58 subjects are recorded (n=58). The missing data 
points were due to a fault in the oximetry-metabolic cart interface. The mean SaOo during 
normoxic rest and exercise was; 95.9% (SD 1.4) and 94.8% (SD 1.6) respectively. The mean 
SaÜ2 during hypoxic rest and exercise was 84.4% (SD 2.1) and 69.8% (SD 2.5) respectively. 
The mean absolute change in SaO: at rest between conditions o f normoxia and hypoxia was -
11.1% (SD 3.5); the mean percent change was -1 1.6% (SD 3.7). The mean absolute change 
in SaO] during exercise between conditions o f normoxia and hypoxia was -25.8 (SD 11.4); 
the mean percent change was -26.0% (SD 7.1). Exercise measurements demonstrated normal 
distributions; however normoxic and hypoxic resting SaOi did not. A Wilcoxon signed rank 
sum test was performed on the differences between normoxia and hypoxia during rest; this 
demonstrated a significant difference (p<O.OOOI). Exercise measurements were compared 
using student t-test and showed a significant difference (p<O.OOOI). Lower than expected 
normoxic exercise resultrs were noted; the cause o f this was individuals gripping the handle 
bars o f the ergometer too tightly, despite instructions not to do so.
Resting SpOj Change
100
S p02
(%)
Normoxia Hypoxia
Exercise SpOz Change
100
Sp02
(% )
Normoxia Hypoxia
Figure 3.10 The change in SaO] from normoxia to hypoxia. The panel on the left shows 
changes during rest; the panel on the right shows changes during exercise. These plots 
demonstrate the decrease in SaCL from normoxia to hypoxia, reflecting the hypoxaemia 
during hypoxic exposure which intensified during exercise.
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Table 3.12. Individual oxygen saturation data and changes between normoxia and hypoxia.
Subject Normoxic Rest % saturation
Normoxic
Exercise
Hypoxic
Rest
Hypoxic
Exercise
ASaOj
(Rest)
ASa02
(Exercise)% saturation % saturation % saturation Sats. % Sais. %
I 9 5 .6 ± 1 .1 9 5 .7 ± 1 .1 85 .8  ± 1 .0 7 6 .9  ±1 -9 .8 -10 .3 -18 .8 -1 9 .62 95 .3  ± 1 .3 93 .5  ± 1 .0 8 2 .0  ± 2 .5 68 .5  ± 1 .5 -13 .3 -1 4 .0 -2 5 .0 -26 .83 9 4 .9 ± i . i 94 .7  ± 1 .0 86 .2  ±1.1 7 4 .9  ± 0 .8 -8 .7 -9 .2 -19 .8 -2 0 .94 95 .8  ± 1 .0 9 5 .4  ± 1 .0 84 .2  ± 1 .2 76.1 ± 1 .5 -1 1 .6 -12.1 -19 .3 -20 .25 97 .8  ± 1 .2 97.1 ± 1 .0 85.3  ± 1 .9 52 .5  ± 1 .5 -12 .5 -12 .8 -44 .6 -4 6 .06 9 4 .9 ± i . l 94 .3  ± 1 .2 85 .2  ± 1 .0 7 1 .8 ± 1 .1 -9 .6 -10 .2 -22 .4 -23 .87 9 5 .6  ± 1 .0 94 .5  ± 1 .3 8 4 .2  ± 2 .7 68 .8  ±1.1 -1 1 .4 -11 .9 -25 .7 -27 .28 96.1 ±1.1 96 .2  ± 1 .0 8 5 .9 ± 1 .7 7 1 .9 ± I .O -1 0 .2 -10 .6 -24.3 -25.39 9 5 .7 ± 1 .1 9 5 .4 ± 1 .1 8 6 .0  ± 1 .6 75 .7  ± 1 .2 -9 .7 -10.1 -19 .7 -20 .7W 95 .8  ± 0 .9 95 .2  ± 1 .3 8 4 .7  ± 1 .8 6 7 .7  ± 1 .2 -1 1 .2 -11 .7 -27 .5 -2 8 .9II 9 4 .7  ± 0 .9 9 4 .0  ± 1 .0 80 .2  ± 2 .0 6 5 .2  ± 1 .4 -14 .5 -15 .3 -28 .8 -30 .612 9 4 .9  ± 0 .8 94 .5  ±1.1 8 3 .7 ± 1 .2 79.2  ± 1 .3 -1 1 .2 -11 .8 -15 .3 -16 .213 9 5 .4  ± 1 .3 93 .3  ± 1 .2 8 5 .6  ± 1 .7 78.3 ± 1 .3 -9 .8 -10 .3 -14 .9 -1 6 .014 95 .9  ± 1 .2 9 3 .6  ± 1 .6 85 .5  ± 2 .0 74 ,7  ± 1 .4 -1 0 .4 -10 .8 -1 8 .9 -20 .2IS 94 .8  ± 2 .7 9 1 .4 ± l .7 84. ± 2 .6 7 6 i .7 ± 1 .3 -1 0 .2 -10 .7 -29 .7 -32 .516 94 .2  ± 1 .0 9 2 .6  ±1.1 8 0 .6  ± 1 .9 59.3 ±1.1 -1 3 .6 -14 .5 -33 .4 -3 6 .017 96 .0  ± 1 .2 9 5 .9  ± 1 .3 8 6 .0  ± 2 .0 7 4 .7 ± 1 .5 -1 0 .0 -10 .5 -21 .2 -22.1IS 95.1 ± 1 .2 94 .2  ± 1 .3 83.1 ± 2 .3 73 .0  ± 1 .4 -12.1 -1 2 .7 -21 .2 -22 .519 94 .3  ± 1 .6 94.1 ±1.1 81 ,2  ± 1 .2 6 6 .9  ± 1 .9 -13.1 -1 3 .9 -27 .2 -28 .920 9 4 .5  ± 0 .8 94.1 ± 1 4 80 .5  ± 1 .9 5 9 .8 ± 1 .2 -1 3 .9 -1 4 .8 -34 .3 -36 .421 9 4 .5  ± 0 .9 92 .9  ±1.1 9 1 .5 ± 1 .5 6 8 .9  ± 1 .6 -2 .9 -3.1 -24 .0 -25 .822 9 7 .4  ± 1 .0 97 .5  ± 0 .8 7 9 .5  ± 1 .9 5 9 .8 ± 1 .1 -1 7 .9 -1 8 .4 -37 .8 -38 .723 9 6 .7  ± 1 .2 9 5 .4  ±1.1 84.1 ± 1 .4 6 5 .4  ± 1 .5 -1 2 .6 -13.1 -30.1 -31 .524 9 6 .0  ± 1 .3 95.1 ± 1 .3 8 6 .0  ± 1 .3 7 5 .8  ± 0 .9 -1 0 .0 -1 0 .4 -19.3 -20.325 9 6 .0  ± 1 .2 96.1 ±1.1 84 .3  ± 0 .7 7 3 .2  ±1.3 -1 1 .6 -12.1 -22 .9 -23 .926 9 5 .0  ± 1 .3 94 .4  ± 1 .3 80.1 ± 1 .7 7 2 .0  ± 1 .6 -1 4 .9 -1 5 .7 -2 2 .4 -23 .727 9 6 .8 ± 1 .3 9 5 .4  ± 1 .0 90 .5  ± 1 .4 - -6.3 -6 .5 -9 5 .4
28 98 .5  ± 1 .4 97 .8  ± 1 .5 87.1 ± 2 .2 7 5 .9  ± 1 .4 -1 1 .4 -1 1 .6 -2 1 .9 -22 .429 9 9 .6  ± 0 .8 97 .8  ± 1 .2 9 1 .7  ± 2 .5 6 1 .9 ± 1 .5 -7 .8 -7 .9 -35 .9 -36 .7
30 95 .3  ± 1 .7 95.1 ± 0 ,9 81.1 ±2.1 7 1 .7 ± l .5 -14.1 -1 4 .8 -2 3 .4 -24 .631 9 6 .9  ± 1 .4 9 4 .7  ±1.1 9 0 .8  ± 1 .0 79 .5  ± 1 .5 -6.1 -6 .3 -1 5 .2 -16 .032 9 7 .6  ± 2 .2 94 .5  ± 3 .2 8 5 .9  ± 2 .8 7 8 .0  ± 2 .6 -1 1 .7 -1 2 .0 -1 6 .5 -17 .433 95.1 ± 1 .6 96 .5  ± 1 .4 84.1 ± 1 .9 7 1 .3 ± 1 .3 -1 1 .0 -1 1 .6 -2 5 .2 -26.134 9 5 .2  ± 1 .3 9 2 ,6  ± 1 .7 8 2 .8  ± 1 .8 5 7 .4  ± 1 .3 -1 2 .4 -1 3 .0 -35.1 -38 .035 9 4 .2  ± 1 .3 9 4 .6  ± 1 .6 8 2 .0  ± 1 .3 6 7 .7  ± 1 .6 -1 2 .2 -1 2 .9 -2 6 .9 -28 .436 9 6 .2  ± 1 .3 94 .5  ± 1 .3 8 1 .6  ± 0 .9 6 2 .0  ± 2 .0 -1 4 .6 -1 5 .2 -32 .5 -3 4 .4
37 9 6 .9  ± 1 .5 93 .5  ± 1 .5 8 5 .7  ± 2 .3 7 1 .0 ± 1 ,3 -11 .2 -1 1 .6 -2 2 .4 -2 4 .038 9 6 .5 ± 1 .1 96.1 ±1.1 8 6 .6  ± 1 .8 7 5 .0  ± 0 .8 -9 .9 -1 0 .2 -21.1 -22 .0
39 94 .7  ± 0 .9 93 .5  ± 1 .3 85 .3  ± 1 .0 6 8 .4  ± 2 .7 -9 .4 -1 0 .0 -2 5 .2 -2 6 .9
40 9 4 .2  ± 1 .5 9 3 .0  ± 0 .7 8 ! .3 ± 1 .8 6 8 .0  ± 1 .6 -1 2 .9 -1 3 .7 -25.1 -2 6 .941 96 ,8  ± 0 .7 9 7 .7  ±1.1 8 4 .7  ± 1 .5 6 1 .0 ± 1 .5 -12.1 -12 .5 -3 6 .6 -37 .542 9 6 .0  ± 1 .2 94 .5  ± 1 .2 8 3 .4  ± 1 .4 67 .4  ± 1 .6 -1 2 .6 -1 3 .2 -27.1 -2 8 .6
43 9 5 .2  ± 0 .8 94.3  ± 1 .0 8 3 .0 ± 1 .3 63 .6  ± 1 .4 -12 .2 -1 2 .8 -3 0 .6 -32 .5
44 9 5 .9  ± 1 .2 95.3  ±1.1 87.1 ± 2 .3 80 .5  ± 1 .0 -8 .8 -9 .2 -14 .8 -15 .5
45 9 7 .9  ± 1 .7 93 .4  ± 2 .4 8 9 .4  ± 2 .2 82 .4  ± 1 .6 -8 .6 -8 .8 -1 1 .0 -11 .8
46 9 8 .7  ± 1 .0 9 3 .0  ± 2 .3 84.1 ± 2 .0 6 4 .2  ±1.1 -14 .6 -1 4 .8 -28 .8 -3 0 .947 95.1 ± 1 .5 94,5  ± 0 .6 7 8 .7 ± 1 .4 6 4 .7  ±2.1 -16 .4 -17 .3 -2 9 .7 -31 .548 9 7 .4  ± 1 .2 96 ,8  ± 1 .0 7 4 .8  ± 2 .4 65 .7  ± 2 .9 -22 .5 -2 3 .2 -31.1 -32.149 9 4 .9  ± 1 .4 96 .0  ±1.1 8 1 .9 ± 1 .5 6 9 .8  ± 1 .8 -1 3 .0 -1 3 .7 -26 .2 -27.3
50 9 6 .8  ± 1 .0 9 5 .9  ± 1 .0 -
51 9 7 ,4  ± 1 ,8 95.1 ± 2 .5 8 7 .4  ± 3 .0 72 .2  ± 2 .5 -9 .9 -1 0 .2 -2 2 .9 -24.1
52 95 .2  ± 1 .3 9 5 .7  ± 1 .3 8 0 .7  ± 1 .6 6 8 .4  ±1.1 -14 .5 -1 5 .2 -27.3 -28 .6
53 96 .6  ± 1 .3 96.1 ± 2 .0 8 5 .9 ± 1 .8 70.8  ± 1 .4 -10 .7 - i  1.1 -25 .3 -26 .354 96.1 ± 1 .5 9 4 .6  ± 1 .0 8 4 .7  ± 1 .4 6 2 .0 ± 1 .1 -11.3 -1 1 .8 -3 2 .6 -3 4 .455 9 6 .6  ± 1 ,4 90 .3  1.8 8 5 .4  ± 1 .6 79.1 ± 3 ,3 -11 .2 -1 1 .6 -11,1 -12 .356 96 .8  ±1.1 9 5 .6  ± 1.1 86 .2  ± 3 .9 7 5 .4  ± 1 .2 -10 .6 -1 0 .9 -20.1 -21.157 9 3 .9  ± 1 .8 94 .7  ± 1 .3 8 3 .9  ± 3 .4 76 .2  ±1.1 -1 0 .0 -1 0 .7 -18 .5 -19 .558 9 5 .6  ± 2 .8 93 .7 ± 1 .0 86 .7  ± 3 .3 71.8  ± 3 .6 -9 .0 -9 .4 -2 1 .9 -23.359 99 .5  ± 0 .7 9 8 .9 ± 1 .3 86 .0  ± 2 .7 6 3 .0  ± 2 .0 -0 .6 -0 .6 -2 1 .9 -25 .860 9 2 .7  ± 1 .2 92 .4  ±1.1 84 .4  ± 1 .8 69.1 ±2.1 -0 .0 -0 .0 -15 .3 -18.1
Group
Mean 95,9 ±1.4 94.8 ±1.6 84.4 ±2.1 69.8 ±2.5
-1 1.1
±3,6
-11.6
±3.7
-25.8
±11.4
-26.0
±7.0
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3.3.5 Tidal volume
Tidal volume data (Vj) data for the whole subject group is displayed in table 3.13 and figure
3.11. Complete data points for the entire subject group were measured (n=60). The mean Vt 
during normoxic rest and exercise was 0.87 litres (SD 0.40) and 1.78 litres (SD 0.47) 
respectively. The mean Vx during hypoxic rest and exercise was 0.99 litres (SD 0.40) and
2.03 litres (SD 0.57) respectively. The mean absolute change in Vx at rest between 
conditions of normoxia and hypoxia was 0.12 litres (SD 0.38); the mean percent change was 
18.9% (SD 26.5). The mean absolute change in Vx during exercise between conditions of 
normoxia and hypoxia was 0.25 litres (SD 0.24); the mean percent change was 14.3 litres 
(SD 12.3). Resting measurements o f Vx did not demonstrate a normal distribution; Wilcoxon 
sign sum rank analysis showed a significant change between normoxia and hypoxia 
(p<0.0001). Exercise measurements were in a normal distribution and significant change 
between normoxia and hypoxia was demonstrated using a paired student t-test (p<0.0001).
Resting Vt change Exercise Vr change
Normoxia Hypoxia Normoxia Hypoxia
Figure 3.11 The change in tidal volume from normoxia to hypoxia. The panel on the left 
shows changes during rest; the panel on the right shows changes during exercise. These plots 
demonstrate the wide range o f responses o f tidal volume during rest and exercise during 
hypoxic exposure. Some individuals demonstrated a rise in Vx, whilst others had a decrease 
in Vx (in red) during hypoxic exposure. The majority o f subjects demonstrated a rise in Vx 
during exercise, but o f a variable degree. Two subjects exhibited clear evidence of 
hyperventilation at rest, one during normoxia, the second during hypoxia.
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Table 3.13. Individual tidal volume data and changes between normoxia and hypoxia
Subject Normoxic Rest (litres)
Normoxic
Exercise
Hypoxic
Rest
Hypoxic
E.xercise
A V; 
(Rest)
AVt
(Exercise)(litres) (litres) (litres) litres % litres %
I 1.17 ± 0 .4 8 2 .5 6  ± 0 .5 4 1.66 ± 0 .6 7 2 .9 8  ± 0 .4 7 0 .4 9 41 .8 0 .4 2 16.32 1.24 ± 0 .93 2 .5 6  ± 0 .6 0 1.47 ± 0 .3 8 2 .7 4  ± 0 .42 0 .2 2 18.1 0 .18 6 .93 1.07 ± 0 .8 2 3 .04  ± 0 .7 4 1 .1 5 ± 0 .2 1 3 .66  ± 0 .58 0 .08 7 .0 0 .63 20 .74 1.02 ± 0 .4 9 2 .88  ± 0 .3 5 1.20 ± 0 .7 5 3 .06  ±0.41 0 .1 8 17.6 0 .18 6.35 1.08 ± 0 .7 8 1.81 ± 0 .4 3 0 .9 5  ± 0 .3 2 .1 8  ±0.41 -0 .13 -12.1 0 .3 7 20 .46 0 .6 0  ± 0 .2 0 1.43 ± 0 .2 5 0 .8 4  ± 0 .3 2 1.74 ± 0 .18 0 .2 4 40.1 0.31 21.87 1.55 ± 0 .6 9 2 .05  ± 0 .4 9 1.90 ± 0 .8 6 2 .33  ± 0.63 0 .35 22 .8 0 .28 13.58 0 .7 7  ± 0 .3 4 1.51 ± 0 .4 2 1.05 ± 0 .6 4 1.59 ± 0.43 0 .28 36 .6 0 .0 9 5.99 0 .7 0  ± 0 ,1 8 1.84 ±0.21 0 .8 5  ± 0 .6 6 2 .4 2  ± 0 .4 9 0 .15 2 0 .7 0 .5 9 31 .810 0.75  ±0.31 1.91 ± 0 .3 5 1.10 ± 0 .6 4 2 .3 8  ± 0 .4 0 0 .35 4 6 .8 0 .4 7 24 .611 0 .9 2  ± 0 .2 9 2 .4 0  ± 0 .4 9 1.35 ± 0 .6 5 2 .8 2  ± 0 .28 0.43 46 .5 0 .42 17.612 0 .9 7  ± 0 .6 8 1.99 ± 0 .5 5 0 .7 6  ± 0 .1 4 1.86 ± 0 .42 -0.21 -2 1 .8 -0 .12 -6.213 0 .7 7  ± 0 .43 1.68 ± 0 .4 6 0 .8 2  ± 0 .4 5 1.76 ± 0 .1 7 0 .05 6.5 0 .07 4 .414 1.27 ± 0 .9 3 2 .0 4  ± 0 .1 8 1.19 ± 0 .5 9 2 .4 4  ± 0 .3 0 -0 .08 -6 .6 0 .4 0 19.4
IS 0 .8 0  ± 0 .2 6 2 .0 4  ± 0 .4 7 1.08 ± 0 .5 3 2 .3 4  ± 0 .55 0 .2 7 34 .0 0 .2 9 14.316 0.85  ±0.21 2 .3 7  ± 0 .4 3 1.06 ±0.51 2 .1 6  ± 0 .2 9 0.21 25 .0 -0.21 -8 .917 0 .9 5  ± 0 .5 2 2 .1 9  ± 0 .2 8 i .04 ± 0 .5 3 2 .4 6  ± 0 .2 2 0 .0 9 9.5 0 .2 7 12.418 1.09 ± 0 .4 5 2 .1 2 ± 0 .5 1 1.63 ± 0 .5 9 2 .3 0  ± 0 .3 2 0 .5 4 49.1 0 .18 8.719 1.15 ± 0 .6 9 1.91 ±0.31 1.25 ± 0 .4 5 2 .3 2  ± 0.33 0.11 9.2 0 .4 2 21 .820 1.17 ± 0 .7 2 1.94 ± 0 .3 4 0 .9 8  ± 0 .4 4 2 .5 9  ± 0.33 -0 .2 0 -1 6 ,8 0 .65 33.721 1.63 ±0.41 2 .5 7  ± 0 .4 2 3.11 ± 0 .6 3 3 .1 6 ± 0 .3 1 1.48 90 .7 0 .5 9 22.822 0.73  ± 0 .2 6 1.93 ± 0 .1 7 1.28 ± 0 .7 4 2 .3 7  ± 0 .2 0 0 .55 74 .2 0 .45 23 .223 0.81 ± 0 .4 4 1.43 ± 0 .3 3 0 .7 0  ± 0 .2 2 1.59 ± 0 .1 9 -0.11 -1 3 .6 0 .1 6 11.324 0,91 ± 0 .3 9 1.88 ± 0 .3 3 1.27 ± 0 .4 9 2 .1 2  ± 0 .35 0 .3 6 39 .8 0 ,25 13.225 0 .5 2  ± 0 .1 5 1.73 ± 0 .2 8 0 .8 6  ± 0 .1 5 1.64 ± 0.13 0 .3 4 65 .2 -0 .09 -4 .926 0 .7 7  ± 0 .4 8 1.15 ± 0 .3 9 0 .6 6  ± 0 .3 4 1 .1 2 ± 0 .3 5 -0.11 -14 .7 -0 .03 -2 827 0 .5 0  ± 0 .3 2 1.23 ± 0 .2 4 0 .6 3  ± 0 .2 5 1.30 ± 0 .24 0.13 25 .9 0 .0 7 5.728 0.63  ± 0 .3 9 0 .9 9  ± 0 .2 4 0 .6 2  ± 0 .2 3 1.12 ± 0.23 -0.01 -1 .2 0 .13 12.9
29 1.30 ± 0 .9 2 1.76 ± 0 .2 4 1 .1 4 ± 0 .3 6 2 .0 7  ±0.31 -0 .1 7 -12 .7 0.31 17.830 0 .5 2  ± 0 .2 2 1.05 ± 0 .1 5 0 .6 0  ± 0 .2 4 1.18 ± 0 .2 0 0 .08 14.5 0 .12 11.831 1.86 ± 0 .3 4 2.11 ± 0 .5 0 1.55 ± 0 .2 7 3 .4 4  ± 0 .36 -0 .32 -1 6 .9 1.33 63 .232 0 .8 4  ±0.61 1.80 ± 0 .6 5 0.81 ± 0 .6 5 2 .1 0  ± 0 .47 -0 .0 2 -2 .6 0 .3 0 16.433 0 .7 2  ± 0 .65 1.54 ± 0 .3 9 0.81 ±0.21 1.77 ± 0 .39 0 .0 9 13.1 0 .23 14.934 0.73  ± 0 .2 0 1,80 ±0.41 0.91 ±0.31 2 ,3 4  ± 0 .15 0 .18 24.1 0 .5 4 30.0
35 0 .8 5  ±0,21 1.97 ± 0 .4 4 1.14 ± 0 .2 9 2.13  ± 0 ,36 0 .2 9 34.1 0 .1 6 8,4
36 0 .4 8  ± 0 .1 0 1.09 ± 0 .1 8 0 .63  ± 0 .11 1 .4 7 ± 0 .1 8 0 .1 5 30 .6 0 ,3 9 35.6
37 0 .4 8  ± 0 .1 5 1.11 ± 0 .1 6 0 .6 9  ±0.21 1.44 ± 0 .26 0.21 4 3 .9 0 .33 29 ,3
38 0 .5 9  ± 0 .0 9 1.41 ± 0 .2 3 0 .5 6  ± 0 ,0 9 1.71 ±0.21 -0 .0 4 -5 .9 0 .2 9 20 ,739 0 .6 3  ± 0 .0 8 1.50 ± 0 .3 3 0 .8 7  ± 0 .3 9 1.62 ± 0 .2 7 0 .2 4 38.3 0 .13 8.4
40 0 .6 2  ± 0 .2 5 1,41 ± 0 .1 7 0 .7 2  ± 0 .2 4 1.83 ±0,21 0.11 17.3 0 .42 29 .4
41 0.61 ± 0 .1 9 1.72 ±0.41 0 .83  ± 0 .4 6 1.84 ± 0 .33 0 .2 2 35 .9 0 ,12 7.3
42 0 .7 2  ± 0 .1 6 2 .1 0 ± 0 .1 7 0 .8 2  ±0.21 1,82 ± 0 .15 0 .1 0 13.7 -0 .28 -13 .3
43 0 .7 2  ±0.11 1.28 ± 0 .1 7 0.71 ± 0 .2 2 1.59 ±0.21 -0.01 -1 .2 0 .3 0 23 ,744 0 .8 0  ± 0 .7 9 1.48 ± 0 .2 2 0.81 ± 0 .1 9 1.67 ± 0 .18 0.01 1.0 0 .1 9 13.2
45 0 .7 2  ± 0 .4 7 1.24 ± 0 .4 0 0 .7 2  ± 0 .4 4 1.28 ± 0 ,28 0 .0 0 0 .2 0 .0 4 2,9
46 0 .5 8  ± 0 .0 8 1.18 ± 0 .4 4 0 .6 9  ± 0 .2 3 1.32 ± 0 .30 0 .12 2 0 .2 0 .15 12 5
47 0 .6 2  ± 0 ,2 7 1.42 ± 0 .1 6 0 .6 9  ± 0 .2 6 1.69 ± 0.13 0 .0 7 11.8 0 .2 7 18.9
48 0 .5 6  ±0.11 1.29 ± 0 .2 7 0 .6 3  ± 0 .2 8 1.38 ± 0 .24 0 .0 7 12.7 0 .0 9 7.0
49 0 .7 4  ± 0 .4 2 1.53 ± 0 .2 0 0 .8 0  ± 0 .3 2 1.66 ± 0 .42 0 .0 7 9.1 0 .13 8,4
50 0.61 ± 0 .2 6 1.41 ± 0 .2 2 0 .7 8  ± 4 .2 6 1.66 ± 4 .2 9 0 .1 7 27 .8 0 .25 17.9
51 1.26 ± 0 .2 0 2 .5 8  ±0.61 1.24 ± 0 .5 2 .9 0  ± 0 .45 -0 .0 2 -1 .6 0 .32 12.4
52 0 .6 9  ± 0 .1 0 2 .0 8  ± 0 .4 7 1.11 ± 0 .9 2 2 .23  ± 0 .4 9 0 .42 61.1 0 .15 7.0
53 0 .4 2  ± 0 .0 7 1.05 ±0.11 0 .5 7  ± 0 .2 1.28 ± 0 .12 0 .15 34 .4 0 .23 2 1 5
54 0 .8 4  ± 0 .13 2.01 ±0.21 i .05 ± 0 .2 7 2 .08  ±0.21 0 .2 0 24 .2 0 .0 7 3.7
55 0 .6 9  ± 0 .2 4 2 .0 0  ± 0 .6 7 1.02 ± 0 .4 3 2 .2 2  ± 0 .32 0.33 4 7 .5 0 .23 11.3
56 0 .7 6  ± 0 .2 5 2 .0 2  ± 0 .53 0 .7 5  ± 0 .4 1.89 ± 0 .3 6 -0 .0 2 -2.1 -0 .13 -6 .2
57 0.71 ± 0 .5 5 1.27 ± 0 .3 7 0 .93  ± 0 .5 9 1.60 ± 0 .43 0 .23 31 ,9 0 .33 25 .558 0 .5 4  ± 0 .13 1.54 ± 0 .3 9 0 .7 7  ± 0 .6 8 1.66 ± 0.45 0 .2 4 4 4 .4 0 .1 2 8.059 2 .9 5  ±1.01 1.98 ± 0 .6 2 0 .8 6  ± 0 .4 7 2 .1 9  ± 0 .4 7 -2 .0 8 -7 0 .7 0 .2 0 10.2
60 0 .7 9  ± 0 .0 8 1.78 ± 0 .2 2 0 .9 5  ± 0 .2 3 2.01 ± 0 .18 0 .1 6 20 .3 0 .23 12.9
Group
Mean 0.87 ±0.40 1.78 ±0.47 0.99 ±0.40 2.02 ±0.57
0.12
±0.38
19.0
±26.5
0.25
±0.24
14.3
±12.3
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3.3.6 Respiratory rate
Respiratory rate (RR) data for the whole subject group is displayed in table 3.14 and figure
3.12. Complete data points for the entire subject group were measured (n=60). The mean RR 
during normoxic rest and exercise was 15.0 bpm (SD 3.1) and 20.9bpm (SD 4.2) 
respectively. The mean RR during hypoxic rest and exercise was 15.4bpm (SD 3.3) and 23.7 
bpm (SD 4.8) respectively. The mean absolute change in RR at rest between conditions of 
normoxia and hypoxia was 0.4 bpm (SD 2.4); the mean percent change was 4.0% (SD 17.9). 
The mean absolute change in RR during exercise between conditions of normoxia and 
hypoxia was 2.8 bpm (SD 2.8); the mean percent change was 14.5% (SD 15.7). Respiratory 
rate during rest and exercise demonstrated normality under conditions of normoxia and 
hypoxia; paired student t-tests demonstrated significant change between normoxia and 
hypoxia for exercise (p<0.0001), but not during rest (p=0.182).
Resting RR change
RR
(bpm) ,5
Hypoxia
Exercise RR change
R R  25  
(bpm)
20
Hypoxia
Figure 3.12 The change in respiratory rate from normoxia to hypoxia. The panel on the left 
shows changes during rest; the panel on the right shows changes during exercise. Similar to 
the responses seen with tidal volume, there is a wide range of response in RR, with both 
increases and decrease (in red) evident. The high RR evident in some of the subjects a degree 
of hyperventilation.
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Table 3.14. Individual respiratory rate data and changes between normoxia and hypoxia.
Subject Normoxic Rest (bpm)
Normoxic
Exercise
Hypoxic
Rest
Hypoxic
Exercise
ARR
(Rest)
ARR
(Exercise)
(bpm) (bpm) (bpm) bpm % bpm %
I 11.4 ± 4 .0 17,0 ± 2 .9 9 ,5  ± 3 ,4 18.1 ± 3 ,3 -1 ,9 -16 .3 1.2 7,0
2 11.8 ± 4 .7 15.4 ±4.1 8 ,4  ± 2 ,9 1 7 .0 ± 1 .8 -3 ,4 -2 8 ,6 1.6 10,1
3 16.0 ± 3 .6 18.7 ± 4 .8 16.7 ± 2 ,8 18.7 ± 2 .9 0 ,6 4 ,0 -0 .0 -0,3
4 13.1 ± 2 .9 1 6 ,0 ± 1 ,4 14 ±2,1 19.7 ± 2 ,5 0 ,9 6 ,9 3.7 23 ,0
5 13.5 ± 4 .3 2 0 ,7  ± 2 ,9 14,2 ± 1 ,9 2 0 .2  ± 2 ,6 0 ,7 4 ,8 -0 .5 -2 ,6
6 19.3 ± 4 .3 2 1 ,9 ± 3 ,2 16,3 ± 3 ,7 2 2 ,9  ± 2 .2 -2 .9 -15 .3 1.0 4 .7
7 9.3 ± 1 .5 2 1 ,2  ± 3 ,8 8 ,8  ± 2 ,5 22.1 ± 4 .7 -0 .5 -5 .0 0 .8 4 ,0
8 13.7 ± 3 .4 2 3 ,5  ± 5 ,2 13,3 ± 5 ,4 2 8 .5  ± 5 .4 -0 .4 -3 .2 5 .0 21.1
9 14.7 ± 2 .7 19,2 ±3,1 18,4 ± 3 ,9 19.9 ± 4 .5 3 ,7 2 5 .0 0 ,7 3.6
10 16,0 ± 3 .5 2 1 ,4  ± 2 .9 13.4 ± 5 ,7 2 2 .0  ± 3 .0 -2 .6 -16.1 0 ,6 2 .8
11 16,9 ± 6 .8 16.6 ± 2 ,4 11,4 ± 3 19.7 ± 2 ,2 -5 .5 -32 .4 3,1 18,5
12 12.7 ± 3 .2 16.6 ± 2 .8 1 4 .6 ± 1 ,9 2 0 ,4  ± 3 ,6 1.9 14.8 3,8 22 .7
13 16.5 ± 5 .6 2 1 .2  ± 4 ,3 17,2 ± 2 .5 2 5 ,4  ± 2 .4 0 .7 4.3 4,1 19.5
14 13.9 ± 2 .6 19,6 ± 2 ,0 14,9 ± 3 .9 2 0 .8  ± 2 .5 1.1 7 .6 1.2 6 .0
15 16,7 ± 4 ,4 19,2 ± 2 ,2 19,8 ± 2 ,6 2 4 .6  ± 4 .6 3,1 18,5 5.3 2 7 .7
16 17,3 ± 3 ,7 16,5 ± 2 .7 16,8 ± 3 .8 30 .5  ± 3 .2 -0 .5 -3 .2 14.0 84 .9
17 14.0 ± 3 ,4 19,3 ± 1 ,5 13,8 ± 2 .6 2 4 ,0  ± 1 .8 -0 .2 -1 .4 4 .8 2 4 .7
18 14,4 ±3,1 2 1 ,2  ± 3 ,8 12.4 ± 3 .2 26 .5  ± 4 ,7 -2 .0 -1 3 .7 5.3 2 5 ,0
19 10.9 ± 3 ,9 19,0 ± 2 .7 12,2 ±2,1 2 2 ,6  ±2,3 1.2 11.2 3 ,6 18.8
20 10,1 ± 3 ,3 18.8 ± 2 .7 15.6 ± 5 15.9 ± 2 ,4 5 .5 55 ,0 -2 ,9 -15 .6
21 9 ,9  ± 2 .0 17.6 ± 3 .5 1 2 .9 ± 3 2 1 .2  ± 2 .6 3 .0 30,1 3,6 20 .4
22 16.9 ± 2 .9 2 4 .6  ±2.1 1 2 .0 ± 1 ,3 28 .3  ± 2 .7 -4 .9 -2 8 ,9 3 ,7 15.0
23 13.6 ± 8 .3 19.8 ± 5 .4 1 6 .0 ± 5 .3 2 0 .9  ± 3 .2 2 .4 17,6 1,1 5 .6
24 10.3 ± 5 .7 18,8 ± 2 .8 9,1 ± 1 ,6 2 2 ,0  ±3.1 -1 .2 -!  1,5 3,3 17.4
25 14.3 ± 3 ,6 20.1 ± 2 .7 1 3 .4 ± 3 ,1 26.1 ± 3 ,0 -1 .0 -6 ,6 6.1 30 .2
26 15,4 ± 2 ,9 2 3 ,0  ± 4 .6 1 5 .7 ± 3 ,4 2 7 ,6  ± 4 ,8 0 ,3 1,9 4 ,6 20 .2
27 17,9 ± 4 ,5 2 6 ,9  ± 4 .0 17,1 ± 2 .6 3 0 .6  ±3,1 -0 ,8 -4 .7 3 .7 14.0
28 2 4 ,3  ± 1 2 .9 34,1 ± 6 .2 2 3 .7  ± 4 .2 3 7 .7  ±6,3 -0 ,6 -2 .5 3 ,6 10,6
29 12.6 ± 3 ,7 2 2 ,8  ± 3 ,8 12.6 ±2.1 2 6 ,5  ± 2 ,7 -0,1 -0 .4 3 .6 15,9
30 17,8 ± 5 ,9 2 6 ,3  ± 4 ,2 18.2 ± 7 .6 2 7 .4  ± 5 ,7 0 ,4 2.3 11 4,1
31 8 ,9 ± 1 .6 2 2 ,9  ± 6 ,6 14.0 ± 2 ,6 2 2 ,7  ± 3 .7 5,1 57 ,9 -0.1 -0 ,5
32 17,7 ± 7 .9 22,1 ± 9 ,9 20,1 ± 6 .7 2 3 ,9  ± 4 ,0 2 .5 14,0 1.8 8,4
33 16,1 ± 3 .3 2 1 ,5  ± 3 ,3 14.9 ± 4 .5 21 .8  ± 3 .6 -1 .2 -7 .6 0.3 1,3
34 1 1 .0 ± 1 .1 16,4 ± 3 ,3 14 ± 2 .4 1 6 ,9 ± 1 ,6 3 .0 27.3 0.5 2 ,9
35 16.2 ± 2 .9 19.6 ± 3 .4 12.7 ± 2 ,5 2 0 ,6  ± 2 ,0 -3 .5 -2 1 .4 1.1 5.4
36 2 2 .2  ± 3 .7 30.1 ± 4 ,7 2 0 .5  ± 4 ,6 31,1 ± 4 ,6 -1 ,7 -7 .6 1.0 3.3
37 18,9 ± 3 .2 2 8 ,6  ± 3 ,6 15,5 ±5,1 2 7 ,5  ± 4 .2 -3 .4 -1 7 .8 -1.1 -3 ,8
38 15,9 ± 2 ,4 19,4 ± 3 ,5 16,1 ± 1 ,4 17.6 ± 2 ,5 0 ,2 1,3 -1 .9 -9 .6
39 17,3 ± 2 ,3 2 1 ,2 ± 5 ,1 15,4 ± 2 ,6 28.1 ±5.3 -1 ,8 -10 .6 6 ,9 32 .7
40 17,8 ±3,1 1 8 ,8 ± 1 ,1 17,9 ± 2 .9 2 1 ,6  ± 2 .6 0.1 0 .7 2 .8 15,1
41 14,0 ± 3 .4 15,9 ± 2 ,8 11.9 ± 2 ,7 17.9 ± 2 .7 -2 .0 -14 .4 2.1 12.9
42 12.1 ± 2 .8 17,4 ± 2 ,4 16.3 ±4,1 2 6 .4  ± 4 .3 4 .2 34.3 9 .0 51 .6
43 17.6 ± 5 .2 2 4 .2  ± 4 .6 2 0 .6  ± 5 ,9 2 4 .4  ± 3 .6 3 .0 16.9 0 .2 0 .9
44 14.6 ± 3 ,2 2 0 .4  ± 4 .0 17.8 ± 3 ,2 2 6 .0  ± 3 .3 3 .2 21 .9 5 .6 27 .2
45 17,8 ± 8 ,0 2 5 .8  ± 5 ,3 2 0 ,5  ± 1 0 .6 30 ,8  ±6.3 2 .6 14.9 5 ,0 19.3
46 15,9 ± 2 ,7 2 3 .4  ± 9 ,7 17,2 ± 3 ,6 2 6 .0  ± 8 .4 1.3 8 3 2.5 10.7
47 14,1 ± 5 ,6 17,5 ± 2 .5 17,2 ± 2 .9 22.1 ±2,1 3.1 2 1 .9 4 .6 26 .2
48 15,7 ± 3 ,2 2 7 .7  ± 4 .7 16.6 ± 5 .0 32 ,8  ± 4 ,9 0 .9 5.5 5,1 18.5
49 17,2 ± 4 ,3 2 4 .2  ± 2 ,2 16 .4  ± 4 .9 2 5 ,9  ± 2 ,7 -0 .9 -5.1 1.7 6 .9
SO 16,4 ± 4 .7 2 6 ,4  ± 3 ,8 18,5 ± 4 .3 2 9 ,4  ± 1 ,5 2 .2 13.4 3 ,0 11,2
51 8,8 ± 3 .4 9 ,9  ± 3 ,2 9.1 ± 2 .0 11,5 ± 2 .0 0.3 3 .7 1,6 15 8
52 18.0 ± 2 .3 2 1 ,2  ± 3 ,9 16 .6  ± 4.1 25 ,3  ±4.1 -1 .4 -7 .7 4,1 19,3
53 17.4 ±4.1 25,1 ± 4 .4 19.5 ± 4.1 2 6 .7  ±4,1 2,1 11,9 1,6 6 ,4
54 M .9 ± 1 .9 16.0 ± 2 .9 1 2 ± 1 .8 19.6 ±2.3 0,1 0 ,9 3,7 2 3 ,0
55 16,6  ± 3 ,0 2 2 .2  ± 3 ,8 16.8 ± 3 .9 2 6 ,4  ± 4 ,3 0 ,2 1,5 4,3 19,2
56 14.9  ±2.1 15,5 ± 2 .6 16.5 ± 4 ,8 16.5 ± 4 ,8 1,6 111 1,0 6 ,7
57 17.0  ± 9 .2 2 6 .8  ± 5 .4 2 3 .3  ± 2 0 ,5 2 9 ,7  ± 9 ,0 6,3 37 .2 2 ,9 10.7
58 14.9 ± 4 .3 19.4 ± 5 .3 1 6 .0 ± 3 ,7 2 2 ,7  ± 5 ,6 1,2 8 .0 3,3 17.3
59 14,8 ± 2 ,7 2 0 .9  ± 3 ,0 15.2 ± 3 ,9 20 .3  ± 2 .4 0,3 2.3 -0 ,6 -2 .9
60 1 5 ,3 ± 1 ,1 15,3 ± 4 ,6 15.8 ± 2 ,5 2 3 ,9  ± 2 .8 0 .5 3.3 8,6 5 6 .6
Group
Mean 15.0 ±3.1 20.9 ±4.2 15.4 ±3.3 23.7 ±4.8
0.42
±2.4
4.0
±17.9
2.8
±2.8
14.5
±15.7
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3.3.7 Minute ventilation
Minute ventilation (VE) data for the whole subject group is displayed in table 3.15 and figure
3.13. Complete data points for the entire subject group were measured (n=60). The mean VE 
during normoxic rest and exercise was 11.32 litres (SD 2.26) and 35.28 litres (SD 6.80) 
respectively. The mean VE during hypoxic rest and exercise was 13.65 litres (SD 2.74) and 
46.17 (SD 10.20) respectively. The absolute change in VE at rest between conditions of 
normoxia and hypoxia was 2.33 (SD 1.92); the percent change was 21.9% (SD 18.2). The 
mean absolute change in VE during exercise between conditions of normoxia and hypoxia 
was 10.88 litres (SD 5.02); the mean percent change was 30.6% (SD 12.4). Minute 
ventilation measurements during normoxia demonstrated normality, but hypoxic VE data 
during rest and exercise were not. Wilcoxon sign rank sum analysis demonstrated a 
significant change between normoxia and hypoxia during rest and exercise (both p 
values<0.0001).
Resting ventilatory change Exercise ventilatory change
Ve
(l/min) 50
Normoxia HypoxiaNotmox a Hypoxia
Figure 3.13 The change in minute ventilation from normoxia to hypoxia. The panel on the 
left shows changes during rest; the panel on the right shows changes during exercise. The 
wide variation in response is seen as with the other plots. The resting plot shows 6 subjects 
that demonstrated a higher Ve during normoxic rest in comparison to hypoxia; these subjects 
also had a decrease in VCO2 and increase in PetCOz on exercise. This suggests that 
hyperventilation during this portion o f the protocol was present.
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Table 3.15. Individual minute ventilation and changes between normoxia and hypoxia.
Subject Normoxic Rest (l/min)
Normoxic
Exercise
Hypo.xic
Rest
Hypoxic
Exercise
AVE
(Rest)
AVE
(E.xercise)(l/min) (l/min) (l/min) l/min % l/min %
I 11,95 ± 2 .8 4 3 ,0 6  ± 6 ,5 14,77  ± 5 .9 5 4 ,1 6 ± n ,7 2 ,8 2 23 .6 11,1 25,82 12,06 ± 6 .2 3 7 ,08  ± 5 ,5 12.34  ±5.1 4 6 ,2 4  ± 6 .2 0 ,2 8 2.3 9 .16 24 ,73 16.04 ± 7 .4 53 ,9 9  ± 7 .6 18.80  ± 3 .0 66 ,65  ± 6 .2 2 ,7 6 17.2 12,66 23,54 12.58 ± 4 .8 46 ,4 5  ± 7 16.11 ± 6 ,8 60 ,65  ± 13 3 ,53 28.1 14,2 30 ,65 13,21 ± 7 .9 3 7 ,0 7  ± 5 ,9 13,32 ± 3 ,6 4 3 ,7  ± 8 ,2 0,11 0 .9 6 ,63 17,96 1 1,06 ± 2 .8 30 ,85  ±4.1 13,36 ± 4 ,6 39,81 ± 3 ,9 2 ,3 0 2 0 .8 8 ,96 29
7 13 ,88  ± 5 ,3 42 .3  ± 6 .9 16,06  ± 6 ,0 49 ,5 6  ± 7 ,5 2 ,1 8 15,7 1.26 17,2
8 9 .8 4  ±3,1 34 .1 8  ± 7 .6 1 3 .3 9 ± 8 ,8 44,1 ± 9 ,2 3 .5 5 36 .0 9 ,92 2 9
9 10,19  ± 2 .4 3 5 .5  ± 7 .3 14.21 ± 5 .7 4 6 ,8 6  ± 4 .5 4 .0 2 3 9 .4 11,36 32
10 11,65 ± 3 ,9 4 0 ,5 4  ± 7 .3 12,32 ± 4 .3 52 ,63  ±11.1 0 .6 7 5 .7 12,09 29 .8II 15,66 ± 8 .9 39,3  ± 6 ,4 14,59  ± 4 ,9 55 ,3 7  ± 6 ,7 -1 .0 8 -6 ,9 16,08 40 .912 10.87 ± 4 ,4 32 .18  ± 5 ,9 10,92 ± 1 ,7 37 ,22  ± 6 ,5 0 ,0 6 0.5 5 .04 15.713 11,73 ±4.1 30,61 ± 7 ,6 13,44  ± 5 ,2 45,1 ± 4 .4 1,71 14,6 14,49 47,314 16,07 ± 8 ,2 34 .2  ± 4 ,5 17,81 ±6,1 4 4 .2 8  ± 5 ,7 1,74 10,8 10,08 29 .515 12,73 ±3.1 39,71 ± 6 ,8 2 0 .2 8  ±5.1 50 ,35  ± 8 ,9 7 .55 59.3 10,65 26 .816 14.83 ± 5 .2 38 ,7 9  ± 8 .6 16,80 ± 4 .7 55,71 ± 9 ,9 1,97 13,2 16,92 43 ,617 12,61 ± 6 .7 38 ,7 4  ± 4 ,6 13,44 ±4,1 65 ,45  ± 5 ,8 0 ,83 6 ,6 26,71 68 .9
18 15.01 ± 4 .9 4 1 ,7 7  ± 8 .3 19,05 ± 4 .9 5 8 ,8 8 ± i l ,8 4 .03 2 6 .9 17,11 4 0 .919 11.74 ± 5 ,2 44 .13  ± 8 .6 15,56  ± 6 .7 60,61 ± 1 0 ,6 3 .8 2 32 .5 16,47 37,3
20 10,97 ± 5 ,0 36 ,58  ± 8 .7 14,03 ± 5 .2 52.71 ± 4 ,7 3 ,0 6 2 7 ,9 16,13 44.1
21 10,57 ± 4 ,4 36 ,65  ± 5 ,3 14,48 ±8,1 36 ,7 7  ± 10 ,8 3.91 37 .0 0 ,12 0.322 12,69 ± 5 ,7 44 ,1 8  ± 5 ,7 14,78 ± 7 ,8 67 ,3 9  ± 6 ,8 2 ,0 9 16.5 23,21 52.523 9 .63  ± 4 ,6 47 ,3 8  ± 0 .2 10,86  ± 3 ,5 67 ,0 2  ± 3 ,5 1.23 12.8 19,63 41 .4
24 8 .85  ± 4 ,9 26 ,8 7  ± 3 .5 11,37  ± 4 .0 32 ,8  ±5,3 2 .5 2 28 .5 5,93 22.1
25 7.41 ± 2 ,6 34 ,33  ± 5 ,2 11.32 ± 2 .9 45,91 ±5,1 3.91 52 .7 11,58 33.7
26 11,73 ± 6 ,9 34 ,38  ±5,1 10.01 ± 4 ,4 42 ,7 6  ± 6 ,8 -1 .7 2 -1 4 .7 8 ,37 24 .4
27 8 ,25  ±3.1 25 ,6 2  ± 5 ,3 10,23 ± 2 ,4 30 ,06  ± 4 .9 1.98 2 4 .0 4 ,4 4 17.328 12,83 ± 5 .4 32 ,53  ±5,1 14,11 ±3,1 39 ,38  ± 6 .7 1.27 9 .9 6 ,85 21.1
29 14,63 ± 8 .0 32 ,6 7  ± 4 ,2 13.75 ± 2 ,7 41 ,33  ± 6 ,5 -0 ,8 8 -6 .0 8 ,66 26 .5
30 8.61 ± 3 .9 39 ,2 9  ± 4 .7 10,77  ±7,1 54 ,18  ±7,1 2 .1 6 25 .0 14.88 37.9
31 16,57 ±3,1 2 7 ,6 2  ±9,1 2 1 .2 0  ± 4 ,0 31 ,97  ± 1 2 .4 4 ,63 2 7 .9 4 .35 15.7
32 13,51 ± 8 ,2 55 ,1 9  ± 7 .6 14.62 ± 8 ,8 78 ,03  ± 9 ,5 1.11 8.2 22 .8 4 4 1 .4
33 10,66  ± 7 ,9 35.91 ± 7 ,2 12,22  ± 4 ,3 49 ,33  ± 7 .6 1.55 14.6 13.42 37.434 8 ,0 2  ± 2 .3 32 ,5  ± 3 ,8 12.58 ± 1 ,7 3 7 ,97  ±3.1 4 .5 6 56 .9 5 ,47 16.835 13.79 ± 4 .4 28 ,63  ± 5 ,6 14.42  ± 4 .7 39 ,23  ± 7 0 .63 4 ,6 10.6 37
36 10,65 ± 2 ,6 37 ,7 4  ± 6 ,7 12.49  ± 2 .4 43 ,65  ± 7 ,8 1.84 17.3 5.91 15.637 9 ,0 6  ± 3 ,2 32 ,65  ± 3 ,5 10.08 ± 2 .5 3 9 ,9  ± 7 ,7 1.03 11.3 7 .25 22 ,2
38 9 ,4 0  ±2,1 3 1 ,52  ± 3 ,3 9 .0 0  ± 1 ,6 3 9 ,4  ± 2 .6 -0 .4 0 -4 ,3 7 .88 25
39 10,79 ± 2 ,0 2 6 ,93  ± 5 ,4 1 3 ,1 4 ± 4 ,8 4 3 ,6 7  ± 9 ,9 2 .3 6 21 .8 16.74 62 .2
40 10,76  ± 4 ,0 26 ,53  ± 2 ,9 12,96  ± 5 ,2 3 9 ,47  ± 5 ,8 2 .1 9 20 .4 12,94 48 ,841 8 ,32  ± 2 .5 2 6 ,93  ± 6 ,4 9 ,3 8  ± 3 ,5 3 2 ,87  ± 6 .2 1.06 12.7 5.93 22
42 8 .75  ± 2 ,8 3 6 ,5 2  ± 5 ,8 13.01 ± 4 .3 47 ,88  ± 6 ,8 4 .2 6 4 8 .7 11.36 31,1
43 12,30 ± 3 ,0 30,61 ± 4 ,7 14,09  ± 4 .4 3 8 ,14  ± 4 ,2 1.79 14.6 7.53 2 4 .6
44 11,38 ± 9 ,2 29 ,5 7  ± 4 ,4 14,20  ± 3 ,4 43 ,3 7  ± 5 ,8 2 .8 2 24 .8 13.8 46 ,7
45 12,72  ± 9 ,8 31,11 ±4,1 14,19  ± 9 ,2 3 8 ,48  ± 7 ,5 1.47 11.5 7 .36 2 3 .7
46 9 ,2 2  ± 1 ,9 2 5 ,2 8  ± 9 ,2 11,97  ± 4 ,3 3 5 .25  ± 7 2 ,7 4 2 9 .7 9 .9 7 39.4
47 8.71 ± 5 ,9 2 4 ,6 6  ± 3 .7 11.56  ± 3 ,2 3 7 .06  ±4,3 2 .8 5 3 2 .7 12,4 50.3
48 8 ,62  ±2,1 35,21 ± 6 ,5 10,05 ± 4 ,3 4 4 ,9 9  ± 7 ,4 1,44 16.7 9 .77 27 .849 12,38 ± 6 ,5 3 6 ,78  ± 4 ,1 13,24  ± 8 ,3 42 ,4 4  ± 9 .5 0 ,8 6 7,0 5 ,66 15.4
50 9,41 ± 2 ,4 36 .83  ± 5 ,5 13,73 ± 0 ,2 4 8 ,6 2  ± 0 ,2 4 ,3 2 4 6 .0 ! 1,79 32
51 9,91 ± 3 ,6 25 .2 6  ± 5 11.21 ± 4 ,7 3 2 .64  ± 3 ,9 1,31 13.2 7 ,38 29.2
52 12.53 ± 2 ,8 4 2 .8 6  ± 5 .3 16,20  ± 7 ,9 5 4 ,8  ±7,1 3 ,6 7 29 .3 11,94 2 7 .9
53 7,51 ± 2 ,6 26 .2 5  ± 4 ,5 10,81 ± 2 ,6 3 4 .02  ± 5 .4 3,31 4 4 .0 7 .77 2 9 .6
54 9 ,9 6 ± 1 8 3 1 .64  ± 3 ,8 12,31 ± 3 ,0 4 0 .73  ± 5 2 .3 5 2 3 ,6 9.1 28 .7
55 11.68 ± 4 ,0 4 2 ,3 9  ± 9 ,7 17,04 ±7,1 58.1 ± 9 ,2 5 ,36 4 5 .9 15.71 37.156 11,22 ± 3 ,7 3 0 .82  ± 7 ,3 11,22 ± 3 ,7 3 8 .7  ± 7 ,5 -0.01 -0.1 7 ,88 2 5 .657 10,55 ± 7 ,2 3 3 ,27  ± 7 ,5 17.71 ± 1 2 .3 45 ,45  ±9.3 7 .15 6 7 .8 12.19 36 .658 7 .9 0  ± 2 ,9 2 8 ,6 9  ± 7 10.28 ± 4 .0 3 6 ,66  ± 8 ,9 2 .3 8 30 .2 7 .98 27 .8
59 12,15 ± 9 ,0 4 0 ,6 7  ± 7 ,2 13 ,02  ± 7 .6 4 4 ,1 9  ± 8 ,5 0 .8 8 7.2 3 ,52 8.760 1 1 .1 5 ± 2 ,0 3 5 ,53  ± 5 ,6 18.84  ± 3 .5 4 5 ,4  ± 5 ,7 7 .6 9 6 9 .0 9 ,87 27 ,8
Group
Mean 11.32 ±2.3 35.28 ±6.8 13.65 ±2.7 46.17 ±10.2
2.33
±1.9
21.9
±18.2
10.9
±5.0
30.8
±12.4
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3.3.8 Patterns of ventilation and etCOz
The increase in ventilation evident upon hypoxic exposure demonstrated a wide variation in 
respiratory rate and tidal volume response between individuals. In the absence of 
measurements of physiological deadspace, end-tidal CO2 was used as an mdex of alveolar 
ventilation. Correlation plots of minute verrtilation, respiratory rate and tidal volume were 
plotted agamst PetC02. Results are given hr SI units (kilopascals -  kPa). In addition the 
Pear son correlation coefficient was calculated and regression lines were included in the plots.
Regression plot of etC02 against ventilation 
during rest and normoxia
I
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■•ff 4 SI R egression  95% a
Minute ventilation (i/min)
Regression plot of etC02 against ventilation 
during exercise and normoxia
p=0.97
R=0,005
R eg ress io n  
95%  Cl
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Figure 3.14 Regression plots of minute ventilation and PetCOz in normoxic conditions. The 
left panel shows resting response; the right panel shows the exercise response. The red 
dashed Imes are tire 95% confidence intervals. There is no significant correlation between 
PetCO: and Ve during rest or exercise (p=0,16 and 0.97 respectively). The resting plot 
demonstrates a trend toward a negative correlation that might belie a degree of 
hyperventilation during rest whilst cormected to the circuit. The lack o f conelation during 
normoxic exercise is to be expected since exercise ventilation is closely coupled to CO2 
production and elimination.
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Regression plot of etC02 against ventilation during rest and hypoxia Regression plot of etC02 against ventilation during exercise and hypoxia
1
8 . U
i1
,  . . .  * pcO.DOOl 
■*.**.4 . .  R = -0 .5 3
-------- R eg ressio n
...........  95%  Cl
I
CM 5 .0 -  8 
•§
P=o.ooa
R = -0 ,3 4
---------R eg ressio n
...........  95%  Cl
10 ZO 30 40
Minute ventilation (l/mln)
30 40  60 GO 70 00
Minute ventilation (l/mln)
Figure 3.15 Regression plots o f minute ventilation and etCO: in hypoxic conditions. The left 
panel shows resting response; the right panel shows the exercise response. The red dashed 
lines are die 95% confidence inteivals. There is a liiglily significant conelation between 
PetCOz and Ve during rest and exercise (p<0.0001 and p=0.008 respectively). This is 
expected, since ventilation in hypoxic conditions is driven by hypoxia as opposed to CO2 . 
The resting response is made more significant by one individual that may have exhibited a 
degree of hyperventilation; however removal o f this subject retamed the significance of this 
correlation (p=0.03)
Regression plot of etC02 against respiratory rate 
during rest and normoxia
Regression plot of etC02 against respiratory rate 
during exercise and normoxia
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Figure 3.16 Regi'ession plots of respiratory rate and etCOz in normoxic conditions. The left 
panel shows resting response; the right panel shows the exercise response. The red dashed 
lines are the 95% confidence inteivals. There was no significant coiTelation between RR and 
PetCOi during rest (p=0.75), but a significant correlation diuing exercise (p=0.001).
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Regression plot of etC02 against respiratory rate 
during rest and hypoxia
Regression plot of etC02 against respiratory rate 
during exercise and hypoxia ,
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Figure 3.17 Regi’ession plots o f respii'atoi’y rate and PetCO] in hypoxic conditions. The left 
panel shows resting response; the right panel shows the exercise response. The red dashed 
lines are the 95% confidence intervals. There was no significant correlation between RR and 
PetCOz dining rest (p=0.13), but a significant coiTelation dining exercise (p<0.0001).
Regression plot of etC02 against tidal volume during rest and normoxia
Regression plot of etC02 against tidal volume 
during exercise and normoxia
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Figure 3,18 Regi’ession plots of tidal volume and PetCOz in normoxic conditions. The left 
panel shows resting response; the right panel shows the exercise response. The red dashed 
lines aie the 95% confidence intervals. There was no significant correlation between V t and 
PetC 0 2  during rest (p=0.66), but a significant correlation during exercise (p=0.01).
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Regression plot of etC 02 against tidal volume
during rest and hypoxia
Regression plot of elC02 against tidal volume during exercise and hypoxia
Tidal volume (litres)
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Figure 3.19 Regression plots of tidal volume and PetCOz in hypoxic conditions. The left 
panel shows resting response; the right panel shows the exercise response. The red dashed 
lines are die 95% confidence intervals. The resting plot suggests a significant negative 
correlation between PetC0 2  and V t during hypoxic rest; however this appear s to be the effect 
of one outlier, who demonstrated a significant degree o f hyperventilation during this portion 
of the protocol (the same subject increased die significance of the minute ventilation plot 
during hypoxic rest). The removal o f this subject fi*om the correlation calculation produced a 
non-significant result (p=0.85). There was no significant correlation between V j and PetCO^ 
diuing exercise (p=0.66).
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3.4 Bio-impedance cardiac output results
In addition to the study data, validation studies were performed comparing bioimpedance 
with invasive cardiac output measurement.
3.4.1 Catheter laboratory validation of bioimpedance cardiac output monitoring
The validity of the Physioflow PF-05 bioimpedance cardiography unit was verified by 
comparison with pulmonary catheter studies and thermodilution measurement of cardiac 
output during diagnostic studies in four patients. The results are shown in table 3.16, figure 
3.20 and figure 3.21.
Subject
number
(Test)
CO# Catheter CO (l/miu)
Catheter Mean 
CO 
(l/min)
Bioimpedance
CO
(l/min)
Bioimpedance 
mean CO 
(l/min)
Subject
I
(rest)
1
2
3
4
3.25
3.01
3.03
2.97
3.06
2.85
3.28
3.20
3.10
3.11
Subject 1 3.3 3.441
I 2 3.3 3.23 3.627 3.50
(exercise) 3 3.1 3.42
Subject 1 3.89 3.876
2 2 3.79 3.91 3.696 3.80
(rest) 3 4.05 3.84
Subject 1 4.47 4.042
2 2 4.36 4.52 4.089 4.14
(exercise) 3 4.72 4.284
1 3.8 3.84Subject
2 2 4.33 4.13 4.134 4.02
(exercise) 34 4.28
3.95
4.16
Subject 1 5.61 5.85
3 2 5.9 5.66 6.2 5.91
(rest) 3 5.48 5.7
Subject 1 7.37 8.1
3 2 7.16 7.33 7.9 8.07
(exercise) 3 7.46 8.2
Subject 1 5.72 4.9
4 2 5.85 5.70 4.6 4.77
(rest) 3 5.55 4.8
Subject I 9.01 9.3
4 2 9.29 9.06 10 9.57
(exercise) 3 8.89 9.4
Table 3.16 The results of simultaneous thermodilution and bioimpedance cardiac output 
measurement in 4 patients. At least 3 measurements of cardiac output were performed; the 
mean o f these results is show in the relevant column. Subject 2 underwent two periods of 
exercise as shown.
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Bland Altman plot of catheter vs. bioimpedance CO measurements
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Figure 3.20a Bland Altman plot comparing raw cardiac output measurements using 
bioimpedance and tliermodilution simultaneously. Measuiements were made dining rest and 
exercise and have been pooled. The two metliods show reasonable agieement, with tlie 
exception of one outlier.
Scatter plot of biompedance vs catheter CO measurements
8 aQ>
Btoim pedance CO (l/min)
Figure 3.20b Scatter plot o f  raw cardiac output measinements using bioimpedance and 
thermodilution simultaneously.
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Bland Altman plot of catheter vs. bioimpedance CO measurements 
(average of 3 values-minimum)
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Figure 3,21a Bland Altman plot comparing the mean o f 3-4 measui'ements made in 
succession. The measurements aie o f pooled rest and exercise recordings. The degree of 
agi'eement is much improved by averaging several results.
Scatter plot of biompedance vs catheter CO measurements 
(average of 3 values-minimum)
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Figure 3.21b Scatter plot o f the mean of 3-4 measinements made in succession, using 
bioimpedance and tliermodilution simultaneously. The measurements aie of pooled rest and 
exercise recordings.
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3.4.2 Subject group biometric data
The majority of the subjects presented in this aspect of the study were a subset the previous 
group; except for two subjects denoted ‘A ’ and "B \ the subjects retain the subject numbers 
from the first study for continuity. A brief description of this group is provided. Thirty one 
subjects were included in these studies, 15 male; 16 female. Biometric data is presented 
below in table 3.17. The mean age o f the group was 23.0 years (SD 4.1 years; range 18-37); 
the mean height was 174.6 cm (SD 7.9 cm; range 160-186 cm); the mean weight was 71.0 kg 
(SD 10.9 kg; range 53-92). The whole group demonstrated normality for height and weight.
Subject ACEgene Age Sex
Height
(cm)
Weight
(kg) Subject
ACE
gene Age Sex
Height
(cm)
Weight
(kg)
21 II 25 M 185 80.4 45 II 22 F 168 58.5
23 If 18 F 176 74.0 46 II 23 F 168 58.0
25 ID 23 F 171 60.2 47 II 19 F 173 70.0
26 ID 22 F 179 63.3 48 D D 20 F 160 63.6
27 ID 21 F 171 56.2 49 D D 20 M 183 80.0
28 ID 23 F 169 59.4 50 ID 21 F 169 67.0
29 D D 34 M 182 78.6 A ID 21 M 179 70.6
30 DO 21 F 165 57.8 52 ID 21 M 177 88.8
31 II 21 M 186 82.2 53 ID 27 F 163 62.0
32 D D 27 M 185 76.6 26 ID 28 M 179 71.0
33 ID 20 M 184 84.3 55 D D 37 M 183 92.3
34 ID 24 M 178 79.0 56 ID 20 M 182 82.7
35 II 21 M 184 85.0 58 ID 26 M 174 74.3
36 D D 23 F 165 58.2 59 ID 20 F 163 73.4
39 ID 21 F 171 53.0 60 ID 21 M 182 76.2
44 II 22 F 163 60.5
Table 3.17 Biometric data for cardiac output subject group.
The following sections present the bioimpedance cardiography results in the form o f tables 
and graphs and are laid out in a similar fashion as presented in the previous section. 
Measurements of CO during rest and exercise are over a period o f 90 seconds toward the end 
of the resting and exercise segments of the protocol. Exercise measurements were made after 
4 minutes to ensure steady state.
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3.4.3 Heart rate
Heart rate data for the subgroup is displayed in table 3.18 and figure 3.22. Complete data 
points were measured for the entire subject group (n=31). The mean heart rate during 
normoxic rest and exercise was; 73.3 bpm (SD 12.4) and 117.0 bpm (SD 16.7) respectively. 
The mean heart rate during hypoxic rest and exercise was; 85.6 bpm (SD 13.5) and 142.3 
bpm (SD 18.5) respectively. The mean absolute change in heart rate at rest between 
conditions of normoxia and hypoxia was 12.3 bpm (SD 5.8); the mean percent change was 
17.3% (SD 8.0). The mean absolute heart rate change during exercise between conditions of 
normoxia and hypoxia was 25.2 bpm (SD 6.1); the mean percent change was 21.9 (SD 5.7). 
All heart rate responses demonstrated normality; paired student t-test analysis showed a 
highly significant difference between normoxia and hypoxia during rest and exercise (both p 
values <0.0001).
Subject Normoxic rest 
(bpm)
Normoxic
Exercise
(bpm)
Hypoxic Rest 
(bpm)
Hypoxic exercise 
(bpm)
A Heart rate 
(Rest)
A Heart rate 
(Exercise)
bpm % bpm %
I 89 .5  ± 3 .3 1 2 7 .8 ± 1 .8 109.8 ± 2 .6 1 4 6 .9 ± 1 .8 20 .3 2 2 .7 19.1 15.02 87 .8  ± 4 .6 142.1 ± 2 .5 9 6 .9  ± 5 .7 168.6 ± 2 .2 9.1 10.4 26 .6 18.73 81.1 ± 5 .2 110.5 ± 2 .7 8 8 .9  ± 4 ,7 139.2 ± 2 .6 7 ,9 9 .7 2 8 .7 25  94 6 6 .2  ± 4 .0 116.6 ± 2 .0 7 6 ,5  ± 3 .5 1 4 1 .3 ± 1 .2 10.3 15.5 24 .7 21 .2
5 6 4 .4  ± 4 .9 1 0 ! .7 ± 1 .8 7 4 ,7  ± 3 .9 129.5 ± 1 .9 10.3 16.0 27 .8 27 .36 55 .8  ± 2 .5 104.1 ± 1 .9 6 7 .4  ± 5 ,4 134 .8 ± 1 .1 11.6 2 0 .9 30.7 29 ,57 84 .6  ±4.1 135 9 ± 3 .1 95 .3  ± 4 .5 160 .0± 1.3 10.6 12.6 2 4 .0 17.7S 64 .3  ±4.3 100.3 ± 2 .9 70 .5  ± 5 ,2 1 2 3 .2 ± 1 .8 6.1 9 .6 22 .9 22 .89 6 7 .2  ± 3 .6 116.7 ±2.1 7 9 ,2  ± 4 .0 143.9 ± 2 .0 12.0 17,9 27 .2 23 .310 77 .7  ± 2 .8 1 1 2 .5 ± 1 .4 93.1 ± 1 .8 1 3 4 ,2 ± 1 .0 15.4 19.9 2 1 .7 19.311 6 0 .5  ± 4 .8 8 9 .6  ± 1 .4 6 7 .9  ± 2 .6 103.5 ± 1 .6 7 .4 12.2 13,9 15.5
12 8 7 .5  ± 1 .9 123.5 ± 2 .2 82.1 ± 7 .0 148,8 ± 0 .9 -5 .4 -6 .2 25 .3 20 .513 7 5 .6  ±5.1 113.0 ± 3 ,4 8 8 .9  ± 4 .2 146.7 ± 3 .3 13.3 17.6 33.7 29 .8
14 8 5 .8  ± 4 .5 127.7 ± 2 .3 106.8 ± 5 .4 160.9 ± 4 .8 2 1 .0 24 .5 33.1 2 5 .915 9 1 .7  ± 5 .3 135.8 ± 2 .5 111.6 ±3.1 175.6 ± 4 .2 19.9 21 .7 39.8 29 .316 7 8 .2  ± 3 .0 1 1 5 .9 ± 1 .0 9 2 .9  ± 3 .8 144.1 ±1.1 14,8 18.9 28 .2 24 .3
17 7 3 .7  ± 3 .2 134.4 ± 2 .5 9 5 .9  ± 4 .5 156.9 ± 9 .2 22 .3 30 .2 22 .4 16,7
18 5 5 .0  ± 3 .6 9 6 .4  ± 2 .7 6 9 .6  ± 6 .7 1 1 7 .9 ± 1 .3 14.6 26 .5 21 .5 22 .3
19 72 .2  ± 3 .7 109.1 ± 2 8 3 ,2  ± 2 .7 126.8 ±1.3 11.1 15.3 17.7 16.2
20 80 .8  ± 3 .0 1 5 4 .8 ± 1 .6 98.1 ±3.1 175.4 ± 1 .3 17.2 21 .3 2 0 .6 13.3
21 53 .5  ± 1 .6 8 0 .8 ± 1 ,5 6 6 .9  ± 4 .0 104.8 ± 3 .3 13.4 25.1 24 .0 2 9 .7
22 66 .3  ± 3 .8 97.5  ± 6 .9 8 0 .0  ± 3 .3 125.0 ± 4 .0 13.7 2 0 .7 2 7 .4 2 8 .2
23 8 2 .0  ± 6 .2 130.8 ± 2 .6 87 .5  ± 4 .0 146.0 ± 0 .9 5 .4 6 .6 15.2 11.6
24 95.3  ± 1 .4 130.4 ± 1 .8 100.4 ± 3 .3 153 .5 ± 1 .1 5 .0 5.3 2 3 .2 17,8
25 6 4 .2  ± 3 .4 112.5 ± 1 .9 7 7 .9  ± 3 .9 135.8 ± 3 .5 13.7 21 .3 23 .3 2 0 .7
26 82 .9  ± 3 .0 135.3 ± 1 .5 101.1 ± 4 .3 164.8 ± 1 .3 18.1 21 .8 29 .5 21 .8
27 7 6 .9  ± 3 .9 129.1 ± 2 .6 9 1 .5  ± 3 .7 166.3 ±2.1 14.6 19 37 .2 28 .828 5 3 .6  ±2.3 104.4 ± 1 .0 7 0 .6  ± 2 .0 124.0 ±2.1 17.0 31 .8 19.7 18.9
29 81 .4  ± 2 ,3 1 1 4 .9 ± 1 .7 88.3  ± 1 .4 135.1 ± 1 .3 7.0 8.6 20 .2 17.630 5 5 .6  ± 4 .0 101.0 ± 2 .2 62 .3  ± 2 .7 134.2 ±3.1 6 .7 12.1 33 .2 32 .931 62 .8  ±4.3 123 2 ± 3 .3 78 .5  ± 4 .6 142.9 ± 1 .3 15.7 25 19.7 16.0
Group
mean
73.4 ±12.4 117.0 ±16.7 85.6 ±13.5 142.3 ±18.5 12.3
±5.6
17.2
±8.0
25.2
±6.1
21.9
±5.7
Table 3.18. Individual heart rate data and changes between normoxia and hypoxia
Exercise heart rate changeResting heart rate change
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Figure 3.22 The change in heart rate horn normoxia to hypoxia. The panel on the left shows 
changes during rest; the panel on the right shows changes dining exercise. The wide variation 
in response is seen as with the other plots. One subject had a higher heait rate during 
normoxic rest in comparison to hypoxic rest (data point in red), this subject did not have 
conciuTently elevated ventilation during this part of the protocol; tlierefore it is difficult to 
assess whetlier this was due to anxiety. All subjects increased then heart rate from normoxia 
to hypoxia dining exercise.
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3.4.4 Stroke volume
Stroke volume data for the subgroup is displayed in table 3.19 and figure 3.23. Complete data 
points were measured for the entire subject group (n=31). The mean stroke volume during 
normoxic rest and exercise was; 89.3 mis (SD 25.6) and 113,7 mis (SD 29.0) respectively. 
The mean stoke volume during hypoxic rest and exercise was; 91.7 mis (SD 26.3) and 121.0 
mis (SD 34.6) respectively. The mean absolute change in stroke volume at rest between 
conditions of normoxia and hypoxia was 2.4 mis (SD 5.4); the mean percent change was 
2.8% (SD 6,7). The mean absolute stroke volume change during exercise between conditions 
o f normoxia and hypoxia was 7.2 mis (SD 8.5); the mean percent change was 5.9% (SD 5.8). 
All stroke volume responses demonstrated normality; paired student t-test demonstrated a 
highly significant difference during exercise (p<0.0001) and a significant difference at rest 
from normoxia to hypoxia (p=0.023).
Subject Normoxic rest 
(mis)
Normoxic
Exercise
(mis)
Hypoxic Rest 
(mis)
Hypo.xic exercise 
(mis)
A Stroke volume 
(Rest)
A Stroke volume 
(Exercise)
nils % mis %
1 6 8 .2  ± 1 .0 95.1 ±4.1 7 3 .6  ± 2 .9 102.5 ± 4 .0 5.3 7 .8 7 .4 7 .8
2 101.2 ± 2 .9 147.3 ± 4 .9 111.8 ± 3 .0 162.5 ± 1 1 .6 10.6 10,5 15.2 10,3
3 6 7 .7  ± 1 .8 82.6  ± 7 .8 7 1 .0 ± 1 .7 82.9  ± 5 .0 3,3 4 ,9 0 .4 0.4
4 39 .2  ± 0 .9 4 0 .7  ± 1 .9 4 3 .9 ± 1 .1 4 4 .8 ± 1 .9 4 .7 12.0 4 .0 10.0
5 97 .4  ± 5 .5 1 1 5 .9 ± 1 2 .5 83 .2  ± 1 8 .5 115.2 ± 8 .2 -1 4 .2 -1 4 .6 -0 .6 -0 .5
6 130.5 ± 2 .4 142.5 ± 1 .5 135.1 ± 5 .0 146.1 ± 2 .5 4 .7 3 .6 3 .6 2 ,5
7 7 4 .4  ± 2 .2 87 .2  ± 3 .3 7 6 .7  ±5.1 88.8 ± 2 .4 2.3 3,1 1.6 1.8
8 95.1 ±4.1 139.6 ± 7 .7 9 8 .4  ± 4 .2 158.1 ± 1 1 .2 3.3 3.4 18.5 13.3
9 1 1 4 .6 ± 1 .7 125.5 ± 2 .4 1 1 7 .8 ± 1 .6 130.2 ± 1 .2 3.1 2 .7 4 .7 3 ,8
10 7 6 .7  ± 6 .4 126 .9  ± 3 .9 85.3  ± 6 .5 134.0 ± 7 .8 8.5 11.1 7 .0 5 .6
11 97.3  ± 7 .9 137.6 ± 2 3 .2 93 .3  ± 5 .3 149.7 ± 20 .3 -4 .0 -4.1 12.1 8 .8
12 83 .9  ± 7 .9 9 9 .2  ± 1 1 .8 91.1 ± 6 .6 98 .2  ± 7 .3 7 .2 8.5 -0 .9 -1 .0
13 107 .0  ± 2 .0 107,2 ± 4 .4 109.1 ± 2 .0 107.5 ± 4 .0 2.1 2 .0 0 .3 0.3
14 6 2 .8  ± 2 .9 86 .7  ± 6 .2 6 6 .8  ±5.1 97 .5  ±10.1 4 .0 6 .4 10,8 12.4
15 118.1 ± 2 .5 116 6 ± 1 .9 116.6 ± 0 .9 i l 9 , 3 ± l . l -1 .5 -1 .2 2.8 2 .4
16 7 5 .9  ± 2 .7 9 2 .2  ±3.1 76.1 ±4.1 93 ± 4 .9 0.2 0.3 0 ,7 0 .8
17 6 9 .2  ± 2 .2 107.2 ± 4 .6 73.1 ± 2 .0 112.3 ± 7 .0 3.9 5 .6 5.1 4.8
18 141.7 ± 2 ,5 173.1 ± 7 .5 144.9 ± 3 .7 2 06 .8  ± 1 3 .0 3.2 2 .3 33 .7 19.5
19 7 3 .6 ± 1 .5 100.5 ± 4 .9 7 2 ,0  ± 3 .4 115 ± 5 .7 -1 .7 -2.3 14.5 14.5
20 95 .5  ± 2 .5 96 .2  ± 2 .2 9 3 .7 ± 1 .8 9 8 .0  ± 2 .6 -1 .9 -1 .9 1.8 1.9
21 83 .5  ± 4 .2 98 .2  ± 3 .2 86.1 ± 3 .2 108.6  ± 5  8 2 .6 3.2 10.4 10.6
22 82.3  ± 6 .8 1 1 0 .7 ± n .8 85 .8  ± 4 .3 115.5 ± 9 .4 3 .5 4 .3 4 .8 4 .4
23 1 3 4 ,4 ± 1 .7 142.5 ± 1 .0 134.9 ± 0 .8 144.9 ± 1 .4 0 .5 0 .4 2.5 1.7
24 5 7 .6  ± 6 .7 103.9 ± 4 .7 4 7 .7  ± 8 .6 9 9 .8 ± I3 .1 -9 .9 -17 .2 -4.1 -4 .0
25 85 .2  ± 2 .6 115.2 ± 4 .6 9 0 .0  ± 4 .9 1 1 3 .2 ± I6 .I 4.8 5 .6 -2.1 -1.8
26 4 4 .9  ± 1 .8 6 3 .4  ±2.1 4 6 .0  ± 1 .6 68.5  ± 3 .9 1.0 2 .3 5.1 8.0
27 101.1 ± 3 .5 137.5 ± 1 0 .8 117.4  ± 6 .3 151.4 ± 2 2 .6 16.2 16.0 13.9 10.1
28 126.4 ± 2 .5 179.3 ± 1 7 .3 124.4 ± 4 .2 206 .2  ± 2 6 .9 -1 .9 -1 ,5 2 6 .9 15,0
29 72 .2  ±4.1 111.8 ± 6 .4 75.1 ± 3 .4 120.2 ± 6 .8 2 ,9 4.1 8 .4 7.5
30 7 6 .0  ± 1 .8 114.4 ±8.1 8 0 .2  ± 4 .1 1 2 8 .7 ± 1 5 .8 4 ,2 5,5 14.4 12.6
31 115,5 ± 2 .0 129.2 ± 2 .4 121.8 ± 2 .5 129.9 ± 2 .9 6,4 5.5 0 .7 0.5
Group
mean
89.3 ±25.6 113.7 ±29.0 91.7 ±26.3 121.0 ±34.6 2.7
±5.4
2.8 
±6.7
7.2
±8.5
5.9
±5.8
Table 3.19. Individual stroke volume data and changes between normoxia and hypoxia
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Resting stroke volume change Exercise stroke volume change
1 6 0
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1 4 0 190 '
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Figure 3.23 The change in stroke volume from nonnoxia to hypoxia. The panel on the left 
shows changes during rest; the panel on the right shows changes during exercise. The wide 
variation in response is seen as with the other plots. There were 6 subjects tliat demonstrated 
a decrease in SV from normoxia to hypoxia during rest and 4 different subjects decreased 
tlieir SV during exercise (data sets in red).
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3.4.5 Cardiac output
Cardiac output data for the subgroup is displayed in table 3.20 and figure 3.24. Complete 
data points were measured for the entire subject group (n=31). The mean CO during 
normoxic rest and exercise was; 6.44 l/min (SD 1.81) and 13.19 l/min (SD 3.40) respectively. 
The mean CO during hypoxic rest and exercise was; 7.74 l/min (SD 2.21) and 16.99 l/min 
(SD 4.56) respectively. The mean absolute change in CO at rest between conditions of 
normoxia and hypoxia was 1.30 (SD 0.79); the mean percent change was 20.6% (SD 11,7). 
The mean absolute CO change during exercise between conditions of normoxia and hypoxia 
was 3.90 l/min (SD 1.65); the mean percent change was 29.1% (SD 9.4). All CO responses 
demonstrated normality; paired student t-tests showed a highly significant difference at rest 
and during exercise, between normoxia and hypoxia (both p values <0.0001)
S u b je c t N o rm o x ic  re st  
( l/m in )
N orm o x ic
E x ercise
(l/m in )
H y p o x ic  R est  
( l/m in )
H yp ox ic  ex e rc ise  
(l/m in )
A C a r d ia c  o u tp u t  
(R est)
A C a rd ia c  o u tp u t  
(E x er c ise )
I/mill % l/min %
/ 6.11 iO .3 12.15 ± 0 .6 8 .0 9  ± 0 .5 15.07 ± 0 .7 1.98 3 2 .3 8 2.91 2 3 ,9 72 8.9 ± 0 .7 2 0 .9 2  ± 0 .8 10.84 ± 0 .7 2 7 .4  ± 2 1.94 21 .85 6 .47 30 .9 43 5 .48  ± 0 .2 9.11 ± 0 .8 6.31 ±0.3 11.54 ± 0 .7 0 .83 15.15 2 .42 26.614 2.6  ± 0 .2 4 .75  ± 0 .3 3 .3 6  ±0.1 6 .32  ±0.3 0 .7 6 2 9 .25 1.57 33 .155 6 .2 6  ± 0 .4 1 1 .7 9 ± 1 .4 6 .23  ± 1 .4 14.91 ± 0 .9 -0 .03 -0 .53 3 .12 2 6 .4 46 7 .28  ± 0 .4 14.84  ± 0 .4 9 .1 3 ± 1 .0 19.7 ± 0 .4 1.85 2 5 .3 7 4 .8 6 32 .7 7
7 6 .2 9  ± 0 .2 11.87 ± 0 .6 7 .2 9  ±0.3 14.21 ± 0 .4 1.00 15.98 2 .34 19.72
8 6 .1 2  ± 0 .5 14.0 ± 0 .9 6 .9 5  ± 0 .8 19.48 ± 1 .4 0 .83 13.59 5 .48 39.11
9 7 .7  ± 0 .5 14.65  ± 0 .4 9 .33  ± 0 .6 18.74 ± 0 .4 1.63 21 .1 4 4 .1 0 27 .9610 5 .95  ± 0 .4 14.28  ± 0 .5 7 .9 4  ± 0 .7 17 .98± 1  1 1.99 3 3 .4 5 3 .70 2 5 .9 011 5 .8 7  ± 0 ,4 12.33 ±2.1 6 .33  ± 0 .5 15.5 ± 2 .2 0 .4 7 7 .98 3 .17 2 5 .7 612 7 .3 4  ± 0 .7 1 2 .2 3 ± 1 .3 7 .4 6  ± 0 .5 14.61 ±1.1 0 .1 2 1.59 2 .38 19.4513 8 .08  ± 0 .5 12.12 ± 0 .8 9 .7  ± 0 .4 15.77 ± 0 .6 1.62 2 0 .0 0 3.65 30 .1 214 5 .3 9  ± 0 .5 11.08  ± 0 .8 7 .12  ± 0 .5 15.7 ± 1 .9 1.73 3 2 .1 0 4 .62 41.71
15 10.82 ± 0 .5 15.83 ± 0 .3 13.02 ± 0 .4 2 0 .9 6  ± 0 .6 2 .1 9 2 0 .2 5 5.13 32.41
16 5.93  ± 0 .2 10.69 ± 0 .4 7 .0 7  ± 0 .5 13.39 ± 0 .7 1.14 19.28 2 .70 25 .2817 5.1 ± 0 .2 14.41 ± 0 .7 7.01 ± 0 .4 17.62 ± 1 .7 1.92 3 7 .5 6 3 .22 22 .32
18 7 .7 9  ± 0 .6 16.7 ± 0 .9 1 0 .0 9 ± 1 .1 2 4 .3 9  ± 1 .4 2 .2 9 29 .4 .0 7 .69 46 .05
19 5 .3 2  ±0.3 10.97 ± 0 .6 5 .9 9  ± 0 .4 14.59 ± 0 .7 0 .6 8 12.72 3 .62 33.01
20 7 .7 2  ± 0 .3 14.89  ± 0 .4 9 .1 9  ± 0 .4 17.18 ± 0 .5 1.46 18.95 2 .30 15.43
21 4 .4 7  ±0.3 7 .94  ± 0 .3 5 .7 7  ± 0 .5 11.39 ± 0 .8 1.30 2 9 .0 9 3.45 4 3 .5 0
22 5 .45  ± 0 .6 10.84  ± 1 .7 6 .8 7  ± 0 .6 1 4 .4 6 ± 1 .5 1.42 2 5 .9 9 3 .62 33 .39
23 11.03 ± 0 .9 18.64  ± 0 .4 11.8 ± 0 .6 2 1 .! 6 ± 0 .2 0 .7 7 6 .9 7 2 .52 13.51
24 5 .4 9  ± 0 .6 13.55 ± 0 .7 4 .7 7  ± 0 .8 15.33 ±2.1 -0.71 -1 2 .9 9 1.78 13.14
25 5 .48  ± 0 .4 12.96  ± 0 .4 7.01 ± 0 .5 15.38 ± 2 .4 1.53 2 7 .8 9 2 .43 18.72
26 3.73  ±0.3 8 .57  ± 0 .2 4 .6 5  ± 0 .3 11.28 ± 0 .6 0 .9 2 2 4 .6 6 2.71 31.61
27 7 .78  ± 0 .5 17.74  ± 1 .7 10.74  ± 0 .8 2 5 .1 7  ± 3 .6 2 .9 6 38.11 7.43 4 1 .9 0
28 6 .7 7  ±0.3 18.71 ± 1 .8 8 .78  ± 0 .4 25 .58  ± 3 .5 2 .0 2 2 9 .8 0 6 .88 3 6 .76
29 5 .8 7  ± 0 .4 12.83 ± 0 .6 6 .6 4  ± 0 .4 16.23 ± 1 0 0 .7 7 13.09 3 .40 26 .53
30 4 .2 2  ±0.3 1 1 .5 7 ± 1 .0 4 .9 8  ± 0 .2 17.09 ±2.1 0 ,7 6 18.00 5 .52 4 7 .7 2
31 7 .26  ± 0 .6 15.92  ± 0 .5 9 .5 8  ± 0 .7 18.57 ± 0 .3 2 .3 2 31 .93 2 .65 16.62
Group
mean
6.44 àzl.81 13.19 ±3.40 7.74 ±2.21 16.99 ±4.56 1.30
±0.79
20.6
±11.7
3.80
±1.65
29.1
±9.4
Table 3.20. Individual cardiac output data and changes between normoxia and hypoxia.
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Resting cardiac output change Exercise cardiac output change
C ard iac
o u tp u t(l/mlti)
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o u tp u t
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Figure 3.24 The change in cardiac output from normoxia to hypoxia. The panel on the left 
shows changes during rest; the panel on the right shows changes during exercise. The wide 
variation in response is seen as with the other plots. There were 3 subjects that demonstrated 
a decrease in CO from normoxia to hypoxia during rest (data sets in red), this may have been 
due to a degree o f anxiety when being initially connected to the exercise equipment and 
circuit. All subjects demonstrated a rise in CO from normoxia to hypoxia during exercise.
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3.4 ACE gene polym orphism  and cardiopulm onary exercise results
The following section compares the CPET results previously presented by the ACE I/D 
genotype for each subject. The distribution o f genotypes (displayed for each individual in 
table 3.2) was 14: II, 30; ID and 16: DD; this distribution is in Hardy-Weinberg equilibrium ( 
X^=0.005). Table 3.20 summarises the biometric data for each subject group; furthermore, the 
distribution o f age, weight and oxygen uptake between groups is similar. This was verified 
using ANOVA. The power calculation for the ANOVA analysis o f the exercise ventilation 
results from the three groups allowing for a maximal standard deviation o f 15.4 and the mean 
percent changes from normoxia to hypoxia from the three groups is 0.99.
Genotype II ID DD
Number 
Age (years) 
Height (cm) 
Weight (kg) 
VO2 max (ml/kg) 
VO2 at VT (ml/kg)
14
23.6 (±4.7) 
178.3 (±8.3)
71.9 (±8.3)
55.9 (±13.2)
33.9 (±7.6)
30
23.2 (±4.3) 
177.1 (±8.14) 
73.4 (±11.7)
49.3 (±11.0)
29.3 (±9.1)
16
24.7 (±6.1)
178.5 (±7.9) 
75.9 (±10.4)
52.8 (±11.6) 
32.1 (±10.4)
Table 3.21 The physical characteristics of the subject groups by ACE genotype.
The following sections present the cardiopulmonary and bioimpedance results according to 
ACE genotype. The response to hypoxia during rest and exercise is compared between 
groups. The insertion homozygous group is denoted by the abbreviation II; the heterozygous 
and deletion homozygous groups are denoted by ID and DD respectively. The following 
sections have a similar layout and present the data in both graphic and tabulated form.
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3.5.1 Oxygen uptake
The group oxygen data is displayed by ACE genotype in table 3.22 and figure 3.25. The 
absence of any significant change in percent VO2  from normoxia to hypoxia during rest and 
exercise was verified by ANOVA analysis (p values are displayed on table 3.20 and 
graphically on figure 3.25).
C h a n g e  in re s tin g  V 0 2  from  no rm o x ia  to  hypox ia 
by A G E g e n o ty p e
C h a n g e  in e x e rc is e  V 0 2  from  no rm ox ia  to  hypoxia 
by A C E  g e n o ty p e
1 5  -
0
■E 5  -
1Ê 0 -uII
ID DD
§C0)D)I -H
-3  -
-4  _0>CL
II ID DD
A C E g en o ty p e A C E  g e n o ty p e
P = 0 .1 5 p = 0 .54
Figure 3.25 ANOVA analysis o f change in VO2 from normoxia to hypoxia. The left panel 
shows the response during rest; the right panel during exercise. The central point marks the 
group mean, the bars represent the 95% confidence interval for each group. Neither the 
response during rest or exercise demonstrates any significant difference between normoxia 
and hypoxia (ANOVA p values: rest p= 0.15, exercise p= 0.54).
Rest/
exercise II ID DD
ANOVA 
p value (ls.%)
Resting 
VO2  (l/min)
Normoxia 
Hypoxia 
Absolute change 
Percent change (A%)
0.42 ±0.12 0.40 ±0.10 0.42 ±0.08 
0.41 ±0.10 0.42 ±0.09 0.40 ±0.06 
-0.008 ±0.06 0.02 ±0.07 -0.02±0.05 
0.11 ±16.6 7.2 ±21.0 -3.2 ±11,5
0.15
Exercise 
VO2  (l/min)
Normoxia 
Hypoxia 
Absolute change 
Percent change (A%)
1.59 ±0.45 1.64 ±0.41 1.66 ±0.36 
1.56 ±0.43 1.64 ±0.36 1.63 ±0.27 
-0.02 ±0.09 0.007 ±0.12 -0.03 ±0.16  
-1.0 ±7.1 1.42 ±7.16 -0.6 ±9.0
0.54
Table 3.22 Oxygen uptake results grouped by ACE genotype. Group means are expressed as 
absolute values o f baseline data and change from normoxia to hypoxia, in addition to percent 
change; standard deviation is denoted by the ± symbol. ANOVA p values are in the far right 
column.
188
3.5.2 Carbon dioxide production
Group data for VCO2 is displayed by ACE genotype in table 3.23, and graphically on figure
3.26. There was no significant difference in VCO2 from normoxia to hypoxia during rest or
exercise by ACE genotype (ANOVA p values 0.24 and 0.67, respectively).
C h a n g e  in res ting  V C 0 2  from  norm ox ia  to  hypoxia 
by A C E  g e n o ty p e
3 0  -I
0)D)I 20  -I 10  -I
II ID DD
A C E  g en o ty p e
p = 0 .2 4
C h a n g e  in e x e rc is e  V C 0 2  from  n o rm o x ia  to  hypoxia 
by  A C E  g e n o ty p e
ID
A C E  g e n o ty p e
p = 0 .6 7
Figure 3.26 ANOVA analysis of change in VCO2 from normoxia to hypoxia. The left panel 
shows the response during rest; the right panel during exercise. The central point marks the 
group mean, the bars represent the 95% confidence interval for each group. Neither the 
response during rest or exercise demonstrates any significant difference between normoxia 
and hypoxia (ANOVA p values: rest p= 0.24, exercise p= 0.67).
Rest/
exercise II ID DD
ANOVA 
p value (A%)
Resting
VCO2
(l/min)
Normoxia 
Hypoxia 
Absolute change 
Percent change (A%)
0.35 ±0.10 0.33 ±0.09 0.35 ±0.07 
0.426 ±0.155 0.40 ±0.09 0.40 ±0.07 
0.08 ±0.08 -0.07 ±0.06 -0.05 ±0.04 
21.7±18.7  25.5 ±21.2 15.6±13.1
0,24
Exercise
VCO2
(l/min)
Normoxia 
Hypoxia 
Absolute change 
Percent change (A % )
1.35 ±0.10 1.41 ±0.34 1.44 ±0.23 
1.55 ±0.48 1.60 ±0.36 1.62 ±0.26 
0.20 ±0.17 0.17±0.11 0.18 ±0.09 
13.9 ±10.0 11.5 ±7.9 12.4 ±6.5
0.67
Table 3.23 Carbon dioxide production results grouped by ACE genotype. Group means are 
expressed as absolute values o f baseline data and change from normoxia to hypoxia, in 
addition to percent change; standard deviation is denoted by the ± symbol. ANOVA p values 
are in the far right column.
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3.5.3 Oxygen saturation
Group data for oxygen saturation is displayed by ACE genotype in table 3.24, and 
graphically on figure 3.27. There was no significant difference in Sa02 from normoxia to 
hypoxia during rest or exercise by ACE genotype (ANOVA p values 0.24 and 0.67, 
respectively).
C h a n g e  in re s tin g  S p 0 2  from  n o rm o x ia  to  hypox ia 
by A G E  g en o ty p e
g
g  -10  
«  -11 
g> -12I -13
c
o5CL -15
ID
A C E  g e n o ty p e
P = 0 .1 3
C h a n g e  in e x e rc is e  S p 0 2  from  norm ox ia  to  hypoxia 
by A C E  g e n o ty p e
-20 -
O
-25  -
I -30 -
DDID
A C E  g e n o ty p e
p -0 .6 6
Figure 3.27 ANOVA analysis of change in SaC^ from normoxia to hypoxia. The left panel 
shows the response during rest; the right panel during exercise. The central point marks the 
group mean, the bars represent the 95% confidence interval for each group. Neither the 
response during rest or exercise demonstrates any significant difference between normoxia 
and hypoxia (ANOVA p values: rest p= 0.13, exercise p= 0.66).
Rest/
exercise II ID DD
ANOVA 
p value (A%)
Resting
Sa02
Normoxia 
Hypoxia 
Absolute change 
Percent change (A%)
95.7 ±1.1 95.8 ±1.5 96.5 ±1.3 
85.3 ±1.1 84.3 ±2.3 83.8 ±3.8 
-10.4 ±3.3 -10.7 ±3.5 -12.6 ±3.6 
-10.8 ±3.5 -12.3 ±3.6 -13.1 ±3.7
0.13
Exercise
Sa02
Normoxia 
Hypoxia 
Absolute change 
Percent change (A%)
94.3 ±1.1 94.8 ±1.6 95.2 ±1.8 
71.2 ±7.6 69.1 ±5.3 69.8 ±7.7 
-23.1 ±7.4 -27.33 ±14. -25.4 ±8.9 
-24.6 ±7.9 -26.5 ±5.4 -26.6 ±9.0
0.66
Table 3.24 Oxygen saturation results grouped by ACE genotype. Group means are expressed 
as absolute values o f baseline data and change from normoxia to hypoxia, in addition to 
percent change; standard deviation is denoted by the ± symbol. ANOVA p values are in the 
far right column.
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3.5.4 End-tidal carbon dioxide
End tidal carbon dioxide data is presented by ACE genotype on table 3.25 and figure 3.28.
There was a significant difference by ANOVA analysis, with the insertion homozygous
group demonstrating a greater decrease in etCOi during exercise (p=0.003)
C h a n g e  in resting  e tC 0 2  from  norm oxia  to  hypoxia 
by  A G E g e n o ty p e
C h a n g e  in e x e rc is e  e t C 0 2  from  n o rm o x ia  to  hypoxia 
by A G E  g e n o ty p e
-5  -
oy^ - 
g  -8 -
o> -9 - 
ro  - 1 0  —
0  -1 1  -
1 12-
Q-
ID DD
“  -3 0
A C E  g en o ty p e
II ID
A C E  g e n o ty p e
p=0.3£ p = 0 0 0 3
Figure 3.28 ANOVA analysis o f change in etCO^ from normoxia to hypoxia. The left panel 
shows the response during rest; the right panel during exercise. The central point marks the 
group mean, the bars represent the 95% confidence interval for each group. During exercise 
the II group demonstrated a greater fall in etCÜ2 (p=0.003), no significant decrease was 
evident at rest (p=0.38).
Rest/
exercise II ID DO ANOVA p value (A%)
Resting
etC02
(kPa)
Normoxia 
Hypoxia 
Absolute change 
Percent change (A%)
4.79 ±0.41 4.95 ±0.38 5.08 ±0.33 
4.38 ±0.58 4.60 ±0.32 4.75 ±0.31 
-0.42 0.37 -0.35 ±0.33 -0.33 ±0.20  
-9.0 ±7.7 -6,80 ±6.26 -15.1 ±4.6
0.38
Exercise
etC02
(kPa)
Normoxia 
Hypoxia 
Absolute change 
Percent change (A%)
5.60 ±0.57 5.77 ±0.43 5.90 ±0.42 
4.70 ±0.33 4.92 ±0.41 5.01 ±0.42 
-1.62 ±1.87 -0.85 ±0.29 -0.89 ±0.28 
-22.2 ±12.1 -14.6 ±4.8 -15.1 ±4.5
0.003
Table 3.25 End-tidal CO2 results grouped by ACE genotype. Group means are expressed as 
absolute values of baseline data and change from normoxia to hypoxia, in addition to percent 
change; standard deviation is denoted by the ± symbol. ANOVA p values are in the far right 
column.
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3.5.5 Respiratory rate
Group data for respiratory rate is displayed by ACE genotype in table 3,26, and graphically 
on figure 3.29. There was no significant difference in RR from normoxia to hypoxia during 
rest or exercise by ACE genotype (ANOVA p values 0.15 and 0.71 respectively); however 
there appears to be a trend towards a higher ventilation rate in the Il-group.
C h a n g e  in re s tin g  re sp ira to ry  ra te  from  n o rm o x ia  to  hypoxia 
by A C E  g en o ty p e
20  -
10 -
I
-10 4
DDID
A C E  g e n o ty p e
JEM.
C h a n g e  in e x e rc is e  re s p ira to ry  r a te  from  n o rm o x ia  to  hypox ia 
by A C E  g e n o ty p e
ID
A C E  g e n o ty p e
P = Q .7 1
Figure 3.29 ANOVA analysis of change in respiratory rate from normoxia to hypoxia. The 
left panel shows the response during rest; the right panel during exercise. The central point 
marks the group mean, the bars represent the 95% confidence interval for each group. There 
appears to be trend toward a higher RR in the II group but this is not significant (rest: p=0.15, 
exercise p^0.71).
Rest/
exercise II ID DD
ANOVA 
p value (à%)
Resting RR 
(bpm)
Normoxia 
Hypoxia 
Absolute change 
Percent change (A%)
14.7 ±3.2 15.3 ±2.9 14.8 ±3.3
16.0 ±3.1 15.7 ±3.2 14.5 ±3.8 
1.3 ±19.4 0.4 ±2.6 -0.24 ±2.1
11.0 ±19.4 3.8±18.3 -1.7±14.5
0.15
Exercise
RR
(bpm)
Normoxia 
Hypoxia 
Absolute change 
Percent change (A%)
19.9 ±3.0 21.0 ±4.0 21.6 ±5.0  
23.1 ±4.0 23.7 ±4.8 24.2 ±5.5 
3.2 ±3.8 2.8 ±2.7 2.7 ±1.8 
17.4 ±22.4 14.2 ±18.3 12.8 ±8.1
0,71
Table 3.26 Respiratory rate results grouped by ACE genotype. Group means are expressed as 
absolute values of baseline data and change from normoxia to hypoxia, in addition to percent 
change; standard deviation is denoted by the ± symbol. ANOVA p values are in the far right 
column.
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3.5.6 Tidal volume
Group data for tidal volume is displayed by ACE genotype in table 3.27, and graphically on
figure 3.30. There was no significant difference in Vt from normoxia to hypoxia during rest
or exercise by ACE genotype (ANOVA p values 0.86 and 0.55 respectively).
C h a n g e  in res ting  tidal vo lu m e from  norm ox ia  to  hypoxia 
by A C E  g en o ty p e
E
1
2
30  -
20  -
10 -
"cg0}
CL
A C E  g e n o ty p e
p = 0 .S 6
C h a n g e  in e x e rc is e  tidal v o lu m e  from  no rm ox ia  to  hypox ia 
by A C E  g e n o ty p e
Q)E
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2 5  -
15  -
I(ÜQ.
10  -
A C E  g e n o ty p e
Figure 3.30 ANOVA analysis o f change in tidal volume from normoxia to hypoxia. The left 
panel shows the response during rest; the right panel during exercise. The central point marks 
the group mean, the bars represent the 95% confidence interval for each group. Neither the 
response during rest or exercise demonstrates any significant difference between normoxia 
and hypoxia (ANOVA p values: rest p= 0.86, exercise p= 0.55).
Rest/
exercise / /  ID DD ANOVA p value (A%)
Resting Vr 
(litres)
Normoxia 
Hypoxia 
Absolute change 
Percent change (A%)
0.90 ±0.39 0.86 ±0.47 0.87 ±0.27 
1.07 ±0.67 0.95 ±0.27 1.01 ±0.31 
0.17 ±0.42 0.09 ±0.44 0.14 ±0.23 
15.8 ±25.1 20.5 ±26.7 18.9 ±26.3
0.86
Exercise
Vt
(litres)
Normoxia 
Hypoxia 
Absolute change 
Percent change (A % )
1.74 ±0.48 1.78 ±0.50 1.80 ±0.44 
2.05 ±0.66 2.01 ±0.60 2.07 ±0.43 
0.30 ±0.36 0.23 ±0.21 0.24 ±0.17 
17.4±16.8 13.0±10.9 14.0 ±10.2
0.55
Table 3.27 Tidal volume results grouped by ACE genotype. Group means are expressed as 
absolute values of baseline data and change from normoxia to hypoxia, in addition to percent 
change; standard deviation is given after the ± symbol. ANOVA p values are in the far right 
column.
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3.5.7 Minute ventilation
Minute volume data is presented by ACE genotype on table 3.28 and figure 3.31. There was 
a significant difference by ANOVA analysis, with the insertion homozygous group 
demonstrating a greater increse in Ve during exercise fron normoxia to hypoxia (p=0.003). 
There is no evidence of a co-dominant effect, since the heterozygous response is lower than 
the deletion homozygous group.
Ii
C h a n g e  in res ting  ventila tion from  norm oxia to  hypoxia 
by A C E  g e n o ty p e s
o
25 -1 20  -I
15 -
I 10 -(UDl
A C E g en o ty p e
p=0.49
C h a n g e  in e x e rc is e  ven tila tio n  from  n o rm o x ia  to  hypox ia 
by A C E  g e n o ty p e s
ID
A C E  g e n o ty p e
p = 0 .0 0 3
Figure 3.31 ANOVA analysis o f change in Ve from normoxia to hypoxia. The left panel 
shows the response during rest; the right panel during exercise. The central point marks the 
group mean, the bars represent the 95% confidence interval for each group. During exercise 
the II group demonstrated a greater increase in Ve (p"=0.008), no significant decrease was 
evident at rest (p=0.49). In addition, there is no evidence o f a co-dominant effect with the 
heterozygous group.
Rest/
exercise II ID DD
ANOVA 
p value (ts%)
Resting Ve 
(l/min)
Normoxia 
Hypoxia 
Absolute change 
Percent change (A%)
11.92±2.40 11.15 ±2.47 11.42 ±2.05 
15.50 ±7.22 13.85 ±2.95 13.28 ±2.37 
2.13 ±1.46 2.70 ±2.36 1.86 ±1.70 
18.2 ±9.3 23.6 ±17.7 17.4 ±15.2
0.49
Exercise
Ve
(l/min)
Normoxia 
Hypoxia 
Absolute change 
Percent change (A%)
33.87 ±8.58 35.53 ±6.60 36.10 ±5.59  
47.35 ±13.60 45.40 ±9.98 46.57 ±9.60 
13.50 ±6.50 9.87 ±4.15 10.51 ±4.50 
39.6 ±15.4 27.9 ±10.7 28.4 ±8.9
0.008
I
:%
Table 3.28 Minute ventilation results grouped by ACE genotype. Group means are expressed 
as absolute values o f baseline data and change from normoxia to hypoxia, in addition to 
percent change; standard deviation is given after the ± symbol. ANOVA p values are in the 
far right column.
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3.5 ACE genotype and bioim pedance cardiac output results
The following section compares the bioimpedance cardiography results for the subgroup 
previously presented by the ACE I/D genotype for each subject. The distribution of 
genotypes (displayed for each individual in table 3.2) was 8; II, 16: ID and 7: DD; this 
distribution is in Hardy-Weinberg equilibrium (x^ = 0.03). Table 3.29 summarises the age, 
heights and weight. The small size of the subject groups resulted in non-normal distribution; 
therefore the Kruskal-Wallis test, a non-parametric equivalent o f ANOVA was used to 
confirm the absence o f significant difference between the genotype groups for age, height 
and weight.
Genotype I I ID DD
Num ber 
A ge (years) 
H eight (cm) 
Weight (kg)
8
20.8 ±1.4 
173.0 ±8.42 
67.56 ±12.56
16
23.7 ±4.4 
173.9 ±7.6 
71.98 ±10.6
1
23.7 ±5.2 
178.1 ±8.1
72.8 ±10.4
Table 3.29 The physical characteristics of subjects included in the cardiac output studies, 
grouped by ACE genotype.
The results o f the bioimpedance studies are laid out in a similar fashion to the previous 
sections. The normality of heart rate, stroke volume and cardiac output hypoxic response for 
each genotype group was verified during resting and exercise measurements, before the 
application of ANOVA testing.
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3.6.1 Heart rate
Heart rate data for each genotype group is presented on table 3.30 and figure 3.32. There was
no significant difference in heart rate response between the genotype groups during resting
and exercise measurements by ACE genotype (ANOVA p values 0.94 and 0.75 respectively).
C h a n g e  in res ting  h e a rt ra te  from  norm oxia to  hypoxia 
by A C E  g e n o ty p e
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Figure 3.32 ANOVA analysis o f change in heart rate from normoxia to hypoxia. The left 
panel shows the response during rest; the right panel during exercise. The central point marks 
the group mean, the bars represent the 95% confidence interval for each group. Neither the 
response during rest or exercise demonstrates any significant difference between normoxia 
and hypoxia (ANOVA p values; rest p= 0.94, exercise p= 0.75).
R est/
exercise II ID DD
ANOVA  
p  value (is%)
Resting  
H eart rate 
(bpm)
Nonnoxia 
Hypoxia 
Absolute change 
Percent change (A % )
75.1 ±12.8 72.2 ±13.6 74.0 ±10.2  
87.3 ±8.7 84.1 ±14.1 87.2 ±11.6 
12.2 ±8.7 11.9 ±4.5 13.2 ±5.2  
16.8 ±11.4 17.0 ±6.8 18.2 ±7.0
0.94
Exercise 
Heart rate 
(bpm)
Normoxia 
Hypoxia 
Absolute change 
Percent change (A % )
116.1 ±10.2 115.5 ±20.6 121.5 ±13.5 
142.0 ±12.7 140.8 ±22.7 146.0 ±14.6 
25.8 ±5.5 25.2 ±7.1 24.5 ±4.8 
22.3 ±4.5 22.3 ±6.6 20.4 ±4.8
0.75
Table 3.30 Heart rate results grouped by ACE genotype. Group means are expressed as 
absolute values of baseline data and change from normoxia to hypoxia, in addition to percent 
change; standard deviation is given after the ± symbol. ANOVA p values are in the far right 
column.
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3.6.2 Stroke volume
Stroke volume data for each genotype group is presented on table 3.31 and figure 3.33. There 
was no significant difference in heart rate response between the genotype groups during 
resting and exercise measurements by ACE genotype (ANOVA p values 0.60 and 0.70 
respectively).
C h a n g e  in re s tin g  s tro k e  v o lu m e  from  n o rm o x ia  to  hypoxia 
by A C E  g e n o ty p e
C h a n g e  in e x e rc is e  s tro k e  v o lu m e  from  n o rm o x ia  to  hypoxia 
by A C E  g e n o ty p e
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Figure 3.33 ANOVA analysis o f change in stroke volume from normoxia to hypoxia. The 
left panel shows the response during rest; the right panel during exercise. The central point 
marks the group mean, the bars represent the 95% confidence interval for eaeh group. 
Neither the response during rest or exercise demonstrates any significant difference between 
normoxia and hypoxia (ANOVA p values: rest p= 0.60, exercise p= 0.70).
Rest/ II ID DD ANOVAexercise p value (ts%)
Resting
Stroke
Normoxia 82.3 ±27.2 95.7 ±23.1 82.8 ±29.4
Hypoxia 85.4 ±25.6 97.7 ±25.0 85.1 ±30.5 0.60volume Absolute change 3.1 ±2.9 2.0 ±7.4 2.3 ±2.1(mis) Percent change (A%) 4.9 ±4.6 1.9 ±8.6 2.7 ±2.4
Exercise Normoxia 105.5 ±40.5 121.7 ±29.9 105.4 ±25.6
Stroke Hypoxia 113.5 ±48.4 128.8 ±29.9 116.6 ±25.8 0.70volume Absolute change 8.4 ±9.9 7.0 ±9.4 6.15 ±4.23
(mis) Percent change (A%) 7.3 ±6.4 5.2 ±6.3 6.1 ±4.4
Table 3.31 Stroke volume results grouped by ACE genotype. Group means are expressed as 
absolute values of baseline data and change from normoxia to hypoxia, in addition to percent 
change; standard deviation is given after the ± symbol. ANOVA p values are in the far right 
column.
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3.6.3 Cardiac output
Cardiac output data for each genotype group is presented on table 3.32 and figure 3.34. There 
was no significant difference in heart rate response between the genotype groups during 
resting and exercise measurements by ACE genotype (ANOVA p values 0.85 and 0.76 
respectively).
C h a n g e  in re s tin g  c a rd ia c  o u tp u t from  n o rm o x ia  to  hypoxia 
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Figure 3.34 ANOVA analysis o f change in cardiac output from normoxia to hypoxia. The 
left panel shows the response during rest; the right panel during exercise. The central point 
marks the group mean, the bars represent the 95% confidence interval for each group. 
Neither the response during rest or exercise demonstrates any significant difference between 
normoxia and hypoxia (ANOVA p values: rest p= 0.85, exercise p^ 0.76).
Rest/ II ID DD ANOVAexercise p value (i\Vo)
Resting
Cardiac
"Normoxia 6.04 ±1.63 6.87 ±2.04 5.90 ±1.35
Hypoxia 7.31 ±1.87 8.22 ±2.56 7.15 ±1.66 0.85output Absolute change 1.27 ±0.68 1.34 ±0.96 1.25 ±0.53
(l/min) Percent change (A%) 22.3 ±10.8 19.5 ±13.4 21.5 ±8.8
Exercise Normoxia 11.97 ±3.86 12.59 ±2.30 7.31 ±1.86
Cardiac Hypoxia 15.74 ±5.44 18.02 ±4.68 16.05 ±2.93 0.76output Absolute change 3.77 ±1.77 3.96 ±1.89 3.46 ±0.84
(l/min) Percent change (A%) 31.2 ±7.9 28.6 ±11.6 27.7 ±5.2
Table 3.32 Cardiac output results grouped by ACE genotype. Group means are expressed as 
absolute values o f baseline data and change from normoxia to hypoxia, in addition to percent 
change; standard deviation is given after the ± symbol. ANOVA p values are in the far right 
column.
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CHAPTER FOUR: DISCUSSION
The studies in this thesis have examined the ventilatory and cardiac responses to acute 
hypoxia during rest and exercise in relation to the ACE insertion/deletion genotype. The 
larger study, examining the ventilatory response, has demonstrated a significantly higher 
ventilatory response to hypoxia during exercise in the insertion homozygote group; this 
finding may offer a possible explanation for the excess of insertion alleles in elite 
mountaineers and the higher oxygen saturation associated with the insertion allele during 
rapid ascents to altitude. However, the higher level of exercise ventilation in the insertion 
homozygous group was not matched by an intermediate level of ventilation in the 
heterozygous group, which demonstrated hypoxic ventilatory responses during exercise 
similar to those seen in the deletion homozygous group. The concurrent decrease in end-tidal 
CO2  suggests that the ventilatory responses across the genotype groups are accompanied by 
an increase in alveolar ventilation. There was a diverse range o f response in the patterns of 
breathing between individuals, which did not demonstrate any significant difference between 
genotype groups. Cardiac output responses to hypoxia did demonstrate expected patterns of 
response to hypoxia, with an increase in cardiac output, mediated predominantly by increase 
in heart rate under hypoxic conditions. An increased cardiac output was evident at rest and at 
equal work loads performed in hypoxic conditions in comparison with normoxic 
measurements, as expected; however, there was no significant difference in heart rate, stroke 
volume and cardiac output response between the three ACE genotype groups.
The higher hypoxic exercise ventilatory response seen in the insertion homozygous group (11- 
group) raises several questions: First, what was the mechanism of the increased response? 
Second, why was there no concurrent increase in oxygen saturation with the increase in 
ventilation seen in the 11-group? Third, why was there no evidence o f co-dominance in the 
hypoxic exercise ventilatory response seen between the three ACE genotype groups? Fourth, 
why was there no evidence o f a similar ventilatory response during rest? And finally, why 
was there no evidence of a significant cardiac output response between the genotype groups? 
This chapter considers each o f these questions, but begins by considering the important 
points in the study design, the subject characteristics and how the physiological responses in 
these studies compare with established models o f physiological response to both hypoxia and 
exercise.
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4.1 Study design and cardiopulmonary exercise test validation
4.1.1 Study design
The object o f these studies was to compare the ventilatory and cardiac output response in 
normal healthy individuals under conditions o f normoxia and then hypoxia during rest and 
exercise in relation to the insertion/deletion ACE gene polymorphism. Therefore the study 
was designed to minimise the possible interference with ventilatory measurements by lactate 
accumulation under hypoxic conditions, hence a constant load of 50% of the work at 
ventilatory threshold during maximal testing was chosen. This offered a reasonable level of 
work intensity under hypoxic conditions, whilst ensuring the subject did not pass the hypoxic 
ventilatory threshold. This was confirmed during the steady state exercise tests by real time 
monitoring o f heart rate and ventilatory variables, including ventilatory equivalents for 
oxygen and carbon dioxide. Other studies, investigating hypoxic response during exercise 
have used different work loads; aimed toward a specific heart rate response [419, 420] or a 
percentage o f maximal heart rate [421]; at low intensity, that would not induce lactate 
accumulation [422, 423]; at work loads 50% of that attained during maximum exercise [424] 
or based on predicted VO2 max [425]. These studies were designed to examine different 
aspects of physiological response to hypoxia, including ventilation; however the aim o f these 
studies was to examine the physiological responses in relation to a genetic polymorphism. 
From the outset, it was appreciated that the differences in physiological response between 
ACE genotype groups may have been quite subtle; therefore a precise measure of steady state 
exercise work load was deemed essential. For similar reasons, the physiological responses 
were compared in terms of percentage changes, in order to express the individual response in 
terms suitable for comparison; therefore establishing the ventilatory threshold and exercising 
at 50% work loads of the work at VT, meant that each individual was exercising within their 
own range. A possible criticism is that the VT represents a variable percentage of total work 
capacity as measured by VO2 max; and that the actual work performed in hypoxic conditions 
may constitute a different level o f work intensity between subjects, with some exercising at 
low rather than moderate intensities. The impact of this is difficult to assess, but hypoxia 
does have the effect o f increasing the intensity of exercise when compared to normoxic 
conditions if the same degree o f physiological stress is elicited (e.g. similar exercise heart 
rate responses) [426]. Therefore exercising at the same work load in hypoxic conditions 
would then place a work rate that might be perceived as low intensity in normoxia into the
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moderate intensity. Any further increase in normoxic work load may push the hypoxic work 
intensity into the high range and lactate could accumulate. The method used ensured that 
individual subjects did not exercise above their hypoxic ventilatory threshold.
The choice o f poikilocapnic hypoxia was also deliberate. The original reports o f enhanced 
performance with the ACE I/D gene polymorphism under hypoxic conditions were at high 
altitude [326, 330, 331]; therefore, poikilocapnic hypoxic challenge was chosen to emulate 
the effects of altitude. This had the potential to interfere with the pure hypoxic response, but 
the aim o f these studies was to examine any possible link between hypoxia, physiological 
response and the ACE genotype, including the effect o f variable PaCO] upon hypoxic 
response.
4.1.2 The reproducibility of steady state tests and validation
Establishing the reproducibility o f the steady state tests was also essential, in order to 
appreciate the small difference in physiological response that might otherwise be lost in 
poorly conducted tests with a wide margin of inter-test variability. The resting portion of the 
protocol, during both normoxia and hypoxia, did demonstrate a wider degree of variation in 
measured variables, both during the test and between repeated testing. This in part could be 
attributed to subject awareness and possible anxiety during rest; however the difference in 
measured response at rest during the validation studies was within 10%. The repeatability of 
ventilatory and VO2 measurement during the exercise portion o f the protocol was much 
closer with differences between tests to within 6%, which is the degree o f acceptable inter­
test variability for calibration purposes of cardiopulmonary exercise equipment [389]. The 
degree of variability during exercise was less than resting measurements; this is an expected 
finding since interference from distracting factors or hyperventilation is much less once 
attention is fixed during exercise. The repeatability of tests was also demonstrated by the 
Bland-Altman plots, which show inter-test variability within 2 standard deviations for both 
VO2 and minute ventilation during exercise with the majority of responses during rest 
demonstrating a similar degree o f agreement. Familiarisation with the test surroundings and 
equipment are strategies used to reduce the degree of subject anxiety during studies; this was 
achieved by conducting the hypoxic testing in the same surroundings as the maximal test 
(performed during the first visit) and allowing a period of familiarisation with the hypoxic 
circuit during the resting period.
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A further measure of quality control is demonstrated by the relatively small degree of 
variation in VO2 between the normoxic and hypoxic exercise tests for all the subjects. Since 
both the steady state tests were performed at the same work load, the VO2 should 
theoretically be the same. The majority of subjects demonstrate similar VO2 responses 
between the two parts o f the protocol, with a reduced degree o f variation during exercise, as 
seen in the repeatability studies. The degree o f variation falls largely within the acceptable 
limits of repeatability, but there are two other considerations that might have had an 
influence. Firstly, the two steady state tests were conducted at the same visit, consecutively 
with a short period between the tests, this would entail 16 minutes o f exercise in total, albeit 
at low to moderate exercise intensity. This raises the possible of increased VO2 during the 
second test due to a raised body temperature and increased blood flow to the skin for 
thermoregulation [171]. The second consideration is the increased ventilation during hypoxia 
and the increased oxygen demands of the respiratory muscles, one study examining the 
effects of hypoxia on VO2 suggested the effect was appreciable, but difficult to quantify 
[427]. Both o f these factors could contribute to the variation in VO2 between tests; however, 
the rest period between steady state test should have allowed sufficient cooling time and the 
sub-maximal intensity of exercise should have reduced the difference between normoxic and 
hypoxic oxygen uptake by respiratory muscles.
4.2 Subject group
The subject group was mainly comprised o f students from the University o f Glasgow with 
some members o f staff from the medical department in the Glasgow Western Infirmary and 
officers from the Glasgow University Officer training corp. This is reflected in the skewed 
distribution of ages towards the younger end of the range. The height range was slightly 
skewed towards the higher end o f the range; this may reflect the disproportionate number of 
male subjects. The weight distribution demonstrated a normal distribution. The mean VO2 
max in the subject group reflected the higher degree o f fitness in a group of motivated 
individuals that undertake regular exercise; this was one prerequisite o f the study, due to 
safety and ethical considerations of exercise under hypoxic conditions. The fitness o f the 
subject group is also evident from the participation across a broad range o f sports activities; 
furthermore, the degree o f participation varied, with some individuals competing at a national 
level in some sports. The spirometric data did not reveal any cases o f undiagnosed asthma or
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air flow limitation, the wide range of measured spirometric values were within predicted 
values for each individual, with many subjects demonstrating supra-normal values.
The subject group was entirely Caucasian in ethnicity; this was intentional since both the 
distribution and effects of the ACE gene polymorphism can differ with ethnicity. The 
original work describing the variation in ACE activity between genotype was measured in a 
Caucasian population [312] and subsequent studies have demonstrated less of a difference in 
ACE activity between genotype groups in black populations [428]. Furthermore, the 
distribution of ACE genotype in different ethnic groups may not be in Hardy-Weinberg 
equilibrium [429]. The variation in response to ACE inhibition in different ethnic populations 
is also well documented, with Afro-American and Afro-Caribbean populations demonstrating 
a reduced response to ACE inhibitors [430-432]; furthermore, the decreased response has 
been linked with reduced vascular reactivity and response to bradykinin [433]. Therefore the 
choice of a Caucasian population was designed to maximise any effect ACE genotype may 
exert on cardiorespiratory response.
The distribution of ACE genotypes was in Hardy-Weinberg equilibrium. These individuals 
demonstrated a similar distribution of baseline physical characteristics between genotype 
groups; furthermore the level of fitness, as measured by VO2 max was also similar. Previous 
studies examining the association of the ACE gene polymorphism and physical performance 
have shown an increased frequency o f the insertion allele in endurance athletes, suggesting a 
link between the I-allele and endurance performance. There was no ACE allele 
disequilibrium in the VO2 max distribution o f the sample group with the distribution o f VO2 
max demonstrating a similar distribution between genotype groups. This might reflect the 
wide range o f physical activities undertake by the subject group, at differing degrees of 
involvement, with only some activities classed as endurance sports. The original link 
between enhanced performance during hypoxia was in a group of mountaineers. 
Mountaineering requires endurance and power (as well as mental stamina); therefore is not 
strictly a homogenous group in terms o f endurance activity. Furthermore, comparisons 
between mountaineers, sedentary controls and long distance runners have shown that the VO2 
max in climbers was between that o f sedentary individuals and runners. In addition, the 
maximum anaerobic power in climbers was the same as sedentary controls and 40% less than 
long distance runners [434]. This would suggest that mountaineers are distinct from 
endurance athletes in terms of physical performance and that any observed benefit from 
possessing the 1-allele is only evident at altitude and under conditions o f hypoxia. This might
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explain why the differences in the physiological response between genotype groups seen in 
these studies were only apparent under hypoxic conditions.
4.3 Responses in metabolic variables during hypoxia and exercise
The responses in individual VO2 between normoxia and hypoxia, at rest and during exercise, 
have been discussed previously. This section examines the response o f VCO2 , etC02 and 
Sp0 2  during the steady state tests and the responses from normoxia to hypoxia.
4.3.1 Carbon dioxide production
The production of CO2  as measured during the tests reflects the metabolic production of CO2 , 
but also the degree of ventilation that eliminates CO2  from the body. As reviewed previously, 
ventilation is closely coupled to arterial CO2 tensions and ventilatory changes are coupled to 
CO 2 production during exercise in normoxia. In hypoxic conditions it is hypoxaemia and the 
effects on the carotid body that are the dominant stimulus to ventilation; consequently, CO2 
elimination is increased and is in excess o f metabolic production, with a concomitant 
reduction in arterial CO2 tensions. Therefore VCO2 is increased during acute hypoxic 
exposure. This is what essentially happened across the whole subject group, except during 
the resting period, where 6 individuals demonstrated a higher VCO2 during normoxic rest in 
comparison to hypoxic conditions. Hyperventilation during the initial stages o f the steady 
state protocol could explain the higher than expected ventilation during normoxia, since 
higher cortical stimulation of ventilation may have provided unexpectedly high ventilation 
because of mild anxiety; the ventilatory measurements confirmed the presence of a relative 
hyperventilation in these subjects. There was wide range of individual responses to hypoxia 
during both rest and exercise, with a wider degree of variability during resting measurements 
as compared to exercise measurements
4.3.2 End-tidal CO2
End-tidal CO2 is dependent on the rate of CO2  production and the alveolar ventilation. The 
use of etC0 2  as a measure of alveolar ventilation has been reviewed previously and though it 
is not as accurate as invasive determination o f alveolar ventilation, it is a useful indicator. 
The majority of subjects demonstrated a decrease in etC02 from normoxic to hypoxic 
conditions, as expected when ventilatory drive became dependent on hypoxia. This was the 
case for all exercise measurements, but 5 subjects demonstrated a lower etC02 during
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normoxia than during hypoxia. These subjects demonstrated a degree o f hyperventilation as 
described previously, the 6'*^  individual did not decrease his etC0 2  the reason for this may 
have been due to a higher level of initial V/Q inequality that may have impeded the 
elimination o f CO2 .
4.3.3 Oxygen saturation
Finger pulse oximetry demonstrated a reduction in oxygen saturation upon hypoxic exposure 
that intensified during exercise. This is to be expected as oxygen extraction from exercising 
muscles further reduces the degree o f hypoxia at rest, induced by diffusion limitation in the 
lung. There was a wide range o f resting and exercise hypoxic responses with marked inter­
subject variability. The oximetry values were slightly lower than anticipated during exercise 
(resting 95.9%, SD 1.4; exercise 94.8%, SD 1.6). The reasons for this may have been due to 
motion artefact or malpositioning o f the oximeter during exercise (despite the best efforts o f 
the investigator). Another factor was the circulation to the finger probe during exercise; some 
subjects insisted on gripping the handle bars of the ergometer very tightly (despite being 
encouraged to relax), thus constricting the circulation in the fingers. The finger probe was 
chosen because of better accuracy [399]; however experiments with ear probes did not 
overcome these problems because of motion artefact. The range o f desaturation during 
exercise also draws into question the accuracy of the oximetry data, since over half the 
subjects dropped their Sp02 to less than 70%, below the range of reliable measurement by 
non-invasive methods (rest 84.4%, SD 2.1; exercise 69.8%, SD 2.5) [394, 395].
4.4 Ventilatory responses to hypoxia and exercise
One o f the primary objectives o f the studies presented in this thesis was to examine the 
ventilatory response to hypoxia during rest and exercise. The measured minute ventilation, 
respiratory rate and tidal volume demonstrated a wide range o f individual variation across 
rest and exercise during normoxia and hypoxia. Furthermore, the degree o f change between 
normoxia and hypoxia was also varied between subjects. The increase in ventilation was 
mediated by a mixed pattern of increased respiratory rate and tidal volume. The features o f 
the absolute response to hypoxia are discussed in this section, in addition to the effects of 
altered patterns of ventilation on end-tidal CO2 .
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4.4.1 Minute ventilation
Qualitatively there was a wider variation in resting minute ventilation values in comparison 
to exercise values and was reflected in the higher ventilation seen in six subjects during 
normoxic rest in comparison to resting hypoxic minute ventilation. This could only be 
attributed to hyperventilation during this phase, despite familiarisation with the surroundings 
during the first visit and a period o f familiarisation with the circuit prior to data collection. A 
possible explanation is a degree o f self awareness during the initial part o f the protocol which 
abated once distracted by the onset of exercise. Whether the resting hypoxic response is 
consistent with other studies is problematic, since there is a wide inter-subject variation in 
HVR and the ventilatory response varies with the degree o f hypoxia. Similarly, during 
exercise the degree o f ventilatory response is variable with the degree o f hypoxia and the 
intensity o f exercise. Therefore, it is difficult to make comparisons between the various 
combinations of different levels o f hypoxia and exercise used by previous studies [419-424, 
435].
4.4.2 Tidal volume, respiratoiy rate and patterns of breathing
A wide range of individual response was evident for both tidal volume and respiratory rate 
across the subject group, with a mixture of respiratory rate and tidal volume increases. The 
resting values demonstrated a wider range of variation as seen with the other variables (Vt: 
normoxic mean 0.87 litres, SD 0.40; hypoxic mean 0.99 litres, SD 0.40. RR: normoxic mean 
15.0 bpm, SD 3.1; hypoxic mean 15.4 bpm, SD 3.3). Twenty four o f the sixty subjects had a 
higher respiratory rate during normoxic rest than during hypoxia; similarly, 14 subjects had a 
higher tidal volume during normoxic vs. hypoxic rest. The range of variability was reduced 
during exercise measurements (Vj: normoxic mean 1,78 litres, SD 0.47; hypoxic mean 2.02 
litres, SD 0.57. RR: normoxic mean 20.9 bpm, SD 4.2; hypoxic mean 23.7 bpm, SD 4.8). 
Seven subjects demonstrated a higher exercise respiratory rate response during normoxia in 
comparison to hypoxia; in addition, 7 different subjects demonstrated a higher tidal volume 
during normoxic exercise than during normoxic exercise. As described previously, the 
overall ventilation during exercise was invariably higher during hypoxic exposure; therefore 
it appears the contribution o f increased RR and V j to increased Ve had a demonstrable 
individual variability. Dead space ventilation is increased by the effects o f exercise and 
hypoxia on V/Q inequality; however, in the absence of reliable measures o f Yd, it is difficult
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to assess the effect that individual variability of Vt and RR might have had upon the 
efficiency o f ventilation.
The use of etCOi as an index o f alveolar ventilation has been reviewed and was used to 
examine any relationship between ventilatory variables and alveolar ventilation. The total 
minute ventilation during normoxia did not demonstrate any correlation at rest or during 
exercise with etC02, as one would expect. In normoxia, ventilation and CO2 production are 
closely coupled, and maintains a stable intravascular CO2  tension and pH during the dynamic 
changes in CO2 production caused by exercise; this would explain this finding. The responses 
under hypoxic conditions demonstrated a significant negative correlation between hypoxic 
ventilation and etC02 during both rest and exercise, again this is expected. Under hypoxic 
conditions, ventilatory drive is dominated by arterial O2  tension; therefore the higher 
ventilatory rate is reflected in increased CO2  excretion, lower arterial CO2 and since etC 0 2  is 
dependent on PaC02, a reduction in etC02. There was no relationship between tidal volume 
and etC0 2  during normoxic rest; furthermore, the removal o f one outlier (who appeared to 
have a degree of hyperventilation) from the resting hypoxic data produced an insignificant 
correlation between V t and etC02. The response to exercise was somewhat different; the 
normoxic exercise V t had a significant positive correlation with etC0 2 , whereas the hypoxic 
exercise V t did not demonstrate any correlation. This is an unexpected finding which is 
difficult to explain. One possible explanation may lie with the respiratory rate response to 
exercise and hypoxic exercise. The respiratory rate during both normoxic and hypoxic 
exercise demonstrated a significant negative correlation with etC0 2 , with the hypoxic 
exercise response demonstrating a stronger negative correlation (R= -0.40 vs. R= -0.46, 
normoxia and hypoxia respectively). Exercise in normoxia, results in an increase both VT and 
RR from resting values, stimulated by CO2 produced as a consequence of increased 
metabolism; in addition, CO2  tensions tend to increase tidal volume by changes in both Ti 
and Te. The positive correlation between etC 02 and V t seen during normoxic exercise may 
reflect these factors. During hypoxic exercise, the drive to ventilation is dependent on 
hypoxaemia and arterial CO2 tensions decrease. The diminished contribution o f PaC02 to 
ventilatory drive may explain the reduced correlation between etC 0 2  and V t during hypoxic 
exercise. A further factor is the steeper response in respiratory rate seen during hypoxic 
exercise in comparison with normoxic measurements, which may reflect a stronger stimulus 
to RR change due to the combined effects of hypoxia and exercise.
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The correlation analyses o f ventilatory variable and etCO] do not provide any clear indication 
o f the contribution of increased Vd, due to increased V/Q inequalities, upon alveolar 
ventilation. This may be due to the confounding effects of altered V/Q states with hypoxic 
exposure upon etCOz as a marker o f alveolar ventilation or that the hypoxie stimulus to 
ventilation masks any negative affects of increased V/Q mismatch upon etC02 and alveolar 
ventilation.
4.5 Responses in cardiac variables during hypoxia and exercise
The investigation o f cardiovascular responses to hypoxia and exercise in relation to the ACE 
gene polymorphism was one o f the primary objectives of this thesis; however, the 
practicalities o f implementing and evaluating a useful physiological measurement modality 
meant that bioimpedance cardiography was introduced into the study protocol after the 
ventilatory studies had commenced. As a consequence 3 1 subjects were included in the study 
of cardiac response to hypoxia and exercise.
4.5.1 Bioimpedance validation studies
Prior to using the Physioflow bioimpedance equipment for exercise testing, the validity of 
measured cardiac output (CO) response was validated against thermodilution measurements 
of CO in 4 patients undergoing right heart catheterisation. The results demonstrated a 
reasonable degree of agreement for individual measurements of cardiac output; the degree of 
agreement between the two methods was greatly improved by taking the average o f at least 3 
measurements. The steady state measurements of cardiac output variables during the 
different parts o f the test protocol were mean measurements over a 90 second period in order 
to provide a steady state measurement o f CO, but also to improve the fidelity of CO 
measurements as much as possible.
4.5.2 Heart rate, stroke volume and cardiac output
Cardiac output increased upon hypoxic exposure during rest in 28 of the 3 1 subjects. Three 
subjects had an elevated heart rate during normoxic rest and this was reflected in a cardiac 
output higher than hypoxic rest values. This may have been due to a degree of anxiety; 
however these subjects did not exhibit any evidence of hyperventilation during simultaneous 
measurement of their ventilatory response. The cardiac output response during exercise was 
invariably positive, but as with the other measured variables demonstrated a wide range of 
individual response. The increase in cardiac output was expected, as a means of maintaining
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oxygen delivery in the face o f reduced oxygen content of blood (due to the combined effects 
o f diffusion limitation at the lung and increased O2 extraction during exercise). The rise in 
CO was predominantly due to increases in heart rate response during rest and exercise from 
normoxia to hypoxia (A rest: 12.3bpm SD 5.6: A exercise: 25.2bpm SD 6.1). Stroke volume 
had a variable degree of change between normoxic and hypoxic conditions during both rest 
and exercise with some individuals decreasing their stroke volume during hypoxic exposure; 
however, despite the statistical significance o f the difference, the actual difference between 
normoxia and hypoxia was comparatively small (A rest: 2.7 mis SD 5.4; A exercise: 7.2 mis 
SD 8.5) and could be accounted for by the variation in measurement. Two subjects during 
measured exercise response from normoxia to hypoxia had a marked increase in SV, but the 
remaining 29 subjects had little demonstrable change; this is expected since SV increases 
early in the range o f capable exercise, with heart rate sustaining further increases in CO as 
oxygen demand increases.
4.5.3 Summai*y
The mechanisms underlying the response to hypoxia and exercise involve the interaction 
between ventilatory response, gas exchange, the convective processes of circulation and 
oxygen carriage and utilisation at the tissue level. The basic results of the ventilatory and 
cardiac studies highlight the individual variability in response to the hypoxic stimulus across 
several physiological variables; furthermore, many of the responses in one system are 
inherently dependent upon the response in another (c.f. cardiac output and oxygen uptake). In 
addition to variables that are examined during these studies there are many other factors that 
have a bearing on hypoxic response. Muscle fibre composition has a profound effect on the 
stamina o f a muscle and has a direct bearing upon the onset o f lactate accumulation. 
Substrate utilisation has a direct effect on the burden of oxygen demand of exercise, with 
carbohydrate proving more efficient in terms o f oxygen usage. Certain physiological 
responses have a reproducible pattern (such as ventilation), distinct to an individual, which 
may be encoded within their genes. Any genetic influence on the observed physiological 
response to hypoxia Is almost certainly polygenic and involves multiple gene loci; some of 
the crucial biochemical pathways involved have hypoxia dependent transcription of proteins 
crucial to their function. Furthermore, the identification of a functional genetic polymorphism 
in the ACE gene has been linked with endurance performance. The studies described in this 
thesis have demonstrated a significant difference in the ventilatory response to hypoxia and
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exercise that may contribute to the observed benefit of the insertion allele o f the ACE gene 
polymorphism under hypoxic conditions encountered at high altitude.
4.6 Cardiopulmonary responses to hypoxia and the ACE gene polymorphism
The ventilatory studies demonstrated an enhanced ventilatory response to hypoxic exercise in 
a group of individuals homozygous for the insertion ACE gene polymorphism. However, the 
studies also demonstrate two conflicting responses; there was no evidence of increased 
oxygenation in the insertion group in comparison to the ID or DD- groups and there was no 
evidence of codominance. These points are discussed in detail in addition to the most 
important question: what is the mechanism o f increased ventilatory response in the insertion 
homozygous groups?
4.6.1 The possible mechanisms of enhanced ventilation in the II group
The control of ventilation, as we have seen, is dependent on sensation at the peripheral and 
central chemoreceptors and the subsequent relay of neural afferents from these areas to the 
ventilatory motor areas in the ventral medulla. The nucleus o f the tractus solitarius in the 
dorsomedial medulla is the first synaptic relay between the peripheral chemoreceptors and 
the ventilatory pattern generators centres. During normoxia, CO2 is the dominant stimulus to 
ventilation and the production o f CO2 is closely coupled to ventilation during exercise. 
However, under conditions o f hypoxia, hypoxaemia is the dominant stimulus and ventilation 
is closely linked to the intensity o f both exercise and hypoxia in these circumstances. A 
further point o f complexity is the effects o f changing CO2  during hypoxic exercise and that 
reduced PaC02 might attenuate the hypoxic ventilatory response. There is a wide range in the 
individual hypoxic ventilatory response, both at rest [47, 436] and during exercise [437]. 
Furthermore, studies in monozygotic twins suggests there is a genetic component that 
underlies the individual hypoxic ventilatory response [438-440].
The studies presented in this thesis demonstrate an enhanced ventilatory response in the 
insertion homozygous group in comparison to the other genotypes. The increase in 
ventilation was seen during hypoxic exercise, but was not accompanied by an increase in 
oxygen saturation. This may have been due to technical issues or to the possibility of 
increased V/Q inequality in the ll-group, these points are discussed in detail further in this 
chapter; however, the increased ventilation does suggest increased hypoxic ventilatory 
sensitivity during exercise in the II-group. The increase in ventilation was accompanied by a
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decrease in etCOi which suggests increase in alveolar ventilation; this has two implications. 
First, due to the effects o f Dalton’s law o f partial pressures, the reduced alveolar PaC02 
implies an increase in the alveolar Pa0 2 ; furthermore, the reduction in alveolar PaC0 2  as a 
consequence o f hypoxia induced hyperventilation is one factor that made the Ascent of 
Mount Everest without supplementary oxygen physiologically possible by allowing a higher 
Pa02 than was previously thought. The second consideration is that the reduced etC02 
implies a reduction in arterial PaC0 2 ; therefore, the increase in ventilation in the Il-group 
occurred against a relative hypocapnia and a reduction in the CO2 contribution to ventilatory 
response; this was while there was no significant difference in CO2 production between 
genotype groups.
The precise mechanisms underlying this response are more difficult to elucidate; both the 
carotid body glomus cells and the nTS have local renin-angiotensin systems, as demonstrated 
by the presence of RAS components. The local RAS in the carotid bodies has a stimulatory 
function on the glomus cells. Angiotensin-2 causes Ca^ *^  influx into glomus cells via effects 
on ATiRc [269] and can heighten the hypoxic sensitivity o f glomus cells by inhibiting 
efflux and facilitating depolarisation [273]. The reduction in ACE activity evident in II 
individuals should attenuate this response and have negative effect on hypoxic ventilatory 
response. In contrast, the nTS appears to have a negative response to AT-2, as demonstrated 
by an inhibition of phrenic nerve discharge with the direct microinjection of AT-2; therefore, 
a reduction in ACE activity would have an enhancing effect upon hypoxic ventilatory 
response at the nTS (figure 4.1). O f course the ventilatory control system has many other 
constituent centres and pathways, many of which have yet to be elucidated, and the effects of 
local RAS at any other putative ventilatory pathways remains to be identified; however, these 
studies do highlight the difference in AT-2 response in at least two points in the ventilatory 
control mechanism. Furthermore, the effect o f exercise in this system appears to have an 
amplifying effect on the response since there was no evidence o f a similar effect during rest. 
This could have been due to the wider variability evident in the resting measurements, which 
may have obscured a smaller response during rest; the increased variability may have 
reduced the power o f these studies and resulted in failure to detect any significant difference 
in response between the genotype groups. There was a trend towards a higher respiratory rate 
in relation to the I-allele; however, this failed to reach significance due to wide inter-subject 
variability. Increasing the sample size in combination with further measures to reduce
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hyperventilation during the resting part of the studies may prove the presence of a similar 
hypoxic ventilatory response during rest.
The absence o f  a co-dominant effect on ventilatory response
The differences in response to AT-2 at different points in the ventilatory control pathway 
may explain the absence of a co-dominant effect, since the conflicting effects of ACE gene 
polymorphism upon hypoxic ventilatory response may have altered the expected occurrence 
of an intermediate response in the heterozygous group. The difference in site specific ACE 
response may have been further modified by the effect of other neurotransmitters at both the 
carotid body and the brainstem.
Reduced ACE 
activity has an 
inhibitory 
effect on 
carotid body function
Reduced ACE activity has an 
enhancing 
effect on 
phrenic nerve discharge
i0 2I ICO2I
Central 
chemoreceptors
phrenic discharge)
2 ,Ventilator^*
motor centres
Hypoxic 
Ventilatory 
Response
Figure 4.1 The interaction o f the peripheral and central chemoreceptors in response to 
hypoxia, hypocapnia and the effects of local RAS. The proposed effects of a reduction in
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ACE activity, as seen in insertion homozygotes are shown by the red arrows and notation. 
The reduced stimulatory effect at the carotid body is shown by the symbol; the enhanced 
phrenic nerves discharge by the symbol. The effect of reduced CO2 is also shown.
A second possible explanation is the tissue dependent variability in the co-dominant effect 
seen in some cells; an exclusively homozygous dependent increase in ACE activity has been 
described in monocytes, with high ACE activity only seen in deletion homozygotes [441]. 
Although, no direct influence o f such a mechanism in the brain exists the occurrence of this 
example does set a precedent. A third possibility is that the observed effect may not be linked 
to ACE genotype, but to an unknown genetic factor that is in linkage disequilibrium with the 
ACE gene. To-date no other candidate gene has been located in proximity to the ACE gene 
locus on chromosome 17 that might explain this effect.
Until the mechanisms of carotid body function in man and the functional aspects of central 
ventilatory control are clarified it is difficult to establish with any certainty the mechanism of 
enhanced ventilatory response hypoxic exercise response in insertion homozygotes.
4.6.2 Ventilatory and oxygen saturation responses between ACE genotypes
The increase in hypoxic ventilation during exercise seen in the insertion homozygous group 
was not accompanied by an increase in oxygen saturation. Enhanced ventilation should have 
improved alveolar oxygen partial pressures and this is certainly supported by the decrease in 
end-tidal CO2 ; therefore, the question remains: why was there no concurrent increase in 
oxygen saturation? There are two possible explanations: firstly, the fidelity o f pulse oximetry 
at the oxygen saturations experienced during hypoxic exercise may have fallen below the 
technical limits of the oximeter (Sp02: II 71.2% SD 7.6; ID 69.1% SD 5.3; DD 69.8 SD7.7). 
The use o f arterial blood sampling would have been a preferable measure of oxygenation, but 
informal discussions during the study development determined that this would be ethically 
dubious in the context of healthy subjects and that permission would be denied. The second 
explanation, assuming the fidelity o f the oximetry measurements, was a relative increase in 
ventilation to perfusion mismatch in the 11-group, such that there was no detectable benefit of 
increased ventilation on oxygenation. This seems less likely: firstly, the increase in alveolar 
Pa0 2  by enhanced ventilation would optimise gas exchange by matching alveolar ventilation 
to pulmonary blood flow. Secondly, the genotype dependent decrease in etC02, which was
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commensurate with increases in ventilation suggest that changes in total ventilation were 
matched by an increase in alveolar ventilation. Finally, the evidence in the field, does not 
support such a fundemental impedance to function at high altitude. The original association 
between ACE gene polymorphism and high altitude performance demonstrated significant 
excess frequency o f the insertion allele in climber who had successfully summited some of 
the highest mountains in the world [326]. Furthermore, a more recent study has confirmed 
the excess in I-allele in climbers at lower altitudes, suggesting that this is a fundamental 
effect evident over a range o f hypoxic exposures [330]. The direct effect of ACE genotype on 
physiological response was demonstrated by Woods et al; they showed an insertion allele 
dependent improvement in oxygenation in a group of climbers during a rapid ascent to 
5100m; these measurements were at rest, but represent the first direct evidence of 
advantageous physiological response in association with the I-allele during hypoxia. 
Although these studies support the advantageous influence o f the ACE insertion allele, the 
possible effect o f V/Q inequality as a factor in the acute response to hypoxia needs to be 
excluded by further investigation. Proper invasive measurement o f oxygenation may reveal 
improved oxygenation masked by the poor accuracy of oximeter readings. Arterial sampling 
would also permit the direct measurement of deadspace ventilation and with sufficient 
resolution to elucidate differences in V/Q inequalities between genotype groups. Non- 
invasive measures o f Va and therefore Vd using extrapolations from etC 0 2  are unreliable in 
situations where there may be a wide V/Q mismatch; this has been demonstrated in patients 
with various cardiopulmonary conditions during exercise [163].There are other non-invasive 
methods for ascertaining the degree o f ventilation to perfusion inequality: multiple inert gas 
elimination techniques (MIGET) utilise the differential dissociation o f 6 inert gases from 
solution into the gaseous phase. Infusions of these gases in solution are introduced into the 
subject and the varying rates o f elimination in the expired gas are measured, usually by mass 
spectrometry [442]. This technique has been used to assess V/Q inequalities in several 
pulmonary conditions, including pulmonary embolic disease [443] and could shed light on 
any differences in V/Q matching by genotype; furthermore, MIGET has been used to 
examine response during hypoxia and exercise [419, 444]. The requirement of peripheral 
venous access makes this less attractive for study in large groups of healthy individuals and 
the limited availability o f suitable equipment is a further restriction on the use of this 
technique.
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4,6.3 ACE gene polymorphism and pulmonary vascular effects
The effect o f reduced ACE activity in the pulmonary endothelium is difficult to assess, not 
least because of the complexity o f the RAS and the interaction with bradykinin. 
Angiotensin-2 is generated by ACE and is a potent pulmonary vasoconstrictor and 
pulmonary vascular ACE expression is increased in response to hypoxia [229, 230]; 
furthermore ACE inhibition and AT|Rc antagonists attenuate the hypoxic pulmonary 
vascular response in humans. This suggests the possible benefit of reduced ACE activity and 
AT-2 generation could be via the ameliorating effect on the HPVR and the disparate 
vasoconstrictor response that is evident during ambient exposure. An exaggerated hypoxic 
pulmonary vascular response is one factor in the pathogenesis o f HAPE and though there is 
no evidence that ACE genotype is associated with the development o f HAPE it is possible 
that impairment of gas diffusion as a consequence of subclinical pulmonary oedema could 
occur. One study in Japanese HAPE patients reported higher pulmonary vascular resistance 
in deletion homozygotes when compared to insertion homozygotes during pulmonary 
catheterisation shortly after evacuation from high altitude [332]; this suggests a 
hyperresponsive pulmonary vascular response in deletion homozygotes. Exercise elicits 
further increases pulmonary artery pressures during hypoxia, which are also exaggerated in 
HAPE susceptible individuals [445]. There have been no studies that have demonstrated any 
association with ACE polymorphism, HPVR and hypoxic exercise; however, one study 
examining the effect in chronic obstructive pulmonary disease (COPD) has shown an 
association with heightened pulmonary artery pressure in patients homozygous for the 
deletion allele during exercise.
The studies in this thesis were not structured to examine these elements o f hypoxic response, 
but the physiological responses to hypoxia and demonstrable effects of the ACE 
polymorphism on pulmonary vascular responses in HAPE sufferers and in patients with 
COPD suggest a link between the two. This could provide a benefit at altitude that 
contributed to the observed disequilibrium in ACE genotypes, with the association of the I- 
allele and enhanced altitude performance.
4.6.4 Cardiac output response and ACE genotype
The response in bioimpedance cardiac output results at rest and during exercise from 
normoxia to hypoxia did not demonstrate any significant difference between genotype
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groups. A similar lack o f response was seen in stroke volume and heart rate variables. The 
increase in cardiac output was predominantly due to an increase in heart rate with small 
increases in stroke volume. The resting response between normoxia and hypoxia 
demonstrated a smaller degree of change in HR, SV and CO; furthermore, the resting SV 
response was equivocal, with some subjects demonstrating a slight decrease in SV from 
normoxia to hypoxia. The increase in cardiac output between conditions of normoxia and 
hypoxia was to be expected since this is one of the compensatory mechanisms that allow the 
maintenance o f oxygen delivery in the face of reduced oxygen content o f blood; this is a 
consequence of reduced oxygen saturation caused by diffusion limitation at the lung and 
increased oxygen extraction during exercise. The dominance of heart rate change in this 
response is also expected since stoke volume increases to maximum early in the range of 
exercise and the changes in intravascular volume seen with prolonged hypoxic exposure at 
altitude would not have had time to develop during an acute challenge. The increase in heart 
rate between normoxic and hypoxic conditions during rest and exercise did not demonstrate 
any significant difference between the genotype groups. The increase in stroke volume 
during exercise could reflect the increase in sympathetic nerve activity seen during hypoxic 
exposure; this produces a vasoconstrictor effect that offsets the vasodilator effect o f hypoxia 
in the systemic circulation and maintains blood pressure during hypoxic exposure. It is 
possible that increased vasomotor tone in the capacitance vessels could have produced a 
marginal, but significant increase in venous return and preload to the ventricle; however there 
was no significant difference between the genotype groups.
The absence of significant differences in stoke volume and heart rate response between the 
groups suggests that there was no significant difference in sympathetic nervous activity in 
response to hypoxia as a result o f the ACE gene polymorphism. To date, there have been no 
published reports o f enhanced hypoxia induced sympathetic nerve activation in relation to the 
ACE gene polymorphism. There was a small trend towards a higher cardiac output response 
during exercise in the insertion homozygous group (A exercise cardiac output: II 31.2%, SD 
7.9: ID 28.6%, SD 11.6: DD 27.7%, SD 5.2); this raises the possibility of a significant 
difference, which was overlooked because o f the limited size o f this study and lack o f power. 
Based on the degree o f change in CO between the three genotype groups and the maximal 
variation within the groups a study aimed at a power level of 0.95 using ANOVA analysis 
would require a minimum of 316 subjects in each genotype group. This is o f course assuming 
there is an underlying association between the insertion allele and enhanced cardiac output
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response during hypoxic exercise. The evidence supports the opposite position in normoxic 
conditions with increased left ventricular mass in deletion homozygotes and increased VO2 
max in Caucasian subjects after a regimented course of physical training [323, 446]. As 
previously discussed the subjects had a wide range of physical activities and did not have a 
standardised exercise regimen; therefore, a lack of variation in cardiac output response is not 
unexpected. However, these two studies were conducted under normoxic conditions and as 
we have seen, the effects o f hypoxia have elucidated ventilatory changes in a group of 
subjects with a background of heterogeneous physical activity; therefore, it may be that there 
is an underlying ACE associated effect that the current study is underpowered to detect. A 
further consideration is the utilisation of oxygen by muscle itself and the effects this might 
have on cardiac output.
4.6.5 Cardiac output and muscle
Cardiac output is closely coupled to oxygen consumption, as reviewed previously; however 
the fibre composition of muscle has a direct bearing on the oxidative capacity of muscle and 
oxygen utilisation. Muscle displays marked plasticity in response to exercise and hypoxia 
both in terms of switching o f fibre type and changes in size and oxidative apparatus. The 
duration o f hypoxic exposure and exercise is too brief to allow any such changes to influence 
the outcome of these experiments; however muscle substrate utilisation is one site amenable 
to acute change. ACE inhibition appears to enhance glucose utilisation in exercising muscle 
via a bradykinin/ NO dependent mechanism [303] and glucose metabolism has a reduced 
oxygen cost in stochiometric terms. This provides a possible mechanism for insertion 
genotype associated decrease in ACE activity to exert a beneficial effect during acute 
hypoxia. This is purely theoretical and has yet to be demonstrated experimentally.
The ACE polymorphism has other demonstrable influences on muscle function; an enhanced 
anabolic response in response to exercise regimens [447]. Furthermore, the ACE insertion 
allele is associated with increased muscle efficiency in response to army basic training [327]. 
Muscle efficiency is expressed as delta efficiency, which is the percentage ratio of change in 
work performed per minute to the change in energy expenditure (usually above that required 
for unloaded exercise) i.e.
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Change in work accomplished (joules/min)
Delta efficiency —   X |00Change in energy expended (joules/min)
This is calculated by performing serial steady state exercise regimens whilst measuring work 
load and oxygen uptake. The change in energy expenditure can then be calculated using a 
theoretical-thermodynamic approach based on a ratio of 11.0 kilocalories per mole o f ATP 
hydrolysed. The original ratio of 3 ATP per molecule of oxygen consumed was used by 
Gaesser and Brooks when the method was first proposed [448]: however this is thought to be 
an over estimate and the ratio is now thought to be 2.5 [449]. The work performed is a known 
variable since it is set on the ergometer. The effect demonstrated was after a training program 
with no prior genotype dependent difference in efficiency.
4.6.6 Study findings in relation to prolonged hypoxia
The discussion thus far has focused on the results of studies conducted in acute hypoxic 
conditions; this has inherent implications in terms of the mechanisms that are involved in the 
physiological response. The time scale o f these experiments would have excluded factors that 
are important considerations when examining physiological responses during prolonged 
exposures to hypoxia at altitude. The effects on muscle function and metabolism; cardiac 
output adaptation; increase in oxygen carriage capacity o f blood through the effects of 
erythropoesis; adaptation in the pulmonary circulation to optimise V/Q matching and the 
changes in ventilation over time are all effects that influence performance at altitude. These 
studies have demonstrated a direct link between the insertion homozygous genotype o f the 
ACE gene and a physiological response to ambient hypoxia o f any duration. It remains to be 
seen whether the increase in exercise ventilation is a fundamental feature o f insertion 
homozygosity or whether this response fades in intensity over prolonged periods o f hypoxic 
exposure. However, a feature of successful performance at altitude is the rate of 
acclimatisation during rapid ascents; furthermore, many of the pathological conditions at 
altitude are precipitated by going too high, too quickly. The work by Woods et al. has 
demonstrated that ACE insertion allele dependent improvement in oxygen saturation is only 
seen during rapid ascents. Therefore, the enhanced ventilatory response seen in the insertion
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homozygous group could be perceived as one factor in favour of enhanced performance from 
the earliest point of hypoxic exposure and activity.
4.6.7 Study limitations
The limitations of the studies performed in this thesis have been mentioned in the course of 
the discussion and include: the lack o f reliable oximetry measurement; the lack o f arterial 
blood sampling, which would have given accurate PaOi measurements and a method of 
measuring Vd/Vj ; a more controlled familiarisation with the equipment to avoid increased 
variability resting measurements and an increase in subject numbers to improve the power of 
bioimpedance cardiac output studies.
Further important limitations of the studies performed centre on the size of the subject group 
in the context o f a genetic study. The lack o f significant differences in the other physiological 
variables studied, most notably the cardiac output, may reflect a lack o f sufficient power to 
elucidate any significant differences and would require a much larger sample size. 
Furthermore, a different study design may have offset some of the limitations of sample size. 
The sample group demonstrated a quite varied pursuit of physical activities, not all of them in 
the endurance disciplines. The beneficial effect o f the ACE insertion allele at altitude may 
differ from its normoxic effects, but to date the beneficial effects of the ACE insertion allele 
has been seen in endurance atheletes and in response to a period o f physical training. A case 
control study comparing the effects of hypoxic exercise in endurance atheletes versus 
controls by genotype may offer a better insight into the mechanism o f the beneficial effects 
of the ACE genotype. Another factor which could be addressed by an alternate study design 
is the effect o f ACE genotype on muscle efficiency at altitude and the effect this might have 
on enhanced performance during rapid altitude ascents. A longitudinal study at altitude 
examining the effect o f training at a set altitude could offer an insight into these effects.
The limited size of the sample group also raises the possibility that the observed effect was a 
product of chance and a larger sample would refute the findings; this is always a 
consideration in small genetic studies, particularly when comparisons are being made 
between more than two groups. The p-values for these studies were not corrected for multiple 
comparisons and this is another limitation o f these studies. A final point is that the original 
study was designed in 1999, at that time there were relatively limited numbers of genotypes 
that were available for study (Nitric oxide synthase was of particular interest at that time), 
unfortunately we neither had the ability to study these genotypes nor the manpower to
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perform further genotyping. Modern techniques allow the genotyping o f hundreds of genes 
simultaneously. DNA microarrays offer an insight into RNA expression at the cellular level, 
but have been adapted to the genotyping of single nucleotide polymorphisms. In combination 
with the increasing numbers of genetic polymorphisms and the completed Human Genome 
project there is now the potential to apply techniques to investigate variation in physiological 
responses that to date have been used to investigate the genetic basis of diseases such cancer 
and systemic hypertension.
4.7 Future work
The experiments performed during this thesis were during acute hypoxic exposures in 
poikilocapnic conditions. Future studies should aim to confirm these responses during 
prolonged hypoxic exposure, preferably at high altitude during the first few days o f hypoxic 
exposure designed to examine the longitudinal effects overtime. Furthermore, experiments in 
isocapnic hypoxia should be performed, to elucidate the peripheral chemoreceptor element to 
the ventilatory response seen during exercise in isolation from central chemoreceptor effects. 
Modification of the protocol to address the limitations identified would clarify some o f the 
experimental findings and an increase in study numbers may reveal any cardiac output 
response in association with the ACE genotype. Finally there is now the scope for examining 
numerous genes simultaneously in combination with further candidate genes that offer an 
insight into who will cope well with the stresses of altitude or who might succumb to the 
effects of high altitude disease.
4.8 Conclusion
The experiments in this thesis have demonstrated repeatability and agreement with 
recognised measurement modalities during validation studies. The subject responses are in 
accordance with expected patterns o f cardiopulmonary response to hypoxia and exercise. In 
relation to the ACE gene polymorphism, an increased ventilatory response has been 
demonstrated in a group possessing the insertion homozygous genotype during an 
individually standardised exercise test from conditions of normoxia to hypoxia. This could 
offer an advantage during initial exposure through an enhanced ventilatory response during 
exertion in hypoxic conditions; furthermore the increased exercise ventilation may contribute 
to the enhanced performance at altitude attributed to the insertion allele, as evident by the 
excess 1-allele in those successful in ascending to the highest summits in the world.
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